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ABSTRACT OF DISSERTATION 
 
 
 
DISCOVERY OF NOVEL PHARMACOTHERAPEUTICS  
FOR SUBSTANCE USE DISORDERS 
 
Substance use disorders are serious health concerns in the United States. 
Furthermore, the National Survey on Drug Use and Health reports a continuous 
increase in substance use disorders in the United States during the last 10 years. 
However, there are not many effective pharmacotherapeutics available for 
substance use disorders. The current dissertation is focused on research aimed at 
discovering pharmacotherapeutics for substance use disorders. First part of 
dissertation focused on discovering methamphetamine (METH) use disorder 
therapeutics targeting specific mechanism of METH action on dopaminergic 
neurons. The second part of dissertation focused on opioids and cocaine use 
disorder therapeutics targeting rewarding pathway commonly activated by opioids 
and cocaine.  
With respect to METH, it induces release of dopamine (DA) in neuronal 
terminals by interacting with the vesicular monoamine transporter-2 (VMAT2) and 
DA transporter (DAT). VMAT2 inhibitors have been found by our research group 
to decrease METH-evoked DA release, METH-induced hyperlocomotion, and 
METH self-administration in rats. However, these VMAT2 inhibitors lacked 
selectivity and tolerance developed to these pharmacologic effects after repeated 
administration, thereby limiting their potential as pharmacotherapeutics for METH 
use disorders. In the current study, analogs from a novel scaffold were found to 
selectively inhibit VMAT2 and were evaluated using neurochemical and behavioral 
pharmacological approaches. R- and S-3-(4-methoxyphenyl)-N-(1-phenylpropan-
2-yl)propan-1-amine  (GZ-11610 and GZ-11608, respectively) exhibited 94- to 
3450-fold selectivity for VMAT2 over human-ether-a-go-go (hERG) channel, DAT, 
serotonin transporter, and nicotinic acetylcholine receptors. GZ-11608 
competitively and concentration-dependently inhibited METH-evoked DA release 
via VMAT2. Also, GZ-11610 (56-300 mg/kg, oral) and GZ-11608 (300 mg/kg, oral; 
10-30 mg/kg, s.c.) reduced METH-induced hyperlocomotor activity in METH-
 
 
sensitized rats. Furthermore, GZ-11608 (1-30 mg/kg, s.c.) inhibited METH self-
administration, cue- and METH-induced reinstatement in a dose-dependent 
manner, and 30 mg/kg (s.c.), 10 mg/kg (s.c.), and 17 mg/kg (s.c.) produced 
significant effect, respectively. Importantly, the GZ-11608-induced decrease in 
METH self-administration was not surmounted by increasing the amount of METH 
available. GZ-11608 did not substitute for METH and did not serve as a reinforcer 
in rats self-administering METH and drug naïve rats, respectively. Thus, these 
VMAT2 inhibitors incorporating a new scaffold are novel leads for new 
pharmacotherapeutics to treat METH use disorders. 
Substances with high abuse potential including opioids and cocaine elevate 
extracellular DA concentration in the nucleus accumbens, and this mechanism has 
long been considered to underly substance-induced reward. DA in the nucleus 
accumbens originates from DA neuron cell bodies located in the ventral tegmental 
area in the midbrain. Interestingly, M5 muscarinic acetylcholine receptors 
(mAChRs) are proteins that are highly expressed on ventral tegmental area DA 
neurons. Also, studies investigating M5 mAChRs knockout mice showed reduced 
responding for cocaine in cocaine self-administration and decreased time spent in 
cocaine-paired and morphine-paired place preference studies. Pharmacological 
inhibition of M5 mAChRs function via microinfusing mAChR antagonists exhibiting 
no selectivity among M1-M5 mAChRs subtypes into the ventral tegmental area 
where expression of M5 mAChRs are dominant, reduced morphine-induced 
hyperlocomotion and cocaine seeking behaviors in rats. These studies support 
therapeutic potential of M5 mAChRs selectivity antagonists in opioids and cocaine 
use disorders. Thus, in the current study, affinity of a series of pethidine and 
quinuclidinyl N-phenylcarbamate analogs for M5 mAChRs was evaluated using in 
vitro and ex vivo neuropharmacological assays. Among the pethidine analogs, 
compound 6a showed the highest binding affinity at M5 (Ki = 0.38 µM), but also 
high affinity at  M1 and M3 mAChRs (0.67 and 0.37 µM, respectively). Among the 
quinuclidinyl N-phenylcarbamate analogs, compound 13c exhibited the highest 
affinity at M5 (Ki = 1.8 nM), but also high affinity at M1, M2, M3 and M4 mAChRs 
(Ki = 1.6, 13, 2.6, 2.2 nM, respectively). Also, 13c acted as an agonist of mAChRs 
on oxotremorine-induced DA release from rat striatal slices. In addition, compound 
13b was found exhibiting the highest selectivity (17-fold) at M3 over M2 mAChRs, 
suggesting potential of 13b as a chronic obstructive pulmonary disease 
therapeutics. Taken together, these novel analogs serve as leads for further 
discovery of subtype-selective M5 mAChR antagonists that may have potential as 
therapeutics for substance use disorders, as well as for chronic obstructive 
pulmonary disease. 
 
KEYWORDS: Substance Use Disorders, Methamphetamine, Cocaine, Opioids, 
Vesicular Monoamine Transporter-2, Muscarinic Acetylcholine 
Receptors.  
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1. CHAPTER ONE: INTRODUCTION 
1.1 Substance Use Disorders 
The term, substance use disorders, is the appropriate terminology to refer to what 
used to be known as drug addiction or drug abuse. The National Institute on Drug Abuse 
(NIDA) defined substance use disorder  as a brain disease manifested by compulsive 
substance seeking and obtaining behaviors, despite negative consequences (Volkow, 
Baler, et al., 2011; Volkow et al., 2016). In general, the word, drug, is used as two distinct 
definitions. One definition is substances or medications that potentially treat or prevent 
disease through modifying biochemical or physiological processes. The second definition 
is substances specifically altering mental processes (e.g., cognition, mood) with potential 
for misuse. In this dissertation, drugs and substances are used particularly to refer to the 
second definition. Also, since this dissertation is focused on discovering new 
pharmacotherapeutics/medications for patients who are diagnosed with substance use 
disorders, the terminology, substance use disorders instead of drug addiction, is used in 
this dissertation. 
The Diagnostic and Statistical Manual Mental Disorders (DSM) provides standard 
criteria for mental health disorders diagnosis. Diagnostic criteria for substance use 
disorders are provided also by DSM, which has been published by the American 
Psychiatric Association since 1952.  
Up until the 1970’s, substance use disorders were commonly considered as a 
harmful habit of individuals or as reduced responsiveness of individuals, instead of as a 
brain disease (Stedman, 1976). Correspondingly, substance use disorders were classified  
as a secondary mental disease under ‘Sociopathic Personality Disturbance’ in DSM-I and 
under ‘Personality Disturbance’ in DSM-II, published in 1952 and 1968, respectively 
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(American Psychiatric Association, 1968; Robinson and Adinoff, 2016). However, over 
time, neurobiological observations on the long-lasting structural and functional brain 
changes following repeated substance use were accumulated, and which led perceptional 
changes in the point of view that substance use disorders as ‘a lack of personal 
responsibility’ to ‘a brain disease’ (neurobiological findings are discussed in a section 1.3).  
In agreement with this change in perspective, substance use disorders were 
categorized as a primary mental disease beginning with the third edition of the DSM (DSM-
III) published in 1980. In the DSM-III, two diagnostic terms were used to distinctly diagnose 
patients with  substance use disorders depending on the severity of the disease (American 
Psychiatric Association, 1980). “Substance abuse” was the diagnostic term used for 
relatively less severe individuals. Substance abuse was diagnosed for individuals 
exhibiting the following behaviors: 1) pathological substance use pattern (i.e., repeated 
failure to stopping or reducing use of substances, and required daily use of substance to 
perform adequate function), 2) experiencing impaired social or job-related function due to 
the pattern of pathological substance use, and 3) longer than a month of duration for 
pathological substance use. On the other hand, “substance dependence” was the term for 
more severe cases.  Substance dependence generally referred to more severe substance 
use disorders, which requires physiological dependence exhibiting either tolerance or 
withdrawal. Tolerance is defined as a diminished effect of equal amount of the substance 
used or as the necessity to use increased amount of substance to provide an equivalent 
effect in the same individual. Withdrawal is a series of substance-specific symptoms 
occurred in the abstinence of or reduced use of substances (American Psychiatric 
Association, 1980).  
The DSM-IV published in 1994 retained these two diagnostic terms with minor 
modifications. The first minor modification was that substance use disorder, which was a 
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primary category in DSM-III, became a subcategory of a primary category, ‘substance-
related disorders’. Also, a ‘substance-induced disorder’ subcategory was added under 
substance-related disorders. Thus, the ‘substance-related disorders’ consist of ‘substance 
use disorders’ and ‘substance-induced disorders’. The second minor modification in DSM-
IV compared to DSM-III was that tolerance and withdrawal were added as diagnostic 
terms under substance-induced disorders. There were accumulated individuals who are 
seeking treatment for chronic substance use with exhibiting negative consequences 
without developing tolerance or withdrawal. Conversely, tolerance and withdrawal without 
producing addiction were observed following use of medications acting on the central 
nervous system (e.g., sedatives: benzodiazepines (Valium and Xanax) and barbiturates 
(Nembutal); antidepressants: selective serotonin reuptake inhibitors (Prozac, Soloft, Paxil, 
and Lexapro)). Regarding such modifications, the substance dependence criteria in the 
DSM-IV were 1) pattern of compulsive substance uses (i.e., larger amounts were taken 
often more than was intended, important social activities are reduced or given up due to 
substance use) with and without exhibiting 2) tolerance and/or 3) withdrawal. Whereas 
substance abuse diagnosis criteria include only the negative consequences of repeated 
substance use (i.e., repeated substance use resulting in failure to perform major 
obligations at work, school or home, repeated arrests for substance-related legal problems) 
without pattern of compulsive substance use, tolerance, or withdrawal (American 
Psychiatric Association, 1994). Also, the DSM-IV specifically defined the word “substance” 
as drugs exhibiting abuse liability, which include legal and illegal substances that modify 
mood or behaviors.  
In the most recent edition, DSM-V, the two diagnostic terms, substance abuse and 
substance dependence were combined within “substance use disorder” to reduce 
confusion between dependence and addiction. The severity of the disease is indicated as 
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mild, moderate or severe instead of using two separate diagnostic terms (substance abuse 
or dependence). Due to the criteria difference between DSM-III, -IV verses -V it is difficult 
to directly compare; generally, substance abuse (DSM-III, -IV) refers to mild (DSM-V), and 
substance dependence (DSM-III, -IV) refers to moderate to severe substance use 
disorders (DSM-V). In DSM-V, ‘non-substance-related disorders’ was added, which 
include gambling disorders. Thus, the name of the primary category was changed from 
‘substance-related disorder’ to ‘substance-related and addictive disorders’. Thus, 
substance-related and addictive disorders consist of substance-related and non-
substance-related disorders. The ‘substance-related disorders’ is further subcategorized 
to ‘substance use disorders’, ‘substance intoxication’, and ‘substance withdrawal’ and 
DSM-V provides specific diagnostic criteria for each subcategory. The diagnostic criteria 
of the DMS-V for substance use disorders are discussed in the section 1.1.2.  
Notably, drug addiction has not been used as a diagnostic term in the DSM, except 
the first edition. According to the DSM-V, the term ‘addiction’ was omitted from the DSM 
due to the underlying negative connotation or stigma, and its ambiguous definition 
(American Psychiatric Association, 2013).  
This dissertation describes research aimed at discovering potential 
pharmacotherapeutics for individuals diagnosed with substance use disorders. Thus, the 
official diagnostic term, “substance use disorders” is used instead of drug addiction. Also, 
the word “substances” in this dissertation specifically refers to drugs exhibiting abuse 
liability. In following subsections, various classes of substances (section 1.1.1) and the 
detailed diagnostic criteria for substance use disorders in DSM-V (section 1.1.2) are 
provided.   
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1.1.1 Substance Classifications 
Self-administration of substances that have abuse potential could result in serious 
health problems including the development of substance use disorders. Thus, the United 
States (U.S.) Drug Enforcement Administration (DEA) classifies substances into five 
groups depending on their medical use and abuse potential in order to provide appropriate 
information to the public and to control the legal and illegal uses of substances. Also, the 
DSM-V provides substance classifications based on the similarity of effects induced by 
substances, which can aid in efficient diagnoses of substance abuse. There are several 
substances that result in considerably similar physical and psychological effects, although 
their chemical structures are not the same (e.g., amphetamine and methamphetamine 
(METH)). To provide a brief introduction of various substances and related substance use 
disorders, this section introduces the two substance classification systems provided by 
the DEA and DSM-V in section 1.1.1.1 and 1.1.1.2, respectively.  
 
1.1.1.1 Substance Classification for Controlling and Trafficking of Substances  
The Federal Comprehensive Drug Abuse Prevention and Control Act of 1970, 
commonly known as the “Controlled Substances Act,” was activated on May 1, 1971 
(Gabay, 2013; DEA, 2018). As part of the Act substances are categorized based on their 
medical use and relative abuse liability. This categorization provides appropriate 
substance-related information with the aim to reduce the spread of substance use 
disorders, while ensuring medical availability of substances (DEA, 2018).  
According to the law, substances are classified into one of five classes (Schedules 
I-V). Substances that exhibit high abuse liability and have no accepted medical use are 
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classified as Schedule I. Substances that exhibit high abuse liability and also have 
legitimate medical uses, are classified as Schedule II. If substances have a legitimate 
medical use and relatively lower abuse liabilities compared to Schedule II substances, 
then they are classified as Schedule III, IV, or V depending on their relative abuse liability 
in descending order. For example, two substances exhibiting high abuse liability, heroin 
and lysergic acid diethylamide (LSD) have no accepted medical use, and thus are 
classified as Schedule I (DEA, 2017).  
The abuse liability of substances is determined based on their ability to induce 
stimulant, depressant or hallucinogenic effects (DEA, 2018). Schedule II substances 
include morphine, codeine, fentanyl, methadone, hydrocodone, phencyclidine (PCP), 
oxycodone, cocaine, and METH, all of which have accepted medical uses, but have high 
abuse liability. For example, METH exhibits distinct stimulant effects in individuals at >10 
mg (oral) or at 15 ng/mL plasma (Huestis and Cone, 2007; Sevak et al., 2009). However, 
METH is currently available under the product name, Desoxyn (5 mg/tablet, oral) as a 
legal medication for attention deficit disorder, severe obesity, and narcolepsy as a result 
of the accumulated scientific evidence supporting its pharmacological effects (Huestis and 
Cone, 2007; Sevak et al., 2009; Rau et al., 2016).  
Schedule III consists of substances such as anabolic steroids, ketamine, and some 
barbiturates, which have moderate to low abuse potentials (Morgan, 1990; Lukas, 1996; 
Liu et al., 2016). Substances classified as Schedule IV have legitimate medical uses with 
relatively lower abuse liabilities compared to Schedule III substances and includes 
pentazocine, alprazolam, clonazepam, and pemoline (Chambers et al., 1971; Polchert 
and Morse, 1985; Mumford et al., 1995; Frauger et al., 2011). Schedule V includes 
substances used medicinally and exhibit the lowest abuse liabilities among controlled 
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substances. For example, cough medicines with codeine (<200 mg/100 mL) are examples 
of Schedule V substances (Gabay, 2013; DEA, 2017).  
Laws surrounding the importation and exportation, manufacturing, distribution of 
substances are based on schedule and are controlled by law (DEA, 2018a; b). The 
synthesis, selling and use of Schedule I substances are illegal, with the exception of 
research purposes, which in turn requires DEA approval. However, the synthesis, selling 
and use of substances in Schedules II-V categories are legal when approved by the DEA. 
Thus, research in the current dissertation requiring the use of a Schedule II substance, 
METH, was conducted appropriately as allowed by law.  
 
1.1.1.2 Classification for Substance Use Disorder Diagnosis  
The DSM-V classifies problematic substances into 10 classes: alcohol, caffeine, 
cannabis, hallucinogens, inhalants, opioids, sedatives/hypnotics/anxiolytics, stimulants, 
tobacco and other or unknown substances (American Psychiatric Association, 2013).  The 
alcohol class includes all beverages containing a compound called ethyl alcohol or ethanol 
(e.g., beer, wine, whiskey). Individuals who exhibit pathological use (see criteria in section 
1.1.2) of any kind of ethyl alcohol containing beverage are diagnosed as having alcohol 
use disorder.  
Caffeine (1,3,7-trimethylpurine-2,6-dione) is often consumed via coffee, tea, soda, 
and energy drinks. Due to the lack of clinical significance and the prevalence of caffeine 
use disorder, there is no diagnostic criteria for caffeine use disorder. However, there are 
diagnostic criteria for caffeine intoxication and withdrawal due to the sufficient prevalence 
and clinical significance of each (American Psychiatric Association, 2013).  
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Cannabis refers to all substances containing parts of cannabis plants (e.g., 
Cannabis sativa and Cannabis indica) as well as their corresponding synthetic derivatives. 
Cannabis plant products such as leaves, stems, flowers and seeds contain over 480 
component (DEA, 2017). Delta-9-tetrahydrocannabinol (delta-9-THC) is a well-known 
psychoactive component of cannabis.  The Food and Drug Administration (FDA) has 
approved pharmacotherapeutics containing synthetic delta-9-THC (a psychoactive 
component of cannabis) or its derivative; however,  the pharmacotherapeutical use of the 
whole plant is not approved. FDA-approved pharmacotherapeutics containing delta-9-
THC are controlled as either Schedule II or Schedule III depending on their relative abuse 
potential (Whiting et al., 2015). DSM-V provides diagnostic criteria for cannabis use 
disorder, intoxication and withdrawal.  
The DSM-V also includes hallucinogens, which include many distinct chemical 
structures and different underlying neurochemical mechanisms of action. The definition of 
hallucinogen is based on their common effects, which are the ability to cause alterations 
in perception of the surrounding environment and of inner psychological processes (e.g., 
consciousness, cognition, and mood) (Martinotti et al., 2018). Interestingly, many research 
articles classify cannabis and its psychoactive component, delta-9-THC, as hallucinogens. 
The DSM-V classifies cannabis and hallucinogens separately due to their distinct 
psychological and behavioral effects (American Psychiatric Association, 2013; Garcia-
Romeu et al., 2016). The DSM-V further provides separate diagnostic criteria for two 
different subclasses of hallucinogens (phencyclidines and other hallucinogens) based on 
their distinct physiological and behavioral consequences. The ‘phencyclidines’ subclass 
include PCP and other aryl-cyclohexyl amines such as ketamine, which commonly result 
in nystagmus, analgesia and remarkable hypertension (American Psychiatric Association, 
2013). Other hallucinogens contain several chemical subclasses including 
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phenylalkylamines (e.g., mescaline, 3,4-methylenedioxy-methamphetamine (MDMA)), 
indoleamines (e.g., psilocybin, dimethyltryptamine (DMT)), and ergolines (e.g., LSD, 
morning glory seeds), all of which exhibit common hallucinations without specific 
physiological consequences observed in phencyclidines use disorders.  
The inhalants class includes invisible and volatile hydrocarbon-based inhalant 
substances such as toluene, xylene, propane, butane, which are often contained in glue, 
fuels, spray paints, paint thinner, air conditioning refrigerant, and plastic cement (American 
Psychiatric Association, 2013). Although substances in different classes can be 
administered via inhalation, the inhalants class specifically includes substances taken only 
by inhalation.  
Opioids refer to products of opioid-containing plants or pharmacologically similar 
synthetic chemicals including components extracted from the plant (also called as opiates; 
morphine, codeine), semi-synthetic opioids (derived from opiates; heroin, oxycodone, 
hydrocodone), and synthetic opioids (fully synthesized compounds exhibiting considerably 
similar effects with opiates; propoxyphene, fentanyl, methadone). This class of substances 
are often found in prescribed pain medications (see also section 1.6).  
The seventh substance class in the DSM-V is the “sedatives, hypnotics, or 
anxiolytics” including all prescription sleeping and most antianxiety medications. Since 
there is no significant misuse reported, the DSM-V notes that nonbenzodiazepine 
antianxiety medications are not included in current substance class. However, 
benzodiazepine or benzodiazepine-like substances (e.g., zolpidem, zaleplon), 
carbamates (e.g., meprobamate, glutethimide), barbiturates (e.g., secobarbital), and 
barbiturate-like substances (e.g., glutethimide, methaqualone) are in the sedative, 
hypnotics, or anxiolytics class.  
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The eighth class is stimulants. The stimulant class consists of legal and illegal 
substances including cocaine, amphetamine, amphetamine-type substance (e.g., METH, 
dextroamphetamine, and other synthetic compounds containing a substituted-
phenylethylamine structure). Stimulants class also include methylphenidate, which is not 
structurally similar but has stimulant like effects. Also, there are unspecified stimulants, 
which refer substances exhibiting stimulant-like effect, but have no structural similarity with 
cocaine, amphetamine, or methylphenidate. The plant-derived substance, khât is the 
example of unspecified stimulant. Additional information on cocaine and METH is provided 
in section 1.4 and section 1.5, respectively.  
The ninth class in the DSM-V is tobacco. Tobacco is a common name of the plant 
Nicotiana, which includes more than 70 species worldwide. Among them, Nicotiana 
tabacum and Nicotiana rustica are the major species grown for commercial tobacco 
products around the world (Charlton, 2004). Tobacco contains nicotine (3-(1-methyl-2-
pyrrolidinyl)pyridine), which is considered to be the main psychoactive substance leading 
to tobacco use disorders. Nicotine in tobacco is often consumed as cigarettes or cigars.  
The last class is designated as ”other or unknown substances” and encompasses 
substances that are not able to be classified within the other classes above, but that 
produce clinical impairment or distress in individuals. This class includes anabolic steroids, 
cortisol, nitrous oxide, nitrates, nonsteroidal anti-inflammatory medications, and kava 
(from a South Pacific pepper plant).  
The classification introduced by the DSM-V is based on similarity of physical and 
psychological effects induced by substances, which allows appropriate diagnosis for 
substance use disorders. The following section includes diagnostic criteria for substance 
use disorder introduced by the DSM-V. Depending on the class of substance consumed 
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by the individual, a specific substance use disorder is diagnosed (e.g., METH use disorder, 
cocaine use disorder). This dissertation is focused on METH and cocaine use disorders 
and on opioids use disorders. The DSM-V provides substance-specific diagnostic criteria. 
However, the essential feature of all of the substance use disorders is defined as 
continuous use of the substance despite negative consequences. Thus, DSM-V provides 
both general and substance-specific diagnostic criteria for substance use disorders for all 
substance classes. The general diagnostic criteria for substance use disorder are 
commonly applicable to all substances, with the exception of the caffeine class. The 
general diagnostic criteria for substance use disorder is introduced in the section   
 
1.1.2 Diagnostic Criteria for Substance Use Disorders  
Since this dissertation is focused discovering pharmacotherapeutics for substance 
use disorders including METH, cocaine, and opioids use disorders, the general diagnostic 
criteria for substance use disorder is introduced in this section.  
In the DSM-V, there are a total of 11 diagnostic criteria, consisting of four different 
groups of pathological patterns of behaviors related to substance use. The four groups 
include impaired control (Criteria 1-4), social impairment (Criteria 5-7), risky use (Criteria 
8-9), and pharmacological criteria (Criteria 10-11). The first group consists of behaviors 
that are evidence of impaired control over substance use and include four diagnostic 
criteria. Criteria 1 is that the individual obtains the substance over a longer period or in 
larger amounts than was initially intended, Criteria 2 is that the individual experiences 
multiple failures to discontinue or decrease use of the substance. Criteria 3 is that the 
individual spends excessive amounts of time on obtaining the substance, consuming the 
substance, or recovering from effects of the substance. Criteria 4 is that the individual 
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experiences cravings, which is manifest as experiencing a robust desire or urge for the 
substance and experiencing difficulty to think about anything else other than the substance.  
The second group of behaviors demonstrate social impairment, which includes 
three diagnostic criteria 5-7. Criteria 5 is that the individual continues using the substance 
despite having difficulty fulfilling major obligations at school, work, or home, Criteria 6 is 
that the individual obtains the substance even when experiencing problems in social or 
interpersonal activities caused or exacerbated by the substance effects. Criteria 7 is that 
the individual shows reduced time or gives up the opportunity for important social and 
recreational activities due to the substance use.  
The third group of behaviors reveal the risky use of the substance and is 
associated with Diagnostic Criteria 8-9. Criteria 8 is that the individual continues substance 
use despite resulting in physically hazardous situations. For example, the individual drinks 
alcohol while driving a car or operating machinery, Criteria 9 is that the individual exhibits 
recurrent substance use in spite of knowledge that obtaining the substance has caused 
or exacerbated their physical or psychological problems. 
The last group of behaviors are the pharmacological indicators (tolerance and 
withdrawal).  Criteria 10 is that the individual experiences tolerance, indicated by either 
obtaining increased amount of the substance to accomplish the desired effects or 
experiences decreased effect when the same amount of substance is consumed, Criteria 
11 is withdrawal that results from reduced substance concentration in blood or tissue in 
the individual previously maintaining heavy use due to reduced or stopped substance use. 
Withdrawal manifests when the substance is used to attenuate or avoid withdrawal, or 
when reduced substance use results in specific withdrawal symptoms elicited. Withdrawal 
is differentially characterized depending on the substance consumed. For example, opioid 
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withdrawal is characterized by dysphoric mood, nausea or vomiting, muscle aches, 
lacrimation or rhinorrhea, pupillary dilation, piloerection or sweating, diarrhea, yawning, 
fever, or insomnia. If the individual exhibits three or more of these withdrawal symptoms 
after several weeks of cessation, opioid withdrawal is the diagnosis. Another example is 
cocaine, METH, or other stimulant withdrawal, which is characterized by dysphoric mood 
and two or more of symptoms including fatigue, vivid and unpleasant dreams, insomnia 
or hypersomnia, increased appetite, psychomotor retardation or agitation within a few 
hours to several days after the prolonged cessation of stimulant use. Substance specific 
withdrawal symptoms are included in the DSM-V.  
In summary, an individual is diagnosed as having a mild, moderate, or severe 
substance use disorder if they exhibit 2-3, 4-5, or more than 6 of the diagnostic criteria, 
respectively, within a year. Based on these diagnostic criteria obtained in human clinic, 
there are multiple animal behavioral procedures designed with the aim of modeling the 
above criteria to support research including drug discovery (Lynch et al., 2010; Blanco-
Gandia et al., 2015; Kenny et al., 2018). Thus, this dissertation also employed several of 
these animal behavioral procedures such as self-administration and reinstatement to 
evaluate the potential for the compounds to be evaluated as a pharmacotherapeutic for 
substance use disorder. 
 
1.2 Epidemiology of Substance Use Disorders 
According to the Substance Abuse and Mental Health Services Administration 
(SAMHSA) in 2016 in the U.S., the number of individuals using illegal substances and 
misusing prescription substances was 28.6 million, which was 10.6% of the population 
aged 12 or older (SAMHSA, 2017a). As such, in 2016, one American out of ten (aged 12 
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or older) used illicit substances or misused prescription substances, which was higher 
than in 2002 (8.3% of the population aged 12 or older) or in 2013 (9.4% of the population 
aged 12 or older). These reports indicate continued escalation of misuse substances 
(SAMHSA, 2014a).  
Furthermore, multiple studies also report increased numbers of substance-related 
emergency department (ED) visits and substance overdose deaths. According to the 
Centers for Disease Control and Prevention, the number of nationwide ED visits involving 
illegal and prescription substance misuse increased from 3.3 million to 5.1 million between 
2006 and 2011 (Crane, 2013). Rates of substance-related ED visits showed a pattern of 
increases (1,838 in 2006 to 2,519 in 2013 per 100,000 population aged 15-year and older) 
(Weiss et al., 2016). ED visits specifically associated with substance related disorder 
diagnoses increased by 73.7% in 2014 compared to 2006 (Moore et al., 2017).  
According to the Centers for Disease Control and Prevention (CDC), the number 
of substance overdose-induced deaths increased by 86.1% from 2006 to 2016 (CDC, 
2017). Specifically, the top two classes of substances, opioids and stimulants, contributed 
to the death of Americans of more than 40,000 per year since 2011 (Office of National 
Drug Control Policy (ONDCP), 2016). Also, between 2000 and 2014, every 15 min one 
American died due to use of illicit opioids or misuse of prescribed opioids (Worley, 2017). 
Since 2009, a greater number of individuals died due to the misuse of substances than 
motor cycle accidents (DEA, 2017).   
Among the 24.6 million Americans (aged 12 or older) reporting past-month illicit 
substance use in 2013, 22.6% were 18 to 20 years of age. With respect to the 21 to 25 
years of age individuals, they represent 20.9% of the total population of illicit substance 
users (NIDA, 2015). Taken together, in 2013, individuals between 18 and 25 years of age, 
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represented 43.5% of population of illicit substance users. When comparing to the total 
population, one out of four (23.2%) individuals 18 to 25 years of age in the U.S. in 2013 
reported past-month illicit substance use, which was increased compared to 2006 in which 
19.8% of American 18 to 25 years of age reported past-month illicit substance use 
(SAMHSA, 2017a; b). Additionally, 7% of young adults aged 18 to 25 were diagnosed for 
illicit substance use disorders in 2016 (SAMHSA, 2017b). The 26-year or older age group 
showed lesser increases (7.3% of total population aged 26 years or older in the U.S.) in 
2016 compared to 2013 (8.9% of total population aged 26 years or older in the U.S.). 
Furthermore, according to the NIDA, there were 2.8 million new illicit substance users in 
2013, and 7,800 individuals initiated illicit substance uses per day (NIDA, 2015). More 
than half (54.1%) of new substance users were teenagers (10 to 18 years old) (NIDA, 
2015). 
Moreover, substance use disorders are responsible for high social costs. 
Estimated annual costs of overall substance use disorders have been as much as $740 
billion including costs related to health care, lost work productivity, and crime (ONDCP, 
2016). Among that , the estimated social costs of “illicit substance use” was total $193 
billion (ONDCP, 2016). Notably, social costs ($78.5 billion) associated with prescription 
opioid misuse has increased by more than $20 billion every year between 1997 and 2013. 
Along with recent dramatic increases in opioid use disorder,  social costs associated 
specifically with heroin use disorder  increased also from $21.9 billion in 1996 to $51.2 
billion in 2015 (Jiang et al., 2017; Knipper et al., 2017). 
There are 162 to 324 million people reporting substance use including illicit 
substance and misuse of prescribed medications worldwide in 2013. Among them, 10% 
(16 to 39 million) are diagnosed as having substance use disorders (United Nations Office 
on Drugs and Crime (UNODC), 2014). In addition, relapse rate of substance use disorders 
16 
 
is 40-60% (McLellan et al., 2000). These support that substance use disorder is a long-
term disorder in a considerable number of individuals. For example, METH use disorder 
is characterized by high relapse rates, but there are no FDA-approved medications 
available to treat them. For METH users, 87% experience relapse within 5 years (Wang 
et al., 2012; Brecht and Herbeck, 2014).  
Taken together, the number of substance users is continuing to grow in the U.S., 
especially among the young adults. Furthermore, a 40-60% rate of relapse has been 
reported in individuals with  substance use disorders (McLellan et al., 2000).  Thus, this 
dissertation focuses on pharmacotherapeutic discovery for opioids use disorder, which is 
the current second most common substances in the United States after cannabis, and 
cocaine and METH use disorders, which have no FDA accepted pharmacological 
therapeutics to treat cocaine and METH use disorders currently (SAMHSA, 2017a).        
 
1.3 Neurochemical and Behavioral Pharmacology Underlying Substance Use 
Disorders  
 As described in section 1.1.1, there are various classes of substances where 
following repeated administration has the potential to result in substance use disorders. In 
the process of developing a substance use disorder, there are shared underlying 
mechanisms for many classes of substances. In this section, the progress of development 
of substance use disorder is introduced as three separated stages, including: (1) voluntary 
phase of substance intake, (2) transition phase from voluntary to compulsive substance 
seeking and taking, and (3) the craving and relapse phase that occurs after abstinence. 
The relevant neurochemical and behavioral pharmacology are discussed. 
17 
 
1.3.1 Voluntary Phase: Substance Intake 
1.3.1.1 Substance-Induced Reward 
Initially, substance intake results in rewarding effects, like other natural rewards 
such as food, via activating specific neuronal circuits in brain. This is known as the brain 
reward circuitry (Koob and Volkow, 2016; Volkow et al., 2016). From the behavioral 
neuropharmacology perspective, the term reward is defined as a stimuli that elicits 
approach responses (White, 1989). Multiple neuropharmacological studies reveal that the 
midbrain dopamine (DA) system is highly involved in substance-induced rewarding effects 
(Wise and Rompre, 1989; Leone et al., 1991; Di Chiara, 2002; Wise, 2008). The 
mesocorticolimbic DA system includes DA projections from the ventral tegmental area 
(VTA) to the nucleus accumbens (NA), frontal cortex, and amygdala. Specifically, 
substances increase  extracellular DA in the NA, which is one of the major mechanisms 
mediating substance-induced rewarding effects (Koob, 1992; Di Chiara, 2002; Wise, 2008; 
Volkow et al., 2016).  
Human brain imaging studies using positron emission tomography (PET) scans 
found that substances induce DA level increase in the NA.  The amount of [11C]raclopride 
(an antagonist of DA receptors) bound to DA receptors in the NA was detected by PET 
prior to and after amphetamine or alcohol administration. [11C]Raclopride binding in the 
NA was decreased after amphetamine (0.3 mg/kg, i.v.; a stimulant) or alcohol (1 mL/kg in 
orange juice, oral) administration relative to baseline (prior to substance administration), 
indicating substance induced increase of DA extracellular concentrations in the NA  
(Drevets et al., 2001; Boileau et al., 2003). Importantly, this increase in DA transmission 
in the NA as a response to amphetamine (0.3 mg/kg, i.v.) is highly correlated with 
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responses for “hedonic feeling” and “substance wanting” in humans (Drevets et al., 2001; 
Leyton et al., 2002).  
Most of substances, that engender substance use disorders in human, increase 
extracellular DA in studies using experimental animals (Balster et al., 1976; Ettenberg et 
al., 1982; Kenny et al., 2018). Thus, various animal behavioral models have been used to 
understand underlying the mechanisms and pathophysiology of substance use disorders. 
One of the most popular animal behavioral models to study substance use disorders is 
self-administration (Panlilio and Goldberg, 2007; Lynch et al., 2010). The self-
administration procedure is conducted in an enclosed apparatus called an operant 
conditioning chamber or operant chamber. To conduct self-administration, experimental 
animals are placed in the chamber containing a lever(s) or a nose-poke hole(s). The 
voluntary behavior of the animal in the chamber, such as pressing the lever, results in 
delivery of reinforcers, typically food pellets, sucrose solution, or  intravenous (i.v.) infusion 
of substances. The underlying principal of the self-administration method is that if a 
voluntary behavior results in delivery of reward (a positive reinforcer), then this behavior 
producing reinforcement is repeated with high probability (Panlilio and Goldberg, 2007). 
Self-administration is considered as the gold standard method in research on substance 
use disorders (Mews and Calipari, 2017). Often, food pellets or infusion of substance are 
used as a positive reinforcer during the initial training for substance self-administration. 
When food pellets are used for initial training, then the food pellets are replaced with i.v. 
infusion of substances in the later phase of training. Experimental animals including 
rodents and nonhuman primates acquire and maintain operant behavior to self-administer 
most substances including METH, cocaine, and opioids (Flagel et al., 2010; Kenny et al., 
2018). As such, this dissertation includes self-administration studies. 
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Nonhuman primates, male Macaca Fasciularis monkeys, acquire cocaine (0.5 
mg/kg/infusion) self-administration behavior and exhibit increased extracellular DA in the 
NA during the self-administration as determined using microdialysis (Bradberry et al., 
2000). Likewise, rodents also readily acquire self-administration behavior, which have 
shown by numerous studies, with substances such as METH, cocaine, and opioids (Flagel 
et al., 2010; Kenny et al., 2018). Also,  a series of in vivo microdialysis studies in rats 
revealed that DA in the NA was increased not only during self-administration, but also 
following acute injections of many classes of substances including stimulants (e.g., 
cocaine at 5.0 mg/kg, subcutaneous (s.c.) and amphetamine at 0.25-3.0 mg/kg, s.c.), 
opioids (e.g., morphine at 0.5-10.0 mg/kg, s.c. and methadone at 1.0-5.0 mg/kg, 
intraperitoneal (i.p.)), nicotine (0.6 mg/kg, s.c.), and alcohol (0.5-2.5 mg/kg, i.p.) (Imperato 
and Di Chiara, 1986; Imperato et al., 1986; Di Chiara and Imperato, 1988b; a; Di Chiara, 
1991; Solinas et al., 2002).  
Conversely, when selective lesion of the DA neurons in the NA occurred in drug 
naïve rats by infusing 6-hydoxydopamie (6-OHDA) bilaterally into the NA prior to self-
administration operant training, the acquisition of self-administration of amphetamine 
(0.125 mg/kg/infusion, i.v.) was impaired, indicating that DA in the NA serves a crucial role 
in acquisition of substance self-administration behavior (Lyness et al., 1979). When the 
same lesion occurred in rats trained for amphetamine (0.125 mg/kg/infusion, i.v.) or 
cocaine (0.75 mg/kg/infusion, i.v.) self-administration, responses of rats for amphetamine 
or cocaine infusions were reduced to 5% or 30% of their previous baseline, respectively; 
thus, indicating a considerable role of DA increase in the NA for maintaining substance 
self-administration behavior (Lyness et al., 1979; Pettit et al., 1984). Additionally, DA 
transporter (DAT) knockout (KO) mice showed a decrease in cocaine self-administration, 
but not in mice with serotonin transporter (SERT) KO, supporting the important role of DA 
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not only in acquisition, but also in maintaining self-administration, relative to serotonergic 
transmission (Thomsen et al., 2009).  
Conditioned place preference (CPP) is a behavioral procedure often used to study 
the underlying mechanisms of substance use disorder, which has been used to measure 
rewarding effects of substances (Bardo and Bevins, 2000; Lynch et al., 2010). CPP is 
conducted in a chamber consisting of two outer compartments, having distinct visual and 
tactile cues, and a center compartment. Prior to starting the CPP conditioning, 
experimental animals are placed in the center compartment and allowed entree to both 
compartments freely and inherent preference of the animals for each compartment are 
determined. Based on the inherent preference, to perform the unbiased design study, the 
environmental cues are manipulated to eliminate inherent preference of animals, but 
sustaining distinguishable differences between two outer compartments (Cunningham et 
al., 1999; Kõks, 2015). Although pre-existing preferences for one compartment over 
another would have a significant role in determining conditioned place preference, a bias 
may arise during the repeated access to environment instead of emerging on the initial 
test (Bardo and Bevins, 2000; Cunningham et al., 2003). Also, genetic differences among 
inbred mouse strains may affect to innate preferences to one environment (Bardo and 
Bevins, 2000). The biased design also is used often in research, which does not modify 
environmental cues. In the biased design, when the study assumes that a substance 
induces positive reinforcement, then the preferred environment by each animal is paired 
with a vehicle, and the nonpreferred environment is paired with substances. When the 
substance is assumed to produce aversive effects, then the preferred environment is 
paired with the substance to minimize the effect of intrinsic motivational values of 
environment on the study (Napier et al., 2013; Kõks, 2015). Following the preconditioning 
procedures, on the first conditioning day of CPP, substance is administered to 
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experimental animals; then, and then immediately, the animal is placed in one of the two 
outer compartments to form a paring between the substance administration and the 
respective compartment. On the following conditioning day, the animal receives a vehicle 
administration, and then immediately placed in the other outer compartment. By repeating 
these conditioning sessions over 2-3 days, the paring of substance and vehicle with each 
specific compartment is generated, which is called the conditioning process. Once, each 
outer compartment has been paired with either a substance or vehicle, then a choice test 
is conducted. On the choice test, the animal is placed in the center compartment and 
allowed to freely access both outer compartments, and the time spent in each 
compartment is recorded. The time spent in each compartment is compared to determine 
the preference for one compartment over the other. The observed preference on the 
choice test for one compartment is considered as evidence for a rewarding effect induced 
by the substance or vehicle that was paired with the preferred compartment (Bardo and 
Bevins, 2000; Lynch et al., 2010).   
Lesioned DA neurons 6-OHDA in the NA bilaterally pretreatment of haloperidol 
(0.2 mg/kg, i.p.; an antagonist of DA receptor) attenuated heroin (2.0 mg.kg, i.p.)-induced 
place preference in CPP by 40% and 30%, respectively, relative to control rats (Spyraki 
et al., 1983). Also, bilateral infusion of 6-OHDA into the NA prior to conditioning decreased 
amphetamine (0.75 mg/kg, i.p.)-induced CPP by 70% compared to the control group of 
rats (Sellings and Clarke, 2003). In contrast, systemic administration of 6-OHDA (100 
mg/kg, i.p.) in neonatal rats depleted central and peripheral norepinephrine (NE) without 
altering DA content in striatum, which did not alter heroin-induced CPP. This indicates the 
crucial role of DA transmission relative to NE for heroin-induced reward (Spyraki et al., 
1983). These observations indicate the important role of substance-induced extracellular 
DA increase in the NA of substance-induced rewarding effects.   
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Altogether, multiple experimental observations demonstrated that substance 
administration increased extracellular DA in the NA brain reward circuitry. When the DA 
system is disturbed by neuronal lesion in the NA or DAT was KO, acquisition and 
maintenance of self-administration, and substance induced CPP were decreased. Thus, 
the substance induced extracellular DA increase in the NA provides reinforcing and 
rewarding effects of substances, and which serves a critical role in acquisition and 
maintenance of substance use disorders. On the other hand, although DA systems in the 
midbrain area serve critical roles in substance-induced rewarding effects, multiple 
neuronal systems and various brain areas also are involved to substance-induced 
rewarding effects. Involvements of acetylcholine, gamma-aminobutyric acid (GABA), 
glutamate, ghrelin, orexin, norepinephrine, and serotonin (5-HT) on substance-induced 
rewarding effects have been reported in addition to the DA system (Bardo, 1998; Marquez 
et al., 2017; Zallar et al., 2017; Farzinpour et al., 2019; Foster and Weinshenker, 2019). 
Thus, DA is not the only neuronal system involved in substance-induced rewards and 
development of substance use disorders. However, importantly, legion of DA neuron in 
the NA significantly reduced substance self-administration behaviors and preference for 
substance-induced CPP, further suggesting the crucial role of DA on substance-induced 
reinforcing and rewarding effects, respectively. Hence, this dissertation focus on the DA 
system in substance use disorders (see section 1.3). 
 
1.3.1.2 The Law of Effects and Learning Underlying Substance Use Disorders 
From the perspective of behavioral psychology, behaviors resulting in a pleasant 
consequence (i.e., reward) are more likely be repeated, whereas behaviors resulting in an 
unpleasant consequence are less likely be repeated, which is known as the law of effect 
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(Thorndike, 1898). Learning refers to an association forming between stimuli and 
responses, which leads to a relatively long-lasting change in individuals’ behaviors. 
Additionally, B.F. Skinner, a behavioral researcher, employed several terms and specified 
types of stimuli depending on their effects on responses. B.F. Skinner defined reinforcer 
and reinforcement as stimuli that increases the tendency of a specific behavior and as a 
process resulting in a pleasant consequence following a voluntary behavior, respectively. 
When reinforcement occurred by adding/presenting a desired stimulus (i.e. food, 
substances) and removing undesired stimulus (i.e. anxiety, withdrawal), they are defined 
as a positive and a negative reinforcement, respectively (Holland and Skinner, 1961). A 
punishment is defined by B.F. Skinner as a process resulting in an unpleasant 
consequence following a voluntary behavior, which decrease tendency of behavior  
(Holland and Skinner, 1961). Also, the addition of unpleasant consequences and removing 
desired consequences are defined as positive and negative punishment, respectively 
(Holland and Skinner, 1961). 
Ultimately, during the process learning, the reinforcement strengthens and 
punishment weakens the association between a stimulus (i.e., consequence, experience, 
reward, reinforcer) and a response (i.e., a specific behavior resulting in the pleasant or 
unpleasant consequence) (Landauer, 1969; White, 1989).    
During the substance use disorder development, as well as relapse, both positive 
and negative reinforcement are involved. Initially, as a result of substance intake (a 
behavior), the individual experiences substance-induced rewarding effects (a pleasant 
consequence), which is how the positive reinforcement initiates the acquisition of 
substance use behaviors. After repeated substance intake, substance abstinence results 
in negative states, such as anxiety or withdrawal, which promotes maintenance and 
relapse of the substance use behaviors via negative reinforcement process. Together, 
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substance-induced reinforcement augments continued substance intake (Meyer et al., 
2016).  
Substance-induced rewarding effects repeatedly occurred during repeated 
substance use, which strengthens the association between stimuli (substance or 
substance-related cues) and responses (approaching and taking the substance) through 
learning process. There are two forms of learning involved: Pavlovian (classical) 
conditioning and instrumental (operant) conditioning (Rescorla and Solomon, 1967; Smith 
and Aston-Jones, 2014). Pavlovian conditioning refers to a learning process that 
associates an unconditioned stimulus (US) and a conditioned stimulus (CS) by repeatedly 
presenting them together. Thereby, the response for US (unconditioned response; UR) 
becomes a response for the CS, then called a conditioned response (CR). For example, 
a bell (CS) rang when food (US) was served to a dog. Salivation (UR) of the dog is 
observed. After repeated presentation of the bell ringing (CS) with food (US), the bell 
ringing (CS) results in salivation (UR) of the dog. Then, the salivation following the bell 
ringing (CS) is called a CR. In the other word, after the Pavlovian conditioning the CS 
became a predictor of the US, thus the CS elicited CR.  
In contrast to the Pavlovian conditioning that results in an association between two 
stimuli (CS-US), instrumental conditioning (also called as operant conditioning) associates 
a voluntary behavior and the consequence of the behavior. Thus, instrumental 
conditioning requires a voluntary behavior to be conditioned, and the probability of the 
occurrence of the behavior is affected by the consequences of the behavior. Pavlovian 
conditioning measures reaction such as salivation, whereas operant conditioning 
measures voluntary behaviors of subjects. As an example, a rat presses a lever, if the 
behavior resulted in food delivery, then the rat tends to press the lever more often, which 
is an example of a positive reinforcement. Whereas, when lever pressing resulted in 
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elimination of existing electric foot-shock producing pain, then the rat tends to press the 
lever often, which is an example of a negative reinforcement.  
Regarding substance use disorders, Pavlovian conditioning initially strengthens 
associations between substances-induced rewarding effects (US) and substance-related 
cues (CS), and CS became a predictor of US. In parallel, through the instrumental 
conditioning (substance-induced rewarding effects following a volunteer behavior) then 
the substance-induced rewarding effects stimulate the occurrence of the reward-
approaching behaviors (i.e., substance seeking and intaking), which is a positive 
reinforcement. Later, the reward-approaching behaviors are stimulated also through 
punishment processes, such as anxiety and withdrawal, as instrumental conditioning. 
Additionally, Pavlovian conditioning is able to strengthen instrumental conditioning, which 
suggests that learned Pavlovian conditioning is transferred to the instrumental responses  
(Rescorla and Solomon, 1967; Lovibond, 1983; Cartoni et al., 2013). For instance, a rat 
experiences cue light illumination (CS) when food (US) is delivered. Thus, the rat learned 
cue light and food association through the Pavlovian condition. Then, the rat undergoes 
instrumental conditioning by lever pressing, resulting in food delivery without cue light 
illumination. Later, when the rat is exposed to a lever presented operant chamber with or 
without cue light illumination, then the rat showed higher response for the lever when the 
cue light is illuminated (Cartoni et al., 2013). The rat underwent no training to associate 
cue light and lever pressing, however, because the cue light illumination was paired 
previously with the food delivery in the initial Pavlovian conditioning. The cue light 
illumination was able to enhance the lever-pressing behavior through Pavlovian-to-
instrumental transfer (Rescorla and Solomon, 1967; Lovibond, 1983). This Pavlovian-
instrumental transfer contributes to the cue-induced rise on substance-seeking and taking 
behaviors, indicating the important role of Pavlovian and instrumental conditioning on 
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initiation and maintenance of substance use behaviors (Belin et al., 2009; Hogarth et al., 
2014).  
In experimental animals, an impaired Pavlovian conditioning has been observed 
when the DA system is disrupted by the genetic modification of tyrosine hydroxylase (TH) 
gene in KO mice.TH is the rate-limiting enzyme of DA synthesis. When TH KO mice 
showed decreased (5% of basal DA levels) DA levels in the NA, TH-KO mice were not 
able to learn the association between visual and sound cues and a 20-mg food pellet 
delivery (Darvas et al., 2014). The TH-KO mice exhibited no alteration of normal feeding 
or locomotor behaviors but exhibited specific impairment of Pavlovian conditioning 
between cues and reward delivery. However, interestingly, when L-3,4,-
dihydroxyphenylalanine (L-dopa; the product of TH enzyme activity in the DA synthesis 
pathway) was injected daily into the NA of TH-KO mice prior to the Pavlovian training 
session, the impaired Pavlovian conditioning in the TH-KO mice was improved, which 
restored DA content in the NA to ~30% of the levels in wild-type mice. The level was 
maintained for up to 9 h following L-dopa administration (Darvas et al., 2014). When L-
dopa injections were stopped, the conditioned response (CR; learned reward-approaching 
behavior) expression rate in the TH-KO mice after CS presentation was decreased 
gradually over days (Darvas et al., 2014). On the third day without L-dopa daily 
administration, the CR expression rate was lower compared to control mice, indicating 
that DA in the NA is required not only for acquisition, but also for maintenance of learned 
CR as a response to the CS through Pavlovian conditioning. In agreement with findings 
of Daravs et al (2014), heroin-induced CPP was decreased after bilateral microinfusion of 
6-OHDA into the NA compared to the baseline (prior to the lesion) (Spyraki et al., 1983). 
In addition, when the lesion occurred after CPP conditioning in the NA through 
microinfusion of 6-OHDA, the expression of CPP for amphetamine was decreased 
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(Sellings and Clarke, 2003). These findings suggest an important role of DA in the NA for 
acquisition and expression of association between CS and CR in Pavlovian conditioning. 
Thus, inhibition of substance-induced DA increase in the NA would prevent acquisition 
and expression of cue-induced substance-seeking and taking behaviors. As such, this 
dissertation is focused on the DA system to discover pharmacotherapeutics for substance 
use disorders.     
The instrumental incentive learning was impaired also by the lesion of DA neurons 
in the NA (Lyness et al., 1979). Bilateral microinfusion of 6-OHDA into the NA resulted in 
impaired acquisition and maintenance of amphetamine self-administration when the lesion 
occurred either before or after amphetamine self-administration training (Lyness et al., 
1979). In further investigation, desmethylimipramine (25 mg/kg, i.p.), an inhibitor of NE 
transporter (NET), was administered to rats prior to bilateral 6-OHDA infusion into NA to 
avoid NE content alteration following 6-OHDA (Roberts et al., 1975, 1980; Kelly and 
Iversen, 1976). The desmethylimipramine administered rats resulted in an average of 18% 
of NE decrease compared to the control rats, and 3 out of 8 total rats receiving 
desmethylimipramine showed no difference on NE content relative to control. However, 
80% of reduction in DA content compared to control groups (Roberts et al., 1980). Another 
group of rats receiving 6-OHDA without desmethylimipramine administration also 
exhibited 80% of reduction in DA content (Roberts et al., 1980). Bilateral infusion of 6-
OHDA into NA with or without desmethylimipramine reduced the response of cocaine by 
20% baseline when 6-OHDA occurred after cocaine self-administration (Roberts et al., 
1980). These findings indicate the important role of DA in the NA over NE on maintaining 
cocaine self-administration behavior. Altogether, substance-induced increase in DA 
transmission in the NA is critical for the acquisition and maintenance of substance use 
behaviors learned via instrumental conditioning process. 
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During the learning process, when rewards (US) are food or intracranial VTA 
stimulation, and rewarding events occur repeatedly as predicted (quantity, quality, and 
timing) with cue (CS) presentation, then the DA release in the NA results from reward 
receipt (US), and is shifted gradually to the cue presentation (CS) that predicts the reward 
receipt  (Schultz et al., 1997; Day et al., 2007; Schultz, 2007; Flagel et al., 2011). In 
microdialysis studies in rats, unpredicted consumption of palatable snack foods (Fonzies) 
resulted in a 150% increase in the DA levels in the NA compared to baseline (Bassareo 
and Di Chiara, 1999). Also, early in conditioning, results from fast-scan cyclic voltammetry 
studies showed that extracellular DA concentration in the NA were increased to 25-50 nM 
and 150-200 nM from baseline in response to food reward and intracranial electrical 
stimulation of the VTA, respectively (Day et al., 2007; Owesson-White et al., 2008). 
However, after repeated CS-US paired presentations, the US-induced increase in 
extracellular DA in the NA was reduced over time in both rats trained to press a lever to 
deliver food pellets and intracranial VTA stimulation (Day et al., 2007; Owesson-White et 
al., 2008). The In contrast, the  cue that was simultaneously paired with food reward or 
intracranial stimulation increased DA release over time in both rats trained to press a lever 
to deliver the food and intracranial VTA stimulation following at least 10 trials (Day et al., 
2007; Owesson-White et al., 2008). Together, the data indicate that DA release in the NA 
was shifted from reward receipt to cue presentation following repeated presentation of the 
cue and expected reward over time. 
When the reward is administration of substance, the presentation of CS alone is 
able to result in an increase in the DA in the NA following repeated presentations, similar 
to electrical stimulation or a natural reward. For instance, after cocaine self-administration 
training using 0.25 mg/infusion (i.v.) in rats for 6-9 days, the CS presentation alone that 
previously was associated with cocaine i.v. infusion resulted in an increased extracellular 
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DA in the NA during cocaine extinction (Weiss et al., 2000). In contrast, due to the 
pharmacological properties of substances, the increase of DA in the NA as a response of 
the substance is greater than the natural reward. Cocaine (5 mg/kg, s.c.), morphine (2.5 
mg/kg, s.c.), ethanol (1 g/kg, i.p.), nicotine (0.6 mg/kg, s.c.), and amphetamine (1 mg/kg, 
s.c.) administration results in increases of 250%, 80%, 100%, 100%, and 900%, 
respectively, of basal DA levels in the NA (Di Chiara and Imperato, 1988a). Substances, 
especially stimulants, maintain high levels of DA for a longer period than does natural 
reinforcers. This outcome results in higher motivation to use substances relative to natural 
reinforcers. On the other word, substance-induced DA levels increased in the NA results 
in strong association between cue (CS) and reward (US) in substance intake behavior, 
compared to the natural reward approaching behavior with Pavlovian conditioning (Di 
Chiara and Imperato, 1988a; Bassareo and Di Chiara, 1999). For example, the 
pharmacological properties of cocaine include inhibition of DA transporter (DAT) function. 
Thus, cocaine administration results in increased extracellular levels of DA in the NA. Also, 
cocaine (0.25-2.0 mg/kg, i.v.) inhibits GABA neurons by interacting with voltage-sensitive 
sodium channels in the VTA, which normally inhibits activity of VTA DA neurons. Thus, 
cocaine via inhibiting GABA neurons, also acts to disinhibit DA neurons in VTA 
(Steffensen et al., 2008).  
Amphetamine and METH inhibit DAT function and promote DA release from the 
cytosol into extracellular space by reversing the activity of DAT. Furthermore, METH (2 
and 5 mg/kg, i.p.) dose-dependently increases extracellular acetylcholine concentration in 
the VTA (250% and 400% of baseline VTA acetylcholine, respectively). Cholinergic 
neurons in the VTA innervate the VTA DA neurons which express muscarinic 
acetylcholine receptors (Dobbs and Mark, 2008). Thus, METH increases DA in the NA, 
not only via acting directly on DA neuron terminals in the NA, but also by acting indirectly 
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at VTA DA neurons. These actions of substances in the NA and VTA synergistically 
increase DA extracellular concentration in the NA (Steffensen et al., 2008). 
Similarly, opioids indirectly activate VTA DA neurons projecting to the NA by 
inhibiting the GABA input onto the DA neurons (Johnson and North, 1992; Melis et al., 
2000). Morphine administration (1-4 mg/kg, i.v.) dose-dependently increased NA DA 
neuron activity via this disinhibition pathway (Melis et al., 2000). Detailed mechanisms of 
action of cocaine, opioids, and METH are discussed further in sections 1.4, 1.5, and 1.6, 
respectively.  
Taken together, based on the law of effect, behaviors resulting in pleasant (i.e., 
reward, substance, food) or unpleasant (i.e., anxiety, pain) consequences are more likely 
or less likely repeated, respectively (Thorndike, 1898). Substances increase DA in the NA, 
resulting in rewarding effects. Also, substances, like opioids, reduce pain. Thereby, intake 
of substances resulting in rewarding effects and/or attenuating anxiety and pain is more 
likely repeated, which is named as positive and negative reinforcement. Additionally, 
withdrawal occurred during substance abstinence following chronic use (an unpleasant 
consequence) motivates continuous substance use. This is called relapse and that is an 
example of negative reinforcement.  
Learning refers to the association forming between a behavior and a consequence 
through repetition, which leads long-lasting changes on behaviors. The learning process 
includes Pavlovian conditioning and instrumental conditioning. Through Pavlovian 
conditioning, associations between CS-US is formed, which results in CR following US 
presentation. Through instrumental conditioning, association between a voluntary 
behavior and the consequence is formed. Also, association formed through Pavlovian 
conditioning is able to be transferred to instrumental conditioning. Importantly, inhibition 
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of substance-induced DA increase in the NA decreases acquisition and maintenance of 
Pavlovian conditioning and instrumental conditioning: thus, indicating the crucial role of 
DA in the NA during the learning process. Substance use, substances increases DA in the 
NA, which serves an important role in acquisition and maintenance of substance seeking 
and intake behaviors. Furthermore, during the learning process, substances interacts with 
neuronal systems directly and indirectly to produce greater increase in extracellular DA in 
the NA relative to natural rewards (i.e., food), which may explain why substances are able 
to form stronger association between cues and rewards and engender consumption in a 
compulsive manner (Volkow and Morales, 2015). Thus, this dissertation focuses on 
discovering the pharmacotherapeutic inhibiting effects of substances on the DA system to 
treat substance use disorders. Moreover, the greater increase in extracellular DA in the 
NA following substance intake relative to natural rewards results in long-lasting neuronal 
adaptation after chronic substance use, which is discussed in sections 1.3.2 and 1.3.3.    
Of note, a theory proposing obesity (>30 Body Mass Index) as a “food addiction” 
received increasing attention recently (Meule and Gearhardt, 2014; Lerma-Cabrera et al., 
2016; Volkow et al., 2017). Although food is considered as a natural reward rather than 
substances having abuse potential, obesity shares multiple pathological behaviors with 
substance use disorders such as loss of control over food intake, continued food 
consumption despite negative consequences, and inability to discontinue eating behavior 
despite desire to do so (Meule and Gearhardt, 2014; Lerma-Cabrera et al., 2016). Also, 
consumption of particular food types including fatty, sugary and salty food showed 
potential of resulting pathological behaviors in experimental animals and humans 
(Gearhardt et al., 2011; Narayanaswami et al., 2013; Lerma-Cabrera et al., 2016). 
However, there are a range variation regarding environmental, behavioral, physiological, 
and genetic factors that contribute to the obesity development in individuals. For instance, 
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sugar-sweetened drinks consumption is correlated with rising rates of obesity in humans 
and in experimental animals, but social reasons for the drink consumption may underlying 
the observation, especially in humans (Malik et al., 2006; Brownell et al., 2009; Wilson, 
2010). As such, feeding and eating disorders are a primary mental disorder in DSM-V, but 
obesity is not considered as a mental disorder. Obesity is highly associated with several 
mental disorders including binge-eating disorder and depressive disorders, thereby 
obesity is considered as a risk factor for development of mental disorders (i.e., depressive 
disorders) and side effects in DSM-V (Meule and Gearhardt, 2014).   
 
1.3.2 Transition Phase from Voluntary to Compulsive Substance Seeking and 
Taking 
Initial intake of substance results in rewarding effects, which increases tendency 
of the substance seeking and taking behaviors through positive and negative 
reinforcement, which is the voluntary substance use. During the repeated occurrence of 
substance-induced rewarding effects and substance seeking and taking behaviors, the 
association between reward and behaviors are strengthen. However, chronic substance 
use results in neuronal adaptations. The transition from voluntary substance use to 
compulsive substance seeking and taking behaviors are mediated by numerous neuronal 
adaptations including activation of DA in dorsal striatum causing habit formation (section 
1.3.2.1), depressed DA neuron activity in the NA (section 1.3.2.2), and decreased DA 
neuron activity in prefrontal cortex causing decreased executive function with increased 
impulsivity (section 1.3.2.3). 
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1.3.2.1 Habit Formation for Substance Seeking and Taking via Activating DA 
Neuron in the Dorsal Striatum 
Repeated substance seeking and taking behavior as a response to CS 
presentation also results in increased DA release in the dorsolateral striatum, a brain 
region mediating habit formation (Everitt and Robbins, 2005, 2013; Yager et al., 2015).  
After establishment and learning from the CS-US association by training, CS 
predicted cocaine (0.75 mg/kg/infusion, i.v.) infusion (Ito et al., 2000, 2002). The 
cumulated amount of lever pressing for cocaine infusion (reward, US) was increased 
linearly during the cocaine self-administration session (total 90 min). Escalation in 
response included the CS-only-presentation period and occurred during the initial 20 min 
of self-administration session, which measured cocaine seeking behavior in the absence 
of access to cocaine. Cocaine infusion increased extracellular DA concentrations in the 
NA and dorsal striatum as determined with in vivo microdialysis. However, the cue (CS) 
presentation in the absence of cocaine during the initial 20 min did not alter extracellular 
DA levels in the NA (Ito et al., 2000). In contrast, extracellular DA level increased in dorsal 
striatum during the CS presentation in the absence of cocaine, which resulted in cocaine 
seeking behavior as a response to the CS presentation during the initial 20 min of the 
session (Ito et al., 2002). In the dorsal striatum, extracellular DA increased to a maximum 
of 270% above baseline DA levels during cocaine seeking, and 310% above baseline DA 
levels during cocaine self-administration (Ito et al., 2002). These findings indicate that, 
after establishment of a learned relationship between CS presentation and substance 
seeking behavior, CS presentation elicits seeking behavior not through a reward induced 
by a DA increase in the NA, but through increased DA in the dorsal striatum associated 
with habit formation and automated response (Schiltz, 2006; Smith and Laiks, 2017).  
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Repeated stimulation of the NA reward circuitry via training of  intracranial self-
stimulation (ICSS) results in a gradually decreased DA neuron activation in the NA 
(Ljungberg et al., 1992; Redgrave et al., 1999). ICSS is an animal model that is often used 
in substance use disorder studies to mimic substance-induced reinforcing effects by 
providing short electric pulses in the target brain area related to the reinforcement as a 
result of an operant response of the experimental animal (Garcia Pardo et al., 2017; Kenny 
et al., 2018). ICSS uses similar operant training procedures as with self-administration, 
but the infusion of the substance as a result of operant response is replaced with electric 
pulses directly in the target brain region (Garcia Pardo et al., 2017; Kenny et al., 2018). In 
contrast to substance self-administration, which leads a numerous of neuronal 
modifications including substance-induced reinforcing effects, the ICSS allows the 
measurement of reinforcing effects without additional modifications on numerous neuronal 
cells.    
Impairment of dorsal striatal DA transmission by injection of 6-OHDA into dorsal 
striatum in rats resulted in impaired CS-response association in a conditional visual 
discrimination (CVD) task (Robbins et al., 1990). The CVD task required ‘procedural 
memory’, also called ‘stimulus-response habit’, to form an association between the visual 
stimulus (fast or slow flashing lights) and an arbitrary lever response (left or right) 
(Dudchenko and Sarter, 1991). In rats where the dorsal striatum was lesioned, the 
stimulus-response habit formation was impaired (Robbins et al., 1990). In another study, 
restoration of DA levels in the dorsal striatum of TH-KO mice  resulted in improvement of 
instrumental incentive learning, which requires stimulus-response habit formation (Darvas 
et al., 2014). D1 receptor agonist, SKF-38393, or D2 receptor agonist, LY 171555 infusion 
into dorsal striatum enhanced learning of habitual behaviors in a two-8-arm radial maze 
tasks (Packard and White, 1991). These observations indicate that after forming CS-US 
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association via repeated substance intake (US) in the presence of cues (CS), the CS 
presentation is able to increase extracellular DA in the dorsal striatum, which mediates 
stimulus-response (CS-CR) habit formation. Thus, after repeated substance intake in the 
presence of cues, cue presentations result in DA increase in the dorsal striatum, which 
elicit substance taking or seeking behavior (CR) as an automated response.  
Further support of the involvement of striatal DA in habit formation comes from studies 
in which monkeys self-administering cocaine (0.03 mg/kg/infusion) for 5 days (initial), 3.3 
months (chronic), or 1.5 years (long-term) showed different DA neuronal adaptations 
depending on duration of substance use (Letchworth et al., 2001). Density of DAT 
expression was decreased mainly in the NA at the initial stage. In contrast, at chronic and 
long-term stages, DAT density was increased in the NA and the dorsal striatum, 
respectively. Depending on the duration of cocaine exposure, the progressive change in 
DAT density from the NA to the dorsal striatum was observed, suggesting a differential 
DA increase and activation of DA neurons at each stage over time (Letchworth et al., 
2001). This different neuronal adaptation, depending on the duration of stimulant use, 
supports the role of DA in dorsal striatum as important in habit formation of substance 
seeking and taking behaviors in chronic to long-term stages of substance self-
administration. Together, chronic substance intake behavior results in DA release in the 
dorsal striatum, in contrast to the consequence of acute substance intake behavior. 
Striatal DA release mediates stimulus-response habit formation, and consequently, 
contributes to the transition from voluntary to compulsive substance seeking and taking. 
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1.3.2.2 Depression of DA Neuron Activity in the NA during Withdrawal Following 
Chronic Substance Use  
When the CS-US association is established, presentation of the CS becomes a 
predictor of the receipt of a reward (US). However, when the predicted reward is missed 
or omitted after the CS presentation, DA neuron activity in the NA is depressed below the 
basal firing rate at exactly the timing of the expected reward delivery (Hollerman and 
Schultz, 1998). In the latter study using male Macaca fascicularis monkeys, lever pressing 
for 0.15 mL apple juice served as the natural reward. The CS was a paired visual cue. 
When the expected reward was omitted, DA neuron firing was depressed. In another study, 
rats were trained to self-administer cocaine (0.25 mg/kg/infusion, i.v.), and 10-15 days 
were required to reach stable responding (Weiss et al., 1992). After unlimited-access to 
cocaine for 12 h, there was a 12 h-long cocaine withdrawal session. During cocaine 
withdrawal, DA release in the striatum and NA were reduced and a maximal decrease in 
the NA DA release was observed at 4-6 h of withdrawal (Weiss et al., 1992). In the rat  
model of cocaine self-administration, cocaine withdrawal also increased ICSS reward 
thresholds, indicating an ‘anhedonia’ status during withdrawal of cocaine (Kornetsky and 
Esposito, 1981). Rats previously exposed to either 5 or 10 mg/kg/day of amphetamine via 
implanted osmotic minipump for 6 days exhibited increased ICSS thresholds for reward 
during amphetamine withdrawal, indicating anhedonia during withdrawal of amphetamine 
(Paterson et al., 2000). The decrease in basal DA neuron activity in the NA and DA release 
in striatum reported using animal models may be related to the depressive symptoms and 
anxiety observed during the several days of cocaine withdrawal in humans with cocaine 
use disorders (Gawin and Kleber, 1986). Depression of DA neuronal activity in the NA has 
been observed in patients with major depression (Drevets et al., 1992; Mayberg et al., 
2000; Russo and Nestler, 2013).  Thus, omission of the predicted reward after CS 
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presentation decreases DA neuron activity in the NA, which consequently results in 
anhedonia, and which is a consequence of withdrawal following repeated substance 
exposure and can lead to compulsive substance seeking and taking behavior through 
negative reinforcement process associated with reduced DA neuronal activity in the NA 
(Der-Avakian and Markou, 2012; Volkow and Morales, 2015).  
 
1.3.2.3  Increased Impulsivity and Decreased Executive Function Result from 
Altered DA Receptor Expression Pattern Following Chronic Substance Use 
Altered DA release induced by repeated substance intake also alters DA receptor 
expression patterns in brain, which contributes to the transition from voluntary to 
compulsive substance use via increasing impulsivity and decreasing executive function. 
Increases in extracellular DA concentrations, either directly induced by substance 
administration or by stimulus-response association-related processes, interacts with DA 
receptors to produce downstream signaling ultimately ending in the experience of reward. 
DA receptors are G-protein coupled receptors (GPCRs). There are two types of receptors 
depending on their Gα-protein binding preference, including D1-like receptors (D1, and 
D5 receptors) and D2-like receptors (D2, D3, and D4 receptors) (Missale et al., 1998). D1-
like receptors couple with Gαs-protein activating adenylate cyclase and increase 
intracellular cyclic AMP (cAMP). D1 receptors (D1R) expressed in the NA are critical for 
rewarding effects and incentive learning processes, which are activated by substances 
and natural rewards (Di Chiara et al., 2004). D2-like receptors couple with Gαi-protein 
inhibiting adenylate cyclase and resulting in reduced cAMP intracellular levels (Missale et 
al., 1998; Neves et al., 2002). Activation of D1R in the NA was sufficient to induce 
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substance-induced rewarding effects by itself, but activation of  only D2Rs was not 
(Volkow and Morales, 2015). 
The peak of substance-induced rewarding effects have been associated with both 
D1R and D2R activation (Welter et al., 2007; Steinberg et al., 2014). Since D2R exhibits 
higher affinity for DA than D1R, higher DA levels are required to activate both receptor 
subtypes. Cocaine (8 mg/kg, i.p.) rapidly increased DA levels in  NA and activated both 
D1R- and D2Rs in the NA in mice (Luo et al., 2011). D1R activation by DA resulted in 
increased calcium ion entry into the D1R-expressing neurons. In contrast, D2R activation 
decreased calcium ion entry into the D2R-expressing neurons. The cocaine-induced 
increase in DA reached a peak within 10 min, and then decreased gradually for following 
30 min. During the first 10 min, the increase in calcium ion concentration in D1R-
expressing neurons was rapid, followed by a lower slope in the change in DA 
concentration. In contrast, D2R-expressing neuron activity was consistent during the 30 
min after cocaine administration (Luo et al., 2011). These findings indicate that both D1R 
and D2R were stimulated during the peak DA concentration after cocaine, and then later 
D2R predominantly was activated when the DA concentration was decreasing after the 
peak response; thus, indicating the important role of D2R in decreasing the cocaine-
induced extracellular DA level increase.  
Additionally, in human subjects, brain imaging studies show a fast increase of 
substance-induced DA concentration in the striatum (NA and dorsal striatum) within the 
first 10 min, which correlated with verbal responses of subjects (e.g., I feel “high”;  Volkow 
et al., 2008). Although the duration of the substance-induced increase in extracellular DA 
levels  was over 60 min, only the increase during the early time period was correlated with 
responses of “high” (Fowler et al., 2008; Bello et al., 2011; Volkow and Morales, 2015). In 
agreement with studies in humans,  D1R antagonists (SCH23390 and SCH39166), but 
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not D2R antagonists (raclopride, eticlopride, and spiperone), selectively decreased 
responding for cocaine (0.25 mg/kg/infusion, i.v.) in self-administering rats, without altering 
responding for food pellets (Caine and Koob, 1994). Together, these findings using 
experimental animals and human subjects indicate that D1Rs, activated by the substance-
induced rapid initial increase in extracellular DA in the NA, mediates the reinforcing effects 
of substances including cocaine. In contrast, high affinity D2Rs mediate inhibition of DA 
release, and D2Rs are activated longer than D1R, leading to a reduction over time in 
substance-induced DA release in the NA.  
Furthermore, evidence that D2Rs are involved in the acute response to substance 
comes from studies showing that D2R gene KO in mice exhibited increased sensitivity to 
cocaine-induced hyperlocomotion after acute cocaine (5 and 15 mg/kg, i.p.) compared to 
control mice (Bello et al., 2011). Also, increased dorsal striatal DA release evoked by an 
electronic stimulus pulse on the brain slice and increased DA synthesis were observed in 
the D2R KO mice compared to control mice (Bello et al., 2011).  
After chronic substance use, downregulation of D2Rs in the striatum (NA and 
dorsal striatum) and prefrontal cortex (PFC)  results in reduced inhibition of the substance-
induced increase of DA release in humans (Volkow et al., 2008; Volkow and Morales, 
2015) and monkeys (Nader et al., 2006). In rhesus monkeys (Macaca mulatta), D2Rs 
expression levels in the NA was negatively correlated with response for cocaine during 
self-administration (Nader et al., 2006). Human brain imaging studies using PET scans 
revealed that multiple substances including cocaine, METH, and opioids downregulate 
D2Rs in striatum and PFC  (Volkow et al., 1990, 1996; Wang et al., 1997; Volkow, Chang, 
Wang, Fowler, Ding, et al., 2001; Thanos et al., 2017). In healthy human subjects, who 
had never used substances before, low striatal D2R expression levels were correlated 
with a high “drug-liking” response after methylphenidate (a psychostimulant, 0.5 mg/kg, 
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i.v, infusion); (Volkow et al., 1999, 2002). Furthermore, in rats previously trained for alcohol 
self-administration, D2R overexpression in the NA through adenoviral vector  delivery of 
the D2R gene resulted in a 52% increase of D2R expression and in reduced alcohol intake 
by 64% of previous baseline, indicating critical involvement of D2R expression level on 
repeated substance use (Thanos et al., 2001). Also, in rodents, low D2R expression level 
in the NA was correlated with high impulsivity measured by a five choice serial reaction 
time test (5-CSRT) (Everitt et al., 2008). Rats with low D2R expression did not show fast 
acquisition of cocaine self-administration, but exhibited increased intake of cocaine 
compared to control rats (Everitt et al., 2008). Increased cocaine intake presumably would 
result in an escalation of substance-induced neuronal adaption and eventually compulsive 
substance intake.  
In the absence of any exposure to substance, intrinsically high impulsive rats 
expressed lower D2 expression level in NA compared to non-impulsive control rats based 
on 5-CSRT task prior to cocaine self-administration training. Although both high- and non-
impulsive rats determined by previous 5-CSRT task underwent cocaine self-administration 
training, high impulsive rats exhibited greater cocaine intake during cocaine self-
administration relative to non-impulsive controls (Dalley et al., 2007). Thus, these findings 
suggest that decreased D2R levels in the striatum mediate the high impulsivity, the 
subjective “substance-liking” response, and greater substance intake.  
Furthermore, in humans with substance use disorders, downregulated D2Rs 
support the transition from voluntary to impulsive substance seeking and intake. The 
connection between impulsivity and substance use is supported by observations on high 
impulsive rats. Substances are self-administered by high impulsive rats during the 
withdrawal period to avoid the effect of a negative emotional state and mood dysregulation, 
which induced by high impulsivity instead of staying substance abstinent for longer. These 
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findings are consistent with observations in humans that self-medication of substances is 
observed often in patients diagnosed with obsessive-compulsive disorders (Everitt et al., 
2008). Overall, these findings indicate that repeated substance intake decreases D2R 
expression levels in the striatum and PFC, and contributes to longer lasting substance-
induced extracellular DA increases. 
In an important study, the downregulated striatal D2R levels in humans with METH 
use disorders were correlated with decreased neuronal activity of orbitofrontal cortex 
(OFC) DA neurons, a subdivision of PFC (Volkow, Chang, Wang, Fowler, Ding, et al., 
2001; Black et al., 2010). Downregulated D2Rs in the striatum have been associated with 
decreased baseline activity of a DA contained neuron in PFC, and PFC is involved in 
executive function including decision making and inhibitory control (Black et al., 2010; 
Volkow, Wang, et al., 2011). Thus, impairment of PFC function increases the propensity 
for exhibiting impulsive and compulsive behaviors (Volkow, Chang, Wang, Fowler, Ding, 
et al., 2001). In animal models, decreased baseline activity of PFC has been correlated 
with impairment of inhibitory control over substance seeking (Jentsch and Taylor, 1999; 
Goldstein and Volkow, 2011). Rats continuously seeking and taking cocaine despite 
electronic foot-shock resulted from cocaine seeking, and taking behaviors exhibited lower 
PFC activity compared to foot-shock sensitive rats (Chen et al., 2013). The rescuing 
activity of the PFC using optogenetic method reduced the compulsive cocaine seeking 
behavior in foot-shock resistant rats (Chen et al., 2013). Furthermore, based on a 
computerized gambling task study, stimulant use disorders showed decreased decision-
making cognition (Rogers et al., 1999). The most favored option in the gambling task was 
chosen less frequently by individuals diagnosed with a stimulant use disorder compared 
to healthy control subjects, indicating that individuals with a stimulant use disorder have 
difficulties in approximating outcome probability or lack of concern for the consequences 
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of their actions (Rogers et al., 1999). Similarly, reduced concern for consequences of 
actions was found in patients with OFC damage (Rogers et al., 1999). Also, in Huntington’s 
disease patients, a brain imaging study and a behavioral task study revealed a positive 
correlation between low D2R expression levels in the striatum and impaired planning 
accuracy, an executive cognition function regulated by PFC (Lawrence et al., 1998; 
Pavese et al., 2003). Thus, the transition from voluntary to compulsive substance seeking 
and taking that often is observed in substance use disorders appears to involve decreased 
D2R expression in stratum because of repeated substance use. Downregulated D2R in 
the stratum increases impulsive substance seeking and taking, which results in an 
increase in amount of substances consumed, ultimately resulting in escalation of 
compensatory neuronal adaptations. Also, decreased D2R levels in the stratum results in 
consequent hypoactivity in PFC; which, ultimately results in impaired cognitive and 
executive function, and contributes to the transition to compulsive substance seeking and 
taking.  
 
1.3.3 Craving and Relapse Phase after Abstinence: Consequent Long-lasting 
Neuronal Adaptations Underlying Substance Craving 
In addition to positive and negative reinforcements for acquisition and maintaining 
substance use behaviors (section 1.3.1 and 1.3.2), the formed habit between stimulus-
response behaviors during repeated substance self-administration triggers craving during 
substance abstinence when the substance is no longer self-administered.  
Numerous human brain imaging studies support the idea that changes in brain blood 
oxygenation levels, rate of glucose metabolism, and DA receptor selective antagonists 
binding to receptors occur after substance-related cue presentation (Breiter et al., 1997; 
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Volkow et al., 1999, 2006; Risinger et al., 2005; Sinha et al., 2005). Importantly, 
substance-related cue presentation evokes changes on DA neuron activity in the dorsal 
striatum, which was correlated with self-reported craving scores in individuals with cocaine 
use disorders (Grant et al., 1996). However, in healthy volunteers not using substances, 
such changes were not observed following presentation of either substance-related or 
neutral cue presentation (Grant et al., 1996). Additionally, individuals with low craving 
scores during the cocaine-related cue presentation did not exhibit a change in the rate of 
glucose metabolite production in the dorsal striatum. In contrast, individuals with high 
craving scores showed remarkably changed glucose metabolism in the dorsal striatum 
(Grant et al., 1996). These observations are consistent with findings leading to the 
suggestion that DA in the dorsal striatum mediates stimulus-response habit formation. 
Thus, the presentation of substance-related cues triggers activation of dorsal striatum 
through an automatized habit response, which results in craving (Tiffany, 1990; Volkow et 
al., 2006).  
In animal models, chronic substance use results in impaired reversal learning 
(Schoenbaum et al., 2004; Stalnaker et al., 2006; Calu et al., 2007; Everitt and Robbins, 
2013). Rats repeatedly exposed to cocaine (30 mg/kg, i.p.) for 14 days learned an initial 
association between the cue and reward during the acquisition period. However, these 
rats failed to adjust their responses based on the reversed outcome during the reversal 
period (Stalnaker et al., 2006). Importantly, in contrast to control rats, OFC neurons in rats 
administered cocaine failed to signal the undesired outcomes during their decision making, 
which resulted in the cocaine group of rats repeating behaviors that resulted in adverse 
outcomes. Similarly, in studies evaluating humans with a cocaine use disorders, inability 
to reverse responses during a probabilistic reversal-learning task also was observed 
(Ersche et al., 2008). Furthermore, rats were trained to self-administer cocaine (1.0 mg/kg, 
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i.v.) for 10 days and then they underwent extinction for 30 days, during which time they 
showed robust cocaine seeking behavior and markedly impaired reversal learning, 
indicating the long-lasting effect of cocaine self-administration and a high level of craving 
response (Calu et al., 2007).  
Altogether, chronic substance use results in long-lasting modification on neuronal 
activity, which triggers craving in chronic substance users. Furthermore, the long-lasting 
alterations in the brain contributes to the high relapsing rate of substance use disorders 
(40-60%) (McLellan et al., 2000). Also, substance use disorders result in significant social 
costs, and harmful effects on public health in the U.S. However, there are no 
pharmacological treatments for cocaine or METH use disorders. Opioid use disorders 
have several pharmacological treatments, but the number of opioid use disorders have 
increased rapidly in the past 10 years. Therefore, this dissertation is focused on 
discovering pharmacotherapeutics for opioids, cocaine, and METH use disorder. 
Although substances activate the rewarding circuitry of the brain by using learning 
processes, each substance has a specific mechanism of action depending on its 
pharmacological properties. Thus, the underlying mechanisms for opioids, cocaine, and 
METH are discussed in following sections.   
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Figure 1.1. Dopaminergic neurons and brain region. Substance-induced DA increase 
in the NA is important in substance-induced rewarding effect and voluntary substance 
intake. Repeated substance use leads DA increase in the dorsal striatum and mediates 
habit formation: which consequently, results in compulsive substance seeking and taking 
behaviors. Repeated substance use decreases DA neuronal activity in prefrontal cortex, 
which is the underlying mechanism of decreased executive function (i.e., self-control) and 
increased impulsive substance seeking and taking behavior.
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1.4 METH Use Disorder 
Since 2008, numerous studies have reported a rapid increase in METH use, and 
the number of people who reported nonmedical use of METH in U.S. has also risen to 1.9-
fold in 2016 relative to in 2008 (Maxwell and Brecht, 2011; ONDCP, 2016). Presently, 
global METH use also has escalated (UNODC, 2015, 2017). However, there is no 
pharmacotherapeutics for the treatment of METH use disorders. As a psychostimulant 
exhibiting high abuse liability, METH has a simple and easily synthesized chemical 
structure, which has contributed to the rapid increase of METH use disorder (Gonzales 
and Rawson, 2005). Furthermore, protocols for METH synthesis are available via the 
Internet. Thus, many state governments have restricted over-the-counter purchases of the 
precursors since 2004. Then, the Combat Methamphetamine Epidemic Act was passed 
by the Federal government in 2005 to regulate the sale of precursors. This resulted in 
stable indicators including ED visits between 2005 and 2008 (Cunningham and Liu, 2008; 
Gonzales et al., 2010). However, a more recent rapid growth in METH use disorder shows 
that there are significant needs for pharmacotherapeutics for treatment of METH use 
disorder (DEA, 2018). Thus, the following Chapters (2 and 3) focus on discovering 
therapeutics for METH use disorder using novel compound scaffold. This section reviews 
the brief history and epidemic of METH use disorders, its mechanism of action, and 
research to discover treatments for METH use disorders. 
 
1.4.1 History of METH 
METH is derived from amphetamine, and amphetamine was synthesized first in 
1887 by  Romanian chemist Lazar Edeleanu (Rassool, 2009). During World War II, 
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amphetamine was used by soldiers to reduce fatigue and increase alertness. Additionally, 
amphetamine was sold as an over-the-counter medication for use to treat nasal 
congestion, schizophrenia, mild depression, obesity, migraine, alcoholism in the 1930s 
(Rassool, 2011; Vearrier et al., 2012).  
In 1919, a derivative of amphetamine named METH (N-methyl-amphetamine) was 
synthesized by a Japanese pharmacologist, Akira Ogata (Anglin et al., 2000; Vearrier et 
al., 2012). Initially, the METH was synthesized with the goal of improving the therapeutic 
property of amphetamine as a central nervous system stimulant, bronchodilator, and nasal 
vasoconstrictor. Due to the chemical structural and pharmacological similarity, 
amphetamine, METH, and its stereoisomers such as dextroamphetamine collectively are 
called as amphetamines or amphetamine-type stimulants. Amphetamines commonly 
contain the ephedrine skeleton. Ephedrine is a natural product and alkaloid extracted from 
Ephedra sinica, which often is used as a precursor of METH synthesis (Vearrier et al., 
2012). During World War II, METH also was used by soldiers and war-related workers to 
improve shift work ability by increasing alertness, decreasing fatigue, and suppressing 
appetite (Anglin et al., 2000). Amphetamines also were legally manufactured, which led to 
a variety of individuals using METH including factory workers, truck drivers, housewives, 
students, and other professionals for the purpose of increasing wakefulness, mood,  
attention, and even weight loss. The number of METH users increased during the 1940s 
and 1950s. During the late 1960s, many METH users reported tolerance to the effects of 
METH. As a result, tolerance-related problematic METH use occurred, which led to 
serious physical and psychological health issues including tachycardia, chest pain, 
arrhythmias, seizures, stroke, skin ulcerations, pulmonary edema, dental caries, 
hallucinations, anxiety, and suicidality (Gonzales et al., 2010). METH-related violent 
crimes increased (Vearrier et al., 2012):thus, the Comprehensive Drug Abuse Prevention 
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and Control Act of 1970 limited the use of amphetamines, which markedly reduced 
amphetamines-related health problems in the US (Gonzales et al., 2010). Then illegal 
METH was manufactured in a few limited areas, such as California and Oregon in the late 
1970s. Illegal use of METH resurfaced in the 1980s, often used by motorcycle gangs, 
truck drivers, and construction workers (Gonzales et al., 2010; DEA, 2017). During the 
1990s, METH was synthesized easily in small mom-and-pop home laboratories using 
precursors such as pseudoephedrine (a component of common cold medicine), leading 
to increases in the METH epidemic. Thus, the Combat Methamphetamine Epidemic Act 
was passed by the federal government in 2005 to regulate METH precursors containing 
products (Gonzales et al., 2010; DEA, 2017). Although a slight decrease in the number of 
METH-related ED visits occurred in the mid-2000s, increases in ED visits associated with 
METH were reported in 2016 (Richards et al., 2017). Furthermore, rapid increases in 
METH use since the late 2000s were reported by multiple studies in the US, including  
increases in the number of ED visits, treatment facility admissions for METH, and METH-
related seizures (Maxwell and Brecht, 2011; SAMHSA, 2014; ONDCP, 2016). Also, there 
were worldwide increases in the number of METH-related poisoning deaths and METH-
related seizures since 2008 (UNODC, 2015; DEA, 2017).  Currently, use of METH is under 
the Controlled Substance Act in the United States.  METH is categorized as a Schedule II 
compound (DEA, 2018b), and is prescribed for a limited number of medical uses, including 
for attention deficit hyperactivity disorder (ADHD) and narcolepsy (sleep disorder) 
(Richards et al., 2017).  
Altogether, multiple reports have pointed out that there are many people affected 
by acute overdose or chronic METH use, which would imply needs for 
pharmacotherapeutics to treat METH users, along with laws regulating its use. Especially, 
METH shows high abuse liability, which suggests acute METH users may have high 
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potential to become overdosed or chronic METH user (Huskinson et al., 2014). Thus, 
pharmacotherapeutics for METH use disorders would contribute to combat METH use.  
However, there are no FDA-approved pharmacotherapeutics for the treatment of METH 
use disorders. 
 
1.4.2 Epidemiology 
Illegal METH use has increased since the 1980s. Widespread use of 
amphetamines including METH was reduced due to the designation of amphetamines as 
Schedule II substances by the Comprehensive Drug Abuse Prevention and Control Act in 
1970. However, the use of METH reappeared in Hawaii and the west coast of the United 
States in the late 1980s (Derlet and Heischober, 1990). METH use spread across the 
country towards the northwest and southwest during the 1990s, and then the midwest, 
south, and northeast of the United States during the 2000s (Maxwell et al., 2008). Also, 
based on the most recent report available, there are 1.7 million Americans  who have used 
METH during the year in 2015, which was increased from 1.1 million in 2014 (CDC, 2017a). 
Moreover, during 2015, there were 225,000 Americans who initiated METH use, which 
was 0.1% of total population ages12 or older (CDC, 2017a).  
During 2015, there were 872,000 persons in the United States ages 12-years or 
older who were diagnosed as having a METH use disorder, which was 0.3% of Americans  
in that age group (CDC, 2017a). In 2015, 135,000 people were admitted to a publicly-
licensed treatment facility seeking treatment for METH use disorders (DEA, 2018). 
However, there are no FDA-approved pharmacotherapeutics for METH use disorders.  
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Importantly, METH use disorders showed higher risks for a psychiatric diagnosis 
compared to cocaine use disorders (Copeland and Sorensen, 2001). Hence, chronic 
METH use contributes to the increase in mental illnesses including anxiety, depression, 
paranoia, delusions, and hallucinations due to the effect of METH and its withdrawal 
syndrome (Glasner-Edwards et al., 2010; Su et al., 2017). Moreover, 79% of substance-
related crimes were related to METH use disorders in 2013 (SAMHSA, 2014b). Among 
Americans who used METH in the past month, there were 13,000 adolescents (ages 12-
17 years), 128,000 young adults (ages 18-25 years), and 757,000 adults (ages 26 and 
older) in 2015 (SAMHSA, 2017a). The demographics of this group include 631,000 males 
and 266,000 females, which were 0.5% and 0.2% of each gender population in 2015. The 
estimated rates of METH users were 1.2%, 0.6%, 0.4%, and 0.2% of populations living in 
the west, south, midwest, and northeast, respectively (CDC, 2017a).  
Additionally, between 2009 and 2014, the number of METH-related ED visits with 
chest pain, psychosis, and trauma increased from 64,000 to 110,000 (SAMHSA, 2014; 
CDC, 2017; Richards et al., 2017). Furthermore, METH users showed higher rate of  heart 
failure and dental diseases compared to the general ED populations and general patients 
in dental clinics (Clague et al., 2017; Richards et al., 2018). Of the 5,700 people who died 
due to stimulants overdose, 85-90% were related to METH in 2015 (DEA, 2017). There 
was a 225% increase in stimulant-related deaths between 2000 and 2015 (DEA, 2017). 
Furthermore, global METH use and METH-related problems continued to increase. 
Between 2010 and 2015, there was a 3.1-fold increase in the number of METH-related 
poisoning deaths, and a 158% increase in global METH seizures (UNODC, 2015; DEA, 
2017). Also, worldwide users of amphetamine-type substances reached 37 million, METH 
being the dominant substance. 
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1.4.3 Mechanism of Action 
METH has two enantiomers, (S)- and (R)-METH. (S)-METH exhibits 
psychostimulant effects, but (R)-METH does not. In this dissertation, METH refers to (S)-
METH specifically when there is no additional designation. METH exhibits high lipophilicity 
(logP = 2.10), which is higher than the parent compound amphetamine (logP = 1.76) 
(Gulaboski et al., 2007). Due to its high lipophilicity, METH penetrates the blood-brain 
barrier, allowing a high concentration to reach the brain (Gulaboski et al., 2007). In rats, 
the concentration of METH in the brain was 7-, 13-, and 8-fold higher compared to serum 
at 2 min, 20 min (peak of METH concentration in brain), and 2 h, respectively after 1 mg/kg 
post i.v. injection (Riviere et al., 2000). Furthermore, area under the curve (AUC) ratio of 
serum to brain was 1:9.7, which was based on data collected from 1 min to 3 h after METH 
administration (Riviere et al., 2000). These data show that METH is able to accumulate in 
the brain 9.7-fold higher compared to serum (Riviere et al., 2000). Smoked METH exhibits 
higher bioavailability (90.3 ± 10.4%) than oral administration (bioavailability, 67.2 ± 3.1%; 
Cook et al., 1993). The half-life of METH (i.v.) in rats and humans is 70 min and 12 h, 
respectively (Cho et al., 2001). When METH reaches the brain, it accesses the neuronal 
cytosol by penetrating the plasmalemmal membrane or by being taken up into the neuron 
via monoamine transporters, such as DAT, SERT, and NET (Sulzer et al., 2005). METH 
acts as a substrate at monoamine transporters, resulting in inhibition of monoamine 
uptake from the extracellular space into the neuronal cytosol. METH exhibits comparable 
affinity for DAT (Ki = 0.46 ± 0.06 µM) and NET (0.11 ± 0.01 µM), but lower affinity for 
SERT (31.7 ± 2.40 µM) (Han and Gu, 2006). This profile for METH at neurotransmitter 
transporters is comparable to that for amphetamine, whereas cocaine shows higher 
affinity for SERT than METH or amphetamine. Ki values for amphetamine and cocaine 
DAT were 0.64 ± 0.14 and 0.23 ± 0.03 µM, for NET were 0.07 ± 0.06 and 0.48 ± 0.05 µM, 
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and for SERT 38.5 ± 3.84 and 0.74 ± 0.03 µM, respectively (Han and Gu, 2006). These 
findings support pharmacodynamic differences between METH and cocaine, but 
comparable mechanisms of action between METH and amphetamine at these 
transporters.  
METH-induced inhibition of DAT function results in increased extracellular DA 
concentrations in the NA, which is known to play a key role in METH reward, contributing 
to its high abuse liability (Di Chiara et al., 2004). Similarly, amphetamine-induced 
increases in extracellular DA concentrations in the NA results in acquisition of self-
administration behavior (Lyness et al., 1979). Also, the highest concentration of METH in 
striatum including the NA was found at 5 min post i.v. injection, which was correlated with 
an increased DA concentration in the striatum at 10 min post-METH injection (Melega et 
al., 1995).  
Once METH enters the cytosol of neuron, it penetrates the synaptic vesicle 
membrane and inhibits function of the vesicular monoamine transporter-2 (VMAT2), which 
is expressed on the vesicle membrane (Eshleman et al., 1994; Sulzer et al., 2005; 
Fleckenstein et al., 2007) METH penetration into the synaptic vesicle increases the pH 
within the vesicles, which changes the pH gradient between cell cytosol and vesicle. Since 
the pH gradient is the driving force for DA uptake, METH penetration contributes to DA 
release from the vesicle into the neuronal cytosol (Nickell et al., 2014). Concurrently, 
METH inhibits DA uptake by VMAT2. Also, METH inhibits the metabolism of cytosolic DA 
by inhibiting the mitochondrial enzyme, monoamine oxidase (MAO) (Mantle et al., 1976). 
METH increases the activity of tyrosine hydroxylase (TH), which is the tightly regulated 
rate-limiting enzyme in the DA synthesis pathway (Larsen et al., 2002). Overall, the action 
of METH is to increase cytosolic DA concentrations. This increase in cytosolic DA 
concentration is available for reverse transport by DAT, which then increases extracellular 
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DA concentrations (Sulzer et al., 2005; Fleckenstein et al., 2007). Consequently, the 
METH that was released from the vesicle ultimately is transported to the extracellular 
compartment and activates D1 and D2 DA receptors expressed on the postsynaptic and 
presynaptic neuronal membrane. Activation of DA receptors expressed on the 
postsynaptic membrane in the NA then leads to downstream signaling in GABAergic 
medium spiny neurons and cholinergic interneurons, ultimately producing reward 
(Imperato and Di Chiara, 1986; Di Chiara and Imperato, 1988a; Di Chiara, 1991). METH-
induced inhibition of VMAT2 allows DA concentrations to increase to a level higher than 
does cocaine, which does not interact with VMAT2 (Pifl et al., 1995). Cocaine does not 
increase cytosolic DA levels nor interact with VMAT2 at the vesicle membrane. When 
VMAT2 is present in the cell, METH produces a prolonged DA release compared to 
cocaine, especially compared to the absence of VMAT2 expression (Pifl et al., 1995). The 
multiple mechanisms of METH use contribute to its high abuse liability. The METH-
induced increase in cytosolic DA concentrations via interaction with VMAT2 is an 
additional mechanism where METH ultimately increases extracellular DA concentrations, 
culminating in a reward response.  
Chronic METH administration results in the degeneration of DA neurons. The 
cytosolic oxygen species related neurotoxicity has been observed only in METH users, 
but not in cocaine users (Giovanni et al., 1995; Larsen et al., 2002; Miyazaki et al., 2006). 
Accumulated cytosolic DA forms reactive oxygen species (ROS), which are known to 
induce apoptosis (Giovanni et al., 1995; Larsen et al., 2002; Miyazaki et al., 2006). Also, 
repeated METH use induces DA neuron degeneration by promoting autophagy in DA 
neurons (Larsen et al., 2002). DA neurotoxicity has been observed in chronic METH users, 
as demonstrated by brain imaging studies (Volkow, Chang, Wang, Fowler, Franceschi, et 
al., 2001; Chang et al., 2007). Decreased DAT, VMAT2 and SERT density in the striatum 
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and NA has been observed in chronic METH users (Chang et al., 2007). Also, post-
mortem analysis of the brain from chronic METH users shows elevated antioxidants such 
as copper-zinc superoxide dismutase and glutathione, indicating that METH increases 
oxidative stress (Mirecki et al., 2004). 
 
1.4.4 Clinical and Preclinical Pharmacotherapeutics 
There are no pharmacotherapeutics approved by the FDA for METH use disorder. 
With great need for pharmacotherapeutics, there are multiple research-based approaches 
being investigated with the goal of discovering the first medication for METH use disorder. 
There are several different strategies including an anti-METH antibody and VMAT2 
inhibitors.  
The anti-METH antibody, a pharmacokinetic approach, is aimed at reducing METH 
concentration in brain, which is expected to reduce the METH-induced rewarding effects 
in individuals using METH (Kosten and Owens, 2005; Owens et al., 2011; Y-H Chen et al., 
2013). Without METH action in the brain, there would be no METH-induced reward, which 
is critical for both acquisition and maintenance of METH self-administration (Lyness et al., 
1979). Also, this approach would eliminate the METH-induced rewarding effect if there 
was a lapse in use during abstinence preventing a relapse of METH seeking and taking 
behaviors (Gentry et al., 2009). Thus, decreasing METH concentration in the brain is an 
important factor as a pharmacotherapeutic for METH use disorders. Based on a study 
using rats, anti-METH antibody administration decreased METH self-administration when 
METH was accessible at low unit doses (0.01-0.03 mg/kg/infusion), but not high unit doses 
(0.06 mg/kg/infusion) (McMillan et al., 2004). The first human study investigating anti-
METH antibodies (17-19 day half-life) showed that there were no concerns regarding 
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safety or tolerability (Stevens et al., 2014). The long half-life of the antibody would 
theoretically provide benefit to patients with respect to adherence to the treatment and 
reduction of the potential for a relapse. In the most recent report, the METH specific anti-
METH antibody reduced METH (0.56 mg/kg, i.p.) concentration in the brain by 40-73% of 
sham mice at 21 days post-injection of antibody (Hay et al., 2018).  
Another approach to the discovery of therapeutics to treat METH use disorder is 
using a small molecule that targets VMAT2 to inhibit METH action. A natural alkaloid 
extracted from Lobelia plant, lobeline was the first compound found to inhibit responses 
for METH in rats by  inhibiting VMAT2 (Harrod et al., 2001; Wilhelm et al., 2008; David B. 
Horton et al., 2011). Lobeline completed a Phase 1B Clinical Trial (Jones, 2007), and 
showed no major concerns with regards to safety for individuals with METH use disorder. 
However, relatively minor undesired side effects were observed including nausea, which  
may have been due to the high  affinity of lobeline for nicotinic acetylcholine receptors 
(nAChRs) (Travagli et al., 2006; Babic and Browning, 2014). Thus, further structure-
activity relationship studies were performed and ultimately VMAT2 selective analogs of 
lobeline were discovered that did not develop tolerance or cardiotoxicity (Dwoskin and 
Crooks, 2002; Nickell et al., 2014).  
GZ-793A is an analog of lobeline exhibiting selective VMAT2 inhibition, inhibiting 
METH-evoked DA release from rat brain slices, reducing response for METH in METH 
self-administration and inhibiting METH reinstatement in rats following both oral and s.c. 
administration routes. No tolerance developed and no reinforcing effects were produced 
(D. B. Horton et al., 2011; Alvers et al., 2012; Beckmann et al., 2012; Horton et al., 2013; 
Meyer et al., 2013; Wilmouth et al., 2013; Nickell et al., 2014). Unfortunately, GZ-793A 
exhibited affinity for the hERG channel expressed by HEK cells, suggesting the potential 
for cardiotoxicity (Nickell et al., 2017). Thus, this dissertation focuses on the further 
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investigation of lobeline analogs as a VMAT2 inhibitor to discover pharmacotherapeutics 
for METH use disorder (Chapters 2 and 3).  
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Figure 1.2. Chemical structures of DA, ephedrine, S- and R-amphetamine, and S- 
and R-METH.  
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1.5 Cocaine Use Disorder 
Since 2013, cocaine use indicators have rebounded (DEA, 2018). Both the number 
of cocaine poisoning deaths and new cocaine initiates were 2-fold increased within 3 years, 
between 2013 and 2016 (DEA, 2018). Furthermore, within a year, cocaine overdose 
poisoning deaths were 53%, increased between 2015 and 2016. Based on DSM-IV criteria, 
one in six persons who self-administered cocaine develop cocaine dependence, which is 
equivalent to a moderate to severe cocaine use disorder in DSM-V (Anthony et al., 1994). 
Due to the high abuse liability of cocaine, increased cocaine use indicators suggest 
increased numbers of patients having cocaine use disorder. Also, there was 3.6-fold 
increase in 2017 compared to 2013 in the cultivation of a coca plant, the primary resource 
needed for cocaine production in Colombia, from where 93% of seized domestic cocaine 
originates. This suggests increased domestic cocaine availability (DEA, 2018). Cultivation 
of the coca plant in Colombia has increased 20% between 2016 and 2017, which has 
been the highest level of cocaine production in the last 10 years (DEA, 2018). Despite 
decreasing trends (3.7-fold) in cocaine-related admission to publicly-funded facilities from 
2005 to 2015 (DEA, 2018), recent increases in cocaine use indicators, its high abuse 
liability, and the highest cocaine availability in the US since 2007 reveals the increased 
need for treatments for cocaine use disorder. However, there are no 
pharmacotherapeutics approved by FDA to treat cocaine use disorder. Thus, this 
dissertation conducts a series of studies to discover pharmacotherapeutics for cocaine 
use disorder by targeting M5 muscarinic acetylcholine receptors (mAChRs)  (Chapters 4 
and 5). Since inhibition of M5 mAChRs decreases cocaine- and opioid-induced rewarding 
effects, both cocaine and opioid use disorders are reviewed in the current and next 
sections. The current section reviews a brief history of cocaine, the epidemic of cocaine 
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use disorder, the mechanism of action of cocaine, and research to discover treatments for 
cocaine use disorder.  
 
1.5.1 History of Cocaine  
Cocaine is a natural product and tropane ester alkaloid obtained from the leaves 
of Erythroxylum coca plant, traditionally cultivated in Andean region where Columbia and 
Peru are located (Redman, 2011). The people of ancient civilizations chewed the leaves 
of the plant for recreational or religious purpose and achieved stimulant effects (Redman, 
2011). In the mid-1800s in Germany, cocaine was isolated from the plant, and was used 
as an anesthetic since 1884 (Just and Hoyer, 1977; Calatayud and Gonzalez, 2003; 
Goldstein et al., 2009). Until the late 1800s, cocaine was used as an analgesic for nerve 
block and spinal anesthesia. On the other hand, due to the rewarding effects of cocaine, 
it was sold also as a powder, in a cigarette form and as chocolate cocaine tablets for 
recreational use in the late-1800s. Interestingly, a wine named Vin Mariani was sold (circa 
1863) in France, which included cocaine as an ingredient. Later, in 1886, a beverage 
containing cocaine with sugar syrup was marked with as name of Coca-Cola® in the 
United States (Goldstein et al., 2009). A glass of Coca-Cola® contained 9 mg of cocaine. 
However, due to accumulated reports of adverse effects of cocaine reported in the 20th 
century, cocaine was removed from Coca-Cola® around 1903 (Lundberg et al., 1977; 
Shuster et al., 1977; Redman, 2011). Also, the Harrison Narcotic Tax Act in 1914 was 
passed containing regulations regarding cocaine among other substances.  Cocaine also 
has other medical uses rather than anesthetic. In 1879, cocaine was used therapeutically 
to treat morphine use disorders. Until 1916, cocaine was available as an over the counter 
medication in the United States to treat toothache and nausea.  
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Accumulated evidence supports the high abuse liability of cocaine as well as its 
aversive physical effects including stroke, cardiac arrest, and sudden death (McClenny, 
1991). Also, effects of cocaine on society have been recognized, including serious crimes 
associated with cocaine use and trafficking (Grinspoon and Bakalar, 1981). The Harrison 
Narcotic Tax Act led to a decline in cocaine use rates in the 1920s, and since the 1930s, 
amphetamine became popular. 
Currently, the use of cocaine is regulated by the Controlled Substance Act in the 
United States as a Schedule II drug due to its high abuse liability (Redman, 2011; DEA, 
2017). Cocaine is prescribed rarely as a local anesthetic and blood vessel constrictor in 
the US. Since the epidemic of cocaine use disorders continues to be a growing health 
issue in the United States, numerous research studies have been conducted on cocaine, 
focusing on the effects of cocaine as a substance having abuse potential. Cocaine was 
used widely as an anesthetic in the clinic until the end of the 19th century. Currently, most 
of its anesthetic role has been replaced generally by other synthetic compounds (Redman, 
2011). 
 
1.5.2 Epidemiology 
Between 2007 and 2009, cocaine initiates were decreased from 906,000 to 
617,000, and then it was stable until 2012 at around 630,000. However, a noticeable trend 
of an increase was reported between 2013 and 2016 (DEA, 2018). The number of past 
year cocaine initiates were 601,000 in 2013, and 906,000 in 2016 (DEA, 2018). The 
number of current cocaine users, as indicated by cocaine use within the past month, has 
increased from 1.53 million in 2014 to 1.9 million in 2015 (DEA, 2017). Due to the cardiac 
toxicity of cocaine, with the increase in the cocaine use indicators, cocaine-involved 
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overdose deaths increased also from 4,400 to 13,900 between 2012 and 2017 (CDC, 
2018; DEA, 2018). Since cocaine exhibits high abuse liability, the increase in number of 
cocaine initiates was considered as an important factor in the number of cocaine use 
disorder patients (Anthony et al., 1994). In accordance with these studies,  in the US, 
833,000 Americans ages 18 or older  met cocaine use disorder diagnostic criteria in 2013, 
which has increased to 947,000 in 2017 (Lipari and Van Horn, 2017; CBHSQ, Center for 
Behavioral Health Statistics and Quality, 2018). Moreover, the quantity of cocaine 
imported into the US increased between 2013 and 2015, which was parallel with the 
increase of cocaine initiates during the same period of time (DEA, 2017). Also, cultivation 
of the coca plant in Columbia, was the highest level in 2017 since 2007, which suggests 
the potential of further increase in the number of cocaine use disorder patients (DEA, 
2018). More recently, there has been an emergence of a cocaine and fentanyl mixture in 
the US, which resulted in an increase in the rate of opioid involvement among the cocaine 
overdose deaths in 2017 (70%) compared to 2012 (55%) (CDC, 2018; DEA, 2018). These 
findings suggest that the recent rapid increasing in opioid epidemic since 2013 (section 
1.6.2.) also accelerated cocaine overdose deaths (Dowell et al., 2017; Schiller and 
Mechanic, 2018).  
Taken together, cocaine use has increased rapidly since 2013, which was parallel 
with increase in cocaine use disorder patients and cocaine overdose deaths. The recent 
opioid epidemic has accelerated the number of cocaine overdose deaths, revealing the 
need for pharmacotherapeutics to treat cocaine use disorder, as well as, opioid use 
disorders. Furthermore, cocaine use is a worldwide health issue, and has been used by 
18.2 million of global population aged between 15 and 64 (Milano et al., 2017). Thus, 
discovery of pharmacotherapeutics for cocaine use disorder would contribute to improving 
not only health in the US, but also worldwide cocaine use disorder-related health concerns.  
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1.5.3 Mechanism of Action 
Cocaine is administered via multiple routes. Insufflation (snorting), smoking, and 
i.v. injection results in rapid absorption, whereas oral administration and topical application 
delay absorption (Jeffcoat et al., 1989). Bioavailability of smoked and orally administered 
cocaine are 70% and 30%, respectively (Leikin and Paloucek, 2008). Onset of action for 
cocaine is rapid with inhalation and intravenous injection, requiring 3-5 sec and 10-60 sec, 
respectively. Intranasal administration of cocaine requires 5 min for onset (Leikin and 
Paloucek, 2008; Goldstein et al., 2009). The half-life for cocaine is 0.7-1.5 h (Jeffcoat et 
al., 1989).  
Administered cocaine  crosses the blood brain barrier and dispositions into the 
brain (Ikegami and Duvauchelle, 2004). According to a rat study, ratio of the brain to 
plasma distribution of absorbed cocaine was 2.0 ± 0.59, indicating accumulation of 
cocaine in brain tissues (Pan and Hedaya, 1998; Kulkarni et al., 2016). Cocaine in the 
brain acts as a psychostimulant by inhibiting the reuptake into cytosol of catecholamines 
including DA, NE, and serotonin (5-HT), which results in increased concentration of these 
neurotransmitters in the synaptic cleft and extracellularly (Goldstein et al., 2009). 
Catecholamines are transferred from the synaptic cleft into cytosol via Na+/Cl- dependent 
monoamine transporters expressed on the plasmalemmal membranes (i.e., DAT, SERT, 
and NET). To reuptake a DA from synaptic cleft into cytosol, two sodium ions and a 
chloride ion have to bind to DAT. To reuptake a 5-HT and NE, a sodium and a chloride 
ion are needed to bind to SERT and NET, respectively (De Felice, 2016). Cocaine 
exhibited high affinity for DAT and SERT (IC50 = 256 ± 43 and 299 ± 10 nM, respectively), 
and relatively lower affinity for NET (IC50 = 4700 ± 721 nM) (GM Miller et al., 2001). 
Monoamines including DA, 5-HT, and NE are synthesized in neuron cell bodies and 
terminals, in neuron terminals, and in neuron terminals, respectively. Subsequently, 
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monoamines are stored in vesicles in neuron terminals, which are released into the 
synaptic cleft as tonic and phasic transmission. Monoamine released from neuronal 
terminals to synaptic cleft binds to specific receptors (i.e., DA binds to DA receptors) to 
activate downstream signaling. Monoamine transporters reuptake monoamines from the 
synaptic cleft into cytosol, which is essential to terminate the signaling mediated by the 
released monoamines. Thus, inhibition of reuptake by cocaine results in increased 
extracellular concentrations (Ikegami and Duvauchelle, 2004). The increase in 
extracellular concentration of DA in the NA contributes to cocaine-induced rewarding 
effects and abuse liability of cocaine (Di Chiara and Imperato, 1988a; Wise and Rompre, 
1989; Warner, 1993; Eshleman et al., 1994). The percent occupancy of DAT by cocaine 
was highly correlated with human subjects’ reports of “high” (Volkow, Wang, Fischman, et 
al., 1997). At least 47% of the DAT occupancy by cocaine resulted in human subjects’ 
response “high” (Volkow, Wang, Fischman, et al., 1997). The i.v. cocaine doses (0.3-0.6 
mg/kg) that showed abuse liability in human, resulted in 60-80% of DAT occupancy by 
cocaine (Verebey and Gold, 1988; Volkow, Wang, Fischman, et al., 1997). Cocaine also 
Increases extracellular 5-HT concentrations in multiple brain areas including the ventral 
pallidum, NA, substantia nigra, and orbitofrontal cortex, which would contribute to the 
cocaine reward (Matsui and Alvarez, 2018). Pretreatment of fluoxetine (5 and 10 mg/kg, 
i.v.), a SERT inhibitor, to rats trained for cocaine self-administration decreased cocaine-
self-administration by 50% of baseline, suggesting increased extracellular 5-HT 
contributes to cocaine reinforcing effects (Carroll et al., 1990). DAT KO mice were able to 
acquire cocaine self-administration, however, DAT and SERT double KO mice were not 
able to acquire cocaine self-administration, suggesting 5-HT involvement to cocaine-
induced reinforcement (Rocha et al., 1998; Sora et al., 2001).  Increased extracellular NE 
concentrations in the VTA and prefrontal cortex are critical for cocaine sensitization 
(Robinson and Berridge, 2001; Drouin et al., 2002; Jimenez-Rivera et al., 2006). Although 
64 
 
NET inhibitors (desipramine and nisoxetine; 1 and 3 mg/kg, i.v.) did not alter cocaine self-
administration, disruption of NE signaling by administering an antagonist of alpha-1 
adrenergic receptor (prazosin, 0.5 mg/kg, i.p.) decreased development of cocaine 
sensitization on locomotor activity (Tella, 1995; Jimenez-Rivera et al., 2006). Also, the 
alpha-1 adrenergic receptor KO mice were given daily cocaine (5 mg/kg, s.c.) 
administration for 5 days failed to develop cocaine-induced sensitization on locomotor 
activity, but wild-type mice developed (Drouin et al., 2002). The alpha-1 adrenergic 
receptor KO mice and wild-type mice showed no difference on DA receptor expression 
levels and DAT sites (Drouin et al., 2002). These observations indicate critical role of NE 
signaling on development of cocaine-induced sensitization. 
Cocaine also inhibits voltage-gated ion channels in membranes of cells that 
conduct action potentials (Mittleman and Wetli, 1984; Luft and Mendes, 2007). The 
cocaine inhibits the voltage-gated sodium channels in neurons, which results in inhibition 
of depolarization of the neuron and blocks nerve impulses conveying pain to the brain, 
and cocaine was able to be used as an anesthetic (Luft and Mendes, 2007). Also, cocaine 
modulates voltage-gated cardiac ion channels including sodium, potassium and calcium 
channels expressed in cardiac tissues, which contributes to development of cardiac 
arrhythmias by disrupting maintenance of electrical excitability of cardiac tissues and 
sudden deaths (O’Leary and Hancox, 2010).  
Administered cocaine is metabolized through three main pathways. 
Benzoylecgonine (~40% of absorbed cocaine) and ecgonine methyl ester (~50% of 
absorbed cocaine) are two major metabolites. Norcocaine (~10% of absorbed cocaine) is 
a minor metabolite, relative to benzoylecgonine and ecgonine methyl ester (Goldstein et 
al., 2009). Cocaine is metabolized to benzoylecgonine by hepatic carboxylesterase. 
Benzoylecgonine produces vasoconstriction, but does not penetrate the blood-brain 
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barrier readily (Rohrig and Hicks, 2014). The half-life of benzoylecgonine is 5-6 h. 
Ecgonine methyl ester is formed by butyrylcholinesterase and is an inactive metabolite, 
exhibiting no pharmacological properties. Cocaine is metabolized to norcocaine by 
cytochrome P450, specifically by CYP3A4, which produces hepatotoxicity (Riezzo et al., 
2012). Norcocaine is able to penetrate the blood-brain barrier, and self-administered by 
monkeys (0.05, 0.2, and 0.8 mg/kg/infusion, i.v.) (Bedford et al., 1980; Ikegami and 
Duvauchelle, 2004). However, norcocaine (20 and 40 mg/kg, i.p.) showed lack of 
stimulatory effect on locomotor activity in rats (Bedford et al., 1980). In contrast, cocaine 
(0.2 mg/kg, i.v.) was self-administered by monkeys, and increased locomotor activity at 
20 and 40 mg/kg (i.p.) in rats. Also, the amount of norcocaine produced following cocaine 
administration is ~5% of absorbed cocaine. Thus, cocaine serves reinforcing effects 
predominantly, instead of metabolites of cocaine.  
Repeated cocaine administration results in decreased function of DA in brain, 
which contributes to craving for cocaine with anhedonia, loss of control,  severe 
psychomotor retardation, and psychiatric disorders (Volkow, Wang, Fowler, et al., 1997; 
Goldstein et al., 2009). Based on PET images, the level for an antagonist of D2R 
([11C]raclopride) in cocaine dependent human subjects’ brain was lower than control 
subjects (Volkow, Wang, Fowler, et al., 1997). The cocaine dependent in DSM-IV is 
equivalent to moderate to severe cocaine use disorder in DSM-5 (American Psychiatric 
Association, 2013). Also, the methylphenidate-induced changes in the [11C]raclopride 
binding were higher in cocaine dependents than control subjects. Since methylphenidate 
increases extracellular DA by inhibiting DAT, the decreased methylphenidate-induced 
changes in the cocaine dependents suggests decreased DA availability in the baseline 
state and decreased responsiveness to psychostimulants (Volkow, Wang, Fowler, et al., 
1997). Also, cocaine dependent human subjects showed about 50% decreased DA 
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neuronal activity in striatum and thalamus, which were correlated with restlessness and 
craving, respectively (Volkow, Wang, Fowler, et al., 1997; Volkow et al., 2007). About 80% 
of cocaine users  also reported psychotic symptoms including paranoia, delusions, and 
hallucinations (Smith et al., 2009; Roncero et al., 2012).  
When cocaine is administered with alcohol, the activity of carboxylesterase 
enzyme is reduced, resulting in reduced relative amounts of benzoylecgonine, but 
increased relative amounts of cocaethylene. The cocaethylene inhibits DAT, which 
contributes to cocaine-induced rewarding effects. The half-life of cocaethylene was 3.5-
5.5 h, which was longer than cocaine. Also, cocaethylene exhibited hepatotoxicity 
(Ponsoda et al., 1999). Thus, cocaine administration with alcohol further increases 
hepatotoxicity and the rewarding effects of cocaine.   
 
1.5.4 Clinical and Preclinical Pharmacotherapeutics 
There are no FDA-approved pharmacotherapeutics for cocaine use disorders. In 
the preclinical research arena, there are several therapeutic candidates being considered 
as treatments for cocaine use disorders, including agonist replacements (amphetamine 
and METH), anti-cocaine vaccines, and engineered enzyme approaches, which are 
suggested reduced cocaine-rewarding effects.  
As an agonist replacement approach, d-amphetamine and d-METH (acting as a 
substrate of monoamine transporters) have been considered as therapeutic candidates. 
Due to one chiral center in amphetamine, there are two forms of enantiomers named as 
d- and l-amphetamine, which are also called as S- and R-amphetamine, respectively. 
Racemic mixture of d- and l-amphetamine is a Schedule II substance, which acts as a 
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substrate of monoamine transporter and increases extracellular monoamines (Courtney 
and Ray, 2016). The d-amphetamine exhibited higher reinforcing effects relative to l-
amphetamine in rats, monkeys and humans (Balster and Schuster, 1973; Kirkpatrick et 
al., 2012). The d-amphetamine and a mixture of d- and l-amphetamine (3:1) are approved 
by FDA to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy in the early 
20th century (Sharbaf Shoar and Molla, 2019). Accumulated preclinical data indicated that 
d-amphetamine is also effective to reduce cocaine self-administration in rodents, 
nonhuman primates, and humans (Howell and Negus, 2014). In human subjects, oral d-
amphetamine (0, 30 and 60 mg/day; each dose was administered for a week before the 
test) decreased choice for cocaine and response to “want drug again” after intranasal 
cocaine (100 mg), indicating potential for d-amphetamine to decrease cocaine self-
administration (Greenwald et al., 2010). For a study using nonhuman primates, d-
amphetamine was infused through the implanted i.v. catheters, once every 20 min for 23 
h per day for 3 consecutive days, and the data from the third day were reported. The 
lowest dose of amphetamine test (0.01 mg/kg/h, i.v.) didn’t decrease per cent choice of 
cocaine (0.032 mg/kg/infusion), but the middle and highest doses (0.032 and 0.1 mg/kg/h, 
i.v.) decreased per cent choice of cocaine (Negus, 2003). In another study examined  
longer periods of time (28 consecutive amphetamine treatment days), although during the 
first 7 days of d-amphetamine (0.1 mg/kg/h) administration by s.c. minipump in monkeys, 
it reduced both food-maintained responding and cocaine (0.01 mg/kg/infusion, i.v.) self-
administration (Negus and Mello, 2003). However, response for food pellets was tolerated 
a week after; whereas decreased response for cocaine infusions were maintained for 28 
days, indicating a specific reduction for cocaine intake  (Negus and Mello, 2003). In rats, 
d-amphetamine (5 mg/kg/day) administered by the implanted osmotic mini-pumps 
decreased cocaine (0.75 mg/kg/infusion, i.v.) self-administration (Chiodo et al., 2008). 
Although d-amphetamine has abuse liability, the dose range decreasing cocaine self-
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administration was 30-60 mg/day, which was overlaps with d-amphetamine doses used 
to treat attention deficit hyperactivity disorder (5-80 mg/day in 2-4 divided doses) 
(Greydanus et al., 2009; Greenwald et al., 2010). Also, METH, a Schedule II substrate, is 
a potential replacement therapeutic for cocaine use disorder. METH has one chiral center 
like amphetamine, and the d-METH, which is also called as S-METH, exhibits high abuse 
liability; however, l-METH (also called as R-METH) does not show abuse potential 
(Mendelson et al., 2006). Without discrimination of specific enantiomer, METH is also 
Schedule II substrate. In nonhuman primates, d-METH (0.056 mg/kg/h, i.v., one injection 
every 20 min for 23 h per day) specifically reduced cocaine (0.032 mg/kg/infusion, i.v.) 
self-administration, but did not alter food-maintained responding (Negus et al., 2007). 
Daily METH infusion did not alter food-maintained responding for 7 consecutive days 
(Negus et al., 2007). These experimental animal studies indicate potential of d-
amphetamine and d-METH as therapeutics for cocaine use disorder. Also, amphetamine 
and METH are approved by FDA to treat ADHD and narcolepsy, indicating relatively lower 
potential for safety issues. However, amphetamine and METH exhibit high abuse liability. 
Thus, there is a potential of misuse of amphetamine and METH, which would ultimately 
cause development of amphetamine or METH use disorder or overdose deaths. Thus, 
sustained-release formulations of amphetamine (i.e., Adderall XR capsules) are used to 
prevent rapid increase of amphetamine blood concentration, which would contribute to the 
reinforcing effect of amphetamine (Berman et al., 2009; Sharbaf Shoar and Molla, 2019). 
Amphetamine and METH exhibited efficacy to reduce cocaine use, but their abuse 
potential is the limitation of these replacement therapeutics. Indeed, although 
amphetamine improved narcolepsy patients by 65-85%, modafinil are preferred by 
physicians due to relatively low abuse potential of modafinil (Mitler et al., 1994; Jasinski, 
2000; Berman et al., 2009). Thus, discovering therapeutics have no abuse potential would 
provide advantage to patients compared to these replacement therapeutics in treating 
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cocaine use disorder.  On the other hand, a small molecule, modafinil inhibiting DAT (IC50 
= 4.0 ± 0.39 µM) with low abuse potential should be proposed as a therapeutic for cocaine 
use disorder (Zolkowska et al., 2009; Stoops and Rush, 2013; Shalabi et al., 2017). In 
contrast, cocaine inhibiting DAT (IC50 = 0.49 ± 0.03 µM) showed high abuse liability 
(Zolkowska et al., 2009). According to a Phase I clinical trial, modafinil was administered 
orally 400 mg every 12 h for 7 days, and then 800 mg modafinil was administered orally 
every 12 h for 7 days. On the sixth and seventh day of each modafinil pretreatment, effects 
for the 20 mg and 40 mg of cocaine (i.v.) were obtained, respectively. There was no 
modafinil dose-dependent effect, but both of modafinil doses abolished and decreased 
one of the visual analog scales, “worth of cocaine in dollars”, for i.v. cocaine 20 and 40 
mg in cocaine dependents, respectively (equivalent to moderate-to-severe cocaine use 
disorder) (Malcolm et al., 2006). Also, once daily oral modafinil (200 and 400 mg) for 12 
weeks increased non-use days for cocaine to 13.5 and 15.2 days in patients diagnosed to 
have cocaine dependent, respectively. The non-use days for cocaine in the placebo group 
was 6.6 days (Anderson et al., 2009). These studies in cocaine use disorders suggest 
high potential of modafinil as a pharmacotherapeutic for cocaine use disorders. Moreover, 
in contrast to amphetamine and METH, modafinil exhibited low abuse liability, which 
encourage the use of modafinil as therapeutics for cocaine use disorders (Jasinski, 2000; 
Myrick et al., 2004; Reith et al., 2015). Although modafinil failed to show efficacy to 
increase the non-cocaine use days in the subgroup of patients who are co-diagnosed with 
cocaine and alcohol dependent, modafinil exhibited efficacy to increase non-cocaine-day 
in cocaine dependents who are not an alcohol dependent  (Anderson et al., 2009). In more 
recent studies, nociception opioid receptor agonists showed potential as a therapeutic for 
cocaine use disorders. AT-312 (3 mg/kg, s.c.), a nociception opioid receptor agonist, 
blocked acquisition of cocaine (15 mg/kg, i.p.)-induced CPP in mice (Zaveri et al., 2018). 
Also, AT-202 (3, 10, and 30 mg/kg, s.c.), a nociception opioid receptor agonist, decreased 
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cocaine- and stress-induced using forced swim and yohimbine (2 mg/kg) reinstatement of 
CPP for cocaine in mice (Zaveri, 2016). An alpha-2 adrenergic agonist, guanfacine (3 mg), 
also showed efficacy to decrease cue- and stress-induced cocaine craving in cocaine 
dependents (Fox and Sinha, 2014). Interestingly, guanfacine (3 mg) decreased cue-
induced cocaine and alcohol craving in females, but not among male cocaine dependents, 
indicating potential as a therapeutic for multi-substance use disorders in females (Fox and 
Sinha, 2014). Multiple studies are ongoing to discover small molecules as a therapeutic 
for cocaine use disorders, but currently no therapeutics are available in clinic. Especially 
since a recent rise in cocaine and opioid co-users (McCall Jones et al., 2017), a 
therapeutic molecule which inhibits more than one specific substance (i.e., cocaine and 
opioids) would be additionally beneficial to treat recent burden in cocaine use disorders.  
Anti-cocaine vaccines are aimed to prevent cocaine-induced rewarding effects by 
blocking cocaine entering the brain(referred to as a pharmacokinetic antagonism) (Kosten 
and Owens, 2005; Carfora et al., 2018). In the study using mice , the anti-cocaine vaccine 
administered mice exhibited decreased cocaine-induced locomotor activity compared to 
the control mice (Kosten et al., 2014). However, the anti-cocaine vaccine was able to only 
reduce responding for cocaine (0.1 mg/kg/infusion, i.v.) infusion in one monkey out of 4 
monkeys self-administering cocaine (Evans et al., 2016). While the anti-cocaine vaccine 
increased duration required for reacquisition of cocaine self-administration following 
extinction phase (21-29 sessions) in all four of vaccinated monkeys (19-94 sessions) 
compared to control vehicle monkeys (6 and 41 sessions, n=2), which would suggest 
potential of anti-cocaine vaccines as a treatment for relapse of cocaine use disorder 
(Evans et al., 2016). Higher sample size and a range of cocaine dose for self-
administration would provide stronger evidence to support the potential for anti-cocaine 
vaccines as therapeutics. Especially, the blood level of anti-cocaine vaccines after 
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vaccinations would be critical to evaluate efficacy of the anti-cocaine vaccination in 
reducing cocaine self-administration. According to a human study, the blood level of anti-
cocaine vaccine was related to the effect of cocaine (Haney et al., 2010). In the study, 
cocaine (25 and 50 mg) was smoked by participants who are diagnosed to have cocaine 
dependence one day per week for 13 weeks. The anti-cocaine vaccine was administered 
four times to these participants in Weeks 1, 3, 5, and 9 after the cocaine administration 
session of each week. A group of cocaine dependents exhibiting higher plasma levels of 
the anti-cocaine vaccine showed significantly lower ratings of “good drug effect” in Week 
13 compared to Week 3. However, the other group of cocaine dependents exhibiting lower 
plasma levels of the anti-cocaine vaccine did not show difference on ratings of “good drug 
effect” between weeks 13 and 3. This study indicates that the blood level of the vaccine is 
an important factor to determine efficacy of the anti-cocaine vaccine in order to decrease 
effects of cocaine. The anti-cocaine vaccination may have higher potential as a 
therapeutic for cocaine use disorder when the individual maintains high levels of anti-
cocaine vaccine. However, the cocaine self-administration study in monkeys did not 
include blood levels of the anti-cocaine vaccine. Thus, though anti-cocaine vaccine 
showed potential as a therapeutic for cocaine use disorder, efficacy of anti-cocaine 
vaccine to decrease cocaine self-administration was observed in one out of four total 
monkeys. Also, the shorter duration of onset of the antibody (i.e., two vaccinations instead 
of four vaccinations for 13 weeks) with longer duration of maintenance of the peak blood 
level of anti-cocaine vaccine after vaccination would improve clinical feasibility.  
Another pharmacokinetic approach to antagonism of the rewarding effect of 
cocaine uses engineered enzymes that specifically metabolize plasma cocaine, since the 
enzyme is not able to penetrate the blood-brain barrier (Zheng and Zhan, 2012; Zhang et 
al., 2017). An endogenous enzyme, butyrylcholinesterase is a principal enzyme 
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metabolizing cocaine into ecgonine methyl ester, which exhibits no pharmacological 
properties in human (Goldstein et al., 2009). The engineered butyrylcholinesterase based 
on computational design exhibited 2000-fold improved turnover number (Kcat), indicating 
an enzyme hydrolyzes a 2000-fold higher number of cocaine molecules per min (catalytic 
efficiency) (Zheng et al., 2008). A high dose of cocaine (180 mg/kg, i.p.) resulted in 100% 
lethality and 100% convulsions in all teste control mice (n=6), whereas mice receiving the 
engineered butyrylcholinesterase pretreatment (0.01 and 0.03 mg, i.v.) 1 min prior to 
cocaine 180 mg/kg (i.p.) administration showed no lethality and 30% of occurrence to no 
convulsions (Zheng et al., 2008). These observations suggest potential for the engineered 
butyrylcholinesterase as a therapeutic for cocaine overdose and cocaine use disorders 
with improved catalytic efficiency. Also, the engineered butyrylcholinesterase was fused 
with the Fc region of the antibody that rescued the enzyme from degradation following 
endocytosis, which contributes to the improved half-life of the enzyme (Chen et al., 2018). 
A more recent study reported a single dose of the engineered butyrylcholinesterase (0.2 
mg/kg, i.v.) exhibiting a half-life of 136 h in rats was able to decrease cocaine (15 mg/kg, 
s.c.)-induced hyperlocomotor activity for 11 days (268 h). Contrast to antibody, enzymes 
are able to metabolite multiple substrates while the enzymes are maintained in the blood 
(Zheng et al., 2017). Thus, these studies suggested high possibility for the enzymes as 
therapeutics for cocaine use disorders.     
There have been years of accumulated studies aimed at discovering new 
therapeutics for cocaine use disorders. However, still there is no FDA-approved effective 
therapeutics to treat cocaine use disorders. The lack of a therapeutics indicates the need 
for a novel approach to discover new therapeutics for cocaine use disorders. Also, the 
recent epidemic of global cocaine overdose deaths reveals increased cocaine and opioid 
co-administration and a further increase on overdose deaths. Thus, current this 
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dissertation describes the research on uncovering novel therapeutics for cocaine and 
opioid use disorders by inhibiting DA projection underlying the rewarding effects of multiple 
substances, including cocaine and opioids (Chapters 4 and 5).  
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Figure 1.3. Chemical structures of cocaine and its metabolites.
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1.6 Opioid Use Disorders 
Pain relief medications containing opioids are the second top ranked substances 
being used by those initiating illicit substance use (NIDA, 2015). The first top substance 
being cannabinoids. Pharmacotherapies are available to treat opioid use disorders. Goals 
of treatment are a longer period in the opioid-free condition through reduction of the 
withdrawal syndrome and rescue from opioid overdose. However, opioid use disorder has 
continued to dramatically escalate since 1999, leading to the current epidemic. Thus, to 
improve the outcome of opioid use disorder treatments, this dissertation discusses a novel 
approach to pharmacotherapeutics for opioid use disorder. Below, a review of opioid 
compound classes, mechanisms of action, the current epidemic of opioid use disorders, 
and current treatments for opioid use disorders is presented.  
 
1.6.1 History of Opioids  
Opioids are a class of substances including four groups of chemicals that interact 
with opioids receptors: endogenous opioids, opiates (opioids extracted from opium), semi-
synthetic opioids, and synthetic opioids (Martin, 1967; Feng et al., 2012; NIDA, 2018a).  
 
1.6.1.1 Endogenous Opioids  
Endogenous opioids are a family of peptides including endorphins, enkephalins, 
and dynorphins, which act as analgesics in animals and humans by preferentially 
interacting with mu- (MOR), delta- (DOR), and kappa- KOR) opioid receptors (Feng et al., 
2012). Endogenous opioids are derived from large protein precursors, such as 
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proopiomelanocortin (POMC), proenkephalin (PENK), prodynorphin (PDYN), which are 
cleaved and from endorphins, enkephalin, and dynorphin, respectively (McDonald and 
Lambert, 2005; Le Merrer et al., 2009). Synthesized peptide precursors are cleaved, and 
modified further (i.e., glycosylation, phosphorylation, methylation, acetylation), and then 
stored in vesicles in opioid-containing neurons. Posttranslational modifications allow 
endogenous peptides to exhibit various pharmacological profiles including different 
selectivity at opioid receptor subtypes and different affinities at the subtypes (Akil et al., 
1984). POMC, the precursor of endorphins (endogenous MOR preferring ligands), is 
synthesized only in neurons located in hypothalamus and dorsal medulla. These neurons 
project to the NA, amygdala, hypothalamus, periaqueductal gray, VTA, brainstem and 
spinal cord.  
PENK and PDYN are synthesized and expressed in neurons in multiple different 
brain regions. PENK, the precursor of enkephalins (endogenous DOR preferring ligands), 
is expressed highly in the thalamus. PDYN, the precursor of dynorphin (endogenous KOR 
preferring ligands), is expressed highly in hippocampus, hypothalamus, and NA 
(Benarroch, 2012). These endogenous opioids are released by the central and peripheral 
nerve systems when painful, stressful, or traumatic stimuli are presented. Endogenous 
opioid-induced modulation of multiple neurotransmitters in CNS and PNS, including 
various glands, results in reduced sensitivity to those stimuli by producing analgesic and 
rewarding effects (euphoria) (Froehlich, 1997). 
 
1.6.1.2 Opiates  
Opiates refer to two classes of chemicals interacting with opioid receptors, which 
are identified from exudate obtained by unripe capsules of opium poppy, Papaver 
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somniferum. Opium has been cultivated by humans since 3400 B.C., and has been used 
to reduce pain and anxiety, induce sleep, relieve bowels and reduce coughing, as well as 
to produce pleasurable effects (Bodnar, 2011). Opium consists of opiate alkaloids (also 
called opiates, ~20% of total weight), water (20%), various sugars (20%), and several 
simple organic acids (oxaloacetic acid, lactic acid, fumaric acid, and meconic acid) 
(Najafipour and Beik, 2016). Opiates consist of around 50 different chemicals that are 
obtained from opium and are divided into two chemical groups: phenanthrenes (i.e., 
morphine, 12% of total weight; codeine, 2%; and thebaine, 0.5%) and benzylisoquinolines 
(i.e., noscapine, 5% and papaverine, 1%) (European Food Safety Authority, 2011; 
Hodgson, 2012; Najafipour and Beik, 2016). The pharmacological effects of opium are 
attributed to its predominant ingredient, morphine. In 1806, morphine was isolated as an 
active ingredient with analgesic and rewarding effects (Pathan and Williams, 2012). 
Importantly, morphine acting as an agonist of MOR is the main component of currently 
available prescribed pain medications. Hence, morphine is under government control as 
a Schedule II substance due to its analgesic effects, rewarding effects and high abuse 
potential (DEA, 2018a). Morphine administration results in analgesia and rewarding 
effects at the same or higher dose of analgesia (European Food Safety Authority, 2011).  
In 1832, codeine was isolated from opium extract. Codeine is 3-methylmorphine 
and exhibits 200-fold lower affinity for MOR compared to morphine. Codeine is 
metabolized to form codeine-t-glucuronide (50-70%) and morphine (15%) in the liver by 
UGT2B7 and CYP2D6 enzymes, respectively (Mignat et al., 1995; Thorn et al., 2009). 
These two codeine metabolites, codeine-t-glucuronide and morphine are the compounds 
that mediate codeine-induced analgesic effects, which exhibited 440-fold lower and 200-
fold higher affinity for MOR compared to codeine, respectively (Meyer, 2000; Vree et al., 
2000). Overall, codeine is a less potent analgesic and rewarding substance compared to 
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morphine. However, morphine and codeine are contained in prescribed pain medications. 
Tolerance develops easily to the analgesic and rewarding effects of morphine and codeine, 
which contributes to the misuse of these prescribed pain medications. Furthermore, 
opioids produce respiratory depression, the direct effect resulting in opioid related 
overdose deaths.  
Other ingredients of opium include noscapine and papaverine, which have cough 
suppressant effects and vasodilator properties, respectively (Hao et al., 2015). Also, 
thebaine is used also as a substrate for semi-synthetic compounds such as oxycodone 
and hydrocodone (Najafipour and Beik, 2016).  
 
1.6.1.3 Semi-Synthetic Opioids  
Semi-synthetic opioids refer to derivatives of opiate alkaloids including one of the 
widely used illicit opioid substances, heroin, and prescribed opioids (oxycodone and 
hydrocodone). Heroin was synthesized initially to discover an improved morphine and was 
marketed by the Bayer Company in 1889. Heroin was considered a valuable treatment for 
respiratory diseases (coughs, asthma, bronchitis, dyspnea, and tuberculosis) and to treat 
morphine use disorders (de Ridder, 1994). Heroin exhibited higher potency compared to 
morphine (logP = 1.07), due to heroin’s greater lipophilicity (logP = 1.88), resulting in a 
higher absorption rate into brain (Peckham and Traynor, 2006; Najafipour and Beik, 2016). 
Intravenously administered heroin accumulated (68% of observed heroin) into brain, in 
contrast with 5% of observed morphine (i.v.) located into brain (Oldendorf et al., 1972). 
Also, heroin passes through the blood-brain barrier rapidly, which allows heroin to achieve 
peak concentration within 3-5 min after intravenous injection and 5-10 min after 
subcutaneous injections in mice (Way et al., 1960). After either subcutaneous or 
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intravenous administration, heroin is metabolized to morphine over a 20-30 min time 
course (Way et al., 1960). Rapid disposition of heroin and its metabolites to brain 
contributes to its analgesia, rewarding effects and toxicity, including respiratory depression 
(Sporer, 1999). In the early 1900s, numerous studies reported the habit-forming properties 
and abuse liability of heroin. In 1906, Sollier published on the toxicity of heroin (UNODC, 
1953). Thus, though heroin produces greater analgesic effects per equivalent amount 
relative to morphine, heroin is not used clinically due to its high liability for misuse, and is 
controlled as a Schedule I compound by the U.S. DEA  (UNODC, 1953; DEA2018a).  
Oxycodone was introduced in the clinic first in Germany in 1917 and in the US in 
1981 as an “over-the-counter non-opioid analgesics” (Poyhia et al., 1993; Kalso, 2005). 
Oxycodone was synthesized from thebaine, an opiate, and exhibits comparable 
lipophilicity to morphine (logP = 0.91) (Peckham and Traynor, 2006). Oxycodone has high 
bioavailability (60%) (Poyhia et al., 1993).Oxycodone is an agonist primarily at MOR (Ki = 
18 ± 4 nM) and possibly KOR (Ki = 677 ± 326 nM) (Monory et al., 1999). Oxycodone is 
prescribed as an orally available sedative analgesic to treat moderate to severe pain (Ross 
and Smith, 1997; Najafipour and Beik, 2016). Oxycodone exhibits a 5.5-fold higher ED50 
for antinociception compared to morphine (Kuo et al., 2015). Research revealed that 
oxycodone serves as a reinforcer and has been found to be misused (Comer et al., 2010; 
Knipper et al., 2017). Thus, oxycodone is controlled as Schedule II compound.  
Hydrocodone was synthesized in the early 1920s by Knoll, a Germany 
pharmaceutical company, with the goal of discovering an improved codeine with less side 
effects. Hydrocodone is oxygenated codeine. Comparable with heroin, hydrocodone 
exhibited higher lipophilicity (logP = 1.75) compared to morphine (Peckham and Traynor, 
2006). In 2013, the most commonly prescribed opioids for pain management are 
hydrocodone (128 million prescriptions) and oxycodone (32 million) (Grant Welker, 2018). 
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Hydrocodone is a Schedule II substance and is used to treat moderate pain; however, it 
is prescribed only as a combination formulation with acetaminophen (Lortab® and 
Vicodin®), which are Schedule III compounds (Schiller and Mechanic, 2018).  
 
1.6.1.4 Synthetic Opioids  
Synthetic opioids are compounds exhibiting analgesic effects by interacting as 
agonists at opioid receptors but are structurally unrelated to opiates. Fentanyl and 
methadone are well known synthetic opioids, synthesized in 1939 and 1960, respectively 
(Chen et al., 1993; Raynor et al., 1994). Both opioids exhibit higher affinity for MOR 
compared to morphine. Based on the competitive binding inhibition assays using 
radiolabel receptor specific ligands, the Ki of methadone, fentanyl and morphine for MOR 
was 0.72, 0.39, and 14 nM, respectively, showing 9 to 36-fold higher affinity for MOR 
compared to morphine (Chen et al., 1993). Also, compared to morphine lipophilicity (logP 
= 1.07), methadone (logP = 4.77) and fentanyl (logP = 4.28) exhibited higher lipophilicity, 
indicating that higher amounts of methadone and fentanyl are able to pass through the 
blood-brain barrier relative to morphine when equivalent amounts are administered 
(Peckham and Traynor, 2006). Fentanyl exhibits faster onset of analgesic effects 
compared to morphine. Peak analgesia was observed at 0.6 h and 1 h after subcutaneous 
administration of fentanyl and morphine, respectively, in rats (Haazen et al., 1999). 
Furthermore, the analgesic peak dose for fentanyl and morphine was 0.032 mg/kg (s.c.) 
and 8 mg/kg (s.c.), respectively, indicating 250-fold higher potency of fentanyl relative to 
morphine in rats (Haazen et al., 1999). Also, human studies report 70- to 100-fold greater 
potency of fentanyl relative to morphine (Jeal and Benfield, 1997). Importantly, the 
elimination half-life of fentanyl was longer (8-10 h) compared to morphine (2-3 h), 
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contributing to the  higher risk of fentanyl for overdose relative to morphine (Kharasch, 
2011). Due to the high lipophilicity of fentanyl, transdermal administration resulted in an 
even shorter onset of action (10-15 min) compared to subcutaneous injection (Stanley, 
2014). Fentanyl is prescribed only to treat severe pain including cancer pain, pain after 
surgery, and chronic pain. The first incidence of  prescribed fentanyl misuse was reported 
in the mid-1970s by clinicians; and more recently, escalation of fentanyl misuse and 
overdose deaths have been reported (Silsby et al., 1984; SAMHSA,  2017b). The illegal 
manufacturing of fentanyl has paralleled the recent increase in overdose deaths (CDC, 
Centers for Disease Control and Prevention, 2015). Currently fentanyl is controlled as a 
Schedule II compound, but was classified temporally (February 2018) as a Schedule I 
compound due to the epidemic of its illegal use and overdose rate (DEA, 2018).  
This synthetic opioid, methadone exhibits unique pharmacological properties. 
Methadone was synthesized first at a pharmaceutical company, IG Farben, in Germany 
in 1939. Methadone was approved by the FDA in 1947 for use as an analgesic and to 
treat cough (antitussive agent) (Rettig and Yarmolinsky, 1995). In contrast to opioids such 
as morphine or fentanyl, methadone-induced analgesic effects are mediated by MOR 
agonism and N-methyl-D-aspartate (NMDA) receptor antagonism (Gorman et al., 1997). 
MOR mediates the majority of analgesic effects of methadone, but inhibition of NMDA 
receptors expressed in the pain signal transmission pathway contribute to methadone-
induced analgesia (Gorman et al., 1997; Carpenter et al., 2000). Thus, NMDA receptor 
antagonism by methadone is one of its notable differences in mechanism of action 
compared to other opioids  (Gorman et al., 1997). Importantly, NMDA receptor antagonism 
on top of MOR agonism has allowed methadone to become an effective pain medication.  
In terms of pharmacology, methadone exhibits 75% bioavailability and is absorbed 
mostly by the stomach; peak plasma concentration occurs 2.5-4 h after oral administration, 
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which allows methadone to be suitable for oral administration (Eap et al., 2002). In 
comparison, bioavailability of morphine is 26% after oral administration (Gourlay et al., 
1986). Morphine is metabolically converted to methadone at a ratio of 10 to 1. Thus, a 
patient who chronically used a total of 440 mg/day (oral) of morphine would need 
44mg/day of methadone (15 mg/8 h, oral) for moderate to severe pain (Toombs and Kral, 
2005). Moreover, methadone-induced analgesic effects have an 8-12 h duration, which is 
longer than for morphine (3 h duration) for moderate to severe pain in humans (Toombs 
and Kral, 2005). As a pain medication, methadone exhibited comparable efficacy with 
morphine, but 1.5-fold lower than fentanyl in mice tail-flick studies (Madia et al., 2009). 
Methadone exhibited significantly improved pain reduction in opioid naïve patients 
compared to fentanyl (Haumann et al., 2016).  
Methadone (maximum dose of 30 mg/kg/day) prevented and reversed the 
acquired morphine tolerance on chronic pain (Chatham et al., 2013; Wallace et al., 2013). 
Since the 1980s, methadone has been used for opioid-tolerance chronic pain patients, 
who use opioids chronically (Portenoy and Foley, 1986). Development of methadone 
tolerance for analgesia through its chronic use has been shown to be slower compared to 
the rate of tolerance development with other opioids (Inturrisi et al., 1990).  
Since 1962, methadone was studied for its use as a treatment for narcotic use 
disorders, and specifically, it was promoted to treat heroin use disorders. In March 1973, 
the FDA approved methadone as a treatment for opioid use disorder (Rettig and 
Yarmolinsky, 1995). Methadone showed reductions in heroin craving, symptoms of heroin 
withdrawal, and mortality (Magura et al., 1998; Williamson et al., 2006). Methadone 
exhibits a long duration of action (24-36 h in human) in reducing symptoms of opioid use 
disorders (Kharasch, 2011). Methadone is a racemic mixture, containing one chiral center, 
when it was approved by FDA in 1947 as an analgesic and in 1973 as a therapeutic for 
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opioid use disorder. However, the racemic mixture of methadone exhibited 89-fold higher 
affinity for hERG channel compared to heroin (Zunkler and Wos-Maganga, 2010). 
Importantly, R-Methadone exhibits 10-fold higher affinity for MOR and 50-fold greater 
analgesic efficacy compared to the S-enantiomer (Davis and Walsh, 2001; Eap et al., 
2002). R- and S-enantiomers inhibit NMDA receptors with comparable affinity, indicating 
that both enantiomers prevent and reverse acquisition of morphine tolerance with 
comparable efficacy and potency (Chatham et al., 2013; Wallace et al., 2013). Numerous 
studies have shown that the S-methadone inhibits hERG channels with greater potency 
than the R-enantiomer, and as such, is anticipated to have greater risk of cardiac toxicity 
relative to the R-enantiomer (Kornick et al., 2003; Zunkler and Wos-Maganga, 2010; 
Mccance-Katz, 2011). In 1992, the FDA recommended that the biologically active isomer 
as a medication instead of the racemic mixture (Food and Drug Administration, 1992; 
Rettig and Yarmolinsky, 1995). The R-enantiomer of methadone was responsible for its 
analgesic effects, whereas the S-enantiomer exhibited cardiotoxicity (Davis and Walsh, 
2001; Eap et al., 2002). Thus, in 2006, the FDA warned against the potential lethal 
cardiotoxicity of racemic methadone to reduce associated deaths from overdose (Food 
and Drug Administration Public Health Service Department of Health and Human Services, 
2007).  
Although multiple studies including studies performed by Eli Lilly in the late 1940s 
proved that the R-enantiomer exhibited superior analgesic effects compared to S-
enantiomer, the R-enantiomer has not been commercially available in the US due to the 
substantial costs (Chem, 1948; Van Dyke, 1949). To be approved by FDA, the R-
enantiomer must pass through safety testing and clinical trials to prove that the R-
enantiomer is an improved medication compared to racemic mixture methadone. The R-
enantiomer of methadone is commercially available in the European Union including 
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Germany, Austria and Switzerland, and has a 5-times higher cost compared to racemic 
methadone (Lisberg and Scheinmann, 2013).  
With chronic use, racemic methadone produces rewarding effects like other 
opioids (Jasinski and Preston, 1986; Holuj et al., 2013). Interestingly, unlike morphine 
which produces conditioned place preference that becomes stronger with repeated 
treatment, methadone does not show accumulating reward over repeated treatments 
(Holuj et al., 2013). Based on a self-administration study using progressive ratio in 
monkeys, breakpoints of methadone (0.03 and 0.1 mg/kg/infusion) was 3-fold lower than 
for heroin (0.05 and 0.10 mg/kg/infusion) (Mello et al., 1988; Panlilio and Goldberg, 2007). 
These findings indicate that methadone had abuse liability like other opioids, but the 
labiality is lower relative to heroin. Thus, racemic methadone is categorized currently as a 
Schedule II compound (DEA, Drug Enforcement Administration, 2018b). Racemic 
methadone is prescribed to treat moderate to severe pain and to treat opioid use disorders.  
 
1.6.2 Epidemiology 
Since 1999, the opioid epidemic has had a positive trajectory. On October 16, 2016, 
the U.S. government has responded by officially recognizing the opioid epidemic as a 
national public health emergency (Jones et al., 2018). According to the data collected in 
2015, 92 million people aged 18 or older used prescription opioids during the past year, 
which is 38% of American adults, (Han et al., 2017). Among them, 11.5 million reported 
misuse of opioids, and 1.9 million were diagnosed as having an opioid use disorder during 
the last year (Han et al., 2017). One year later, an increased number (2.0 million) of 
American adults were diagnosed with an opioid use disorder (SAMHSA, 2017b). The 
number of adolescents  between 12 to 17 years old who were diagnosed with an opioid 
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use disorder during the past year also increased from 127,000 to 153,000 between 2015 
and 2016 (SAMHSA, 2017b). Ninety-two million adults in U.S. used opioids, and among 
them at least 1 out of 10 (12.5%) reported misuse of opioids.  
Along with the increase in the diagnosis of opioid use disorders in the U.S., the 
number of ED visits for opioid overdose have increased. Between 2016 and 2017, opioid-
involved ED visits for individuals ages 11 or older were 142,557 in the United States, 
revealing a 29.7% increase compared to the previous year. An increase in opioid-involved 
ED visits was noted in both males (30.2%) and females (24.0%), and across all age groups 
(15-24 years of age (7.3%), 25-34 years (30.7%), 35-54 years (36.3%), and 55 or older 
(31.9%)) between July 2016 and September 2017 (CDC, 2018b).  
There has been three waves or opioid overdose related deaths since 1999. The 
first wave was in 1999, which was accordance with increased opioid prescriptions for pain. 
At that time, opioid overdoses were due to opioids extracted mostly from opium and to 
semi-synthetic opioids. The second wave was in 2010, which mainly involved heroin. 
Reports indicated that 5.1 million people aged 12 or older reported heroin use during their 
lifetime, which account for 1.9% of Americans in 2015. Among them, 882,000 and 329,000 
reported heroin use in the last year and month, respectively; thus, revealing the heroin 
epidemic (SAMHSA, 2017b). Compared to 2010 and 2014, in 2015, there was a 328% 
and 22.8% increase, respectively in heroin overdose deaths (NIDA, 2017). The third wave 
was in 2013 and is related to the increase in illegal manufacturing of fentanyl (Dowell et 
al., 2017; Schiller and Mechanic, 2018). With this rapid and dramatic increase in fentanyl 
deaths, the DEA in February 2018 temporally categorized fentanyl as a Schedule I 
compound (DEA, 2018). Fentanyl and fentanyl-related synthetic opioids were responsible 
for a 72.2% increase in fatal overdoses in one year (2014-2015) (Schiller and Mechanic, 
2018).  
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Interestingly, cocaine overdose deaths rates have stabilized since 2008, but 
increased by 1.8-fold between 2012 and 2015, paralleling the use of  opioid and cocaine 
combinations (Schiller and Mechanic, 2018). Specifically, overdose rates resulting from 
the combination of prescription opioids and cocaine combinations has decreased by 3.9%; 
however, combinations of cocaine with synthetic opioids including fentanyl and fentanyl 
related compounds were associated with increased (22.5%) overdose deaths between 
2014 and 2015 (Kandel et al., 2017).  According to the CDC, overdose deaths from the 
use of fentanyl and cocaine combinations has increased (17.1-fold) between 2013 and 
2016, paralleling the rapid increase in cocaine-induced overdose deaths (Lopez, 2018). 
In contrast, methadone-related death has decreased by 9.1% between 2014 and 2015 
(CDC, 2016).  
Overall, opioid overdose deaths, including prescription and illicit opioids, has 
increased more than 425% in 2016 compared to 1999 (NIDA, 2017). Opioid overdose 
deaths in  2016 was more than 42,200, which was increased compared to 28,647 in 2014 
and 33,091 in 2015 (NIDA, 2017; Jones et al., 2018). In the substance overdose related 
deaths in 2016, the 65% of overdose deaths were opioid-related (Schiller and Mechanic, 
2018). Taken together, rapid increase in opioids use in U.S. is leading the fast growth of 
opioids overdose deaths. Also, the increased opioids use contributed to the growth of the 
national substance overdose deaths.  
 
1.6.3 Mechanism of Action Underlying Opioid Use Disorder  
Opioid-induced rewarding effects have resulted in an epidemic of opioid use 
disorder and overdose deaths. Three opioids are problematic, including morphine (an 
extracted opioid from opium), heroin (a semi-synthesized opioid), and fentanyl (a 
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synthesized opioid) (CDC, 2017). In this section, the mechanism of action of these opioids 
is reviewed, as well as the mechanism of action of endogenous opioids. 
Greater expression of DOR and KOR, but relatively lesser expression of MOR has 
been found in NA (Svingos et al., 2001; Le Merrer et al., 2009). DOR and MOR expression 
on cholinergic neurons cell bodies have been found, but KOR found on the DA neuron 
terminals  (Dourmap et al., 1997; Svingos et al., 2001; Britt and McGehee, 2008). Indeed, 
cholinergic neuron lesion in the NA, intra-NA infused a MOR agonist (DAMGO) were not 
able to increase DA levels in the NA (Dourmap et al., 1997). Thus, the activation of DOR 
and MOR increased DA release in the NA by increasing cholinergic input into the DA 
neuronal terminal in the NA (Longoni et al., 1991; Pentney and Gratton, 1991; Spanagel 
et al., 1992). Whereas KOR activation decreased DA release in the NA by decreasing 
responses to the intended action potential from the VTA (Spanagel et al., 1990; Svingos 
et al., 2001; Britt and McGehee, 2008). 
Historically, the primary use of opioid receptor agonists from ancient to current 
times is inhibition of pain signaling, which is associated with a considerable respiratory 
depression side-effect (Jones et al., 2018). Based on research with KO mice, the 
analgesic effects induced by opioid receptor activation are mainly mediated via MOR 
(Kieffer and Gaveriaux-Ruff, 2002). The analgesic effects of opioid receptor agonists are 
accompanied by rewarding effects at the same doses that produce analgesia. Also, MOR 
activation results in increased extracellular DA concentration in the NA.  
Morphine, an opiate,  exhibits high affinity for MOR (Ki = 1.8 ± 0.6 nM) compared 
to DOR (160 ± 90 nM) or KOR (Ki = 47 ± 3 nM), evidenced by competitive binding assays 
(Mignat et al., 1995). Systemically administered morphine passes through the blood-brain 
barrier due to its lipophilicity (logP = 1.07) and activates brain opioid receptors (Peckham 
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and Traynor, 2006). Also, morphine-induced analgesic and rewarding effects were 
abolished in MOR KO mice, indicating a critical role of MOR in the mechanism of action 
of morphine (Matthes et al., 1996; Schuller et al., 1999). Morphine binding to MOR results 
in coupling to Gi protein. Thus, morphine reduced cytosolic calcium and cAMP, but 
increased potassium efflux. Consequently, morphine reduces neurotransmitter release 
and hyperpolarizes neurons, which mediates its analgesic effects, when activated MOR 
are located on the pain signaling pathways, such as the pain circuitry (spinal cord, 
periaqueductal gray (PAG), brain stem, medulla, hypothalamus, amygdala (Basbaum and 
Fields, 1978). When morphine activates brain MOR, specifically midbrain MOR, it 
produces rewarding effects. Activation of MOR expressed on terminals of GABA neurons 
in the VTA results in a reduction of GABA release onto DA neurons in the VTA. GABA is 
an inhibitory neurotransmitter, so that GABA release into the VTA decreases firing rate of 
VTA DA neurons. Inhibition of GABA neuron in the VTA by microinfusion of a MOR agonist, 
[D-Ala2,N-methyl-Phe4,Gly5-ol]enkephaline (DAMGO; 0.1 and 1.0 nmol), resulted in a 
dose-dependent increase in DA concentration in the NA (Spanagel et al., 1992). Also, an 
agonist of MOR, morphine activates VTA DA neurons in rats (Gysling and Wang, 1983). 
Thus, MOR activation disinhibits DA neuron in the VTA, which elevate DA extracellular 
concentration in the NA (Johnson and North, 1992). Intravenous morphine (1 and 5 mg/kg) 
increased DA levels in the NA to 60-100% of baseline, which was completely inhibited by 
pretreatment with naloxone (1-3 mg/kg, i.p.; a nonselective opioid receptor antagonist ) in 
rats (Kosterlitz, 1985). In contrast, DOR selective antagonist (naltrindole, 1 mg/kg, i.p.) 
partially inhibited morphine-induced DA increase in the NA (Borg and Taylor, 1997). Also, 
morphine injection (0.5-1.5 mg/kg, i.v.) significantly reduced activity of VTA neurons, 
except DA contained neurons in the VTA, which was reversed by naloxone (Gysling and 
Wang, 1983). Additionally, activation of GABA neurons in the VTA by GABA receptor 
agonist (baclofen, 0.1nmol/side) into the VTA inhibited acquisition and expression of 
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morphine (10 mg/kg, s.c.)-induced hyperlocomotion, indicating that morphine-induced DA 
release in NA is mediated via inhibition of VTA GABA neurons (Leite-Morris et al., 2004). 
In addition, intra-NA microinfusion of morphine dose-dependently (125, 250 and 500 ng) 
increased DA levels in the NA, which was significantly inhibited by pretreatment with 
naltrindol (i.p., a DOR antagonist) but not naloxone (Borg and Taylor, 1997). Taken 
together, these findings indicate that morphine activation of MOR in VTA and DOR in NA 
resulted in DA release in NA via both DA dependent and independent mechanisms. Also, 
acute morphine did not cause MOR internalization, while endogenous opioids rapidly 
promoted receptor endocytosis after its activation, indicating higher abuse liability of 
morphine by producing longer lasting DA level increased (Keith et al., 1996, 1998; Sternini 
et al., 1996). Further, systemic morphine injections induced CPP in multiple animal models. 
Also, numerous studies show that animals acquire intravenous morphine self-
administration behavior, like human opioid use disorders. Thus, MOR activation by 
morphine resulted in rewarding effects by disinhibiting DA neurons in the VTA.  
Heroin is a semi-synthetic morphine analog also known as diacetylmorphine 
((5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate (ester)). 
Acetylation of morphine at 3- and 6-positions provides heroin with greater lipophilicity 
(logP = 1.88) compared to morphine (logP = 1.07) (Peckham and Traynor, 2006). Thereby, 
68% of intravenously administered heroin was absorbed into the brain, which is higher 
than morphine (less than 5%) (Oldendorf et al., 1972). Also, according to studies in chronic 
pain patients or healthy volunteers, peak concentrations of heroin in blood were within 1 
min, 3-5 min, and 5-10 min after intravenous, intranasal and intramuscular, and 
subcutaneous administration, respectively; thusindicating rapid absorption of heroin (Way 
et al., 1960; Inturrisi et al., 1984; Skopp et al., 1997). When heroin enters the brain, it is 
hydrolyzed into 6-monoacetylmorphine within 5-10 min by carboxylesterase, and then it is 
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metabolized into morphine within 20-30 min by carboxylesterase (Umans and Inturrisi, 
1981, 1982). The first metabolite of heroin, 6-monoacetylmorphine, produces analgesic 
effects by interacting with MOR and DOR (Rady et al., 1994, 1997). Both metabolites of 
heroin are active and considered responsible for analgesic and rewarding effects of heroin 
(Inturrisi et al., 1983, 1984). Thus, heroin has a 30 min half-life and 4-5 h duration of action 
(Reisine and Pasternak, 1996). The heroin metabolites, 6-acetylmorphine (IC50 = 73 nM) 
and morphine (IC50 = 53 nM) exhibited higher affinity for opioid receptors than heroin (IC50 
= 483 nM) demonstrated using binding assays with radiolabeled naltrexone, a non-specific 
opioid receptor antagonist (Inturrisi et al., 1983). These findings suggested that heroin 
produces its effects via its metabolites, 6-acetylmorphine and morphine. In agreement with 
this, the half-life of heroin, 6-acetylmorphine, and morphine after inhalation of heroin were 
3.2 ± 0.3 min, 26 ± 0.9 min, and 184 ± 7.2 min, respectively (Rook et al., 2006). Also, 
heroin (10 µM) produced 10% of MOR internalization, comparable with morphine (10 µM, 
>5%), but lower than beta-endorphin (1 µM, 28%) (Keith et al., 1998). Overall, the effects 
and mechanism of action of heroin overlap with morphine but has a greater efficacy due 
to the rapid absorption and high penetration rate through the blood-brain barrier.  
Fentanyl is a synthetic opioid involved in the most recent opioid epidemic, and is 
a opioid (Stanley, 2014). Fentanyl is not structurally related to morphine or heroin, but 
produces analgesic and rewarding effects by acting as an agonist at opioid receptors 
(Yoshida et al., 1999). Fentanyl exhibited 2- to 4-fold higher lipophilicity (logP = 4.28) 
compared to heroin and morphine, respectively, which allows fentanyl to readily penetrate 
the blood-brain barrier compared to morphine and heroin (Peckham and Traynor, 2006). 
Also, fentanyl exhibits 16-fold higher affinity for MOR compared to morphine (Bot et al., 
1998). Although, fentanyl (10 µM) produced 18% of MOR internalization, more clinically 
relevant analgesic doses of fentanyl (1-50 nM) did not produce detectable MOR 
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internalization (Keith et al., 1998; Martini and Whistler, 2007). Clinical studies with 
postsurgical patients show that intramuscularly (i.m.) administered fentanyl (0.2 mg) 
exhibits equivalent analgesic effects with 10 mg (i.m.) of morphine, indicating 50-fold 
higher potency of fentanyl compare to morphine in humans (Finch and DeKornfeld, 1967). 
Although, affinity of fentanyl (Ki for MOR = 1.2 ± 0.2 nM) for MOR was comparable to 
morphine (Ki for MOR = 1.8 ± 0.6 nM), the high lipophilicity of fentanyl and low rate of 
fentanyl-induced MOR internalization results in analgesia with 50-fold higher potency 
relative morphine (Maguire et al., 1992; Mignat et al., 1995).  
Respiratory brainstem neurons express MOR and opioids activate MOR 
depressing ventilation (van der Schier et al., 2014). Dose-dependent analgesia and 
respiratory depression produced by morphine was not observed in MOR KO mice 
(Romberg et al., 2003). Fentanyl exhibits high affinity at MOR and induced respiratory 
depression at the same or higher dose as that producing analgesic effects, similar to 
morphine (Downes et al., 1967). In healthy volunteers, fentanyl (1, 2, and 4 µg/kg, i.v.)-
induced analgesic effects lasted for 90 min after administration. With the same dose range 
of fentanyl, respiratory depression had a duration of 120 and 240 min, respectively (Bailey 
et al., 1990).  
Microdialysis showed fentanyl (5 and 10 ug/kg iv, or intra-NA infusion 0.5-5 nmol) 
-induced dose-dependent increases in extracellular DA in the NA in rats, indicating that 
fentanyl activated MOR and DOR (Yoshida et al., 1999). In contrast to morphine exhibiting 
89- and 26-fold selectivity for MOR over DOR or KOR, respectively, fentanyl showed 
higher selectivity for MOR over KOR (Maguire et al., 1992; Mignat et al., 1995). Fentanyl 
exhibited 150- and 242-fold selectivity for MOR over DOR and KOR, respectively (Maguire 
et al., 1992). Due to low affinity of fentanyl for KOR, fentanyl increased DA in NA more 
effectively than morphine (Yoshida et al., 1999). Local NA injection of fentanyl (5 nmol) 
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increased DA release in NA up to 682% of baseline, which was higher than intra-NA 
infusion of morphine (Yoshida et al., 1999). Intra-NA infusion of morphine (250 and 500 
ng) increased DA in the NA by 70 to 80% of baseline (Borg and Taylor, 1997). Moreover, 
fentanyl (0.01 mg/kg, s.c.) or morphine (1 mg/kg) increased DA in NA by 90% or 70% of 
baseline, respectively, suggesting higher abuse liability of fentanyl compared to morphine 
(Di Chiara and Imperato, 1988b).  
Endogenous opioids consisted of endorphins, enkephalins, and dynorphins act by 
activating opioid receptors. MOR, DOR, and KOR, respectively, which are G-protein 
coupled receptors, coupling to Gi proteins. Activation of opioid receptors results in 
inhibition of adenylyl cyclase activity, which decreases cAMP concentration in the 
neuronal cytosol. Activation of opioid receptors decreases calcium ion influx and increases 
cytosolic potassium ion concentration by closing calcium channel and opening potassium 
ion channels, respectively. Consequently, activation of opioid receptors expressed on 
presynaptic neuronal membranes reduces neurotransmitter release by inhibiting a 
response of inward action potential. Activation of opioid receptors located on postsynaptic 
neuronal membranes decreases downstream signaling of the response to excitatory 
neurotransmitters (Kapitzke et al., 2005; McDonald and Lambert, 2005). Depending on 
where the opioid receptors are expressed, multiple effects are observed after opioid 
receptor activation (Froehlich, 1997; Le Merrer et al., 2009).  
To summarize, MOR agonists, including morphine, heroin, and fentanyl, exhibit 
analgesic and rewarding effects. MOR are expressed in numerous regions of the central 
and peripheral nervous systems including within the pain circuitry (spinal cord, PAG, brain 
stem, medulla, hypothalamus, and amygdala) and reward circuitry (midbrain, VTA and 
NA). Other commonalities of MOR agonist administration are increased extracellular DA 
levels in NA, indicating an important role of the mesocorticolimbic DA system in opioid 
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reward and indicating that affinity for MOR underlies the abuse liability of these opioids. 
Activation of MOR by endogenous opioids results in rapid internalization, which decreases 
signaling transduction mediated by MOR (Sternini et al., 1996; Keith et al., 1998). In 
contrast to endogenous opioids, exogenous opioids, including morphine, heroin, and 
fentanyl, show a low rate of internalization of MOR after acute administration, which results 
in enhanced analgesic and rewarding effects induced by exogenous opioids compared to 
endogenous opioids (Hashimoto et al., 2006). Chronic morphine administration (day 1-2, 
10mg/kg; day 3-4, 20 mg/kg; day 5-6, 40 mg/kg; and day 7, 80 mg/kg, s.c. to Porcelluus 
guinea pigs) results in increased internalization, which contributes to tolerance 
development to morphine effects including analgesia and reward (Patierno et al., 2011; 
Allouche et al., 2014). Heroin and fentanyl exhibit 4- to 2-fold greater lipophilicity compared 
to morphine and heroin, respectively, indicating a faster rate of these opioids penetrating 
the blood-brain barrier when an equivalent dose is administered. Although affinity for MOR 
of fentanyl and morphine are comparable, fentanyl exhibits 4-fold higher lipophilicity and 
higher selectivity for MOR over KOR (242-fold) than morphine (26-fold), which results in 
50-fold higher potency in analgesia. The affinity of heroin and it’s a metabolite (6-
acetylmorphine) mediating rewarding effects are also lower than fentanyl by 10- and 1.5-
fold, respectively. Thus, the MOR activation by exogenous opioids including fentanyl, 
morphine, and heroin results in rewarding effects and tolerance development following 
chronic administration of exogenous opioids, which contribute to the development of 
opioid use disorders.  Importantly, respiratory depression, which is also mediated by MOR, 
is of the greatest concern as a side effects due to its contribution to the epidemic of opioid 
overdose deaths. 
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1.6.4 Clinical and Preclinical Therapeutics  
The government of United States has made two political efforts including 
Prescription Drug Monitoring Programs (PDMPs) and the National All Schedules 
Prescription Electronic Reporting Act (NASPER) to reduce opioid prescriptions and to 
prevent prescription opioid-induced overdose deaths. With these systems in place, opioid 
prescriptions and opioid overdose deaths have decreased by 8% and 12%, respectively 
(Dowell et al., 2016). In addition, four pharmacotherapeutics have been approved by the 
FDA to treat opioid use disorders and opioid overdoses. There are two types of 
pharmacotherapeutics approved: agonist substitution therapy to reduce withdrawal, and 
antagonists to reverse overdose effects of opioids.  
Historically, the first pharmacotherapy for heroin use disorders was methadone, a 
synthetic opioid agonist at MOR. Methadone use was approved by FDA in 1947 and was 
approved for treatment of heroin use disorders in the 1960s. Methadone is a long-lasting 
(half-life of 22 h) opioid agonist with high bioavailability (75%) following oral administration 
(Eap et al., 2002). Also, oral administration of levomethadyl acetate (also known as levo-
alpha-acetylmethadol or LAAM), an analog of methadone, exhibited 92-h of half-life and 
was approved to treat heroin use disorder as an alterative to methadone by FDA in 1993.  
However, it  was withdrawn in 2007 due to cardiac adverse effects including increases in 
the cardiac QT interval (Tetrault and Fiellin, 2012).  
Buprenorphine is a semi-synthetic opioid derivative of thebaine and a partial 
agonist at MORs with about 20-fold higher affinity for MOR compared to morphine 
(Vardanyan and Hruby, 2016). Buprenorphine displaces the binding of opioids (such as 
morphine, methadone) at MOR (Bickel et al., 1988; Rosen et al., 1994; Strain et al., 2002). 
Buprenorphine also exhibits a low dissociation rate, which indicates that it can produce a 
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prolonged inhibition of opioid withdrawal and that it requires a less frequent dosing 
schedule than once per day (Amass et al., 1994). When administered via sublingual and 
buccal routes, buprenorphine showed high bioavailability, 51% and 28%, respectively 
(Kuhlman et al., 1996). In addition, buprenorphine is a partial agonist of MOR, which 
indicates that buprenorphine-induced MOR activation efficacy is lower compared to full 
agonists such as morphine, heroin, or methadone. Thus,  the side effects including 
respiratory depression of buprenorphine show a plateau, indicating that a higher dose is 
able to induce less severe side effects compared to full agonists (Center for Substance 
Abuse Treatment, 2004). Buprenorphine was approved to treat pain and opioids 
dependence (equivalent to moderate to severe opioids use disorders in DSM-5) as a 
monotherapy by FDA in 2002 (Center for Substance Abuse Treatment, 2004). Thus, the 
MOR agonist buprenorphine prevents relapse by reducing opioid withdrawal symptoms 
caused by decreased endogenous opioid signaling, including VTA DA neuronal activity 
during withdrawal. Sublingual buprenorphine (16 mg per day) for 12 months was 
administered to opioids dependents. Retention in treatment for 12 months in 
buprenorphine and placebo groups were 75% and 0%, respectively. Also, the urine 
screens revealed 75% negative for opioids, stimulants, and cannabinoids among the 
patients who maintained buprenorphine for 12 months (Kakko et al., 2003).  However, 
buprenorphine is a Schedule III substance, indicating potential to develop moderate or low 
substance use disorders. Heroin dependents who maintained heroin abstinence for about 
a week self-administered 2 and 8 mg of buprenorphine instead of making a choice for $20, 
indicating potential of buprenorphine to substitute heroin in patients who detoxified 
recently (Comer and Collins, 2002). Also, buprenorphine produced mild elevation of the 
liver enzymes AST and ALT, which would suggest benefits for liver function tests prior to 
buprenorphine treatment (Welsh and Valadez-Meltzer, 2005). Thus, buprenorphine 
exhibited efficacy in clinic to increased opioids abstinence rate, but strict control is 
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necessary to prevent misuse of buprenorphine. Also, liver testing and drug-drug 
interaction should be considered prior to buprenorphine treatment to prevent hepatic 
toxicity and unexpected medical condition, respectively.  
Naltrexone is an antagonist at opioid receptors (Ki for MOR, DOR, and KOR are 
1, 149 and 3.9 nM, respectively), and was approved by FDA in the 1970s as a treatment 
for heroin use disorder (Raynor et al., 1994; Newman and Rothman, 2007). Based on 
analyses of 13 studies using oral naltrexone, only 28% of initial participants were retaining 
with the oral naltrexone treatment, which concluded no difference between placebo and 
oral naltrexone (Minozzi et al., 2011). While in a study using intramuscular injectable 
extended-release naltrexone (required once a month injection, maintaining plasma 
naltrexone level to 1-2 ng/mL), naltrexone and placebo groups achieved 51% and 31% 
opioids abstinence for 24 weeks, respectively (Nunes et al., 2015). Another study also 
showed that 62% of patients retained intramuscular extended-release naltrexone for 12 
months, and 51% of remaining participants achieved opioid abstinence (Krupitsky et al., 
2013). The extended-release naltrexone achieved higher retention rate to naltrexone 
treatment relative to oral naltrexone by altering the dosing schedule to once monthly 
injection (380 mg, i.m.) from once daily oral administration (40-200 mg). The intramuscular 
administration of naltrexone exhibited higher bioavailability and increased elimination half-
life (100% and 4.9 days, respectively) compared to oral administration of naltrexone (5-
40% and 9 h, respectively) (Dunbar et al., 2006). However, administration of opioids with 
naltrexone has potential to lead a fatal overdose (O’Connor and Kosten, 1998; Boyce et 
al., 2003). Since naltrexone is an antagonist of opioid receptors, patients may administer 
large quantity of opioids to obtain reinforcing effects of opioids, indicating importance of 
maintaining opioid abstinence condition during the naltrexone treatment to avoid life-
threatening risk.    
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Naloxone is an antagonist at opioid receptors (Ki for MOR, DOR, and KOR are 1.1, 
16 and 12 nM, respectively) (Tam, 1985). FDA approved i.v. and i.m. naloxone in 1971 
and nasal spray naloxone in 2017 to treat opioid overdoses. Naloxone exhibits a shorter 
onset of action (1-2 or 2-5 min after i.v or s.c. administration, respectively) compared to 
naltrexone (1-2 h, oral), indicating advantage of naloxone to treat opioid overdoses by 
rapidly reversing opioid binding on opioid receptors (Licko, 1981; Koyyalagunta, 2007). 
Rapid association-dissociation kinetics of naloxone and high affinity for MOR (Ki = 1.1 nM) 
of naloxone allow effective reversal of opioid-induced respiratory depression (Rzasa Lynn 
and Galinkin, 2018). Naloxone also exhibits 100-fold higher affinity for MOR compared to 
heroin, indicating efficient replacement of heroin by naloxone on MOR to reverse heroin-
induced respiratory depression (Kleber et al., 1985). However, naloxone affinity for MOR 
is comparable to morphine and fentanyl (Ki = 1.8 and 1.2, respectively), and 20-fold lower 
than buprenorphine (Vardanyan and Hruby, 2016). Along the affinity and association-
dissociation kinetics of opioids, multiple factors such as the duration of effect of opioids 
administered, quantity of opioids presented in blood resulting respiratory depression, and 
patients’ ability to clear opioids should be considered to determine the adequate dose of 
naloxone (Rzasa Lynn and Galinkin, 2018). Importantly, the elimination half-life of 
naloxone is 30-80 min. Thus, when opioids exhibiting longer elimination half-life (i.e. 
fentanyl 8-10 h) was administered, or unknown opioids were administered, then observing 
patients at least for 80 min would reduce risk of reoccurrence of respiratory depression 
(Kharasch, 2011). As a therapeutic for opioids overdose, naloxone exhibits beneficial 
properties including rapid onset of action, high affinity for MOR, and rapid elimination, but 
as a mono-therapeutic for opioid use disorders naloxone has limitations with the rapid 
elimination.   
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The buprenorphine and naltrexone as a combination product was approved by the 
FDA in 2002 (Center for Substance Abuse Treatment, 2004). Since a partial agonist of 
MOR, buprenorphine also exhibits abuse liability, like other full MOR agonists, naltrexone 
was included in the combination product to reduce misuse of buprenorphine among those 
with opioid use disorders (Alho et al., 2007). Bioavailability following sublingual 
administration of naloxone is lower than bioavailability of buprenorphine, resulting in 
predominant effects of buprenorphine in patients when it is administered through a 
sublingual route (Preston et al., 1990). However, when injected, naloxone provides the 
predominant effects over buprenorphine due to the high parenteral bioavailability of 
naloxone (Stoller et al., 2001). Thus, patients would experience opioid withdrawal 
symptoms with dysphoria when the combination sublingual tablet was misused via i.v. 
administration. The combination therapy shows no additional safety or side effect issues 
compared to buprenorphine monotherapy (Harris et al., 2000). Thus, the buprenorphine 
and naloxone combination treatment provides advantages compared to monotherapy of 
buprenorphine, naloxone, and naltrexone by reducing abuse potential, improving duration 
of action, and reducing opioids antagonist-induced dysphoria (Center for Substance 
Abuse Treatment, 2004).   
 Patients who received pharmacotherapeutics with behavioral therapy remained 
opioid abstinent longer and exhibited a reduction in their symptoms of opioid withdrawal 
compared to the control group who received behavioral treatment only, which emphasize 
importance of pharmacotherapeutics in treating substance use disorders (Mattick et al., 
2014). Although there has been some success combating the opioid use disorder 
epidemic with available pharmacotherapeutic treatments, the opioid use disorder 
epidemic is currently growing overall in the United States. Continuous growth of the opioid 
use disorder epidemic is due to the limitation of existing pharmacotherapeutics such as 
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low adherence rates and failure on blocking cue-, stress-, or drug-induced relapse 
(Chartoff and Connery, 2014). Thus, this current dissertation focuses on discovering 
pharmacotherapeutics for opioid use disorders by inhibiting cholinergic systems in brain, 
and is further discussed in Chapters 2 and 3 as a potential treatment for the opioid use 
disorder epidemic. 
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Figure 1.4. Structures of opioids. 
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1.7 Hypothesis and Specific Aims 
Substance use disorders are a growing health concern in the United States, which 
lead high social costs in our society (Florence et al., 2016; CDC, 2017). Although much 
research has shown the high abuse liability of METH and cocaine, there are no FDA-
approved pharmacological medication for METH or cocaine use disorders. Thus, millions 
of Americans are currently using METH or cocaine, and suffering currently or in near future 
with METH or cocaine use disorders: there is no pharmacotherapeutic help for them. 
Furthermore, opioid use disorders are the most recent growing issue in the U.S. There 
have been several pharmacotherapeutics for opioid use disorders, but it is still one of the 
highly ranked substances resulting in substance use disorders in the U.S. 
 
1.7.1 Project 1: Discovering Pharmacotherapeutics for METH Use Disorder 
1.7.1.1 Background Information  
In contrast to cocaine or opioids, METH is able to release DA into the synaptic cleft in 
the NA without altering DA projection from the VTA. Thus, a different pharmacological 
target based on the specific pharmacodynamic profile of METH and a different hypothesis 
are investigated in this dissertation (Chapters 2 and 3) to discover pharmacotherapeutics 
for METH use disorders. Since there was no FDA-approved medication for METH use 
disorder, there is a great need for this current research. As reviewed in section 1.6, METH 
increased DA in the cytosol in the neuronal terminal, which was released into the synaptic 
cleft. Especially, METH-induced DA in the NA served a critical role for METH-induced 
rewarding effects. When the substance-induced DA release in the NA was absent, 
acquisition of substance self-administration behavior was not formed (Lyness et al., 1979). 
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Also, maintaining self-administration behavior was reduced when the DA release was 
absent after self-administration training, suggesting that inhibition of substance-induced 
rewording effects reduced maintenance of self-administration behavior (Lyness et al., 
1979). Since the inhibition of VMAT2 DA uptake by VMAT2 inhibitor, lobeline reduced 
METH-evoked DA release, reduced METH self-administration, and VMAT2 was evaluated 
as a novel target for discovering medication for METH use disorders (Harrod et al., 2001; 
Wilhelm et al., 2008). There were continued years of effort to discover VMAT2 selective 
lobeline analogs as a pharmacotherapeutic for METH use disorders. In this current 
dissertation, two analogs of lobeline were investigated based on the hypothesis below and 
specific aims to discover new medication for METH use disorders.     
VMAT2 is one subtype in a family of transmembrane proteins consisting of 12 
transmembrane regions, which are highly expressed in the central nervous system 
(Schütz et al., 1998). VMAT1 is often found in the peripheral nerve system exhibiting high 
affinity for DA, 5-HT, and NE (Schütz et al., 1998); whereas VMAT2 and VMAT1 exhibit 
60% of amino acid sequence homologue, which contributed different uptaking affinity 
(Anne and Gasnier, 2014). VMAT2 uptakes monoamines including DA, 5-HT, and NE from 
cytosol into synaptic vesicles via proton-dependent process (Erickson et al., 1992). The 
amino acids sequence homology of VMAT2 is conserved well across mammalian. The 
sequence of VMAT2 in mice are 96% and 92% identical with rats and humans, 
respectively (Takahashi and Uhl, 1997). The proton-dependent process is mediated via 
the H+-ATPase enzyme, which is expressed on the synaptic vesicle membrane (Anne and 
Gasnier, 2014) . The enzyme uptakes a proton using the energy obtained by hydrolyzing 
one ATP molecule to ADP from the cytosol, which allows the inside of the vesicle to stay 
in an acidic pH of 5.5, compared to cytosol (pH 7.4). This pH gradient between inside and 
outside of vesicles is the driving force of DA uptake from cytosol into vesicle via VMAT2 
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(Chaudhry et al., 2008; Wimalasena, 2011; Chaudhury et al., 2013). A proton in vesicle 
binds to the VMAT2, which leads conformational change of VMAT2. This allows DA 
presented in cytosol binding on the DA binding site at VMAT2. Subsequently, when the 
VMAT2 converts its conformation, the proton bound to VMAT2 is released into the cytosol 
and DA is released into the vesicles. Monoamines stored in vesicles are released via 
exostosis into the synaptic cleft following action potential. After the action potential, the 
released DA is uptaken via DAT into cytosol, and then, it is either metabolized into 3,4-
dihydroxyphenylacetic acid (DOPAC) via monoamine oxidase (MAO) or uptaken via 
VMAT2 into vesicles for storage (Wimalasena, 2011; Anne and Gasnier, 2014).  
 
1.7.1.2 Hypothesis 1 and Specific Aims  
Hypothesis 1 (Chapters 2 and 3). Selective and potent inhibition of the VMAT2 function 
reduces the neurochemical and behavioral response to METH. 
Specific Aim 1. Identify selective inhibitors of VMAT2 using neurochemical approaches. 
Specific Aim 1.1. Determine if analogs exhibit high affinity for VMAT2 and high 
potency at inhibiting VMAT2 DA uptake function. 
Specific Aim 1.2. Determine selectivity of analogs for VMAT2 over human ether-a-
go-go-related gene (hERG) channel, DAT, SERT and nAChRs. 
Specific Aim 1.3. Determine if VMAT2 selective inhibitors inhibit METH-evoked 
vesicular DA release. 
Specific Aim 2. Determine if selective VMAT2 inhibition exacerbates METH-induced 
striatal DA depletion. 
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Specific Aim 2.1. Determine if selective VMAT2 inhibitors alter striatal DA content. 
Specific Aim 2.2. Determine if selective VMAT2 inhibitors exacerbate METH-
induced striatal DA depletion.  
Specific Aim 3. Determine if selective VMAT2 inhibition decreases response to METH in 
animal models using behavioral pharmacological approaches. Determine if 
VMAT2 selective inhibitors, 
- block METH-induced hyperactivity in METH-sensitized rats (Specific Aim 3.1).  
- decrease METH self-administration, but food-maintained response (Specific 
Aim 3.2). 
- substitute METH in METH self-administered rats (Specific Aim 3.3).  
- serve as a reinforcer (Specific Aim 3.4). 
- develop tolerance by repeated injections to decrease METH self-administration 
(Specific Aim 3.5). 
- decrease cue-induced or METH-induced METH reinstatement (Specific Aim 
3.6). 
- are surmountable by increased METH unit doses (Specific Aim 3.7). 
In Chapter 2, potency and selectivity of R-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-
yl)propan-1-amine (GZ-11610, R-enantiomer of GZ-888) are studied and the effect of 
subcutaneous and oral administration of GZ-11610 on METH-induced hyperlocomotor 
activity in METH-sensitized rats is examined. Chapter 3 describes and studies potency 
and selectivity of S-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine (GZ-
11608, S-enantiomer of GZ-888) for VMAT2 over DAT, SERT, and hERG. The ability of 
GZ-11608 to inhibit METH-evoked vesicular DA release is measured. Toxicity of GZ-
11608 on METH-induced striatal DA depletion is evaluated. The effect of subcutaneously 
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administered GZ-11608 on METH-induced hyperlocomotor activity in METH-sensitized 
rats, METH SA, food-maintained response are evaluated. Also, abuse liability of GZ-
11608 is examined using a METH substitute study and a GZ-11608 self-administration 
study. An evaluation to see if GZ 11608 administration is able to develop tolerance is 
presented. Finally, surmountability of GZ-11608 effects on METH self-administration is 
studied using a range of METH unit doses.     
The purpose of this dissertation is to discover pharmacotherapeutics for opioid, 
cocaine and METH use disorders by investigating analogs inhibiting substance-induced 
rewarding effects. For that, two different novel therapeutic targets, M5 mAChRs and 
VMAT2, are investigated. Due to differences of the underlying rewarding mechanism 
among substances, two different hypotheses are proposed; One for discovering opioid 
and cocaine use disorder therapeutics, and the other for METH use disorder treatments. 
The overall hypothesis of this dissertation is that inhibition of substance-induced rewarding 
effects by inhibiting substance-induced DA release in the NA would reduce substance 
seeking and taking behaviors. 
 
1.7.2 Project 2: Discovery Pharmacotherapeutics for Cocaine and Opioid Use 
Disorders 
1.7.2.1 Background Information  
As reviewed by previous sections, especially, substance-induced DA increased in 
the NA served a crucial role in compulsive substance seeking and using (Wise and 
Rompre, 1989; Di Chiara and Bassareo, 2007). Thereby, inhibition of substance-induced 
DA release in the NA by DA neuron specific lesion or pharmacological approaches 
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resulted in inability of acquirement of substance self-administration or maintenance of 
substance self-administration behaviors. Importantly, DA release in the NA was projected 
from the VTA DA neurons. The DA neuron activation in the VTA was depending on 
multiple factors including acetylcholine inputs. Interestingly, among five subtypes of 
mAChRs (M1-M5), M5 subtypes were highly expressed on the DA neurons in the VTA 
(Vilaro et al., 1990; Weiner et al., 1990; Yasuda et al., 1993; Lein et al., 2007; Yeomans, 
2012). In contrast, M1-M4 subtypes were found on cholinergic neurons instead of 
dopaminergic neurons (Vilaro et al., 1990; Yeomans, 2012). Although, in comparison of 
mAChR subtype expression levels in the brain, the M5 mAChRs expression level was 1% 
of total M1-M5 mAChRs in the brain: M5 mAChRs were highly concentrated in the VTA 
(Yasuda et al., 1993; Lein et al., 2007). The cholinergic axons placed in the VTA frequently 
innervated DA synapses in the NA, but rarely prefrontal DA neurons (Omelchenko and 
Sesack, 2006). Indeed, electrical stimulation of the laterodorsal terminal nucleus (LDT) 
from where the cholinergic input in the VTA projected increased extracellular DA in the NA 
(Oakman et al., 1995; Forster and Blaha, 2000). Certainly, LDT-evoked DA release in the 
NA was significantly reduced in the M5 mAChRs KO mice (Forster and Blaha, 2000). 
Specifically, LDT stimulation induced three phages of DA release in the NA: a rapid initial 
increase of DA, a subsequent decrease, and final prolonged increase of DA. In the M5 
mAChR KO mice, cholinergic input following LDT stimulation was not able to induce the 
final prolonged DA release (Forster et al., 2002). Reversely, activation of M5 mAChRs 
using oxotremorine (an agonist of mAChRs without subtype preferences) resulted in DA 
release from striatal slices, which was significantly (>50%) reduced in the M5 mAChRs 
KO mice (Yamada et al., 2003). These findings suggest the possibility of the critical role 
of M5 mAChRs on rewarding effects. Additionally, the LDT innervation that resulted in DA 
release in the NA via activating DA neurons in the VTA was known to mediate natural 
reinforcement, such as food-induced rewarding effects (Sakurai, 2007). Interestingly, the 
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M5 mAChR KO mice exhibited significantly reduced morphine-induced rewarding effects, 
which was measured by CPP without altering morphine-induced analgesia (Basile et al., 
2002). Furthermore, the M5 mAChRs KO mice showed significantly reduced responses 
for cocaine (i.v.) in self-administration study in mice (Fink-Jensen et al., 2003). Importantly, 
the M5 mAChRs KO mice presented no significant abnormal behaviors including food-
maintained responses (Basile et al., 2002; Fink-Jensen et al., 2003; Thomsen et al., 2005; 
Raffa, 2009). Taken together, the M5 mAChRs would be a novel target for substance use 
disorders including cocaine and opioids. These observations drive the first hypothesis (1) 
of this dissertation, which is discussed in Chapters 4 and 5. This hypothesis was 
investigated through the specific aims below. 
 
1.7.2.2 Hypothesis 2 and Specific Aims 
Hypothesis 2 (Chapters 4 and 5). Selective and potent antagonists of M5 mAChRs 
expressed in the VTA provide novel treatments for opioid and cocaine use disorders.  
Specific Aim 1. Determine the affinity and selectivity of analogs for M5 over M1-M4 
mAChRs. 
Specific Aim 1.1. Optimize competitive [3H]N-methylscopolamine ([3H]NMS) 
binding assay using each human mAChR subtype (M1-M5) expressed on Chinese 
hamsters ovary (CHO) cell membranes. 
Specific Aim 1.2. Evaluate binding affinity and selectivity of analogs for M5 
mAChRs over M1-M4 mAChRs. 
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Specific Aim 2. Determine if the M5 mAChR selective antagonists inhibit mAChR agonist-
induced DA release. 
Specific Aim 2.1. Determine if M5 mAChRs selective antagonists inhibit 
oxotremorine, a mAChR agonist without subtype preference, induced DA release 
from rat striatal brain slices. 
Chapter 4 describes the binding affinity of analogs of pethidine structure scaffold for M1-
M5 human mAChR subtypes. The structure activity relationship (SAR) and selectivity for 
M5 versus M1 or M3 is discussed. Chapter 5 describes binding affinity and selectivity of 
novel methyl phenylcarbamate structure scaffold for M5 over M1-M4 mAChRs subtypes, 
and functional potency of the most potent analogs for striatal DA release in the rat brain 
slices were studied.  
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2. CHAPTER TWO: NOVEL SCAFFOLD FOR LEAD COMPOUNDS TO TREAT
METH USE DISORDERS 
2.1 Introduction 
The United Nations reported that METH seizures worldwide increased by 158% 
between 2010 and 2015 (UNODC, 2015), revealing recent dramatic increases in METH 
use. However, there are no pharmacotherapies approved by the U.S. FDA to treat METH 
use disorder.  The abuse liability of METH is the result of its rewarding effects, which are 
mediated by increases in DA release in the mesocorticolimbic system (Di Chiara and 
Imperato, 1988a; Wise and Rompre, 1989). METH penetrates the blood-brain barrier and 
dopaminergic neuronal cell membranes due to its high lipophilicity (LogP = 2.10) 
(Gulaboski et al., 2007) and its ability to act as a substrate for the DAT (Johnson et al., 
1998). Once inside dopaminergic neurons, METH inhibits MAO activity, leading to a 
reduction in DA metabolism and increased cytosolic DA concentrations (Mantle et al., 
1976). Moreover, increased cytosolic DA concentrations result from METH-induced 
inhibition of DA transport from the cytosol into presynaptic storage vesicles via the VMAT2 
(Peter et al., 1994; Sulzer et al., 2005; Horton et al., 2013). Also, METH stimulates DA 
release from the vesicles into the cytosol via reverse transport at VMAT2 and via its weak 
base properties, which reduce the vesicular pH gradient and driving force for VMAT2 
function and retention of DA in the storage vesicles (Sulzer and Rayport, 1990; Schuldiner 
et al., 1993; Sulzer et al., 2005). Increased cytosolic DA concentrations are released from 
the presynaptic terminals into the extracellular space via reversal of DAT, the functional 
outcome being METH-induced reward (Sulzer et al., 1995; Fleckenstein et al., 2007; 
Volkow, Wang, et al., 2011). Support for the concept that METH-induced reward requires 
an increase in extracellular DA is derived from studies in which  bilateral injection of the 
dopaminergic neurotoxin, 6-OHDA into reward-relevant brain regions (e.g., NA) results in 
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a decrease in amphetamine self-administration (Lyness et al., 1979). Thus, a reduction in 
METH-evoked DA release is a desired property of a pharmacotherapy for METH use 
disorder.  
 Based on the complex mechanism of action of METH at dopaminergic presynaptic 
terminals, we identified VMAT2 as a novel target for the discovery of therapeutics for 
METH use disorder (Dwoskin and Crooks, 2002). Moreover, we identified lobeline 
(chemical structure shown in Fig. 6), the major alkaloidal natural product from Lobelia 
inflata, as a potent inhibitor of VMAT2 function using an isolated synaptic vesicle 
preparation from rat brain; as such, lobeline was identified from in vitro studies as having 
potential therapeutic efficacy in the treatment of METH use disorder (Teng et al., 1997; 
Dwoskin and Crooks, 2002). Further evidence supporting the concept that VMAT2 is a 
viable pharmacological target comes from studies showing that METH-evoked DA efflux 
from dissociated cells co-expressing VMAT2 and DAT was reduced by 60% in the 
presence of either lobeline or dihydrotetrabenazene, another VMAT2 inhibitor (Wilhelm et 
al., 2004). Furthermore, lobeline decreased METH-evoked DA release from the intact rat 
brain slice preparation and importantly attenuated METH-induced hyperactivity and METH 
self-administration in preclinical animal models (Miller et al., 2001; Harrod et al., 2003; 
Wilhelm et al., 2004; Nickell et al., 2010).  
Although lobeline decreases the neurochemical and behavioral effects of METH by 
inhibiting VMAT2 function, lobeline has limitations as a therapeutic candidate, in that it 
acts nonselectively, inhibiting nicotinic acetylcholine receptors (nAChRs) and opioid 
receptors (Teng et al., 1997, 1998; Zheng et al., 2005; Miller et al., 2007; Nickell et al., 
2014). Also, lobeline has aversive side-effects, including conditioned taste avoidance in 
rats (Harrod et al., 2004) and nausea in humans, resulting from its bitter taste (Glover et 
al., 2010). Furthermore, lobeline has a relatively short plasma half-life necessitating 
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multiple daily dosing, which would likely decrease medication compliance (Miller et al., 
2003).  
To address these limitations, our research group began a drug discovery program 
and embarked on structure-activity relationship studies aimed to discover compounds with 
improved selectivity for VMAT2 and enhanced drug likeness. Lobelane (Fig. 2.1), a 
chemically defunctionalized lobeline analog, exhibited increased affinity for VMAT2 and 
low affinity for nAChRs, i.e., improved selectivity for VMAT2 relative to lobeline (Miller et 
al., 2004; Zheng et al., 2005). Lobelane also inhibited VMAT2 function and METH-evoked 
DA release from rat brain slices, and importantly, decreased METH-induced hyperactivity 
and METH self-administration in rats (Miller et al., 2004; Neugebauer et al., 2007; 
Beckmann et al., 2010). However, tolerance developed to lobelane’s behavioral efficacy 
following repeated administration (Neugebauer et al., 2007). Upon further iterative 
investigation of the chemical scaffold, GZ-793A (Fig. 2.1) was identified as a lead 
compound, having high affinity and selectivity (>1030-fold)  for VMAT2 over nAChRs 
(Nickell et al., 2017). GZ-793A inhibited METH-evoked DA release from striatal vesicle 
preparations and from nucleus accumbens using in vivo microdialysis (Horton et al., 2013; 
Meyer et al., 2013). Importantly, GZ-793A decreased METH-induced hyperactivity, METH 
reward in conditioned place preference studies, and METH self-administration without the 
development of tolerance (Beckmann et al., 2012). Further preclinical research showed 
that GZ-793A decreased METH-induced and cue-induced reinstatement of METH seeking, 
indicating its potential efficacy in the treatment of relapse of METH seeking (Alvers et al., 
2012; Beckmann et al., 2012; Wilmouth et al., 2013). However, GZ-793A also exhibited 
affinity for the human-ether-a-go-go related gene (hERG) channel, indicating the potential 
for cardiotoxicity (Nickell et al., 2017), prohibiting its further development as a medication.  
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In our continued pursuit of a pharmacotherapy to treat METH use disorder, the 
current study evaluated in vitro inhibition of VMAT2 function produced by a novel, but 
related chemical scaffold represented by the lead compound, R-3-(4-methoxyphenyl)-N-
(1-phenylpropan-2-yl)propan-1-amine (GZ-11610; Fig. 2.1). Selectivity of GZ-11610 for 
VMAT2 over DAT, the serotonin transporter (SERT), nAChRs, and the hERG channel was 
determined. In addition, the ability of GZ-11610 to reduce METH-induced hyperactivity in 
METH-sensitized rats was assessed as an initial in vivo preclinical evaluation of its 
therapeutic potential as a treatment for METH use disorder. 
2.2 Material and Methods 
2.2.1 Animals 
Male Sprague-Dawley rats (200-250 g upon arrival) were purchased from Harlan 
Inc. (Indianapolis, IN, USA) and individually housed with ad libitum access to food and 
water. Following arrival, rats acclimated to the environment for 1 week prior to the start of 
experiments. Experimental protocols involving the animals were in accordance with the 
2011 National Institutes of Health Guide for the Care and Use of Laboratory Animals and 
were approved by the Institutional Animal Care and Use Committee at the University of 
Kentucky.  
2.2.2 Chemicals 
Radiolabeled DA ([3H]DA, dihydroxyphenylethylamine, 3,4-[7-3H], specific activity 
34.8 Ci/mmol), serotonin ([3H]5-HT, 5-hydroxytryptamine creatinine sulfate, 5-[1,2-3H[N]], 
specific activity 29.5 Ci/mmol), nicotine ([3H]NIC, L-(-)-[N-methyl-3H]; specific activity, 80.4 
Ci/mmol) and MicroScint 20 cocktail were purchased from PerkinElmer (Waltham, MA, 
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USA). [3H]Dofetilide ([N-methyl-3H], specific activity, 80 Ci/mmol) and methyllycaconitine 
([3H]MLA, [1α,S,6β,14α,16β]-20-ethyl-1,6,14,16-tetramethoxy-4-[[[2-([3-3H]-[3-3H]-
methyl-2,5-dioxo-1-pyrrolidinyl)benzoyl] oxy]methyl]-aconitane-7,8-diol; specific activity, 
60 Ci/mmol) were purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, 
USA). (+)-METH hydrochloride (METH), sucrose, N-[2-hydroxyethyl]piperazine-N’-[2-
ethanesulfonic acid] (HEPES), tris[hydroxymethyl]-aminomethane hydrochloride (Trizma 
HCl), tris[hydroxymethyl]aminomethane base (Trizma), sodium chloride, magnesium 
sulfate, α-D-glucose, disodium ethylenediamine tetraacetate (EDTA), ethylene glycol 
tetraacetate (EGTA), magnesium sulfate, potassium hydroxide, potassium tartrate, 
adenosine triphosphate (ATP-Mg2+), geneticin, polyethyleneimine (PEI), DA hydrochloride, 
pargyline hydrochloride, catechol, 5-hydroxytryptamine creatinine sulfate (5-HT), 
amitriptyline, nomifensine maleate (nomifensine), 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-
4-(3-phenylpropyl)piperazine dihydrochloride (GBR-12909), 1-[2-
(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR-12935), 
cytisine, and (-)-nicotine hydrogen tartrate salt were purchased from  Sigma-Aldrich (St. 
Louis, MO). Sodium bicarbonate, potassium chloride, calcium chloride, monopotassium 
phosphate, sodium hydroxide, and hydrogen chloride were purchased from Fisher 
Scientific Co. (Pittsburgh, PA). Ascorbic acid was purchased from AnalaR-BHD Ltd. 
(Poole, UK).  Scintillation cocktail 3a70B was purchased from Research Products 
International Corp. (Mount Prospect, IL). Minimum essential medium, 10% fetal bovine 
serum and Hanks' Balanced Salt solution were purchased from Gibco (Grand Island, NY). 
Also, 1% non-essential amino acids was purchased from Thermo Fisher Scientific 
(Waltham, MA). A VMAT2 inhibitor, 2-Ethyl-9,10-dimethoxy-3-(2-methylpropyl)-
1,3,4,6,7,11b-hexahydrobenzo[a]quinolizine-2-ol (RO4-1284) was a kind gift from 
Hoffman-La Roche, Ltd. (Basel, Switzerland),  
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2.2.3 Vesicular [3H]DA Uptake 
Rat striatal synaptic vesicles were prepared as previously described (Teng et al., 
1997) and used to determine GZ-11610-induced inhibition of [3H]DA uptake into the 
isolated presynaptic vesicles. Briefly, striata from individual rats were homogenized in 14 
mL of 0.32 M sucrose solution containing 5 mM sodium bicarbonate (pH 7.4) with 10 up-
and-down strokes of a Teflon pestle homogenizer (clearance ~0.009 inch) using a Maxima 
Digital Overhead Stirrer (400 rpm; Fisher Scientific Co., Pittsburgh, PA). Homogenates 
were centrifuged (2,000 g for 10 min at 4°C), and the resulting supernatants were 
centrifuged (10,000 g for 30 min at 4°C). Pellets were resuspended in 2 mL of 0.32 M 
sucrose solution and were subjected to osmotic shock by transferring samples to tubes 
containing 7 mL of ice-cold MilliQ water.  Then, samples were homogenized with 5 up-
and-down strokes of the Teflon pestle homogenizer. After 5 min, osmolarity was restored 
by transferring the samples to tubes containing 900 µL of 0.25 M HEPES and 900 µL of 
1.0 M potassium tartrate solution. Samples were centrifuged (20,000 g for 20 min at 4°C) 
and resulting supernatants centrifuged (55,000 g for 1 h at 4°C), followed by addition of 
100 µL of 10 mM magnesium sulfate, 100 µL of 0.25 M HEPES, and 100 µL of 1.0 M 
potassium tartrate solution, followed by a final centrifugation (100,000 g for 45 min at 4°C). 
Final pellets were resuspended in 2.4 mL of assay buffer (25 mM HEPES, 100 mM 
potassium tartrate, 50 µM EGTA, 100 µM EDTA, 1.7 mM ascorbic acid, and 2 mM ATP-
Mg2+, pH 7.4). Vesicular suspension (100 µL) was added to tubes containing assay buffer 
(300 µL), various concentrations (0.1 nM - 0.1 mM; 50 µL) of GZ-11610 and 0.1 µM [3H]DA 
(50 µL) to obtain a final assay volume of 500 µL. Nonspecific uptake was determined using 
RO4-1284 (10 µM). After incubation for 8 min at 37°C, uptake was terminated by rapid 
filtration. Scintillation cocktail was added to filters (presoaked GF/B filters in 0.5% PEI for 
1 h). Radioactivity retained by the filters was determined by liquid scintillation spectrometry 
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(TRI-CARB 2100 TR Packard scintillation counter; Packard BioScience Company, 
Meriden, CT).  
2.2.4 Synaptosomal [3H]DA and [3H]5-HT Uptake 
Inhibition of [3H]DA and [3H]5-HT uptake via DAT and SERT, respectively, was 
determined using previously published methods (Teng et al., 1997; Norrholm et al., 2007). 
Briefly, striata from individual rats were homogenized in 20 mL of 0.32 M sucrose 
containing 5 mM sodium bicarbonate (pH 7.4) with 16 up-and-down strokes of a Teflon 
pestle homogenizer (clearance ~0.003 inch) using the Maxima Digital Overhead Stirrer 
(400 rpm). Homogenates were centrifuged (2,000 g for 10 min at 4°C). Resulting 
supernatants were centrifuged (20,000 g for 17 min at 4°C). Pellets were resuspended in 
2.4 mL (DA uptake assay) or 1.4 mL (5-HT uptake assay) of assay buffer (125 mM sodium 
chloride, 5 mM potassium chloride, 1.5 mM magnesium sulfate, 1.25 mM calcium chloride, 
1.5 mM monopotassium phosphate, 10 mM α-D-glucose, 25 mM HEPES, 0.1 mM EDTA, 
0.1 mM pargyline hydrochloride, and 0.1 mM ascorbic acid, and saturated with 95% O2/5% 
CO2, pH 7.4). To determine [3H]DA uptake, synaptosomal suspension (25 µL) was added 
to tubes containing assay buffer (375 µL) and various concentrations (0.1 nM – 0.1 mM; 
50 µL) of GZ-11610. To determine [3H]5-HT uptake, synaptosomal suspension (50 µL) 
was added to tubes containing assay buffer (125 µL) and GBR-12935 (25 µL, 100 nM; a 
DAT inhibitor). After incubation, tubes were placed on ice for 2 min. [3H]DA (50 µL, 100 
nM) or [3H]5-HT (25 µL, 100 nM) was added to each tube, and then incubated at 34°C for 
10 min. Assays were performed in duplicate in a total volume of 500 µL for the DA uptake 
assay, or 250 µL for the 5-HT uptake assay. Uptake was terminated by addition of 3 mL 
of ice-cold assay buffer and subsequent filtration. Nonspecific [3H]DA and [3H]5-HT uptake 
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were determined in the presence of nomifensine (100 µM) and fluoxetine (10 µM), 
respectively. Radioactivity retained by the filters (presoaked in assay buffer containing 
1mM catechol for 1 h) was determined. 
2.2.5 [3H]NIC and [3H]MLA Binding 
GZ-11610-induced inhibition of [3H]NIC and [3H]MLA binding assesses the 
interaction with α4β2 and α7 nAChRs, respectively. Binding assays employed previously 
published methods (David B. Horton et al., 2011). In brief, rat whole brain excluding cortex 
and cerebellum was homogenized in 20 vol of ice-cold assay buffer (2 mM HEPES, 14.4 
mM sodium chloride, 0.15 mM potassium chloride, 0.2 mM calcium chloride and 0.1 mM 
magnesium sulfate at pH 7.5) for 90 sec using a Tekmar polytron (Tekmar-Dohrmann, 
Mason, OH, USA). Homogenates were centrifuged (31,000 g for 17 min at 4°C). Pellets 
were resuspended in 20 vol of assay buffer by sonication (Vibra Cell, Sonics & Materials 
Inc., Danbury, CT). Samples were incubated at 37 °C for 10 min (Reciprocal Shaking Bath 
Model 50, Precision Scientific, Chicago IL, USA). Samples were centrifuged (31,000 g for 
17 min at 4°C). Resulting pellets were resuspended in 20 vol assay buffer by sonication, 
and centrifuged (31,000 g for 17 min at 4°C). Final pellets were resuspended and stored 
in incubation buffer (40 mM HEPES, 288 mM sodium chloride, 3.0 mM potassium chloride, 
4.0 mM calcium chloride and 2.0 mM magnesium sulfate (pH 7.5).  Membrane 
suspensions (100-140 µg protein/100 µL) were added to tubes containing a single 
concentration of GZ-11610 (7-9 concentrations, 0.1 nM – 0.1 mM), 3 nM (50 µL) [3H]NIC 
or [3H]MLA, and incubation buffer for a final assay vol of 250 µL. Samples were incubated 
for 60 min at room temperature. NIC or MLA (10 pM – 100 µM) concentration-response 
curves were obtained as positive controls. Nonspecific [3H]NIC or [3H]MLA binding was 
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determined using 100 µM cytisine and 10 µM nicotine, respectively. Reactions were 
terminated by filtration on Unifilter-96 GF/B filter plates presoaked in 0.5% PEI using a 
Packard Filter Mate Harvester (Perkin Elmer, Inc., Waltham, MA). Plates were washed 3 
times with 350 µL of ice-cold assay buffer, dried for 60 min at 45 °C, bottom sealed, and 
each well filled with 40 µL MicroScint 20 cocktail. Bound radioactivity on the filter was 
determined via liquid scintillation spectrometry (Top Count NXT scintillation counter; 
PerkinElmer, Inc.).  
2.2.6 [3H]Dofetilide Binding 
GZ-11610-induced inhibition of [3H]dofetilide binding to hERG channels assessed 
potential cardiotoxicity. HEK293 cells stably expressing hERG channels were cultured 
according to the Millipore protocol (Millipore, Billerica, MA, USA). The method for 
determining [3H]dofetilide binding to hERG protein expressed by the cell membranes was 
described previously (Sviripa et al., 2014; Nickell et al., 2017). In brief, frozen cells were 
thawed at 37 °C and immediately transferred into T-75 cm2 flasks containing minimum 
essential medium supplemented with 10% fetal bovine serum, 1% non-essential amino 
acids, and 400 µg/mL geneticin. Cells were allowed to adhere for 4-8 h in a humidified 
atmosphere with 5% CO2. Cells were passaged every 6 days, and medium was replaced 
every 2 days. At least three passages were performed before membrane collection. On 
the last passage, cells were seeded into 150 x 25 mm dishes at 2.5 x 106 cells per dish 
and placed at 30 °C, 5% CO2, for 40-48 h prior to membrane preparation. Cells were 
rinsed twice with Hanks' Balanced Salt solution at 37 °C and collected by scraping the 
dishes in ~20 mL of ice-cold 0.32 M sucrose solution containing 5 mM sodium bicarbonate 
(pH 7.4).  Cell membranes were homogenized on ice with a Teflon pestle (~0.003 inch) 
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using a Maximal Digital homogenizer at 280 rpm for 30 sec. Homogenates were 
centrifuged (300 g and 800 g for 4 min each at 4 °C). Pellets were resuspended in 9 mL 
of ice-cold MilliQ water, and osmolarity was restored by adding 1 mL of 500 mM Tris buffer 
(pH 7.4), followed by resuspension and centrifugation (20,000 g for 30 min at 4 °C). Pellets 
were resuspended in 2 mL assay buffer (50 mM Tris, 10 mM potassium chloride, and 1 
mM magnesium chloride, pH 7.4, at 4 °C). Aliquots of cell membrane suspension were 
stored at -80 °C and thawed the day of the [3H]dofetilide binding assay. Protein content 
was determined prior to the assay using a Bradford protein assay with bovine albumin as 
the standard. On the day of the binding assay, thawed cell membrane suspension (5 µg) 
were added to duplicate tubes containing assay buffer (150 µL), a single concentration 
(25 µL; 0.1 nM – 0.1 mM) of GZ-11610 or amitriptyline (0.1 nM – 0.1 mM, as the positive 
control; Teschemacher et al., 1999; Jo et al., 2000), and 25 µL of [3H]dofetilide (5 nM) for 
a final assay vol of 250 µL, and incubated for 60 min at room temperature. Amitriptyline (1 
mM) was used to determine nonspecific binding.  Reactions were terminated by rapid 
filtration through Whatman GF/B filters presoaked in 0.5% PEI. Filters were washed 3 
times with 1 mL ice-cold assay buffer. Radioactivity retained by the filters was determined 
as described.  
2.2.7 METH-Induced Hyperactivity 
The ability of GZ-11610 to decrease METH-sensitized locomotor activity was 
determined using a mixed factor design with METH treatment as a between-subjects 
factor and GZ-11610 as within-subjects factor (Alvers et al., 2012). Briefly, distance 
traveled was measured in locomotor activity chambers (42 x 42 x 30 cm) with clear acrylic 
walls and floor. Chambers contained a horizontal 16 x 16 grid of photo beam sensors 
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located 2.5 cm apart and 7 cm above the chamber floor. Photo beam breaks were 
recorded automatically and expressed as distance traveled using Versamax and Digipro 
System software (AccuScan Instruments Inc., Columbus, OH, USA). Rats were assigned 
randomly to METH treatment or saline control groups. On day 0 (habituation day, no 
injection), rats were placed in the locomotor activity chamber for 60 min and then returned 
to their home cages. On days 1-10, METH (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.) 
injections were administered based on group assignment, and rats were placed 
immediately in the chamber for 60 min. On day 11 (first test day), GZ- 11610 (either 1, 10 
or 30 mg/kg, s.c.) was administered in a randomized order 15 min prior to METH or saline 
injection, and then, rats were placed immediately into the activity chamber.  Between test 
days, 2-3 washout days occurred in which METH (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.) 
was administered in the absence of GZ-11610.  To obtain full dose-response curves, 
additional doses (0, 3 and 5.6 mg/kg) of GZ-11610 were evaluated following s.c. 
administration using the same group of rats and the same procedures.   
In a separate drug-naive group of rats, the ability of oral GZ-11610 to decrease METH-
induced hyperactivity was evaluated using a mixed factor design, with METH treatment as 
a between-subjects factor and GZ-11610 dose a within-subjects factor.  GZ-11610 was 
administered using an ascending dose order. Initially, rats were habituated to the gavage 
procedure on 5 consecutive days during the METH-sensitization period (Wilmouth et al., 
2013). Food was removed from the home cage 2 h prior to each oral gavage. GZ-11610 
(5.6 - 300 mg/kg or sterile water vehicle) was administered by oral gavage followed 15 
min later by either METH (1 mg/kg, s.c.) or saline (1 mg/kg, s.c.) injection, depending on 
group assignment, and then rats were placed immediately into the activity chamber. On 
habituation days and on washout days between test days, 2 mL of vehicle was 
administered 15 min prior to the locomotor activity session.  
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2.2.8 Data Analysis 
Specific [3H]DA and [3H]5-HT uptake as well as [3H]dofetilide, [3H]NIC, and [3H]MLA 
binding were obtained by subtracting nonspecific uptake or binding from total uptake or 
binding, respectively. Concentration of GZ-11610 that produced 50% inhibition of uptake 
or binding (IC50 values) was obtained from the concentration-response curves via an 
iterative curve-fitting program (Prism 4.0; GraphPad Software Inc., San Diego, CA, USA). 
Inhibition constants (Ki values) were determined using the Cheng-Prusoff equation 
(Cheng and Prusoff, 1973). Distance traveled (in meters) during the last 45 min of the 60 
min locomotor activity session was analyzed using two-way or one-way ANOVA followed 
by Tukey’s or Dunnett’s post hoc analysis, as noted. Data from the first 15 min of the 
session was considered to be a habituation period and thus, was not included in the 
analysis. Data analysis was performed using GraphPad Prism 7.03 (GraphPad Software, 
Inc., La Jolla, CA, USA).     
2.3 Results 
VMAT2 affinity and selectivity. GZ-11610 potently (Ki = 8.7 nM) inhibited [3H]DA 
uptake at VMAT2, with a maximal inhibition (Imax) of  >95% (Fig. 2.2).  GZ-11610 also 
inhibited [3H]DA uptake at DAT and [3H]5-HT uptake at SERT (Ki = 2.51 and 5.55 µM, 
respectively), with an Imax at both transporters  >95% (Fig. 2.2).  GZ-11610 exhibited 288- 
and 637-fold greater affinity for VMAT2 relative to DAT and SERT, respectively, Thus, GZ-
11610 is selective for VMAT2 over DAT and SERT. Also, GZ-11610 inhibited [3H]dofetilide 
binding to hERG channels expressed on HEK-293 cell membranes, with a Ki of 9.50 µM 
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and an Imax of >80% (Fig. 2.2). Thus, GZ-11610 was 1090-fold selective for VMAT2 over 
hERG. Further, across a wide concentration range (0.1 nM – 0.1 mM), GZ-11610 exhibited 
an Imax of <20% inhibition of [3H]NIC and [3H]MLA binding to rat brain membranes (Fig. 
2.2); as such, Ki values could not be obtained.  Overall, GZ-11610 exhibited high affinity 
for VMAT2 and greater than two-orders of magnitude selectivity for VMAT2 over DAT, 
SERT, hERG, and α4β2 and α7 nAChRs. 
 METH sensitization.  For Day 0, 1 and 10, data from the two experiments determining 
effects of s.c. and oral administration of GZ-11610 were combined to evaluate effects of 
acute and repeated administration of METH or saline, since these data were obtained 
prior to GZ-11610 administration and groups were handled identically in the two 
experiments.  Two-way ANOVA revealed a significant treatment x day interaction [F2,14 = 
36.44, p < 0.0001].  On Day 0 (habituation, prior to METH or saline administration), no 
differences in distance traveled between the METH-treated and saline-injected groups 
were found (Fig. 2.3). On Day 1, acute METH (1 mg/kg, s.c.) increased (p < 0.05) distance 
traveled compared to saline control (Fig. 2.3). On Day 10, repeated administration of 
METH (1 mg/kg, s.c., once daily for 10 days) increased distance traveled (p < 0.05) 
compared to 10 consecutive daily saline injections (Fig. 2.3). On Day 10, distance traveled 
by the METH group was greater than distance traveled by this same group on Day 1 (p < 
0.05; Fig. 2.3), indicative of sensitization.  
Effect of GZ-11610 (s.c.) on METH-sensitized locomotor activity.  After 10 consecutive 
daily administrations of METH or saline, GZ-11610 (1 - 30 mg/kg) or vehicle (sterile water) 
was administered s.c. to both groups of rats 15 min prior to injection (s.c.) of METH or 
saline, respectively, followed by placement in the activity chamber. Two-way ANOVA 
revealed a GZ-11610 pretreatment x METH treatment interaction [F5, 48 = 68.81, p < 0.0001] 
on distance traveled.  Compared to vehicle injection, GZ-11610 dose-dependently 
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reduced the distance traveled following an injection of METH in the METH-sensitized 
group (Fig. 2.4). Tukey’s test revealed that GZ-11610 at doses from 3 to 30 mg/kg were 
different from vehicle in the METH group. Although GZ-11610 appeared to decrease 
activity in the saline group, this decrease did not reach statistical significance as 
determined by Tukey’s test, likely due to the high variably following the vehicle injection 
(Fig. 2.4, inset). Additionally, pair-wise comparison of the distance traveled between the 
METH group and the saline group after each dose of GZ-11610 revealed a greater 
distance traveled in the METH group (p < 0.05, Tukey’s test), with the exception of the 
highest dose (30 mg/kg) of GZ-11610.  However, using one-way ANOVA to assess the 
effect of GZ-11610 in the saline group revealed a significant dose effect [F = 5.55, p < 
0.005], and Dunnett’s test indicated a significant decrease in locomotor activity following 
3-30 mg/kg (Fig. 2.4, inset).  Thus, GZ-11610 (s.c.) decreased METH-induced
hyperactivity in METH-sensitized rats and in the saline control group, such that the effect 
of GZ-11610 was not specific. The decrease in activity induced by GZ-11610 in saline 
group did not appear to be due to lethargy or pain, as noted by the experimenter.   
Effect of GZ-11610 (oral) on METH-sensitized locomotor activity.  After 10 consecutive 
daily administrations of METH or saline, GZ-11610 (5.6 – 300 mg/kg) or vehicle (sterile 
water) was administered orally to rats in both groups 15 min prior to injection (s.c.) of 
METH or saline, respectively, and placement in the activity monitor. Two-way ANOVA 
revealed a GZ-11610 pretreatment x METH treatment interaction [F7,63 = 7.403, p < 0.0001] 
on distance traveled.  Compared to vehicle injection, GZ-11610 dose dependently reduced 
the distance traveled following an injection of METH in the METH-sensitized group (Fig. 
2.5). Tukey’s test revealed that GZ-11610 at doses from 56 – 300 mg/kg were different 
from vehicle in the METH group; whereas, GZ-11610 did not decrease significantly the 
distance traveled in the saline group compared to vehicle injection (Fig. 2.5, inset). 
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Furthermore, pair-wise comparison of the distance traveled between the METH group and 
the saline group after each dose of GZ-11610 revealed a greater distance traveled in the 
METH group. Using one-way ANOVA to assess the effect of GZ-11610 in the saline group 
also revealed that there were no significant GZ-11610 effects on locomotor activity in 
saline group [F7,32 = 0.572, p > 0.05].   Thus, oral GZ-11610 specifically decreased METH-
induced hyperactivity in METH-sensitized rats. 
Of note, there was a 2.3-fold greater amount of locomotor activity in the saline group 
following oral administration of vehicle (Fig. 2.5, insert) relative to that after s.c. 
administration of vehicle (Fig. 2.4, insert). Despite the habituation to the oral gavage, this 
procedure may have produced some stress, resulting in a greater mean amount of 
locomotor activity. However, the standard errors of the mean in the oral and s.c. vehicle 
conditions overlap, suggesting that there were not significant differences in locomotor 
activity between these control groups. 
 
2.4 Discussion 
Using an iterative drug discovery approach targeting VMAT2, the current study 
identified a new N-butyl(1-methyl-2-phenylethyl)amine, amphetamine-like scaffold, 
containing an important chiral center, and moreover, evaluated the neurochemical and 
behavioral effects of GZ-11610, the pure R-enantiomer. GZ-11610 was found to 
selectively inhibit VMAT2 function and to specifically attenuate METH-sensitized 
locomotor activity when given by the oral route, suggesting that this lead compound has 
potential as a candidate pharmacotherapy for METH use disorder.  
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The current in vitro neurochemical results demonstrate that GZ-11610 exhibited high 
affinity (Ki = 8.7 nM) for VMAT2 and high selectivity (290 to 3500-fold) for VMAT2 over 
DAT, SERT, hERG, α4β2 nAChRs and α7 nAChRs.  The high selectivity for VMAT2 over 
DAT suggests that GZ-11610 may lack abuse liability. Inhibition of DAT function results in 
increased extracellular DA concentrations and stimulation of postsynaptic DA receptors 
leading to reward. Inhibition of DAT function is highly correlated with psychostimulant-
induced behaviors, reward and abuse liability (Stathis et al., 1995; Swanson and Volkow, 
2003; Volkow and Swanson, 2003; German et al., 2015).  
The 4-orders of magnitude selectivity for VMAT2 over hERG suggests reduced 
risk for untoward cardiac arrhythmias at concentrations of GZ-11610 interacting with 
VMAT2 and providing therapeutic efficacy. Interaction at hERG channels has been 
associated with cardiac arrhythmias due to the role of these inward rectifying potassium 
channels during depolarization of the heart muscle and propagation of cardiac rhythm 
(Trudeau et al., 1995; Abbott et al., 1999; Doggrell and Hancox, 2014). Selectivity 
regarding hERG in the current study is particularly compelling, because previous lead 
compounds acting as VMAT2 inhibitors, including lobeline, lobelane and GZ-793A, 
provided only 3 to 26-fold selectivity for VMAT2 over hERG (Nickell et al., 2010, 2017).  
Importantly, the greater than 4-orders of magnitude selectivity for VMAT2 over the 
most abundant nicotinic receptor subtypes (α4β2 and α7) supports the interpretation that 
these nAChR protein targets are not responsible for the decrease in METH’s behavioral 
effects nor their potential therapeutic efficacy. Furthermore, the robust selectivity of GZ-
11606 will allow validation of VMAT2 as an important pharmacological target in the 
discovery for METH use disorder therapeutics.  
125 
 
In the current study, GZ-11610 decreased the psychomotor response to METH in rats 
that previously had been sensitized to repeated METH administration. Based on the 
current findings, GZ-11610 appears to have improved potency and efficacy reducing 
METH-induced locomotor activity relative to our previous lead compounds, lobeline, 
lobelane and GZ-793A (DK Miller et al., 2001; Neugebauer et al., 2007; Alvers et al., 2012). 
However, the behavioral effects of the previous leads were evaluated in these earlier 
studies with respect to their ability to reduce the acute, dose-related hyperactivity induced 
by METH. Behavioral sensitization induced by repeated exposure to psychostimulants has 
been established as an animal model of human addiction due to the associated enduring 
alterations in nucleus accumbens DA neurochemistry leading to reward and persistent 
drug seeking (Kalivas and Stewart, 1991; Vezina et al., 2002; Volkow, Wang, et al., 2011; 
Wang et al., 2017). Thus, the GZ-11610-induced decrease in METH-stimulated locomotor 
activity in METH-sensitized animals provides greater face validity with respect to the 
clinical situation than does a reduction in the acute behavioral response to METH.   
The assertion that the GZ-11610-induced decrease in METH-stimulated locomotor 
activity in METH-sensitized rats was specific is based on the observation that GZ-11610, 
following oral administration, did not significantly alter locomotor activity in the control 
group repeatedly administered saline. However, following s.c. administration, GZ-11610 
was found to decrease locomotor activity in the saline control group. Thus, the GZ-11610-
induced decrease in METH sensitized activity was specific only following oral 
administration of GZ-11610.  This is important because the oral route is the preferred 
clinical route of administration.      
Consistent with previous findings regarding our earlier lead compounds  (DK Miller et 
al., 2001; Neugebauer et al., 2007), GZ-11610  significantly decreased METH-sensitized 
locomotor activity following either s.c. or oral administration. The GZ-11610-induced 
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decrease in METH’s behavioral response supports the interpretation that GZ-11610 
penetrates the blood-brain barrier and accesses the brain and that the lead compound is 
sufficiently orally bioavailable to demonstrate efficacy.  However, an approximately 10-fold 
higher dose was required following oral administration relative to s.c. administration. 
Further, the maximal effect after oral administration of GZ-11610 was about 50% of that 
following s.c. administration. Likely, the physicochemical characteristics (e.g., solubility, 
logP) and/or pharmacokinetic properties (e.g., half-life, clearance, plasma protein binding, 
metabolism) of GZ-11610 may be responsible for the observed reduced potency and 
efficacy following oral versus s.c. administration.  Interestingly, it is possible that GZ-11610 
(R-enantiomer) may be metabolized via oxidative N-CH2 bond cleavage to R-
amphetamine, which has relatively lower psychostimulant effects compared with S-
amphetamine (Heal et al., 2013). Future pharmacokinetic and drug metabolism studies 
will determine the ADME profile of GZ-11610 and also identify its metabolites after oral 
administration, in order to assess the limitations and potential abuse liability of this 
promising lead compound. 
 
2.5 Conclusion 
GZ-11610, a representative compound from a new VMAT2-selective inhibitor scaffold 
(N-butyl(1-methyl-2-phenylethyl)amine), was identified and its effects on METH-
stimulated locomotion in METH-sensitized rats were evaluated following s.c. and oral 
administration. GZ-11610 exhibited high affinity (Ki = 8.7 nM) and high selectivity (290- to 
3500-fold) for VMAT2 over hERG, DAT, SERT, and nAChRs. Of note, GZ-11610 exhibited 
robustly improved selectivity for VMAT2 over the hERG channel (>1000-fold) compared 
to previously reported VMAT2 inhibitors (3- to 26-fold). Oral administration of GZ-11610 
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specifically reduced METH-stimulated locomotor activity in METH-sensitized rats. Further 
studies aimed at improving the bioavailability of GZ-11610 would contribute to the 
development of this lead compound as a treatment for METH use disorders. 
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Figure 2.1. Chemical structures of lobeline, lobelane, GZ-793A and GZ-11610. 
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Figure 2.2. GZ-11610 potently inhibits [3H]DA uptake at VMAT2 and is selective for 
VMAT2 over DAT, SERT, hERG, α4β2 nAChRs and α7 nAChRs. Ki values and 
selectivity ratios are provided in the symbol legend. Data are mean ± SEM specific uptake 
or binding expressed as % of the respective control (CON) uptake or binding in the 
absence of GZ-11610. Control values (mean ± SEM) are the following: for specific [3H]DA 
uptake at VMAT2, 49.6 ± 8.35 pmol/mg of protein/min; for specific [3H]DA uptake at DAT, 
12.2 ± 0.54 pmol/mg of protein/min; for specific [3H]5-HT uptake at SERT, 7.89 ± 0.51 
pmol/mg of protein/min; for specific hERG binding, 1540 ± 178 fmol/mg; for specific 
[3H]NIC binding at α4β2 nAChRs, 22.6 ± 3.38 fmol/mg; and for specific [3H]MLA binding 
at α7 nAChRs, 36.4 ± 2.11 fmol/mg. (n=4 rats for neurotransmitter uptake assays, n=3 cell 
batches for hERG assays, and n=3 for nAChR binding assays). 
130 
 
D a y 0 D a y 1 D a y 1 0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
S e s s io n
D
is
ta
n
c
e
  
T
ra
v
e
le
d
 (
m
)
M E T H  g ro u p
S a lin e  g ro u p
* #
* # $
 
Figure 2.3. Locomotor sensitization to repeated METH administration. Day 0 
(habituation day) represents distance traveled before METH or saline injection. Day 1 
represents distance traveled following acute METH (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.) 
injection.  Day 10 represents distance traveled following 10 daily injections of METH or 
saline. Data are mean ± SEM distance traveled in meters. Data were analyzed using two-
way mixed factor ANOVA followed by Tukey’s post hoc tests. (*p < 0.05 compared to 
respective saline group;  
# p < 0.05 compared to METH group on Day 0; $ p < 0.05 compared to METH group on 
Day 1; n=10/group; however, due to a computer problem, data for n=2 from each of the 
METH and saline groups are not included in the analysis).   
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Figure 2.4. GZ-11610 (s.c.) decreased METH-induced hyperactivity in METH-
sensitized and control rats. GZ-11610 (1 – 30 mg/kg) or vehicle (Veh, sterile water) was 
administered s.c.  to the METH-sensitized group and the saline group (inset) 15 min before 
METH (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.), respectively, followed by placement in the 
activity chamber. Data are mean ± SEM distance traveled in meters. Dotted line 
represents 50% of the distance traveled after vehicle injection.  Data were analyzed by 
two-way mixed factor ANOVA followed by Tukey’s post hoc tests (*p < 0.05 compared to 
vehicle within each group; n = 5/group) or by one-way ANOVA followed by Dunnett’s test 
(#p < 0.05 compared to vehicle). 
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Figure 2.5. GZ-11610 (oral) specifically decreased METH-induced hyperactivity in 
METH-sensitized rats. GZ-11610 (5.6 – 300 mg/kg) or vehicle (Veh, sterile water) was 
administered orally to the METH-sensitized group and the saline group (inset) 15 min 
before METH (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.), respectively, followed by placement 
in the activity chamber. Data are mean ± SEM distance traveled in meters. Dotted line 
represents 50% of the distance traveled after vehicle injection.  Data were analyzed by 
two-way mixed factor ANOVA followed by Tukey’s post hoc tests. (*p < 0.05 compared to 
vehicle within each group; n = 5/group), or by one-way ANOVA for the data in the saline 
control group.  
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3. CHAPTER THREE: GZ-11608, A VESICULAR MONOAMINE TRANSPORTER-2
INHBITOR, DECREASES THE NEUROCHEMICAL AND BEHAVIORAL EFFECTS
OF METH 
3.1 Introduction 
 METH use disorder is characterized by a constellation of symptoms including 
relapse, continued use despite adverse consequences, and social impairment (American 
Psychiatric Association, 2013). From 2010 to 2016, seizures of METH by United States 
law enforcement agencies increased 3.2-fold and METH overdose death rates increased 
4.1-fold, indicative of escalating use (UNODC, 2014, 2018; NIDA, 2018). Importantly, 
METH use has increased among opioid users as access to opioids has diminished; and 
associations between these epidemics are recently being recognized (Ellis et al., 2018). 
In 2015, 135,000 Americans aged 12 and older sought treatment for METH use disorder 
at publicly-licensed facilities (DEA, 2018). Unfortunately, even now, FDA-approved 
pharmacotherapeutics for METH use disorder are not available.  
 Substantial effort has been directed towards discovering a pharmacotherapeutic 
for METH use disorder (see reviews: Ballester et al., 2017; Dwoskin et al., 2017; Reynolds 
et al., 2017). METH redistributes DA from synaptic vesicles into the cytosol by interacting 
with the VMAT2  and disrupting the vesicular pH gradient (Sulzer and Rayport, 1990; 
Sulzer et al., 1995; Dwoskin and Crooks, 2002). Also, METH reverses DAT function, 
resulting in transport of DA from the cytosol into the extracellular compartment, ultimately 
mediating METH reward and abuse liability (Wise and Rompre, 1989; Volkow et al., 2017). 
 The current study extends our iterative drug discovery research targeting VMAT2 
with the goal of obviating the neuropharmacological effects of METH. Initially, lobeline, the 
major alkaloid in Lobelia inflata, was found to inhibit VMAT2 function (Ki = 470 nM) and 
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reduce METH-evoked DA release from superfused striatal slices and from nucleus 
accumbens following in vivo microdialysis in rats (Miller et al., 2001; Nickell et al., 2010; 
Meyer et al., 2013). Lobeline also decreased i.v. METH self-administration in rats without 
the development of tolerance (Harrod et al., 2001). Furthermore, increasing the METH 
unit dose did not surmount the lobeline-induced decrease in responding for METH (Harrod 
et al., 2001). Based on these preclinical findings, lobeline was evaluated in Phase 1 clinical 
trials and found to be safe in individuals actively using METH (Jones, 2007). Due to its 
physicochemical properties and pharmacokinetic profile, enthusiasm for its further clinical 
development diminished. 
 Lobelane, a chemically defunctionalized lobeline analog, was identified from SAR 
studies, as exhibiting greater potency (10-fold) and reduced affinity for α4β2 and α7 
nicotinic acetylcholine receptors, thereby, augmenting selectivity for VMAT2 (Miller et al., 
2004; Zheng et al., 2005; Nickell et al., 2010). Lobelane decreased METH-induced 
hyperlocomotion and decreased METH self-administration, however, the development of 
tolerance limited its therapeutic utility (Neugebauer et al., 2007). Further SAR identified R-
N-(1,2-dihydroxypropyl)-2,6-cis-di-(4-methoxyphenethyl)-piperidine hydrochloride (GZ-
793A), containing an N-1,2,-dihydroxypropyl in place of the N-methyl group in lobelane 
(Horton et al., 2011). GZ-793A exhibited high affinity (Ki = 29 nM) for VMAT2, inhibited 
METH-evoked DA release from striatal slices and synaptic vesicular preparations, and 
from nucleus accumbens using in vivo microdialysis (Horton et al., 2011, 2013; Meyer et 
al., 2013; Nickell et al., 2017).  GZ-793A decreased METH self-administration and 
reinstatement of METH seeking behavior (Alvers et al., 2012; Beckmann et al., 2012). 
Importantly, tolerance did not develop to the GZ-793A-induced decrease in METH self-
administration (Beckmann et al., 2012). Unfortunately, GZ-793A interacted with the  
human-ether-a-go-go-related gene (hERG) channel, revealing potential for cardiotoxicity 
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and precluding its further development (Abbott et al., 1999; Sanguinetti and Tristani-
Firouzi, 2006; Nickell et al., 2017).  
 Expansion of the SAR focused on minimizing the hERG interaction and resulted in 
a new structural scaffold with a phenylalkyl moiety replacing the piperidine ring in GZ-
793A (Lee et al., 2018).  Additionally, the new scaffold has only one chiral center rather 
than three in GZ-793A. The enantiomerically-pure lead analog, R-3-(4-methoxyphenyl)-
N-(1-phenylpropan-2-yl)propan-1-amine (GZ-11610), was identified as having high affinity 
(Ki = 8.7 nM) and selectivity (1090-fold) for VMAT2 over hERG. GZ-11610 (p.o.) 
specifically decreased METH-sensitized locomotor activity. Although limitations in efficacy 
and potency for GZ-11610 were noted, the new scaffold showed good potential for 
identifying a high value lead compound.  
 The current study investigated the pharmacology of enantiomerically-pure S-3-(4-
methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine (GZ-11608). VMAT2 affinity, 
selectivity and mechanism of inhibition of METH-evoked vesicular DA release were 
determined. Ability of GZ-11608 to exacerbate the METH-induced decrease in striatal DA 
content was evaluated ex vivo. Effects of GZ-11608 on METH-sensitized locomotor 
activity, METH self-administration and reinstatement also were determined. Development 
of tolerance and the potential for METH to surmount the efficacy of GZ-11608 to decrease 
METH self-administration were determined. Furthermore, the abuse liability of GZ-11608 
was evaluated by determining its ability to substitute for METH in the self-administration 
assay and by the acquisition of i.v. GZ-11608 self-administration in drug naïve rats.   
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3.2 Material and Methods  
3.2.1 Animals 
Adult male Sprague-Dawley rats (body weight of 300-400 g during conduct of 
experiments, Harlan, Indianapolis, IN) were individually housed for behavioral studies and 
housed under standard conditions for neurochemical and pharmacokinetic assays. Upon 
arrival, rats were given free access to food and water in their home cages, which were 
maintained in an environment maintained at 24 ºC, 45% humidity, and 14/10 h light/dark 
cycle. Rats acclimated to the environment for one week prior to initiation of experiments, 
and when used in behavioral experiments, rats were handled daily. During operant training, 
food in the home cage was limited to 5-10 g/day to maintain bodyweight at ~85%, and 
then, free feeding continued once rats reached criteria for stable responding. Experiments 
were conducted during the light phase. Experimental protocols were approved by the 
Institutional Animal Care and Use Committee at the University of Kentucky and were in 
accordance with the 2011 National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
3.2.2 Chemicals 
[3H]Dopamine ([3H]DA; dihydroxyphenylethylamine, 3,4-[7-3H]; specific activity, 
24.8 Ci/mmol), [3H]5-hydroxytryptamine ([3H]5-HT; 5-hydroxytryptamine creatinine sulfate, 
5-[1,2-3H[N]]; specific activity, 29.5 Ci/mmol), [3H]nicotine ([3H]NIC; (L-(-)-[N-methyl-3H]; 
specific activity, 80.4 Ci/mmol), and MicroScint 20 cocktail were obtained from 
PerkinElmer Inc. (Waltham, MA). [3H]Dofetilide ([N-methyl-3H]; specific activity, 80 
Ci/mmol) and [3H]methyllycaconitine ([3H]MLA; [1α,4S,6β,14α,16β]-20-ethyl-1,6,14,16-
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tetramethoxy-4-[[[2-([3-3H]-[3-3H]-methyl-2,5-dioxo-1-pyrrolidinyl)benzoyl]oxy]methyl]-
aconitane-7,8-diol; specific activity, 60 Ci/mmol) were obtained from American 
Radiolabeled Chemicals, Inc. (St. Louis, MO). (+)-METH hydrochloride, 1-[2-
(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR-12935), 
amitriptyline, cytisine, fluoxetine, S(-)-nicotine hydrogen tartrate salt, nomifensine, 1-
octanesulfonic acid sodium salt, 3-(4-methoxyphenyl)propanoic acid, 5-hydroxytryptamine 
creatinine sulfate, adenosine 5’-triphosphate magnesium salt (ATP-Mg2+), α-D-glucose, 
ammonium chloride, anhydrous sodium sulfate, ascorbate oxidase, catechol, celite, 
dichloromethane, diethyl ether, dimethylformamide, dopamine hydrochloride, ethyl 
acetate, ethylenediamine tetraacetate (EDTA), ethylene glycol tetraacetate (EGTA), 
hexane, hydrochloric acid, Kolliphor EL®, magnesium sulfate, methanesulfonyl chloride, 
methanol, methylene chloride, N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] 
(HEPES), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, pargyline 
hydrochloride, phenyllithium, polyethyleneimine (PEI),  potassium hydroxide, potassium 
tartrate dibasic hemihydrate, R-propylene oxide,  sodium azide, silica, sodium chloride, 
sodium hydroxide, sucrose, tetrahydrofuran, triethylamine, triphenylphosphine, 
tris[hydroxymethyl]aminomethane base, tetrahydrofuran, and tris[hydroxymethyl]-
aminomethane hydrochloride were obtained from Sigma-Aldrich (St. Louis, MO). Calcium 
chloride, citric acid, formic acid, hydrogen chloride, methanol, monopotassium phosphate, 
potassium chloride, sodium bicarbonate, and sodium hydroxide were obtained from Fisher 
Scientific Co. (Pittsburgh, PA). Ascorbic acid, 1% non-essential amino acids, and 
scintillation cocktail 3A70B were purchased from AnalaR-BHD Ltd. (Poole, UK), Thermo 
Fisher Scientific (Waltham, MA), and Research Products International Corp. (Mount 
Prospect, IL), respectively. Minimum essential medium (MEM), Hanks’ Balanced Salt 
solution, and 10% fetal bovine serum were obtained from Gibco (Grand Island, NY). 
(2R,3S,11bS)-2-Ethyl-3-isobutyl-9,10-dimethoxy-2,2,4,6,7,11b-hexahydro-1H-pyrido[2,1-
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a]isoquinolin-2-ol (RO4-1284) was a generous gift from Hoffmann-LaRoche Inc. (Nutley, 
NJ). 
3.2.3 Vesicular [3H]DA Uptake 
To obtain the affinity (Ki value) of GZ-11608 for VMAT2, the ability of GZ-11608 to 
concentration-dependently inhibit [3H]DA uptake into isolated synaptic vesicles, as 
previously described (Teng et al., 1997). Nonspecific uptake of [3H]DA was determined in 
the presence of RO4-1284 (10 µM). Briefly, striata from individual rats were homogenized 
in 14 mL of ice-cold 0.32 M sucrose solution containing 5 mM sodium bicarbonate (pH 7.4) 
with 10 up-and-down strokes of a Teflon pestle homogenizer (clearance ~0.009 inch) 
using a Maxima Digital Overhead Stirrer (400 rpm; Fisher Scientific Co., Pittsburgh, PA). 
Homogenates were centrifuged (2,000 g for 10 min at 4°C), and the resulting supernatants 
were centrifuged (10,000 g for 30 min at 4°C). Pellets were resuspended in 2 mL of 0.32 
M sucrose solution containing 5 mM sodium bicarbonate (pH 7.4) and were subjected to 
osmotic shock by transferring samples to tubes containing 7 mL of ice-cold MilliQ water. 
Samples were homogenized on ice with 5 up-and-down strokes of a Teflon pestle 
homogenizer. After 5 min, osmolarity was restored by transferring the samples to tubes 
containing 900 µL of 0.25 M HEPES and 900 µL of 1.0 M potassium tartrate dibasic 
hemihydrate solution. Samples were centrifuged (20,000g for 20 min at 4°C) and resulting 
supernatants centrifuged (55,000 g for 1 h at 4°C). To the resulting supernatants, 100 µL 
of 10 mM magnesium sulfate, 100 µL of 0.25 M HEPES, and 100 µL of 1.0 M potassium 
tartrate dibasic hemihydrate solution were added, followed by a final centrifugation 
(100,000g for 45 min at 4°C). Final pellets were resuspended in 2.4 mL of assay buffer 
(25 mM HEPES, 100 mM potassium tartrate dibasic hemihydrate, 50 µM EGTA, 100 µM 
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EDTA, 1.7 mM ascorbic acid, and 2 mM ATP-Mg2+, pH  7.4 adjusted dropwise with 10 M 
potassium hydroxide). Aliquots of the resulting suspension of isolated synaptic vesicles 
(100 µL) were added to tubes containing assay buffer (300 µL), one of a range of 
concentrations of GZ-11608 (final concentration 0.1 nM - 0.1 mM; 50 µL) and 0.1 µM 
[3H]DA (final concentration 10 nM; 50 µL) to obtain a final assay vol of 500 µL. After 
incubation for 8 min in a 37°C water bath (Reciprocal Shaking Bath Model 50, Precision 
Scientific, Chicago IL, USA), [3H]DA uptake was stopped by rapid filtration through 
presoaked (0.5% PEI for 1 h at 4 ºC) Whatman® GF/B Glass microfiber filters (1.0 µm 
pore size; Clifton, NJ) via a cell harvester (MP-43RS; Brandel Inc., Gaithersburg, MD). 
Subsequently, filters were washed 3 times with 4 mL of ice-cold wash buffer (25 mM 
HEPES, 100 mM potassium tartrate dibasic hemihydrate, 50 µM EGTA, 100 µM EDTA, 
1.7 mM ascorbic acid, and 2 mM magnesium sulphate; pH 7.4 adjusted dropwise with 10 
M potassium hydroxide). Scintillation cocktail (5 mL) was added to tubes containing the 
filters, followed by shaking for 30 min at room temperature. Radioactivity retained on the 
filters was determined by liquid scintillation spectrometry (TRI-CARB 2100 TR Packard 
scintillation counter; Packard BioScience Company, Meriden, CT).  
3.2.4 Synaptosomal [3H]DA and [3H]5-HT Uptake 
To evaluate the selectivity of GZ-11608 at VMAT2 relative to DAT and SERT, GZ-
11608 inhibition of [3H]DA and [3H]5-HT uptake, respectively, into rat striatal 
synaptosomes was determined using previously published methods (Teng et al., 1997; 
Norrholm et al., 2007). Briefly, striata from individual rats were homogenized in 20 mL of 
0.32 M sucrose containing 5 mM sodium bicarbonate (pH 7.4) with 16 up-and-down 
strokes of a Teflon pestle homogenizer (clearance ~0.003 inch) using the Maxima Digital 
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Overhead Stirrer (400 rpm). Homogenates were centrifuged (2,000 g for 10 min at 4°C). 
Supernatants were centrifuged (20,000g for 17 min at 4°C) and pellets were resuspended 
(2.4 mL for DAT assay; 1.4 mL for SERT assay) in Krebs’ buffer (125 mM sodium chloride, 
5 mM potassium chloride, 1.5 mM magnesium sulfate, 1.25 mM calcium chloride, 1.5 mM 
monopotassium phosphate, 10 mM α-D-glucose, 25 mM HEPES, 0.1 mM EDTA, 0.1 mM 
pargyline hydrochloride, and 0.1 mM ascorbic acid, and saturated with 95% O2/5% CO2; 
pH 7.4 adjusted dropwise with 1 M sodium hydroxide). For DAT and SERT assays, 
aliquots of synaptosomal suspension (25 µL and 50 µL, respectively) were added to tubes 
containing Krebs’ buffer (375 µL and 125 µL, respectively) and one of a range of 
concentrations of GZ-11608 (0, 0.1 nM – 0.1 mM) in 50 µl and 25 µl buffer, respectively. 
Uptake in the absence of GZ-11608 represents control. For nonspecific uptake, assay 
tubes contained nomifensine (final concentration, 100 µM in 50 µl for DAT assays) and 
fluoxetine (final concentration, 10 µM in 25 µl for SERT assays) in the absence of GZ-
11608. For SERT assays, GBR-12935 (final concentration, 100 nM in 25 µL), a DAT 
inhibitor, was added to all assay tubes to prevent [3H]5-HT uptake into dopaminergic 
terminals (Norrholm et al., 2007). DAT and SERT assay tubes (450 µL and 225 µL, 
respectively) were incubated at 34 °C for 5 min. After incubation, tubes were placed on 
ice for 2 min. [3H]DA (final concentration, 10 nM in 50 µl) or [3H]5-HT (final concentration, 
10 nM in 25 µL) was added to each tube. DAT and SERT assay tubes (final assay vol, 
500 µL and 250 µL, respectively) were incubated at 34 °C for 10 min. Uptake was stopped 
by addition of 3 mL of ice-cold assay buffer and subsequent filtration. [3H]DA or [3H]5-HT 
retained on the filters (presoaked in assay buffer containing 1 mM catechol for 1 h at 4 ºC) 
was determined as previously described.  
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3.2.5 [3H]Dofetilide Binding 
GZ-11608 inhibition of [3H]dofetilide binding to hERG assessed potential 
cardiotoxicity and selectivity of GZ-11608 for VMAT2 over hERG. HEK-293 cells stably 
expressing hERG channel protein were purchased from Millipore (Catalog number 
CYL3006, Billerica, MA). Binding assays were performed as previously described (Sviripa 
et al., 2014; Nickell et al., 2017). Briefly, frozen cells were thawed at 37 ºC and placed in 
T-75 cm2 flasks (Becton Dickinson and Company, Franklin Lakes, NJ), containing 20 mL 
of complete media (MEM supplemented with 10% fetal bovine serum, 1% non-essential 
amino acids, and 400 µg/ml geneticin), according to the Millipore protocol. For 4-8 h, cells 
adhered to flasks in a humidified atmosphere (5% CO2 at 37 ºC), after which the media 
was replaced with 20 mL fresh media. Subsequently, media was replaced every 48 h. For 
routine passages, media was removed, cells rinsed with 2 mL of phosphate-buffered 
saline (137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium hydrogen 
phosphate, 2 mM potassium dihydrogen phosphate), followed by addition of Hank’s 
Balanced Salt Solution containing trypsin (0.5 g/L, porcine trypsin) and EDTA (0.5 mM). 
To dissociate the cells, flasks were placed in a 37 ºC incubator for 2-5 min, and then, fresh 
complete media (5 mL) was added to the cell resuspensions, followed by seeding onto 
new flasks at 2-3 x 106 cells/flask. Passages were conducted every 6 days. At least 3 
passages occurred before cell membrane collection. On the last passage prior to 
membrane preparation, cells were seeded onto 150 x 25 mm culture dishes at 2.5 x 106 
cells/dish, and culture dishes were incubated (5% CO2 at 37 ºC) for 40-48 h. Media was 
removed and then culture dishes rinsed twice with 30 °C Hanks’ Balanced Salt solution 
(13 mL). Then, a solution of ice-cold 0.32 M sucrose with 5 mM sodium bicarbonate (20 
mL, pH 7.4) was added to each culture dish on ice. Cells were scraped gently from the 
dishes and then homogenized (30 s) on ice with a Teflon pestle (~0.003 inch) using a 
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Maximal Digital homogenizer (280 rpm). Homogenates were centrifuged (300g and 800g 
for 4 min each at 4 °C). Pellets were resuspended in 9 mL ice-cold MilliQ water, and 
osmolarity restored by adding 1 mL of 500 mM Tris buffer (pH 7.4). Samples were 
centrifuged (20,000g for 30 min at 4 °C). Pellets were resuspended in 2 mL assay buffer 
(50 mM Tris, 10 mM potassium chloride, and 1 mM magnesium chloride, pH 7.4, at 4 °C). 
Aliquots of membrane suspension were stored at -80 °C until use. To perform the 
[3H]dofetilide binding assay, membrane suspension was thawed and protein content 
determined using a Bradford protein assay (Bio-Rad Laboratories, Inc., Hercules, CA), 
with bovine albumin (Sigma-Aldrich Corporation, St. Louis, MO) as the standard. Duplicate 
tubes containing membrane suspension (5 µg/100 µL), one of a range of concentrations 
of GZ-11608 (final concentrations 0, 0.1 nM – 0.1 mM in 25 µL) or amitriptyline (0, 0.1 nM 
– 0.1 mM; positive control), assay buffer (150 µL), and [3H]dofetilide (5 nM in 25 µL) for a 
final assay vol of 250 µL. Amitriptyline (1 mM) was used to determine nonspecific binding 
(Teschemacher et al., 1999; Jo et al., 2000). Samples were incubated for 1 h at room 
temperature. Reactions were stopped by rapid filtration through Whatman® GF/B Glass 
microfiber filters presoaked in 0.5% PEI for 1 h at 4 ºC. Filters were washed 3 times with 
1 mL ice-cold assay buffer. Radioactivity retained by the filters was determined as 
previously described.  
3.2.6 [3H]NIC and [3H]MLA Binding 
To evaluate the selectivity of GZ-11608 for VMAT2 over α4β2 and α7 nicotinic 
acetylcholine receptors (nAChRs), GZ-11608 inhibition of [3H]NIC and [3H]MLA binding 
was determined, respectively, using previously published methods (Horton et al., 2011a). 
In brief, whole brains excluding cortex and cerebellum from individual rats were 
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homogenized for 90 s in 20 vol of ice-cold assay buffer (2 mM HEPES, 14.4 mM sodium 
chloride, 0.15 mM potassium chloride, 0.2 mM calcium chloride and 0.1 mM magnesium 
sulfate, pH 7.5 adjusted dropwise with 1 M sodium hydroxide) using a polytron. 
Homogenates were centrifuged (31,000g for 17 min at 4 °C). Pellets were resuspended 
in 20 vol of assay buffer by sonication (Vibra Cell, Sonics & Materials Inc., Danbury, CT). 
Subsequently, duplicate samples were incubated in a 37 °C water bath for 10 min, and 
then centrifuged (31,000g at 4 °C for 17 min). Resulting pellets were resuspended in 20 
vol of assay buffer by sonication, and centrifuged (31,000g for 17 min at 4 °C). Final pellets 
were resuspended and stored in 10 mL of incubation buffer (20 mM HEPES, 144 mM 
sodium chloride, 1.5 mM potassium chloride, 2 mM calcium chloride and 1 mM 
magnesium sulfate, pH 7.5 adjusted dropwise with 1 M sodium hydroxide) at -20 ºC until 
use. Thawed membrane suspensions (100-140 µg protein/100 µL) were added to tubes 
containing one of 7-9 concentrations of GZ-11608 (final concentration, 0, 0.1 nM – 0.1 mM 
in 50 µL) or nicotine (final concentration, 10 pM – 100 µM; positive control) or 
methyllycaconitine (final concentration, 10 pM – 100 µM; positive control), and [3H]NIC or 
[3H]MLA (final concentration, 3 nM in 50 µL), and incubation buffer (50 µL) for a final assay 
vol of 250 µL. Nonspecific binding of [3H]NIC and [3H]MLA was determined in the presence 
of 10 µM of cytisine (50 µL) and 10 µM of nicotine (50 µL), respectively. Samples were 
incubated for 1 h at room temperature. Unifilter-96 GF/B filter plates (1.0 µm pore size; 
PerkinElmer, Inc., Waltham, MA) were presoaked in 0.5% PEI for 1 h at 4 ºC. Reactions 
were stopped by filtration using a Packard Filter Mate Harvester (Perkin Elmer, Inc., 
Waltham, MA). Plates were washed 3 times with 350 µL of ice-cold assay buffer, and dried 
for 1 h at 45 °C. Plates were bottom sealed, and each well filled with 40 µL Microscint 20 
cocktail. Bound radioactivity on the filter was determined via liquid scintillation 
spectrometry (Top Count NXT scintillation counter; PerkinElmer, Inc.).  
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3.2.7 METH-Evoked [3H]DA Release 
To further evaluate GZ-11608 efficacy as an inhibitor of the pharmacological 
effects of METH, the concentration-dependent effect of GZ-11608 to inhibit METH-evoked 
DA release from isolated striatal synaptic vesicles was determined using previously 
described methods (Teng et al., 1997; Horton et al., 2013). Also, the underlying 
mechanism of GZ-11608 inhibition was determined. Initially, the effect of GZ-11608 to 
release DA from synaptic vesicles was determined. Vesicles were prepared as described 
above for the vesicular DA uptake assay, except that final pellets were resuspended in a 
smaller vol (2.7 mL) of assay buffer. To preload the vesicles, [3H]DA (final 
concentration,0.3 µM in 300 µL) was added to the vesicle suspension, and incubation 
proceeded at 37 °C for 8 min. Samples were placed on ice for 2 min to stop [3H]DA uptake, 
and then centrifuged at 100,000g for 1 h at 4 °C to remove free [3H]DA not transported 
into the vesicles. Pellets were resuspended in a final vol of 4.2 mL of assay buffer. Aliquots 
of [3H]DA-preloaded vesicular suspension (180 µL) were added to tubes containing one 
of 11 concentrations of GZ-11608 (final concentrations, 0, 0.1 nM - 0.1 mM in 20 µL). 
Samples were incubated at 37 °C for 8 min. Reactions were stopped by adding 2.5 mL of 
ice-cold buffer (25 mM HEPES, 100 mM potassium tartrate, 50 µM EGTA, 100 µM EDTA, 
1.7 mM ascorbic acid, 2 mM magnesium sulphate, pH 7.4), followed by rapid filtration onto 
PEI-presoaked GF/B filters, and rinsing of the filters with ice-cold buffer (3 times, 4 mL 
each). Scintillation cocktail was added, and radioactivity retained on the filters determined 
by liquid scintillation spectrometry. GZ-11608-evoked vesicular DA release was 
determined as the amount of [3H]DA retained by the vesicles subtracted from the amount 
retained in control vesicles not exposed to GZ-11608. To determine METH-evoked [3H]DA 
release and GZ-11608-induced inhibition of METH-evoked [3H]DA release, [3H]DA 
preloaded vesicles (180 µL) were incubated for 8 min at 37 °C with one of 11 METH 
145 
concentrations (final concentrations, 0, 0.1 µM - 20 mM in 10 µL) in the absence (control) 
and presence of a single concentration of GZ-11608 (final concentrations, 0, 10, 500 nM 
and 10 µM in 10 µL) in a total vol of 200 µL. Reactions were stopped, radioactivity retained 
on the filter determined, and vesicular [3H]DA release calculated as described above to 
determine GZ-11608-induced inhibition of METH-evoked [3H]DA release. 
3.2.8 METH Sensitization 
As a rapid means of determining if GZ-11608 decreases the in vivo effects of 
METH, locomotor sensitization following repeated METH injection was the initial assay 
employed (Alvers et al., 2012; Lee et al., 2018). Repeated METH administration results in 
a robust and stable increase in locomotor activity from day-to-day, allowing for reliable 
evaluation of the ability of compound to reduce the effects of METH on behavior. 
Locomotor activity was measured in a locomotor chamber (24 x 24 x 30 cm) with clear 
acrylic walls and floor. A horizontal 16 x 16 grid of photo beams was located 7 cm above 
the chamber floor, with each beam 2.5 cm apart. Movement in the chamber resulted in 
beam breaks, which were recorded and transformed into distance traveled (cm) by 
Versamax and Digipro System software (AccuScan Instruments Inc., Columbus, OH). The 
effect of GZ-11608 on METH-sensitized activity was determined using a mixed factor 
design with METH as a between-subjects factor and GZ-11608 as within-subjects factor. 
Rats were assigned randomly to METH or saline groups. After a week of acclimation, rats 
were habituated to the apparatus by being placed in the chamber for 1 h with no injection 
(Day 0). On Days 1-10, rats were injected (subcutaneous, s.c.) daily with either METH (1 
mg/kg) or saline (1 ml/kg), immediately placed in the chamber, and activity measured for 
1 h. METH dose and number of daily injections were chosen to provide stable, sensitized 
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locomotor activity, based on previous findings (Lee et al., 2018). On Day 11, GZ-11608 (0, 
1-30 mg/kg, s.c.) in a quasi-randomized dose order was injected 15 min prior to the daily 
METH or saline injection, and then, rats were placed immediately into the chamber for 1 
h. A washout period (2-3 days) intervened between testing of GZ-11608 doses to avoid 
potential drug accumulation. On washout days, METH or saline was injected and 
locomotor activity determined.  
In a separate experiment employing a mixed factor design, the effect of GZ-11608 
administration by oral gavage (p.o.) on METH locomotor sensitization was determined. 
Following repeated METH or saline for 5 days, rats were habituated to the oral gavage 
procedure. On Day 5-10, rats received vehicle (15% (v/v) Kolliphore EL in saline, p.o., 3 
mL) 15 min prior to METH or saline injection (s.c.) and were placed in the activity chamber 
for 1 h (Wilmouth et al., 2013). On Days 11-27, GZ-11608 (0, 17-300 mg/kg, p.o., 
ascending dose order) was administered, followed 15 min later by either METH or saline 
injection (1 mL/kg, s.c.), depending on group assignment, and immediate placement into 
the chamber for 1 h. Between GZ-11608 doses, 2-3 days of washout occurred. On 
washout days, vehicle was administered p.o. and METH or saline was injected s.c.  
3.2.9 Striatal DA Content 
To determine whether GZ-11608 alters striatal DA content and/or exacerbates 
METH-induced striatal DA depletion, GZ-11608 was administered s.c. to rats in the 
absence and presence of a METH dose known to deplete rat striatal DA content (Bowyer 
et al., 1992, 1994; pilot study). The dose of GZ-11608 was chosen based on its ability to 
reliably decrease METH-sensitized locomotor activity. Following acclimation to the colony 
and 3 days prior to drug injection, a thermal transponder (Bio Medic Data Systems, Inc., 
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Seaford, Delaware) was implanted (s.c.) beneath the scapula to monitor body temperature. 
In the first series of experiments using a between-groups design, GZ-11608 (17 mg/kg, 
s.c.) or saline (1 mL/kg, s.c.) was administered 15 min prior to METH (30 mg/kg, i.p.) or
saline (1 mL /kg, i.p.), according to random assignment to treatment group. In the second 
series of experiments also using a between-groups design, GZ-11608 or saline was 
administered 15 min after METH or saline. Body temperature was monitored every 30 min 
for 8 h following METH injection. If the body temperature increased to 41.3 ºC or higher, 
rats were transferred to a cage placed on ice until  body temperature decreased to 40.0 
ºC or below (Bowyer et al., 1992, 1994; Fukumura et al., 1998). Striata were obtained 72 
h after METH injection and were processed via high performance liquid chromatography 
with electrochemical detection (HPLC-EC). Striata were weighed, placed in 1 mL of 
perchloric acid and sonicated. Tissue samples were centrifuged at 31,000g for 30 min at 
4 °C. Supernatant (50 µL)  was injected onto the octadecylsillica Ultrasphere C18 reverse-
phase column (80 x 4.6 mm, 3 µm ESA Inc., Chelmsford, MA) via autosampler (508 
Beckman Coulter, Inc., Fullerton, CA). DA was detected by a coulometric-II detector with 
guard cell (model 5020; ESA, Inc., Chelmsford, MA) maintained at +0.60 V and an 
analytical cell (model 5011) maintained at E1 = +0.05 V and E2 = +0.35 V. Mobile phase 
(MP) consisted of 0.07 M citrate, 0.1 M acetate buffer with 175 mg/L octylsulfonic acid-
sodium salt, 650 mg/L of sodium chloride and 7% methanol (pH 4.2). Flow rate was 1.2 
mL /min, and 4-5 min were required to analyze each sample. DA standards were used to 
identify and quantify DA peak and amount using 32 Karat software (Beckman Coulter, Inc., 
Fullerton, CA).   
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3.2.10 METH Self-Administration 
The ability of GZ-11608 to dose-dependently decrease the reinforcing effect of 
METH was determined using a within-subject design. Due to the high doses of GZ-11608 
required in the METH sensitization studies and the assumed low oral bioavailability, s.c. 
rather than oral administration was employed for self-administration studies. Two-lever 
operant chambers were used to train rats once daily for 3 days in 1 h sessions to press a 
lever (active lever) for food pellet reinforcement (45 mg pellet, BIO-SERV, #F0021, 
Frenchtown, NJ) on a fixed ratio 1 (FR1) schedule, while responding on the other lever 
(inactive lever) had no programmed consequence. Subsequently, the operant schedule 
was incremented to a FR3 schedule for 3 days, then a FR5 schedule for 14 days until rats 
met the criteria for stable responding, which included: 1) >10 pellets earned/session and 
2) a minimum of a 2:1 ratio of active:inactive lever presses. After delivery of each food 
reinforcer, the lights above both levers were illuminated for a 20-s signaled timeout period. 
After reaching stable responding for food on the FR5 schedule, rats underwent catheter 
implantation surgery. Rats were anesthetized (75 mg/kg ketamine, 7.5 mg/kg xylazine, 
and 0.75 mg/kg acepromazine; i.p.) and a silastic catheter was implanted into the jugular 
vein. The free end of the catheter was affixed with dental acrylic to the skull by metal 
screws and exited through the scalp. Rats were allowed to recover for 1 wk. Prior to the 
start and at the end of each behavioral session. Catheters were flushed daily with 0.1 mL 
heparinized saline to maintain patency. Following recovery from surgery, rats were trained 
to press a lever for i.v. METH (0.05 mg/kg/infusion) during 1 h daily sessions using a 
standard 2-lever procedure as previously reported (Harrod et al., 2001; Beckmann et al., 
2012). The FR schedule was incremented across training sessions (3 days, FR1; 3 days, 
FR3; 14 days, FR5). A 20-s signaled timeout occurred after each METH infusion. Upon 
reaching criteria for stable responding (> 10 infusions/session and a 2:1 ratio of 
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active:inactive lever presses), a dose of GZ-11608 (0, 1, 3, 10, 17, and 30 mg/kg, in 
ascending dose order, s.c.) was administered 15 min prior to the session. GZ-11608 
vehicle (0 mg/kg) was 15% kolliphore in saline (1 mL/kg, s.c.).  
3.2.11 Food-Maintained Responding 
To evaluate the specificity of the GZ-11608-induced decrease in responding for i.v. 
METH, the ability of GZ-11608 to decrease food-maintained responding was determined 
using a within-subject design. GZ-11608 doses and pre-treatment time were as described 
for METH self-administration experiments. Experiments were conducted as described 
above, with exceptions that no surgery was performed, and rats did not self-administer 
METH. Instead, rats were trained to a terminal FR5 to respond for food pellets (45 mg 
pellet, BIO-SERV, #F0021) in daily 1-hr sessions. 
3.2.12 Repeated GZ-11608 Administration 
A within-subject design was used to determine if tolerance developed to the GZ-
11608-induced decrease in METH self-administration and/or food-maintained responding. 
One group of rats underwent operant training for food reinforcement, catheter implantation 
surgery, and operant training for i.v. METH (0.05 mg/kg/infusion) self-administration as 
described above. In these experiments, GZ-11608 (30 mg/kg, s.c.; a dose that reliably 
decreased METH self-administration) was administered 15 min prior to 7 consecutive, 
daily METH self-administration sessions. Then, for 5 consecutive daily sessions, 
responding for METH was determined without GZ-11608 treatment. Another group of rats 
was trained for food-maintained responding, and the effect of repeated GZ-11608 (30 
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mg/kg, s.c.) was determined using the same dose and pre-treatment time as described 
above for METH self-administration.  
3.2.13 Surmountability 
To determine whether increasing the unit dose of METH would surmount the effect 
of GZ-11608 to decrease i.v. METH self-administration, another group of rats underwent 
operant training for food reinforcement, catheter implantation surgery, and operant training 
for METH (0.05 mg/kg/infusion) self-administration as described above. A within-subject 
design was employed to establish the METH dose-response across a range of METH 
doses (0.01-0.25 mg/kg/infusion) in the absence of GZ-11608. Each dose of METH was 
tested for 3 consecutive sessions. Then, the METH dose-response was re-evaluated in 
the same group of rats following treatment with GZ-11608 (30 mg/kg, s.c.) 15 min prior to 
the session. To maintain stable responding, two intervening maintenance sessions 
occurred between each session in which GZ-11608 was administered. For these 
maintenance sessions, no GZ-11608 treatment was administered prior to self-
administration of each METH unit dose.  
3.2.14 Reinstatement 
The ability of GZ-11608 to decrease cue- and METH-induced reinstatement of 
METH seeking behavior was determined using previously published methods (Harrod et 
al., 2003). In brief, 3 groups of rats were trained to self-administer METH (0.05 
mg/kg/infusion) as described above, except that cue lights were illuminated for 5 s at the 
beginning of each session prior to presentation of the levers. For cue-induced 
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reinstatement experiments, upon reaching the criteria for stable responding, rats 
underwent extinction for 14 days. During extinction, cue lights were not illuminated at the 
beginning or during daily 1 h sessions, and active lever presses did not result in METH 
infusion. The day after the last extinction day (test for reinstatement), the cue light was 
illuminated at the beginning and during the session, and the dose effect for GZ-11608 to 
decrease cue-induced drug seeking behavior was determined. Because drug seeking 
behavior is diminished with repeated testing, two groups of rats were needed to generate 
the complete dose response. In one group, low doses (0, 3, 5.6, and 10 mg/kg, s.c.) were 
evaluated in a randomized order 15 min prior to the session, and higher doses (0, 10, 17 
mg/kg, s.c.) were evaluated in a second group. To maintain responding at extinction levels, 
5 intervening sessions occurred between each session in which GZ-11608 was 
administered. On intervening sessions, there was no cue light illumination, no GZ-11608 
pre-treatment and no METH infusion.  
The effect of GZ-11608 (0, 10, 17, and 30 mg/kg, s.c.; in randomized order) on 
METH-induced reinstatement of drug seeking behavior was determined in a third group of 
rats. GZ-11608 or saline was injected 15 min prior to the session and METH (0.5 mg/kg, 
i.p.) was injected immediately prior to the session to reinstate drug seeking behavior. 
Experiments were conducted using similar procedures as in the experiments evaluating 
cue-induced reinstatement of drug seeking, except that the 20-sec contingent cue light 
illumination continued during the 14 days of extinction, as well as on reinstatement tests.  
3.2.15 Substitution of GZ-11608 for METH 
To determine whether GZ-11608 substitutes for METH in rats trained to self-
administer i.v. METH, another experiment was conducted using a mixed factor design with 
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GZ-11608 treatment as a between-subject factor, and dose and session as within-subject 
factors, similar to previously published methods (Harrod et al., 2003; Beckmann et al., 
2012). Rats were trained to stable performance for METH (0.05 mg/kg/infusion) self-
administration under an FR5 schedule of reinforcement as described above. Upon 
reaching the criteria for stable responding, rats were assigned randomly to either the GZ-
11608 or saline groups. For the GZ-11608 group, responding on the active lever under 
the FR5 schedule resulted in i.v. infusions of GZ-11608 (0.01, 0.05, 0.1, and 0.5 
mg/kg/infusion; in ascending order), each dose was administered across 4 consecutive 
sessions. Only saline was available (i.v.) to the saline group across the same number of 
self-administration sessions. Then, for both GZ-11608 and saline groups, METH (0.05 
mg/kg/infusion) was available for 4 consecutive self-administration sessions. 
3.2.16 GZ-11608 Self-Administration 
To determine whether GZ-11608 was self-administered in drug naïve rats, a mixed 
factor design with GZ-11608 treatment as a between-subject factor, and dose and session 
as within-subject factors was conducted, similar to previously published methods (Harrod 
et al., 2003). Rats underwent operant training for food reinforcement, catheter implantation 
surgery, and random assignment to operant training of GZ-11608 or saline i.v. self-
administration. For the saline group, only i.v. saline was available across the experiment. 
For the GZ-11608 group, each GZ-11608 dose (0.5, 0.1 and 0.05 mg/kg/infusion) was 
available in a descending order on a FR1 schedule of reinforcement for 5 consecutive 
days, followed by availability on an FR2 schedule for 3 days. To maintain stable 
responding, intervening maintenance sessions occurred after the evaluation of each GZ-
11608 dose. During the maintenance sessions, rats responded for food reinforcement 
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under FR1 for 2 days, and then, under FR2 for 1 day; GZ-11608 was not available. As a 
positive control, ability to self-administer METH (0.05 mg/kg/infusion) under an FR1 for 5 
days, FR2 for 3 days, and FR5 for 10 days was determined in the GZ-11608 group. To 
further evaluate GZ-11608 as a reinforcer, responding for i.v. GZ-11608 (0.1 
mg/kg/infusion) or saline (depending on random group assignment) was determined in 
drug naive rats under an FR1 for 5 days, FR2 for 3 days, and FR5 schedule for 10 days.  
3.2.17 Data Analysis 
Specific [3H]DA uptake, [3H]5-HT uptake, [3H]dofetilide binding, [3H]NIC binding, 
and [3H]MLA binding were calculated by subtracting nonspecific uptake or binding from 
total uptake or binding, respectively. The GZ-11608 concentration that produced 50% 
inhibition of specific uptake or binding (IC50 values) was obtained from individual 
concentration-response curves via an iterative curve-fitting program (Prism 7.03; 
GraphPad Software, Inc., La Jolla, CA). Inhibition constants (Ki values) were determined 
using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). The selectivity ratio for 
GZ-11608 relative to the off-target sites was determined as the Ki value for inhibition of 
VMAT2 divided by the Ki value for DAT, SERT, hERG and nAChRs, respectively. EC50 
values from individual concentration-response curves for METH or GZ-11608 to evoke 
[3H]DA release from synaptic vesicles was determined using Prism 7.0. Mechanism of 
GZ-11608-induced inhibition of METH-evoked vesicular [3H]DA release was determined 
using Schild analysis. Dose ratios (DR) were obtained by dividing the EC50 for METH-
evoked [3H]DA release in the presence of each concentration of GZ-11608 by that in the 
absence of GZ-11608.  Log (DR-1), plotted as a function of log GZ-11608 concentration, 
provided the Schild regression; linearity of the slope was significantly different from unity 
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if the 95% confidence intervals (CI) did not include 1.0 (Prism 7.03; Kenakin et al., 
2006).  
For all behavioral experiments, distance travelled, and number of responses 
were subjected to analyses of variance (ANOVA), followed by Tukey’s post hoc tests 
when appropriate, unless otherwise indicated.  
3.3 Results 
GZ-11608 potently and selectively inhibits VMAT2 function relative to interactions 
at off-target sites.  GZ-11608 potently inhibited (Ki = 25 ± 4 nM) [3H]DA uptake at VMAT2 
with maximal inhibition (Imax) of >95% (Fig. 3.2). GZ-11608 selectively inhibited [3H]DA 
uptake at VMAT2, having at least 92-fold higher affinity at VMAT2 relative to off-target 
sites (Fig. 2; [3H]5-HT uptake at SERT: Ki = 2.36 ± 0.29 µM, Imax > 95%, 92-fold selective 
for VMAT2; [3H]dofetilide binding to hERG: Ki = 4.16 ± 1.68 µM, Imax > 90%, 163-fold 
selective for VMAT2; and, [3H]DA uptake at DAT: Ki = 6.15 ± 0.74 µM, Imax > 90%, 241-
fold selective for VMAT2). GZ-11608 did not inhibit [3H]NIC and [3H]MLA binding to α4β2 
and α7 nAChRs, respectively (Ki > 30 µM; >1180-fold selective for VMAT2).  Taken 
together, GZ-11608 exhibited high affinity and selectivity for VMAT2 over SERT, hERG, 
DAT, α4β2 nAChRs and α7 nAChRs. 
GZ-11608 evokes vesicular [3H]DA release and inhibits METH-evoked vesicular 
[3H]DA release. Effects of GZ-11608 to release vesicular [3H]DA and to inhibit METH-
evoked vesicular DA release are illustrated in Fig. 3.3. GZ-11608 (0.1 nM – 0.1 mM) 
stimulated [3H]DA release from isolated striatal synaptic vesicles with an EC50 value of 
0.62 ± 0.14 µM and an Emax value of 76.8 ± 5.0%. The GZ-11608 concentration-response 
data fit a one-site model (non-linear regression, R2 = 0.87, p < 0.05; Fig. 3.3A). The effect 
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of GZ-11608 to inhibit METH-evoked [3H]DA release in the absence and presence of a 
low, medium and high concentration of GZ-11608 is illustrated in Fig. 3.3B. METH evoked 
[3H]DA release from isolated vesicles with an EC50 value of 14.5 ± 4.10 µM, an Emax value 
of 90.0 ± 2.04%, and in the absence of GZ-11608, the METH concentration-response data 
fit a one-site model (non-linear regression, R2 = 0.97, p < 0.0001; Fig. 3.3B). Kinetic 
parameters for methamphetamine-evoked [3H]DA release from striatal synaptic vesicles 
were consistent with previously published values (Horton et al., 2013). Concentration-
response data sets for METH in the presence of varying GZ-11608 concentrations (10 nM, 
500 nM, or 10 µM) each fit a one-site model (non-linear regression, R2 = 0.94, 0.95, 0.90, 
respectively, ps < 0.0001; Fig. 3.3.B). METH concentration-response curves for vesicular 
[3H]DA release were shifted rightward, and EC50 values in the presence of GZ-11608 (0, 
10, 500 nM and 10 µM) were 14.5 ± 4.10, 17.3 ± 4.15, 122 ± 32.3, and 388 ± 23.7 µM, 
respectively; whereas, the Emax values were not altered as the concentration of GZ-11608 
increased (90.0 ± 2.04, 94.1 ± 1.25, 88.1 ± 1.27, and 88.4 ± 3.70%, respectively). Two-
way repeated measures ANOVA revealed a METH x GZ-11608 interaction [F33,99=11.2, p 
< 0.0001]. The Schild regression had a slope of 0.90 (CI: 0.603 to 1.20; Fig. 3.3B insert), 
consistent with a competitive mechanism of VMAT2 inhibition.  
 GZ-11608 decreases METH sensitization. GZ-11608 decreased METH 
sensitization (1.0 mg/kg, s.c., once daily for 10 days; Fig. 3.4). Locomotor activity (distance 
traveled) in the METH-treated group increased following acute METH and plateaued after 
5 daily METH injections at an activity level greater than that observed following acute 
injection on Day 1 (i.e., sensitization; Fig. 3.4A). Across the same time period, the 
locomotor activity in the saline-injected control group was not changed (Fig. 3.4A, inset). 
Two-way ANOVA revealed a treatment x session interaction [F10,90 = 21.7, p < 0.001].  
Post hoc analysis revealed no differences between the treatment groups on the initial 
habituation day (Day 0).  However, as expected METH increased distance traveled on 
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Day 1 relative to the saline-injected group (p < 0.001) and distance traveled was greater 
on Days 5-10 than on Day1 in the METH treatment group (ps < 0.05), but not in the saline 
treatment group.  There were no significant differences in activity between Days 5-10 in 
the METH treatment group, indicating that sensitization occurred and stabilized by Day 5.  
 GZ-11608 (s.c.) decreased METH sensitized locomotor activity in a dose-
dependent manner without altering activity in the saline-injected control group (Fig. 3.4B). 
Two-way ANOVA revealed an interaction between METH treatment x GZ-11608 dose 
[F5,28 = 23.5, p < 0.001]. Post hoc analysis revealed that GZ-11608 (10, 17, and 30 mg/kg) 
decreased METH sensitization relative to vehicle (15% Kolliphore EL in saline) (p < 0.005), 
and activity reached the criteria of a 50% reduction relative to activity following vehicle 
(Fig. 3.4B).  In the saline-injected control group, no effect of GZ-1108 at any dose relative 
to vehicle was found (Fig. 3.4B, inset), indicating a specific effect of GZ-11608 on the 
METH-sensitized response. Activity at the highest dose of GZ-11608 (30 mg/kg) in the 
METH group was not different from activity following vehicle injection in the saline group, 
demonstrating GZ-11608 blockade of the expression of METH sensitization.  
 To assess oral bioavailability, the effect of GZ-11608 following oral administration 
on METH sensitization was determined. GZ-11608 (17-300 mg/kg, p.o.) decreased METH 
sensitization in a dose-dependent manner relative to vehicle; however, activity tended to 
increase following oral administration of GZ-11608 in the saline-injected control group (Fig. 
4C). An interaction was found between METH treatment x GZ-11608 dose [F6,53 = 10.1 p 
< 0.001] (Fig. 3.4C). Post hoc analysis revealed that GZ-11608 (300 mg/kg) decreased 
sensitized locomotor activity relative to vehicle in the METH treatment group (p < 0.05; 
Fig. 3. 4C). Activity following the highest dose (300 mg/kg) of GZ-11608 reached the 
criteria of a 50% reduction relative to vehicle. Activity following GZ-11608 (17-300 mg/kg) 
in the saline-injected group tended to increase, but did not reach statistical significance 
(Fig. 3.4C; inset). Activity at the highest dose of GZ-11608 (300 mg/kg) in the METH group 
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was not different from activity following vehicle in the saline group, demonstrating GZ-
11608 blockade of the expression of METH sensitization. Taken together, GZ-11608 
following s.c. and p.o. administration specifically decreased METH sensitization. 
 GZ-11608 does not alter striatal DA content and does not exacerbate the decrease 
in DA content produced by METH. To determine the effect of GZ-11608 on striatal DA 
content, a dose of GZ-11608 (17 mg/kg, s.c.) that both reliably and specifically decreases 
METH sensitization was employed (Fig. 3.5). One-way ANOVAs revealed significant 
differences in DA content after either GZ-11608 pretreatment or post-treatment and a 
relatively high dose (30 mg/kg, i.p.) of METH (pretreatment, F3,34 = 6.26, p < 0.05, Fig. 
3.5A; post-treatment, F3,21 = 16.5, p<0001, Fig. 3.5B). Post hoc analysis revealed that DA 
content was decreased (40-50%) following METH alone compared with the respective 
saline control groups. GZ-11608 alone did not alter DA content compared with the 
respective saline control. DA content following GZ-11608 pretreatment or post-treatment 
and METH was not different from that following METH alone (Fig. 3.5A and 3.5B, 
respectively), indicating that GZ-11608 did not exacerbate the effect of METH to decrease 
striatal DA content. 
 GZ-11608 decreases responding for i.v. METH, but not for food. To determine if 
GZ-11608 specifically decreases METH self-administration, the effects of GZ-11608 (1-
30 mg/kg, s.c.) on METH (0.05 mg/kg/infusion) self-administration and food-maintained 
responding were evaluated. One-way ANOVAs revealed that GZ-11608 dose-
dependently decreased METH self-administration, but not food-maintained responding 
([F5,45 = 3.92, p < 0.005], Fig. 3.6A;  [F5,60 = 3.23, p = 0.0119], Fig. 3.6B, respectively). Post 
hoc analysis revealed that after the highest dose of GZ-11608 (30 mg/kg), responding for 
METH was lower than following vehicle (p < 0.05, Fig. 3.6A). Post hoc analysis also 
revealed that GZ-11608 did not alter responding for food (p > 0.05, Fig. 3.6B). Thus, GZ-
11608 specifically decreased METH self-administration. 
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 Tolerance does not develop to the effect of GZ-11608 to decrease responding for 
i.v. METH. One-way ANOVA revealed that following acute administration, GZ-11608 (30 
mg/kg, s.c.) decreased responding for METH (0.05 mg/kg/infusion) and that responding 
continued to be decreased across 7 consecutive, once/daily GZ-11608 treatments [F7,43 = 
3.68, p < 0.05], indicating that tolerance did not develop to this effect of GZ-11608 (Fig. 
3.7). Upon cessation of GZ-11608 treatment, responding for METH returned to baseline 
(F5,26 = 3.67, p < 0.05; Fig. 3.7).  Post hoc analysis revealed that responding during post-
treatment sessions 1 and 2 was decreased compared to baseline (p < 0.05), and that 
responding during post-treatment sessions 3-5 was not different from baseline (p > 0.05). 
Of note, repeated administration of GZ-11608 (30 mg/kg, s.c., once daily for 7 days) 
initially decreased responding for food, but tolerance developed to this effect after 5 daily 
administrations (Fig. 3.12).  
 Increasing the unit dose of METH does not surmount the effect of GZ-11608 to 
decrease responding for i.v. METH. This experiment assessed if  the GZ-11608-induced  
decrease in METH self-administration could be surmounted by increasing the unit dose of 
METH. Inverted U-shaped METH dose-response curves were obtained with no treatment 
and following GZ-11608 (30 mg/kg, s.c.) treatment. Following GZ-11608 treatment, the 
METH dose-response curve was downward and rightward shifted relative to the curve 
obtained with no treatment (Fig. 3.8). Two-way ANOVA on the data expressed as number 
of METH infusions revealed an interaction between GZ-11608 treatment x METH unit 
dose [F5,68 = 2.55, p < 0.05]. Post hoc analysis revealed that GZ-11608 decreased the 
number of  METH infusions when low unit doses (0.01-0.05 mg/kg/infusion) were available, 
whereas GZ-11608 had no effect on number of infusions when higher unit doses (0.1 and 
0.25 mg/kg/infusion) of METH were available. Without GZ-11608 treatment, the peak 
number of METH infusions (20 infusions) occurred with a unit dose of 0.025 mg/kg/infusion.  
Following GZ-11608 treatment, the peak number (9 infusions) of METH occurred with 0.1 
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mg/kg/infusion, representing a ~50% decrease relative to no GZ-11608 treatment (Fig. 
3.8). Thus, increasing the METH unit dose did not surmount the effect of GZ-11608. 
 GZ-11608 decreases cue- and METH-induced reinstatement of METH-seeking 
behavior. These experiments determined if GZ-11608 decreases cue- and METH-induced 
reinstatement (models of relapse). In a dose-related manner, GZ-11608 decreased cue- 
and METH-induced reinstatement of METH seeking (Fig. 3.9A and 3.9B, respectively). 
For both cue- and METH-induced reinstatement experiments, one-way ANOVAs revealed 
that METH seeking was decreased in a dose-related manner by GZ-11608 ([F6,99 = 34.5, 
p < 0.001] and [F5,54 = 17.1, p < 0.001], respectively). Post hoc analyses revealed that 
lever pressing was decreased following 14 extinction sessions compared to baseline and 
that both the cue and METH (0.5 mg/kg, i.p.) reinstated METH seeking  following a vehicle 
pretreatment (ps < 0.05). GZ-11608 dose-dependently decreased both cue- and METH-
induced reinstatement (ps < 0.001). Thus, GZ-11608 dose-dependently decreased cue- 
and METH-induced reinstatement of METH seeking. 
 GZ-11608 does not substitute for METH. One potential mechanism underlying the 
GZ-11608-induced decrease in METH self-administration may be due to an action as a 
substitute reinforcer. In rats trained to self-administer METH, METH was replaced by 
either i.v. GZ-11608 or saline. Fig. 3.10 illustrates that responding across a range of GZ-
11608 doses was not different from responding for saline. Two-way ANOVA revealed no 
main effect of treatment [F1,3 = 0.206, p = 0.681] and no treatment x session interaction 
[F20,60 = 0.368, p = 0.99]; however, there was a main effect of session [F20,60 = 7.46, p < 
0.001]. Post hoc analysis revealed no differences between the groups at baseline (p > 
0.05) and no differences between groups responding for the range of doses of GZ-11608 
and saline across sessions 1-16. During sessions 17-20, in which METH was available 
and responding returned to baseline, there were also no differences in responding 
between groups. Thus, GZ-11608 did not substitute for METH as a reinforcer. 
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 GZ-11608 does not serve as a reinforcer. To assess the abuse liability of GZ-
11608, drug naïve rats were trained to respond for GZ-11608 using the same procedure 
as that used for METH self-administration. Fig. 3.11 shows that GZ-11608 was not self-
administered, and may have had aversive properties at the highest dose evaluated. Two-
way ANOVA on the number of responses at the highest GZ-11608 dose (0.5 
mg/kg/infusion) revealed a main effect of session [F7,70 = 4.50, p < 0.05], a trend for a GZ-
11608 x session interaction [F7,70 = 2.01, p = 0.0658], but no main effect of GZ-11608 [F1,10 
= 2.30, p = 0.160]. Post hoc analysis revealed that responding during sessions 1 and 2 
was decreased when GZ-11608 (0.5 mg/kg/infusion) was available compared to the saline 
group (p < 0.05), supporting that the high dose of GZ-11608 served as a punisher (Fig. 
3.11A). Analysis of the intermediate dose of GZ-11608 (0.1 mg/kg/infusion) revealed no 
main effects of treatment or session (F1,10 = 0.51, p = 0.492 and F7,70 = 2.09, p = 0.056, 
respectively), and no treatment x session interaction (F7,70 = 0.42, p = 0.884; Fig. 3.11B). 
Analysis of the lowest dose of GZ-11608 (0.05 mg/kg/infusion) revealed no main effects 
of treatment or session (F1,9 = 0.69, p = 0.426; F7,59 = 1.92, p = 0.082, respectively) and no 
treatment x session interaction (F7,59 = 0.20, p = 0.984; Fig. 3.11C). Thus, responding for 
GZ-11608 (0.05-0.1 m/kg/infusion) was not different from the saline group. The lack of 
responding for GZ-11608 was not due to lack of i.v. catheter patency, because as 
expected, responding increased subsequently when METH was available (Fig. 3.11D). 
During the FR1/FR2 components of the session, a main effect of session [F7,42 = 2.56, p < 
0.05] was found, with no main effect of treatment [F1,6 = 2.87, p = 0.14] and no treatment 
x session interaction [F7,42 = 1.22, p = 0.31].  During the FR5 component, a main effect of 
treatment [F17,102 = 2.09, p < 0.05] was found with no main effect of session [F1,6 = 5.66, p 
= 0.055] and no treatment x session interaction [F17,102 = 1.11, p = 0.37]; Fig. 3.11D). Thus, 
GZ-11608 does not have reinforcing properties.  
 
161 
 
3.4 Discussion 
 The current drug discovery program probed VMAT2 as a therapeutic target for 
identification of medications for METH use disorder. While a previous lead, GZ-793A, 
showed VMAT2 potency, selectivity and efficacy, without development of tolerance 
(Horton et al., 2011b; Alvers et al., 2012; Meyer et al., 2013; Nickell et al., 2017), it had 
potential cardiotoxicity (Nickell et al., 2017). Structural modification aimed at eliminating 
hERG affinity resulted in GZ-11610 and GZ-11608. GZ-11610 exhibited 9 nM Ki and 1090-
fold selectivity for VMAT2 over hERG, and specifically decreased METH sensitization (Lee 
et al., 2018), revealing advantages of this structural scaffold. In the current study, GZ-
11608 potently inhibited VMAT2 (Ki = 25 nM), with >100-fold selectivity at VMAT2 over 
nAChRs and hERG, and also decreased METH sensitization, METH self-administration 
and reinstatement, without exhibiting intrinsic reinforcing properties itself. 
 Interaction of METH with the DA system underlies its abuse liability (Koob and 
Volkow, 2016). METH increases cytosolic DA concentration by releasing vesicular DA 
(EC50 = 9-15 µM, Emax = 90%) and inhibiting vesicular uptake (Ki = 2.5 µM) (Nickell et al., 
2010; Horton et al., 2013; current study). At VMAT2, METH inhibits uptake ~4-fold more 
potently than it evokes release. In contrast, GZ-11608 inhibits uptake 25-fold more 
potently than it evokes release (EC50 = 0.62 µM, Emax = 77%). GZ-11608 releases vesicular 
DA 23-fold more potently and inhibits uptake at VMAT2 100-fold more potently than METH. 
Moreover, the current study shows that GZ-11608 inhibits METH-evoked vesicular DA 
release and shifts rightward by 100-fold the METH concentration-response curve, with no 
change in Emax. The Schild slope not being different from unity suggests a competitive 
mechanism, such that GZ-11608 and METH appear to act at the same site on VMAT2. 
 Although most compounds known to interact with VMAT2, both release and inhibit 
its function, they are categorized as either releasers (substrates) or inhibitors based on 
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relative Emax (Partilla et al., 2006). Generally, as compared to inhibitors, releasers have 
greater vesicular DA release Emax values. Classified as a releaser, METH releases 65% 
of preloaded DA and 90% of tyramine. In contrast, tetrabenazine and reserpine, classified 
as inhibitors, release DA and tyramine by 45% and 50%, respectively (Partilla et al., 2006). 
Current work shows that METH releases 90% of DA; whereas tetrabenazine and reserpine 
release 49% and 28%, respectively (Horton et al., 2013). Since GZ-11608 and GZ-793A 
release 77% and 86%, respectively, they would be classified likely as releasers. The 
current study employed classical pharmacological methods to determine mechanism of 
action (Kenakin, 1997). Schild analysis revealed that GZ-11608 and tetrabenazine 
competitively inhibit METH at VMAT2, whereas GZ-793A exhibited allosteric inhibition 
(Horton et al., 2013; current study).  
 The in vitro neurochemical effects of GZ-11608 translated to in vivo behavioral 
efficacy.  GZ-11608 decreased METH sensitization following repeated administration. 
METH sensitization reflects dynamic brain changes associated with METH use disorder 
(Robinson and Berridge, 2008; London et al., 2015). GZ-11608 specifically decreased 
(>50%) METH sensitization. Interestingly, the R-enantiomer GZ-11610, was not specific 
following s.c. administration, reducing activity in non-sensitized saline controls at doses 
that decreased METH sensitization (Lee et al., 2018).   
 METH self-administration is considered the gold standard animal model of MUD 
(Panlilio and Goldberg, 2007; Mews and Calipari, 2017). GZ-11608 dose-dependently 
decreased METH self-administration. Behavioral efficacy was found within the maximal 
concentration-exposure window, as indicated by the dose-dependent linear 
pharmacokinetics, including similar Emax values across doses. Tolerance did not develop 
to GZ-11608’s efficacy in the METH self-administration assay. Further, GZ-11608 
specifically decreased METH self-administration, especially when given across repeated 
injections. While acute high doses of GZ-11608 (10-30 mg/kg) decreased food-maintained 
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responding by ~20%, this effect was not significant. Moreover, repeated high dose (30 
mg/kg) administration significantly decreased food-maintained responding, but tolerance 
developed after 5 sessions. Different results between acute and repeated studies on food-
maintained responding using the 30 mg/kg dose of GZ-11608 may be explained by the 
escalating-dose design of the acute study, such that some tolerance may have developed 
across the incrementing 1-17 mg/kg doses given prior to the 30 mg/kg dose of GZ-11608.  
Interestingly, during the post-treatment sessions after repeated administration, an 
apparent increase (10-40%) above baseline in food-maintained responding was observed. 
Since MUD is often associated with decreased body weight (Sommers et al., 2006), 
increases in food intake may be a beneficial side effect.  
 METH use disorder is characterized by high relapse rates with ~90% relapsing 
within 5 years (Wang et al., 2012; Brecht and Herbeck, 2014). Preclinical models 
characterize relapse using both surmountability and reinstatement assays. Prevention of 
a lapse developing into a relapse was evaluated by determining if higher METH doses 
could surmount the inhibitory effect of GZ-11608 on METH self-administration. GZ-11608 
produced a downward and rightward shift of the dose-response curve for METH self-
administration. Thus, increasing the METH dose did not surmount the GZ-11608-induced 
decrease in responding for METH. In that experiment, it was notable that GZ-11608 
tended to suppress responding for saline infusions compared to the no treatment condition 
(Fig. 3.8), suggesting a non-specific suppressant effect.  However, the locomotor data do 
not support this interpretation, as GZ-11608 did not decrease activity. An alternative 
explanation is that GZ-11608 accelerated the within-session rate of extinction that 
occurred when saline was substituted for METH.   Moreover, GZ-11608 dose-dependently 
blocked both cue- and METH-induced reinstatement of METH seeking, supporting its 
potential utility in preventing relapse to METH seeking. 
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 Decreases in METH self-administration and reinstatement may have been due to 
reinforcing effects of GZ-11608, such that it acts as a substitute for METH. Consistent with 
this possibility, GZ-11608 tended, although not significantly, to increase locomotor activity 
in the control group repeatedly injected with saline. However, in additional experiments, 
GZ-11608 did not substitute for METH in the self-administration assay and did not 
engender self-administration in drug naïve animals. The lack of reinforcing effects of GZ-
11608 was not due to faulty cannula, since availability of METH resulted in a return to 
maintenance levels of responding. Thus, GZ-11608 appears to decrease METH self-
administration by inhibiting the reinforcing effect of METH, rather than by producing 
reinforcement. The lack of intrinsic reinforcing effects of GZ-11608 and the prediction of 
low abuse liability are consistent with its >200-fold selectivity for VMAT2 over DAT, with 
DAT inhibition being most closely associated with abuse liability (Seeman and Lee, 1975; 
Stathis et al., 1995).  
 METH is well known to deplete striatal DA content (Bowyer et al., 1992, 1994). The 
current study shows that GZ-11608 neither reduces DA content nor exacerbates the 
METH-induced decrease in content. Thus, during a relapse event when both GZ-11608 
and METH may be onboard, no additional dopaminergic neurotoxicity would be predicted 
to occur. In contrast, tetrabenazine, a classical and reversible VMAT2 inhibitor with only 
2-fold lower affinity for DAT, exacerbates METH-induced DA depletion (Kenney and 
Jankovic, 2006; Guay, 2010). Importantly, at low doses, tetrabenazine increases 
responding for  METH, whereas at high doses responding for METH decrease; however, 
responding for food also decreases, indicating a lack of specificity (Meyer et al., 2011). 
Thus, relative to this classical VMAT2 inhibitor, GZ-11608 has considerable advantages 
as a potential METH use disorder therapeutic.  
 Several lead compounds, i.e., lobeline, lobelane, GZ-793A and GZ-11608, have 
been identified from our iterative drug discovery program (Harrod et al., 2001, 2003; 
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Neugebauer et al., 2007; Meyer et al., 2011; Alvers et al., 2012; Beckmann et al., 2012; 
Horton et al., 2013; current study). VMAT2 affinity has increased, reaching the low nM 
range with GZ-793A and GZ-11608. Schild regression on METH-evoked vesicular DA 
release revealed a surmountable allosteric mechanism for GZ-793A and an orthostatic 
mechanism for GZ-11608. Generally, the leads exhibit good selectivity for VMAT2 over 
DAT, do not exacerbate METH-induced striatal depletion, and have behavioral efficacy 
and specificity decreasing METH self-administration, without decreasing food-maintained 
responding. Interestingly, lobeline and GZ-793A produced downward shifts of the METH 
self-administration dose-response curve, whereas GZ-11608 produced a downward and 
rightward shift, suggesting potentially different underlying mechanisms. Nevertheless, the 
GZ-11608-induced decrease in METH self-administration was not surmounted by 
increasing the unit dose of METH.  Although tolerance developed to lobelane’s efficacy in 
decreasing METH self-administration, this was not the case for lobeline, GZ-793A and 
GZ-11608.  Although lobeline was not efficacious in decreasing reinstatement of METH-
seeking behavior, GZ-793A and GZ-11608 showed efficacy. However, since GZ-793A 
was eliminated as a potential therapeutic for METH use disorder due to its potential 
cardiotoxicity, these new results advance GZ-11608 as a potential therapeutic due its 
ability to specifically decrease METH self-administration and reinstatement. Moreover, 
GZ-11608 does not have intrinsic reinforcing properties and is expected to have low abuse 
liability.  
 
3.5 Conclusion 
 GZ-11608, a potent and selective VMAT2 inhibitor, specifically decreases METH 
reinforcement and tolerance does not develop to its efficacy. METH does not surmount 
the GZ-11608-induced decrease in responding for METH, and GZ-11608 decreased both 
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cue- and METH-induced reinstatement of METH-seeking behavior.  GZ-11608 also 
appears to have low abuse liability. These preclinical findings suggest that GZ-11608 has 
good efficacy and potential as a therapeutic for METH use disorder with the exception of 
its low oral bioavailability. 
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Figure. 3.1. Structures of lobeline, lobelane, GZ-793A, GZ-11610 and GZ-11608 
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Figure. 3.2. GZ-11608 potently and selectively inhibits VMAT2 relative to SERT, 
hERG, DAT, α4β2 nAChRs, and α7 nAChRs. Chemical structure for GZ-11608 is 
shown in the insert. Ki values for GZ-11608 from the various neurochemical assays are 
provided in an ascending order in the legend. Data are mean ± SEM specific uptake or 
binding as a percentage of the respective control (Con), in the absence of GZ-11608. 
Control values for each assay are as follows: VMAT2, 56.3 ± 10.9 pmol/min/mg; SERT, 
54.5 ± 7.16 fmol/min/mg; hERG, 888 ± 80.3 fmol/mg; DAT, 91.0 ± 10.1 fmol/min/mg; 
α4β2 nAChRs,  21.5 ± 3.28 fmol/mg; α7 nAChRs, 31.4 ± 2.72 fmol/mg. n = 4 rats for 
neurotransmitter uptake assays, n = 3 cell batches for hERG binding assays, and n = 3 
rats for nAChR binding assays. 
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Figure. 3.3. GZ-11608 evokes vesicular DA release (panel A) and competitively 
inhibits METH-evoked vesicular DA release (panel B). Data are mean ± SEM [3H]DA 
release from striatal vesicles as a percentage of control. Control (CON) values for 
[3H]DA release in the absence of GZ-11608 or METH (METH) were 3290 ± 564 dpm 
(panel A) and 3380 ± 708 dpm (panel B), determined in duplicate in each experiment.  
Panel A: EC50 and Emax for GZ-11608 are provided in the insert. Panel B: GZ-11608 
concentrations are provided in the legend, and Schild regression and slope are shown in 
the insert.  n = 6 rats, panel A; n = 4 rats/assay, panel B.   
 
L o g  [G Z -1 1 6 0 8  (M ) ]
V
e
s
ic
u
la
r 
[3
H
]D
A
 r
e
le
a
s
e
(%
 C
o
n
tr
o
l)
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
-9 -8 -7 -6 -5 -4C O N
E C 5 0  =  0 .6 2 ±  0 .14 µ M
E m a x  =  7 6 .8 ±  5 .0 %
A
-1 0
170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3.4. Locomotor sensitization following repeated METH administration 
(panel A) is decreased in a dose-dependent manner by GZ-11608 (s.c., panel B; 
oral, panel C). Data are mean ± SEM distance traveled in meters (m) during the last 45 
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min of the 60-min sessions. Panel A: Day 0 shows activity on a habituation day prior to 
the first METH or saline injection. METH (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.) was 
administered once daily for 10 days (Days 1-10). Locomotor activity for the saline group 
is shown in the insert. Panels B and C: GZ-11608 or vehicle (Veh, 15% (v/v) Kolliphor 
EL®:/saline; 1 mL/kg) was administered s.c. (panel B) or p.o. (panel C) 15 min prior to 
METH (METH; 1.0 m/kg, s.c.) or saline injection. Dashed line represents 50% of the 
distance traveled following vehicle. Locomotor activity for the saline group following GZ-
11608 or vehicle is shown in panel B and C inserts. +p < 0.05 compared to Day 0; #p < 
0.05 compared to Day 1 within group (panel A). *p < 0.05 compared to vehicle within 
group (panel B and C); n = 10 rats/group in panel A, which were subdivided into n = 5 
rats/group for panels B and C. Note:  METH was administered inadvertently to two of the 
rats in the saline group and saline was administered inadvertently to one rat in the 
METH group on the day before the 300 mg/kg dose of GZ-11608 (panel C), and these 
data were not included in the analysis.   
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Figure. 3.5. GZ-11608 does not exacerbate METH-induced striatal DA (DA) depletion. 
Data are mean ± SEM striatal DA content expressed as ng/mg tissue. GZ-11608 (17 
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mg/kg, s.c.) was administered 15 min prior to METH (METH, 30 mg/kg, i.p.) or saline (1 
mL/kg, i.p.) (panel A, n=7-12 rats/group) or 15 min after METH (30 mg/kg, i.p.) or saline 
(1 mL/kg, i.p.) (panel B, n = 4-8 rats/group). As a result of the lethality associated with 
METH, data were not collected for 18 of the 80 rats in the experiment (5 in the 
METH/saline group; 5 in the METH/GZ-11608 group; 3 in the saline/METH group; and 4 
in the GZ-11608/METH group). *p < 0.05 compared to the respective saline/saline control 
group. 
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Figure. 3.6. GZ-11608 specifically decreases responding for i.v. METH, without 
altering responding for food. GZ-11608 or vehicle (Veh, 15% (v/v) Kolliphor EL®:in 
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saline, 1 mL/kg) was administered (s.c.) to rats trained to self-administer METH (METH, 
0.05 mg/kg/infusion; panel A) or to respond for food pellet reinforcers (panel B) during 60 
min FR5 operant sessions. Data are mean ± SEM number of reinforcers earned as a 
percentage of the respective vehicle control (Veh; 16.4 ± 2.6 METH infusions, panel A; 
38.4 ± 5.0 food pellets, panel B). Dotted line represents 50% of the reinforcers earned 
following vehicle injection. The complete GZ-11608 dose-response curve was not 
collected for 1 rat in the METH self-administration experiment due to an insecure head-
mount; data following head mount loss were not included in the analysis. *p < 0.05 
compared to vehicle control; n = 8 - 9 rats, panel A; n = 11 rats, panel B). 
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Figure. 3.7. Repeated GZ-11608 decreases i.v. METH self-administration, without 
the development of tolerance. Baseline represents the number of METH infusions (22.2 
± 4.0) after vehicle injection (15% (v/v) Kolliphor EL®:in saline, 1 mL/kg) 15 min prior to 
60-min FR5 sessions. GZ-11608 (30 mg/kg, s.c., once daily for 7 days) was administered 
15 min prior to METH self-administration sessions, followed by 5 METH self-administration 
sessions with no GZ-11608 treatment. Data are presented as mean ± SEM METH 
infusions earned as a percentage of baseline. Dotted line represents 50% of baseline 
responding for METH, and dashed line represents 100% of baseline. GZ-11608 treatment 
decreased (55-75%) responding for METH. Responding for METH returned to baseline 
levels after discontinuation of GZ-11608 treatment. Complete data were not collected for 
2 rats due to insecure head mounts; data following head mount loss were not included in 
the analysis. *p < 0.05 compared to baseline. n = 5 - 7 rats. 
0
3 0
6 0
9 0
1 2 0
1 5 0
M
E
T
H
 In
fu
si
o
n
s
(%
 B
a
s
e
li
n
e
)
* * * * * **
5 0 %  B a s e lin e
B a
se
lin
e 1 2 3 4 5 6 7 1 2 3 4 5
1 0 0 %  B a s e lin e
* *
S e s s io n  n u m b e r
G Z -1 1 6 08
(3 0  m g /k g , s .c .)
P o s t-
tre a tm e n t
s e s s io n
177 
 
 
Figure. 3.8. Increasing the unit dose of self-administered i.v. METH does not 
surmount the GZ-11608-induced decrease in responding for METH. Data are 
presented as mean ± SEM METH or saline infusions earned during 60-min FR5 operant 
sessions. The initial training dose of METH was 0.05 mg/kg/infusion, followed by varying 
unit doses of METH or saline presented in a randomized order of presentation. Open 
circles represent no GZ-11608 treatment, and closed circles represent GZ-11608 (30 
mg/kg, s.c.) treatment 15 min prior to the session.  To maintain stable responding, two 
intervening maintenance sessions occurred between each GZ-11608 treatment session, 
in which METH was available and no GZ-11608 was administered. Complete data were 
not collected for 1 rat due to an insecure head-mount; data following head mount loss 
were not included in the analysis. #p < 0.05 compared to saline infusion for the 
respective group; *p < 0.05 compared to the no treatment condition for each unit dose of 
METH; n = 6 - 7 rats.  
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Figure. 3.9. GZ-11608 dose-dependently decreases cue-induced and METH-induced 
reinstatement of METH seeking. Data are presented as mean ± SEM number of lever 
presses. Baseline (BL) represents lever presses on the last day of maintenance during 
which METH (0.05 mg/kg/infusion) was available for self-administration. For cue-induced 
reinstatement (panel A), extinction (Ext) represents lever presses on the last of 14 days in 
which no cue light was presented and no METH was available. GZ-11608 treatment 
decreased cue-induced lever presses relative to vehicle injection (0 dose; Kolliphor EL). 
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Number of cue-induced lever presses following GZ-11608 (10 mg/kg) was not different 
between the two groups of rats evaluated (p > 0.05), and these data were combined for 
analysis. Between each session in which the effect of GZ-11608 was evaluated, 5 
extinction sessions occurred. For METH-induced reinstatement (panel B), extinction (Ext) 
represents lever presses on the last day of 14 days in which the cue light was presented, 
but no METH was available. GZ-11608 decreased METH-induced lever presses relative 
to vehicle injection (0 dose).  Between each session in which the effect of GZ-11608 was 
evaluated, 5 extinction sessions occurred.  No reinstatement was exhibited by 3 rats 
(defined as <10 cue-induced responses following vehicle); data from these rats were not 
included in the analysis. The complete GZ-11608 dose-response curve was not collected 
for 2 rats in the cue-induced reinstatement experiment (panel A) due to an insecure head-
mount; data following head mount loss were not included in the analysis. *p < 0.05 
compared to the respective vehicle control, #p < 0.05 compared to respective last day of 
extinction prior to GZ-11608 treatment. n = 6 - 12 rats/experiment.         
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Figure. 3.10. GZ-11608 does not substitute for METH self-administration. Data are 
presented as mean ± SEM number of i.v. infusions (METH, GZ-11608, or saline) across 60-
min, FR5 sessions. Baseline represents the number of METH infusions on the last day of 
maintenance for both the GZ-11608 and saline groups. Ascending doses of GZ-11608 for the GZ-
11608 group or saline for the saline group were available as reinforcers for 4 sessions/unit dose. 
Then, METH was available during the final 4 sessions of the experiment. n = 4 rats/group. 
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Figure. 3.11. GZ-11608 is not self-administered by drug naïve rats. Responding 
during successive operant sessions is illustrated across panels A-D, with the 
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exception of 3 intervening sessions between each GZ-11608 unit dose and prior to the 
METH self-administration sessions, in which responding for food pellet reinforcers 
occurred (data not shown). Data are presented as mean ± SEM number of i.v. infusions 
of GZ-11608 (descending dose order) for the GZ-11608 group or saline (1 mL/kg/infusion, 
i.v.) for the saline group across 60-min FR1 and FR2 sessions (panels A-C). METH self-
administration was available to the GZ-11608 group, and saline was available to the saline 
group under the FR1, FR2 and FR5 schedules of reinforcement (panel D). Complete data 
were not collected for 1 rat in the GZ-11608 group due to a faulty catheter and for 3 rats 
in the saline group due to an insecure head mount; data following procedural interruptions 
were not included in the analysis.  *p < 0.05 compared to the saline group on the respective 
session, n = 3 - 6 rats/group.   
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Figure. 3.12. GZ-11608 decreased food-maintained responding and tolerance 
developed to this effect over repeated administration. GZ-11608 (30 mg/kg, s.c., 
once daily for 7 days) was administered 15 min prior to 60-min sessions, in which rats 
responded for food pellets under an FR5 schedule. Data are presented as mean ± SEM 
food pellets earned. Baseline was the number of food pellets earned following vehicle 
(15% (v/v) Kolliphore EL in saline) injection. Dotted and dashed lines represent 50% and 
100% of baseline responding, respectively. One-way ANOVA revealed a main effect of 
GZ-11608 relative to baseline [F7,40 = 2.81, p < 0.05]. One-way ANOVA also revealed no 
alterations in responding for food during post-treatment sessions relative to baseline 
[F5,30 = 0.25, p > 0.05]. (n = 6 rats).  
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4. CHAPTER FOUR: MUSCARINIC AGONIST, (±)-QUINUCLIDIN-3-YL-(4-
FLUOROPHENETHYL)-(PHENYL)CARBAMATE: HIGH AFFINITY, BUT, LOW 
SUBTYPE SELECTIVITY FOR HUMAN M1 - M5 MUSCARINIC ACETYLCHOLINE 
RECEPTORS  
4.1 Introduction 
Many drugs of abuse including cocaine, amphetamine, METH, and morphine 
increase extracellular DA in the NA at doses that produce rewarding effects (Di Chiara 
and Imperato, 1988a). Indeed, bilateral microinjection of 6-OHDA which produces 
dopaminergic neuron damage in the NA inhibited initiation of amphetamine self-
administration in rats when 6-OHDA was administered before self-administration training, 
and disrupted responding during maintenance of amphetamine self-administration 
(Lyness et al., 1979). DA containing VTA neurons project to NA, and are important for 
drug seeking behavior. Electrical stimulation of acetylcholine-containing laterodorsal 
tegmental nucleus (LDT) neurons, which innervate VTA dopaminergic neurons, results in 
an increase in extracellular DA concentrations in the NA (Oakman et al., 1995; Forster 
and Blaha, 2000). Important to the current study, M5 mAChRs, among five different 
subtypes of mAChRs (M1, M2, M3, M4, and M5), are highly expressed on the postsynaptic 
DA neurons in VTA (Vilaro et al., 1990; Weiner et al., 1990; Lein et al., 2007; Yeomans, 
2012). In M5 mAChRs KO mice, LDT stimulation and morphine-induced DA release in the 
NA is reduced relative to wild-type mice (Basile et al., 2002; Forster et al., 2002). M5 KO 
mice also have decreased cocaine self-administration and cocaine- or morphine-induced 
CPP when compared to wild-type controls (Basile et al., 2002; Fink-Jensen et al., 2003). 
Microinfusion into VTA of scopolamine, a mAChR antagonist, robustly decreased cocaine-
seeking behavior during withdrawal in rats (Solecki et al., 2013).  Together, these findings 
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led us to hypothesize that selective antagonism of M5 mAChRs represents a novel target 
for the treatment of drug abuse.   
Recently reported a class of M5-preferring orthostatic antagonists was based on 
the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid (Zheng et al., 2013). 
Compound 1 (Figure 4.1., Table 1) was identified as the most selective M5 mAChRs 
antagonist in this series. Interestingly, removal of the meta-methoxy group in 1 (compound 
2) significantly increased binding affinities at both M1 and M5 receptors, but resulted in a 
complete loss in selectivity for M5 over M1. To further explore the structure-activity 
relationship (SAR), studies were planned to reposition the carboxylate group in 1 and 2 
from C-3 to C-4 of the piperidine ring. New analogs resulted from such rearrangement 
resembling pethidine (3, Figure 4.1.), a once popular analgesic. Interestingly, pethidine 
has been identified as an antagonist at mAChRs in guinea-pig ileum assays (Hustveit and 
Setekleiv, 1993). Thus, analogs based on the pethidine scaffold may afford interesting 
SAR at mAChRs. In addition to ester containing analogs (4 and 6), we also planned to 
evaluate amides (5 and 7), carbamates (8 and 9), and carbamides (10). Herein, binding 
affinity and selectivity for M5 over M1 and M3 mAChRs were evaluated. 
 
4.2 Method 
Analog affinities for M1, M3 and M5 mAChRs were determined by measuring 
inhibition of [3H]N-methylscopolamine (NMS) binding to Chinese hamster ovary (CHO) cell 
membranes expressing M1, M3, or M5 recombinant human mAChRs. CHO cells stably 
expressing each of the human mAChRs were obtained from Dr. Tom Bonner of National 
Institute of Mental Health (NIMH). Detailed materials and methods for cell culture and cell 
membrane preparation were described previously (Zheng et al., 2013). Briefly, [3H]NMS 
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binding assays were performed using 96-well plates. Membrane aliquots containing 10 µg 
of protein per well for M1 or M5 subtypes and 3 µg of protein per well for M3 subtype were 
added to wells containing 1 nM to 100 µM of test analog, 0.3 nM [3H]NMS (specific activity 
84.2 Ci/mmol; Perkin-Elmer/NEN, Boston, MA), and buffer (50 mM Tris-HCl, pH 7.4), and 
then incubated for 2 h at 25 ˚C. Nonspecific binding of [3H]NMS was determined in the 
presence of 1 µM atropine. Reactions were terminated by rapid filtration onto GF/B filters 
using a Filtermate harvester (PerkinElmer Life and Analytical Sciences, Boston, MA) and 
washed three times with buffer (50 mM Tris-HCl, pH 7.4). Subsequently, 40 µL of 
MicroScint 20 (PerkinElmer Life and Analytical Sciences, Waltham, MA) was added to 
each well and radioactivity bound determined using liquid scintillation spectrometry. IC50 
values were obtained and Ki values were calculated using the equation of Cheng and 
Prusoff (Cheng and Prusoff, 1973).  
 
4.3 Results and Discussion 
Results are summarized in Table 1. Similar to the SAR generated for the parent 
compounds 1 and 2, mono-methoxy substituted analogs (4b, 5b, 6b, 7b, and 10b) 
consistently exhibited higher affinity (2 to 9-fold at M1; 3 to 19-, fold at M3; 2 to 8-fold at 
M5) when compared to their corresponding di-methoxy substituted analogs (4a, 5a, 6a, 
7a, and 10a, respectively). The corresponding carboxylate moiety repositioned in 
molecule 4a exhibited 2- and 19-fold higher affinity at M1 and M3 mAChRs, respectively, 
compared with compound 1. However, the affinity of 4a at M5 mAChRs was decreased 
by 30%. Thus, compound 4a was not subtype selective.  
In addition, replacement of the ester link in 4a/b or 6a/b with an amide link (5a/b 
and 7a/b, respectively) resulted in a loss of affinity at all three mAChR subtypes (4a vs 5a, 
187 
 
2 to 4-fold; 4b vs 5b, 5 to 8-fold; 6a vs 7a, 3 to 7-fold; 6b vs 7b, 4 to 5-fold). In general, 
analogs with carbamate and carbamide linkers exhibited up to an 8-fold lower affinity 
compared to the esters. Furthermore, the reverse ester of 4a (i.e., 6a) exhibited a 
moderate 1 to 3-fold increase in affinity at all three mAChRs. A similar increase in affinity 
was observed for the other reverse ester/amide series, i.e., 4b vs 6b and 5b vs 7b. Analog 
6b was identified as the most potent compound at M5 in this series. 
 
4.4 Conclusion 
A series of pethidine analogs was synthesized and evaluated to determine binding 
affinity for the [3H]NMS binding site on M1, M3, and M5 human mAChRs expressed by 
CHO cell membranes. Compound 6b showed the highest binding affinity at M1, M3 and 
M5 mAChRs (Ki = 0.67, 0.37, and 0.38 µM, respectively). However, this series of new 
analogs did not exhibit selectivity for M5 mAChRs over M1 and M3 subtypes. Further SAR 
and pharmacological evaluations are needed to identify potent and selective M5 mAChR 
antagonists. 
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Figure 4.1. Structure of compounds 1 and 2, pethidine (3), and design of pethidine 
analogs 4-10 as novel mAChR ligands. 
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Table 1. Structures and binding affinity for analogs at M1, M3, and M5 mAChRsa 
 
 
  [3H]NMS binding  
Ki ±SEM (µM) 
com
pd R M1 M3 M5 
1b - 25.3 >100 2.24 
2b  - 0.02± 0.002 ND
c 0.03± 0.005 
4a  10.8 ± 0.67 5.26 ± 0.33 6.95 ± 0.47 
4b  1.20 ± 0.11 0.64 ± 0.037 0.87 ± 0.053 
5a 
 
> 30 > 10 > 30 
5b 
 
> 10 3.29 ± 0.80 6.97 ± 0.77 
6a 
 
3.63 ± 0.22 4.60 ± 0.61 2.14 ± 0.22 
6b 
 
0.67 ± 0.078 0.37 ± 0.045 0.38 ± 0.011 
7a 
 
> 10  > 30 > 10 
7b 
 
3.44 ± 0.93 1.54 ± 0.19 1.81 ± 0.11 
8  5.09 ± 0.29 4.03 ± 0.57 5.41 ± 0.59 
9  2.91 ± 0.17 2.30 ± 0.22 2.05 ± 0.30 
10a 
 
> 10 > 10 ˃ 10  
10b 
 5.40 ± 1.22 3.55 ± 0.11 4.30 ± 0.29 
a Three independent experiments, each experiment included duplicate samples, were 
performed to obtain Ki values (Mean ± SEM) 
b Data from reference Zheng et al., 2013 
c Not determined 
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5. CHAPTER FIVE: NOVEL METHYL PHENYLCARBAMATE ANALOGS
BINDING AFFINITY AT HUMAN M1-M5 MUSCARINIC ACETYLCHOLINE 
RECEPTORS EXPRESSED ON CHO CELLS 
5.1 Introduction 
Muscarinic acetylcholine receptors (mAChRs) consist of five subtypes (M1, M2, 
M3, M4 and M5 mAChRs). Each mAChR subtype has a unique expression pattern and 
activates distinct cholinergic signaling mechanisms and cellular functions (Eglen, 2006). 
Each mAChR subtype can be considered as a therapeutic target for relevant diseases 
that are associated with specific cell functions modulated by the mAChR subtype. For 
example, M1 mAChRs expressed in cerebral cortex, striatum and hippocampus mediate 
learning and memory processes (Levey, 1996). M1 mAChRs allosteric agonists, 
VU0357017 and VU0364572, enhance spatial learning in rats in the Morris water maze 
(Digby et al., 2010; Lebois et al., 2010). Agonists at M1 mAChRs have been proposed as 
pharmacotherapeutics for Alzheimer’s disease and schizophrenia (Fisher et al., 2003; 
Eglen, 2006; Jiang et al., 2014). Another example is the M3 mAChR, which mediates 
contraction of smooth muscles in the respiratory system (Barnes, 1989). M3 mAChR 
antagonists, such as tiotropium or umeclidinium have been approved by the FDA as 
therapeutics for chronic obstructive pulmonary disease (COPD) (Eglen, 2006; Food and 
Drug Administration, 2015; Chin et al., 2016). Also, a combination therapy including 
umeclidinium and vilanterol, a β2-adrenergic agonist, was approved by the FDA for COPD 
(Goldenberg, 2014). Thus, mAChRs are viable targets for drug discovery. 
M5 mAChRs are specifically and highly expressed in the VTA, a brain region 
containing DA neuronal cell bodies, which project to the NA (Vilaro et al., 1990; Weiner et 
al., 1990; Yasuda et al., 1993; Omelchenko and Sesack, 2006; Lein et al., 2007; Yeomans, 
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2012). Importantly, NA DA release mediates the rewarding effects of many substances 
with high abuse liability, including opioids (e.g., morphine) and psychostimulants (e.g., 
cocaine and amphetamines) (Lyness et al., 1979; Di Chiara and Imperato, 1988a; Koob 
et al., 1998; Chevrette et al., 2002). With respect to opioids, morphine-induced DA release 
in the NA is absent in M5 mAChR KO mice, linking M5 mAChRs to opioid-induced reward 
(Steidl et al., 2011). Direct infusion into VTA of a virus containing M5 mAChR DNA 
increased both M5 mAChR expression and morphine-induced locomotor activity 
compared to control mice, suggesting that M5 mAChRs mediate DA-related behaviors 
(Wasserman et al., 2013). Relative to wild-type mice, M5 mAChR KO mice exhibit a 
decreased amount of time spent in the cocaine-paired compartment in the conditioned 
place preference assay (Fink-Jensen et al., 2003; Raffa, 2009) and decreased cocaine i.v. 
self-administration (Thomsen et al., 2005), suggesting M5 mAChRs mediate cocaine 
reward and reinforcement, respectively. 
Since M5 mAChRs are highly expressed in VTA, micro infusion of nonselective 
mAChRs antagonists (e.g., scopolamine and atropine) into VTA allows for quasi-selective 
inhibition of M5 mAChR function. Scopolamine microinfused unilaterally into VTA 
decreased morphine-evoked DA release in the NA in mice (Steidl et al., 2011). Atropine 
microinfused bilaterally into VTA also decreased morphine-induced hyperlocomotion in 
mice, supporting a critical role for VTA M5 mAChRs in modulating opioid effects on 
behavior (Steidl and Yeomans, 2009). Thus, both pharmacological and genetic 
approaches to reduce M5 mAChR function provide consistent results implicating this 
mAChR subtype in the effects of opioids on DA neurochemistry and related behaviors. 
Based on these findings, a hypothesis that discovery of selective M5 mAChRs 
antagonists may provide novel pharmacotherapeutics that act to decrease the activity of 
VTA DA projections to NA, thereby reducing the reinforcing effects of substances with high 
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abuse liability. Previously, described a 1,2,5,6-tetrahydropyridine-3-carboxylic acid 
scaffold from which several M5 mAChRs antagonists were found (Zheng et al., 2013). 
From this series of compounds, compound 11 (Fig. 5.1) exhibited the greatest selectivity 
(11-fold) at M5 over M1 mAChRs; however, 11 provided only modest affinity (Ki = 2.24 
μM) for M5 mAChRs.29 Compound 11 inhibited oxotremorine-induced DA release from 
superfused rat striatal slices, revealing an antagonist action at M5 mAChRs (Zheng et al., 
2013).  
The 3,4-dimethoxyphenethyl group in compound 11 was suggested to play an 
important role in its binding preference at the M5 subtype (Zheng et al., 2013). 
Quinuclidinyl carbamate mAChR antagonists such as SVT-40776 (Fig. 5.1) and its 
analogs also have high affinity at mAChRs (Prat et al., 2011). In an effort to improve analog 
affinity and selectivity at M5 mAChRs, herein the synthesis and evaluation of hybrid 
compounds, 12a and 13a (Fig. 5.1), and a series of related analogs (Tables 2 and 3). 
5.2 Method 
5.2.1 [3H]NMS Binding Assay 
[3H]NMS binding assays were performed using 96-well plates. Membrane aliquots 
containing 10 μg of protein per well for M1 or M5 mAChRs subtypes, 20 μg of protein per 
well for M2 or M4 mAChRs subtypes, and 3 μg of protein per well for M3 mAChRs were 
added to wells containing 1 nM to 100 μM of analog, 0.3 nM [3H]NMS (specific activity 
84.2 Ci/mmol; Perkin-Elmer/NEN, Boston, MA) and buffer (50 mM Tris–HCl, pH 7.4) and 
then incubated for 2 h at 25 ºC. Nonspecific binding of [3H]NMS was determined in the 
presence of 1 μM atropine. Reactions were terminated by rapid filtration onto GF/B filters 
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using a Filtermate harvester (PerkinElmer Life and Analytical Sciences, Boston, MA) and 
washed three times with 50 mM Tris–HCl buffer (pH 7.4). Subsequently, 40 μL of 
MicroScint 20 (PerkinElmer Life and Analytical Sciences, Waltham, MA) was added to 
each well and radioactivity bound determined using liquid scintillation spectrometry.  
 
5.2.2 [3H]DA Release Assay 
Rat striata were dissected and sliced (500 μm, 4-6 mg). Striatal slices were 
incubated in Krebs’ buffer (108 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1 mM NaH2PO4, 
1.3 mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM L-ascorbic acid and 0.004 
disodium EDTA, pH7.4) for 60 min at 34 °C. During the latter 30 min of the incubation, 
[3H]DA (0.1 μM) was added to the incubation buffer. Each striatal slice was placed in a 
superfusion chamber after incubation, and then superfused (0.6 mL/min) with Krebs’ buffer 
for 60 min in the presence of nomifensine (a DA transporter inhibitor; 10 μM) and pargyline 
(a monoamine oxidase inhibitor; 10 μM). Samples were collected every 5 min for a total 
of 75 min. Samples collected during the first 15 min were used to determine [3H]DA 
overflow. Samples were collected for 35 min in the absence or presence of scopolamine 
or 13c, followed by 25 min in absence or presence of oxotremorine (100 μM) in the 
superfusion buffer. [3H]DA overflow was determined as the summation of radioactivity in 
superfusate samples during exposure to compound following the subtraction of basal 
outflow across the same time period. Radioactivity was determined using liquid scintillation 
spectroscopy.  
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5.3 Results and Discussion 
Initially, affinity at M5 mAChRs was determined for all analogs. Since M5 mAChRs 
has relatively high sequence homology with M3 > M1 > M4 > M2 mAChRs (85%, 79%, 
73% and 68%, respectively) (Bonner et al., 1988), thus, next affinity of all analogs at M3 
and M1 mAChRs were determined. Analogs with high affinity (Ki < 10 nM) were evaluated 
also at M2 and M4 mAChRs to assess subtype selectivity. CHO cell lines individually 
expressing each of the human M1-M5 mAChRs were generously provided by Dr. Tom 
Bonner, National Institute of Mental Health. Analog-induced inhibition of [3H] NMS binding 
was used to determine affinity at each of mAChR subtypes (Lee et al., 2015). Amount of 
[3H]NMS bound after a 60-min incubation in the absence and presence of a range of 
analog concentrations was plotted as a function of analog concentration to obtain IC50 
values. IC50 values were used to calculate compound affinity (inhibition constant, Ki) using 
the Cheng and Prusoff equation (Cheng and Prusoff, 1973). Maximal inhibition (Imax) of 
specific [3H]NMS binding was represented as a percent of control (absence of compound). 
Atropine was used as the positive control, and its Ki values at M1, M2, M3 and M5 were 
0.44, 0.90, 0.53, and 0.60 nM, respectively, in good agreement with literature values 
(Moriya et al., 1999; Hirose et al., 2001). 
The Ki and Imax values of analogs with general structure 2 (Fig. 5.1) at M1, M2, 
M3, and M5 mAChRs are provided in Table 2. Compound 12a, in which the R group is 
3,4-dimethoxy-phenethyl, is the prototypic analog in this series. Compared with parent 
compound 11, 12a retained affinity at M5 mAChRs, however, selectivity over other 
mAChR subtypes was diminished. Substituents on the phenyl ring of the R group and the 
length between the phenyl ring and O atom had important influences on binding affinity. 
Thus, a wide range of Ki values (19 nM - 6.98 μM) was obtained, whereas the majority of 
the compounds completely inhibited [3H]NMS binding (Imax = 85.9 - 100% of control). 
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Overall, analogs with a one-carbon linker (12b, 12d, 12j, 12l, 12o, and 12q) had the 
highest affinity within each subgroup of compounds having the same substituents on the 
phenyl ring. However, analogs with a longer linker generally exhibited higher preference 
for M5 compared with the corresponding one-carbon linker counterparts. Among the 
analogs in this series, 12m, in which the R group is 3,4-dichlorophenethyl, exhibited 
relatively high affinity (Ki = 80 nM) and the greatest selectivity (4.5-fold) for M5 over M1 
mAChRs.  
Transposition of the phenylalkyl group and the quinuclidin-3-yl group in 12 resulted 
in analogs 13a, 13b, and 13c as enantiomeric mixtures (Table 3). The design of this group 
of “rearranged” analogs was based on hypotheses that spatial rearrangement or 
reorientation of the pharmacophore elements in mAChR ligands would alter affinity and 
selectivity profiles (Hirose et al., 2001). Compound 13c with an N-4-fluorophenethyl group 
exhibited the highest affinity at M5, M1 and M3 mAChRs (Ki = 1.8, 2.0 and 2.6 nM, 
respectively). Thus, 13c is ~5-fold and 32 to 48-fold, respectively, higher than 13b having 
a 3-methoxyphenethyl, and 13a having a 3,4-dimethoxyphenethyl group. These findings 
indicate that substituents on the phenyl ring have major impact on affinity and that an 
electron-withdrawing group may be favorable for receptor binding. Replacement of the 
quinuclidin-3-yl group in 13 with an N-methylpiperidin-3-yl, an N-methylpiperidin-4-yl, or a 
tropan-4-yl provided analogs 14a/b/c, 15a/b/c, and 16a/b, respectively (Table 3). Affinity 
at M5, M1 and M3 mAChRs for these analogs was lower than their corresponding 
quinuclidine-containing analogs 13a/b/c. Despite the overall increase in affinity in this 
series of analogs compared to analogs in the 12 series, none of these compounds 
exhibited preference for M5 mAChRs. Of note, analogs in the 12, 13, and 14 series were 
racemic. 
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As in previous studies (Zheng et al., 2013), the lead analog 13c was evaluated 
using a functional assay determining inhibition of oxotremorine-induced DA release from 
superfused rat striatal slices. Oxotremorine is a nonselective agonist at mAChRs (Barocelli 
et al., 2000). If analog-induced inhibition is observed, then this suggests that the analog 
acts via an antagonist action at mAChRs. For the [3H]DA release assay, rat striatal slices 
were incubated with 0.1 μM [3H]DA for 30 min, and then, were superfused with buffer for 
60 min to obtain stable efflux of [3H]DA (Prat et al., 2011; Zheng et al., 2013). Samples 
were collected for 15 min to determine basal [3H]DA outflow. Superfusion continued for 35 
min in the absence and presence scopolamine (1 and 10 μM, positive control) or 13c (0.1, 
1, and 10 μM) added to the superfusion buffer. Then, oxotremorine (100 μM) (Steidl and 
Yeomans, 2009) was added to the buffer for 25 min. The ability of scopolamine and 13c 
to inhibit oxotremorine-evoked [3H]DA overflow was determined. In agreement with 
previous findings, oxotremorine increased [3H]DA overflow compared to control, and 
scopolamine (1 and 10 μM) inhibited (51% and 59%, respectively) oxotremorine-evoked 
[3H]DA overflow ([F3,35 = 6.13], p < 0.005, one-way ANOVA followed by Tukey’s test; Fig. 
5.2). The results are consistent with the predicted outcome that scopolamine (positive 
control) inhibits oxotremorine-evoked DA release from rat striatum. The ability of lead 
compound 13c to inhibit oxotremorine-evoked [3H]DA overflow from superfused rat striatal 
slices was determined (Fig. 5.3). Scopolamine (10 μM) was included as a positive control 
in these experiments. Similar to the results illustrated in Fig. 5.2, oxotremorine increased 
[3H]DA overflow and scopolamine decreased the stimulatory effect of oxotremorine. In 
contrast to expectations, 13c did not inhibit oxotremorine-evoked [3H]DA overflow, but 
rather, augmented oxotremorine-evoked [3H]DA overflow. One-way ANOVA followed by 
Tukey’s test revealed that 13c (10 μM) increased oxotremorine-evoked [3H]DA overflow 
relative to oxotremorine alone (scopolamine 0 μM; [F3,11=6.83], p < 0.005; Fig. 5.3). 
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Augmentation of the effect of oxotremorine by 13c suggests that 13c acts as an agonist 
at mAChRs.  
To further determine if 13c acts as a mAChR agonist, the ability of scopolamine to 
inhibit 13c-evoked [3H]DA overflow was determined. One-way ANOVA followed by 
Tukey’s test revealed that the 3c-evoked increase in [3H]DA overflow was inhibited by 
scopolamine (10 μM) ([F5,42=6.92], p < 0.0001; Fig. 5.4). Since the effect of 13c was 
inhibited by a nonselective mAChR antagonist, scopolamine, these results support the 
interpretation that 13c acts as an agonist at mAChRs to increase [3H]DA overflow from rat 
striatal slices.  
Whereas oxotremorine (1, 10, and 100 μM)-evoked striatal [3H]DA overflow was 
not altered in M1 or M2 mAChR KO mice, oxotremorine-evoked [3H]DA overflow was 
increased in M3 KO mice, abolished in M4 KO mice, and decreased by 50% in M5 KO 
mice (Zhang et al., 2002). Thus, M1 or M2 mAChRs do not appear to have a role in 
mediating striatal DA release in mice. Also, M3, M4 and M5 mAChRs appear to play 
differing roles in mediating striatal DA release in mice. In contrast to VTA where M5 
mAChR subtype expression predominates, M3, M4 and M5 mAChRs mediate 
oxotremorine-evoked [3H]DA overflow from striatal slices in mice. If allowed to extrapolate 
from these results obtained using striatal slices from KO mice, the current results suggest 
that oxotremorine increases striatal DA release via stimulation of M4 and/or M5 mAChRs, 
but not via M3 mAChRs. Based on the results from the KO studies  (Zhang et al., 2002), 
stimulation of M3 mAChRs would be expected to decrease DA release. Assuming mAChR 
modulation of DA release is similar in rats and mice, the lead compound 13c appears to 
evoke DA release from rat striatal slices either though an agonist action at M4 and/or M5 
mAChRs, or through an antagonist action at M3. In any case, 13c increases striatal DA 
release via an agonist action at mAChRs, since this effect is inhibited by scopolamine.  
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Another important finding from the present study is that the two structural scaffolds 
provided analogs that exhibit selectivity for M3 over M2. Out of the 30 analogs evaluated, 
9 analogs (12d, 12j, 12l, 12n, 12o, 12q, 13a, 13b and 13c) exhibit relatively high affinity 
(Ki < 100 nM) at M3 mAChRs. For these 9 analogs, selectivity at M3 over M2 mAChRs 
was determined in consideration of their potential efficacy in treating COPD. Of note, 
compound 13b exhibited 17-fold selectivity for M3 over M2 mAChRs. Selectivity between 
M3 and M2 subtypes is important because antagonists at M3 mAChRs decrease airway 
smooth muscle contraction and decrease mucus secretion, which would be beneficial in 
the treatment of COPD; whereas, antagonism at M2 mAChRs increases acetylcholine 
release from parasympathetic nerves innervating the airway smooth muscle and 
submucosal glands, ultimately stimulating M3 mAChRs and counteracting the beneficial 
M3 antagonism produced by therapeutic agents targeting M3 (Gosens et al., 2006; Buels 
and Fryer, 2012). Using the [3H]NMS binding assay, several compounds have been 
reported previously to be highly potent (low nM range) and selective for M3 over M2 
mAChRs (Dowling and Charlton, 2006). Specifically, (2R)-1-((2S,4R)-4-hydroxy-1-[3,3,3-
tris(4-fluoro-phenyl)propanoyl]-pyrrolidine-2-yl)carbonyl-N-(4-piperidinylmethyl)pyrolid-
ine-2-carboxamide (compound 14A) and (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-
4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide (compound A) exhibit 
1600- and 193-fold selectivity, respectively, for M3 over M2 (Sagara et al., 2006; Sykes et 
al., 2012). Compound 14A and A act as M3 mAChR antagonists as indicated by inhibition 
of carbachol-induced contraction of the isolated rat tracheal muscle (Sagara et al., 2006; 
Sykes et al., 2012). Interestingly, tiotropium and umeclidinium, exhibit only 2 to 3-fold 
selectivity at M3 relative to M2 mAChRs, as indicated from [3H]NMS binding assays 
(Salmon et al., 1999; Dowling and Charlton, 2006). Despite, marginal selectivity for M3, 
tiotropium and umeclidinium have kinetic selectivity for M3 and long dissociation half-life 
(Salmon et al., 1999). Moreover, both compounds are FDA-approved COPD inhalation 
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therapeutics. Thus, the current findings that 3b has high affinity (Ki = 7.6 nM) and 17-fold 
selectivity for M3 over M2 mAChRs suggest that this compound may have beneficial 
therapeutic effects over currently available medications for COPD. 
5.4 Conclusion 
Through the synthesis and evaluation of two series of carbamates, 13c was 
identified as the most potent (Ki =1.8 nM) analog interacting at M5 mAChRs. Although 13c 
exhibited 1,200-fold higher affinity for M5 mAChRs compared to compound 11, 13c lacked 
selectivity for M5 mAChRs. Interestingly, compound 11 inhibited oxotremorine-evoked DA 
release from rat striatal slices, whereas 13c augmented oxotremorine-evoked DA release, 
and moreover, itself increased DA release, indicating that 13c acts as a mAChR agonist. 
Future structure activity relationship studies using 13c as the lead compound will be 
needed to identify analogs with high affinity and selectivity for M5. Additionally, 13b 
exhibited high affinity and selectivity for M3 over M2 mAChRs and may have potential to 
be developed as a COPD treatment.  
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Figure 5.1. Structures of compound 11, SVT-40776, 12a, 13a, and structure 2. 
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Table 2. Structures and binding affinity at M1, M2, M3, and M5 mAChRs for atropine 
and analogs with general structure 2a  
N
N
Ph
O
O
R
2  
 
 
Compd 
 
R 
[3H]NMS binding Ki ± SEM (µM) 
(Imax ± SEM, % inhibition) 
Selectivity 
M1 M2 M3 M5 M1/M5 M2/M3 
Atropine - 0.00044 ± 
0.0001a 
(99.5 ± 0.28) 
0.0009 ± 
0.00005 
(99.4 ± 0.74) 
0.00053 ± 
0.00006 
(99.3 ± 0.63) 
0.0006 ± 
0.00003 
(96.7 ± 0.50) 
1.7 0.7 
11 b - 25.3 >100 >100 2.24 11 - 
12a O
O  
6.98 ± 0.65  
(90.6 ± 0.61) 
NDc 2.76 ± 0.23  
(85.9 ± 1.55)d 
3.49 ± 0.09 
(94.0 ± 0.63) 
2.0 
 
- 
12b O
O  
0.77 ± 0.03  
(96.8 ± 0.24) 
ND 1.02 ± 0.11  
(95.4 ± 0.45) 
0.55 ± 0.02 
(98.7 ± 0.41) 
1.4 - 
12c O
O  
1.46 ± 0.14  
(97.1 ± 0.33) 
ND 1.56 ± 0.22 
(96.3 ± 0.58) 
1.61 ± 0.09  
(99.0 ± 1.9) 
0.9 - 
12d 
 
0.19 ± 0.02 
(99.5 ± 0.15) 
0.12 ± 0.01  
(99.4 ± 0.28) 
0.09 ± 0.004  
(98.6 ± 0.42) 
0.15 ± 0.03  
(97.2 ± 0.24) 
1.3 1.2 
12e 
 
0.79 ± 0.08  
(88.5 ± 1.37) 
ND 0.30 ± 0.01  
(99.1 ± 0.504) 
0.26 ± 0.03  
(96.9 ± 4.4) 
3.0 - 
12f 
 
0.78 ± 0.05  
(99.1 ± 0.28) 
ND 0.55 ± 0.03  
(98.9 ± 0.42) 
0.26 ± 0.008  
(95.7 ± 0.17) 
3.0 - 
12g 
O  
0.71 ± 0.06  
(97.9 ± 0.21) 
ND 1.15 ± 0.06 
(95.7 ± 0.52) 
0.47 ± 0.05  
(97.1 ± 0.89) 
1.5 - 
12h 
O  
0.76 ± 0.02  
(98.4 ± 0.08) 
ND 0.42 ± 0.05  
(99.3 ± 0.22) 
0.23 ± 0.005  
(98.9 ± 0.09) 
3.3 
 
- 
12i 
O  
0.59 ± 0.02  
(98.5 ± 0.19) 
ND 0.39 ± 0.04  
(96.8 ± 1.25) 
0.64 ± 0.10  
(99.5 ± 3.5) 
0.9 - 
12j 
O
O
 
0.03 ± 0.003  
(100 ± 0.18) 
0.03 ± 0.005  
(99.4 ± 0.87) 
0.019 ± 0.002  
(99.9 ± 0.72) 
0.04 ± 0.003  
(99.7 ± 0.37) 
0.8 1.7 
12k 
O
O
 
0.63 ± 0.10 
(99.6 ± 0.40) 
ND  0.29 ± 0.03  
(98.0 ± 0.53) 
0.24 ± 0.06  
(97.1 ± 4.8) 
2.6 - 
12l Cl
Cl 
0.06 ± 0.002 
(100 ± 0.24) 
0.22 ± 0.009 
(97.5 ± 1.76) 
0.07 ± 0.009  
(95.8 ± 0.78) 
0.06 ± 0.001  
(98.6 ± 4.75) 
0.9 3.3 
12m Cl
Cl 
0.37 ± 0.02  
(99.9 ± 0.36) 
ND 0.26 ± 0.02  
(99.8 ± 0.27) 
0.08 ± 0.02  
(98.8 ± 0.30) 
4.5 - 
12n Cl
Cl 
0.17 ± 0.01  
(100 ± 0.10) 
0.30 ± 0.02   
(99.9 ± 0.063) 
0.06 ± 0.003  
(100 ± 0.25) 
0.13 ± 0.003  
(99.4 ± 0.30) 
1.3 4.7 
12o F
O  
0.07 ± 0.003  
(99.5 ± 0.99) 
0.10 ± 0.01  
(98.8 ± 0.64) 
0.05 ± 0.003  
(100 ± 0.022) 
0.04 ± 0.01  
(96.7 ± 0.50) 
1.5 1.8 
12p F
O  
0.43 ± 0.03 
(100 ± 0.14) 
ND 0.25 ± 0.03 
(99.8 ± 1.08) 
0.26 ± 0.004 
(99.4 ± 0.22) 
1.7  
12q F
 
0.04 ± 0.001 
(100 ± 0.14) 
0.03 ± 0.001  
(99.7 ± 0.60) 
0.02 ± 0.0003  
(99.0 ± 0.56) 
0.03 ± 0.003  
(97.4 ± 0.13) 
1.2 1.3 
12r F
 
0.20 ± 0.004  
(100 ± 0.25) 
ND 0.13 ± 0.009  
(100 ± 0.29) 
0.13 ± 0.004  
(99.9 ± 0.45) 
1.5  
12s F
F 
0.30 ± 0.02 
(100 ± 0.25) 
ND 
 
0.22 ± 0.008  
(99.5 ± 1.09) 
0.10 ± 0.003  
(99.4 ± 0.30) 
3.0 - 
a Three independent experiments, each w ith duplicate samples, w ere performed to obtain Ki values (Mean ± SEM) 
b Data from Zheng et al., 2013 
c Not determined 
d No plateau for the mean inhibition curve w as obtained; Imax % inhibition at 100 µM analogs w as reported    
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Table 3. Structures and binding affinity at M1, M2, M3, M4, and M5 mAChRs for analogs 
13-16a  
 
O N
O
R2
3-6
R1
 
 
Co
mpd 
 
R1 
 
R2 
[3H]NMS binding 
Ki ± SEM, µM 
(Imax ± SEM, % inhibition) 
Selectivity 
M1 M2 M3 M4 M5 M1/
M5 
M2/
M3 
13a 
N  
O
O  
0.095 ± 
0.0037 
(100 ± 0.14) 
0.35 ± 
0.02   
(98.6 ± 
1.57) 
0.06 ± 0.006 
(99.7 ± 0.91) 
NDb 0.065 ± 0.002 
(99.8 ± 0.56) 
1.5 5.7 
14a 
N  
O
O  
4.30 ± 0.49  
(94.3 ± 0.61) 
ND 4.36 ± 0.90  
(85.6 ± 0.85)c 
ND 4.49 ± 0.32  
(89.2 ± 0.87) 
1.0  
15a N
 
O
O  
0.77 ± 0.082  
(99.0 ± 0.16) 
ND 
 
1.28 ± 0.10  
(96.6 ± 0.58) 
ND 0.38 ± 0.03  
(96.5 ± 2.81) 
2.0  
16a N
 
O
O  
1.87 ± 0.17  
(95.3 ± 0.25) 
ND 2.80 ± 0.03  
(88.8 ± 0.49)c 
ND 1.37 ± 0.07 
(95.9 ± 0.91) 
1.4  
13b 
N  O  
0.01 ± 0.0003 
(100 ± 0.16) 
0.13 ± 
0.025   
(99.7 ± 
0.48) 
0.008 ± 0.0003  
(99.9 ± 0.41) 
0.025 ± 
0.0002   
(99.9 ± 
0.37) 
0.01 ± 0.0005 
(100 ± 0.68) 
1.0 17 
14b 
N
 O  
0.69 ± 0.092 
(98.6 ± 0.36) 
ND 1.32 ± 0.069  
(96.2 ± 0.28) 
ND 1.05 ± 0.02 
(97.7 ± 0.45) 
0.7 - 
15b N  
O  
0.28 ± 0.038  
(99.8 ± 0.33) 
 0.57 ± 0.092  
(99.7 ± 0.43) 
ND 0.19 ± 0.01 
(99.7 ± 0.82) 
1.5 - 
16b N
 O  
0.35 ± 0.02  
(99.7 ± 0.05) 
ND 0.27 ± 0.01  
(98.9 ± 0.35) 
ND 0.24 ± 0.02  
(97.9 ± 2.0) 
1.5 - 
13c 
N  F 
0.002 ± 
0.0001  
(99.9 ± 0.11) 
0.013 ± 
0.003  
(100 ± 
0.71) 
0.0026 
±0.0001  
(100 ± 1.39) 
0.0022 ± 
0.0001  
(99.8 ± 
0.33) 
0.0018 ± 
0.0001  
(99.8 ± 0.71) 
1.1 5.0 
14c 
N
 F 
0.12 ± 0.006  
(99.9 ± 0.07) 
ND 0.35 ± 0.05  
(99 ± 1.37) 
ND 0.15 ± 0.01  
(99.9 ± 1.64) 
0.8 - 
15c N  
F 
0.07 ± 0.002  
(100 ± 0.14) 
ND 
 
0.14 ± 0.019  
(100 ± 0.50) 
ND 0.06 ± 0.002 
(100 ± 0.35) 
1.2 - 
a Three independent experiments, each w ith duplicate samples, w ere performed to obtain Ki values (Mean ± SEM) 
b Not determined 
c No plateau for the mean inhibition curve w as obtained; Imax % inhibition at 100 µM analogs w as reported 
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Figure 5.2. Scopolamine (1 and 10 µM, positive control) inhibits oxotremorine 
(100 µM)-evoked [3H]DA overflow from superfused rat striatal slices. Data are 
presented as mean ± SEM. *p < 0.05 compared to buffer; #p < 0.05 compared to 
oxotremorine alone (scopolamine 0 µM), n=10. 
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Figure 5.3. Compound 13c increases oxotremorine (100 µM)-evoked [3H]DA 
overflow from rat striatal slices. A range of concentrations (0.1, 1, and 10 µM) of 
13c were evaluated. Scopolamine (10 µM) was used as the positive control. * p < 0.05 
compared to buffer, # p < 0.05 compared to oxotremorine alone (scopolamine 0 µM), 
n=4-10. 
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Figure 5. 4. Scopolamine (10 µM) inhibits 13c-evoked [3H]DA overflow from 
superfused rat striatal slices. * p < 0.05 compared to buffer (in the absence of 13c), 
# p < 0.05 compared to 13c (10 µM) in the absence of scopolamine, n=6. 
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6. CHAPTER SIX: OVERALL DISCUSSION
6.1 Review 
Substance use disorders are a growing health concern in the US. In 2016, there were 
28.6 million Americans ages 12 or older reporting, within the past month, illegal substance 
use and prescription drug misuse including opioids, and psychostimulants (i.e., cocaine 
and METH), which has increased compared to 19.9 million in 2007 (SAMHSA, 2017; CDC, 
2018). One out of ten (10.6%) Americans (ages 12 or older) used illegal substances in 
2016. Among ED visits, the number of individuals who were diagnosed with substance-
related disorders increased by 73.7% between 2006 and 2014 (Moore et al., 2017). Also, 
in 2016, the number of nationwide substance overdose-induced deaths was the highest 
number on record, and was increased by 86.1% and 21% compared to 2006 and 2015, 
respectively (UNODC, 2017, 2018). Especially, the number of opioid-induced (excluding 
methadone) deaths was doubled in 2016 compared to 2015, indicating a recent rapid 
growth in the opioids epidemic in the US (UNODC, 2018). The second most popular 
substance among the overdose-induced deaths following opioids was cocaine-involved 
overdose deaths in 2016 (DEA, 2018). In addition, in 2016, the number of cocaine-induced 
overdose deaths was doubled compared to 2014 (5,415 to 10, 375) (DEA, 2018). The 
third highest population was psychostimulants-involved overdose deaths. Importantly, 80% 
of psychostimulants-involved overdose deaths were due to METH. Reports commonly 
indicate rapid growth in illegal substance use and prescribed substance misuse in the US. 
The rapid increase in ED visits related to substances and the number of overdose-induced 
deaths reflect the severity of the substance use-induced health concerns in the US.    
Moreover, according to the report from the UNODC in 2018, the two second most 
popular substances used worldwide by populations 15-64 years old were amphetamines, 
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including METH (34 million past-year users) and opioids (34 million past-year users); the 
most popular being cannabis (192 million past-year users). Cocaine (18 million past-year 
users) was the fourth most popular substance worldwide (UNODC, 2018). Also, based on 
the number of countries reporting substance-related seizures during 2012 and 2016, 
cocaine (146 countries) was the second most popular substance following cannabis (151 
countries), followed by opioids (139 countries) and amphetamines, including METH (131 
countries) (UNODC, 2018). Worldwide, there were 31 million people who were diagnosed 
as having substance use disorders in 2016, indicating the high need of 
pharmacotherapeutics for substance use disorders (UNODC, 2018). However, there are 
no pharmacotherapeutics that have been approved by FDA for cocaine or METH use 
disorders. For opioids use disorders, there are FDA-approved medications including 
methadone, buprenorphine, and naltrexone. However, currently in the US and worldwide, 
the opioid epidemic is rapidly growing, with a large population of individuals using opioids. 
Thereby, discovering novel pharmacotherapeutics for opioid use disorders may help to 
accelerate the fight to combat the opioids epidemic.  
To explain the high abuse liability of substances such as METH, cocaine, and opioids, 
there are three steps of underlying neurobehavioral mechanisms. Initially, these 
substances activate a rewarding process in the brain by increasing extracellular DA 
concentration in the NA (Koob and Volkow, 2016; Volkow et al., 2016). The increased 
amount and duration of extracellular DA after substance administration is greater and 
longer, respectively, than natural rewards (i.e., food)-induced increases in DA in the NA, 
resulting in a stronger motivation for substance intake (Di Chiara and Imperato, 1988a). 
The strong motivation for substance intake leads to repeated substance use. The repeated 
activation of the reward circuitry following substance administration strengthens the 
association between cues that lead to the anticipation of substance intake and substance-
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induced reward. Also, the repeated substance-induced rewarding effects result in 
neuronal adaptations, which induces a transition from voluntary to compulsive substance 
seeking and taking (Black et al., 2010; Volkow and Morales, 2015; Yager et al., 2015). 
Since repeated substance self-administration behaviors result in long-lasting neuronal 
adaptation, the relapse rate of substance use behavior is high (40-60%) (McLellan et al., 
2000). 
As indicated above, there are no FDA-approved pharmacotherapeutics for METH and 
cocaine use disorders, as there are for opioid use disorders. According to clinical data 
from opioid use disorders, patients who received pharmacotherapeutics (i.e., 
buprenorphine, methadone, naltrexone) showed a longer duration of opioid-abstinence 
and higher adherence to a therapeutic program than the placebo group (Kakko et al., 2003; 
Mattick et al., 2014; Nunes et al., 2015). Thus, multiple clinical findings in opioid use 
disorders support the importance of pharmacotherapeutics for substance use disorders.  
Importantly, substance use disorders show high relapse rate (40-60%) (McLellan et 
al., 2000). Accordingly, PET brain imaging studies in humans and monkeys proved that 
repeated substance use results in long-lasting neuronal adaptations after substance 
abstinence periods (i.e., 3-4 months in human and 1.5 years in monkeys) (Volkow et al., 
1992; Letchworth et al., 2001). These observations indicate that substance use disorders 
require long-term follow-up care, and that pharmacotherapeutics are vital for substance 
use disorder treatment. Thus, this dissertation is focused on developing 
pharmacotherapeutics for METH (Project 1 in Chapters 2 and 3), cocaine, and opioid 
(Project 2 in Chapters 4 and 5) use disorders via classical drug discovery approaches 
using novel lead scaffolds.  
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6.2 Project 2 Review: Discovery Pharmacotherapeutics for Cocaine and Opioid 
Use Disorders         
The second aim of this dissertation is to discover selective and potent antagonists 
of M5 mAChRs as pharmacotherapeutics to treat cocaine and opioid use disorders. 
Currently, opioids with METH are the second most popular substance in the world, 
followed by cocaine (UNODC, United Nations Office on Drugs and Crime, 2018). However, 
there are no pharmacotherapeutics for cocaine use disorders. Also, recently, a rapid 
increase has been observed in the opioid epidemic, indicating an increasing need for 
treatments for this population. Thus, additional novel therapeutics would provide further 
options to combat the opioid epidemic. Moreover, co-use of cocaine and opioids are often 
reported. Perhaps novel therapeutics could decrease the use of both substances, which 
would more efficiently rescue patients from substance use disorders (NIDA, National 
Institute on Drug Abuse, 2015).     
6.2.1 M5 mAChRs Antagonists as Pharmacotherapeutics for Cocaine and 
Opioids Use Disorders 
Multiple substances Including cocaine and opioids exhibit high abuse liability due 
to their rewarding effects as a result of increasing extracellular DA in the NA (Di Chiara 
and Imperato, 1988a; Weiss, Paulus, et al., 1992; Basile et al., 2002). Cocaine, a DAT 
inhibitor, inhibits DA re-uptake from synaptic cleft into cytosol, which results in high 
extracellular concentration of DA that then interacts with DA receptors expressed on post-
synaptic membranes, stimulating downstream signaling (Di Chiara and Imperato, 1988a; 
Weiss, Paulus, et al., 1992). Opioids, including morphine and heroin, increase 
extracellular DA in the NA by downregulating GABAergic neuronal activation (an inhibitory 
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pathway including VTA DA neurons) through binding at MOR expressed on GABAergic 
neuronal membranes innervating VTA (Gysling and Wang, 1983; Leite-Morris et al., 2004). 
Moreover, lesion of DA neurons in NA by bilaterally microinfusing neurotoxins, 6-OHDA 
or kainic acid, resulted in decreased cocaine and heroin self-administration (Zito et al., 
1985). Altogether, these findings indicate the crucial role of DA in neurons projecting into 
NA in the expression of self-administration behavior for opioids and cocaine. 
Interestingly, a high density of expression of M5 receptors, a subtype of mAChRs, 
was found on DA containing neurons in VTA, but rarely in other brain regions or peripheral 
nerve systems (Yasuda et al., 1993; Lein et al., 2007; Yeomans, 2012). In contrast to most 
of mAChRs subtypes (M1-M4) being expressed on cholinergic neurons, M5 is expressed 
on postsynaptic DA neurons in VTA (Weiner et al., 1990). M5 mAChRs modulate DA 
projection from VTA to NA (Weiner et al., 1990). M5 is a GPCR coupled receptor that 
signals through Gq protein. Thus, activation of M5 increases intracellular calcium ion 
concentrations in DA VTA neurons that project to NA ( Felder, 1995; Forster and Blaha, 
2000; Forster et al., 2002). M5 KO mice showed decreased cocaine-induced 
hyperlocomotion, preference for cocaine-paired place in CPP, and cocaine self-
administration compared to wild-type mice (Fink-Jensen et al., 2003; Thomsen et al., 
2005). Also, morphine-evoked DA release in the NA and hyperlocomotion, and preference 
for morphine-paired place in CPP was decreased in M5 KO mice compared to wild-type 
mice (Basile et al., 2002; Steidl and Yeomans, 2009).  
In addition to the studies using genetic approaches, pharmacological approaches 
also provide information emphasizing the crucial role of M5 mAChRs in the action of 
cocaine and morphine. Due to regional localization of M5 expression in the VTA, 
microinfusion of mAChR antagonists, including scopolamine and atropine, into the VTA 
allows quasi-selective inhibition of M5. Unilateral microinfusion of scopolamine into the 
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VTA abolished morphine-induced increase in extracellular DA in the NA (Steidl et al., 
2011). Also, atropine, but not the mecamylamine (a nAChR antagonist), decreased 
morphine-induced hyperlocomotion (Steidl and Yeomans, 2009). Both scopolamine and 
mecamylamine significantly decreased cocaine-evoked extracellular DA increases in NA 
in rats never trained for cocaine self-administration (cocaine naïve rats), and cocaine-
seeking behavior following 3 days of cocaine extinction in cocaine self-administering rats 
(Solecki et al., 2013). Thus, M5 mAChRs highly expressed in VTA DA neurons serve 
crucial roles in opioid- and cocaine-induced rewarding and reinforcing effects.  
An M5 selective antagonist (compound 1) containing 1,2,5,6,-tetrahydropyridine-
3-carboxylic acid scaffold, exhibited 11-fold selectivity for M5 over M1 mAChRs: however,
affinity of compound 1 for M5 mAChRs was modest (Ki = 2.24 µM) (Zheng et al., 2013). 
Thus, this dissertation (Chapters 4 and 5) conducted further SAR studies to test the 
hypothesis that novel M5 selective antagonists would provide pharmacotherapeutics for 
opioids and cocaine use disorders. 
6.2.2 Affinity and Selectivity of Pethidine Analogs for M5 mAChRs over M1 and 
M3 mAChRs 
SAR studies on compound 1 were conducted with the aim of improving affinity and 
selectivity of analogs for M5 mAChRs over M1-M4 mAChRs. Repositioning of carboxylate 
group in compound 1 resulted in a series of pethidine analogs. The repositioning of the 
carboxylate group of compound 1 from C-3 to C-4 of the piperidine ring resulted in 
pethidine, which exhibited antagonistic properties at mAChRs (Hustveit and Setekleiv, 
1993). Also, removing the meta-methoxy group of compound 1 resulted in a 75-fold 
increase in binding affinity for M5 mAChRs (Zheng et al., 2013). Initially, the carboxylate 
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group of compound 1 was repositioned from C-3 to C-4 of the piperidine ring to generate 
the pethidine scaffold. Subsequently, esters (analogs 4 and 6 series), amides (5 and 7 
series), carbamates (8 and 9 series), or carbamides (10 series) were added to the 
pethidine scaffold. Additionally, each analog series contained a phenyl ring with meta- and 
para-methoxy groups (analog a series; di-methoxy substitution in Table 1), and para-
methoxy group (analog b series; mono-methoxy substitution in Table 1). Affinities of 
analogs for mAChRs were evaluated to generate SARs. As a first approach, the affinity of 
analogs for M1, M3, and M5 mAChRs were determined because M1 and M3 were the top 
two subtypes exhibiting the highest amino acid homology (79% and 85%, respectively) 
with M5 mAChRs (Bonner et al., 1988). [3H]NMS binding assays revealed that ester-
containing pethidine analogs (4 and 6) exhibited the highest affinity for M1, M3, and M5 
mAChRs. Replacing ester (4a/b and 6a/b) to amide (5a/b and 7a/b, respectively) reduced 
affinity at M1, M3, and M5 (2- to 7-fold). Analogs containing carbamate (8 and 9) and 
carbamide (10) exhibited lower affinity for M1, M3, and M5 up to 8-fold compared to ester 
analogs (4 and 6). In addition, reversed ester in 6a/b exhibited higher affinity at M1, M3, 
and M5 mAChRs compared to 4a/b. Also, in agreement with the previously published 
literature (Zheng et al., 2013), the analogs containing the mono-methoxy substitution (4b, 
5b, 6b, 7b, and 10b) exhibited higher affinity for M5 (2- to 8-fold), M1 (2- to 9-fold), and 
M3 (3- to 19-fold) in comparison with their corresponding di-methoxy substitution 
contained analogs. In summary, the pethidine scaffold exhibited up to a 6-fold greater 
affinity for M5 mAChRs compared to compound 1, but low selectivity for M5 over M1 or 
M3. Among the pethidine analogs, compound 6b showed the highest affinity at M1, M3, 
and M5 mAChRs (Ki = 0.67, 0.35, and 0.38 µM, respectively) with low selectivity for M5 
over M1 and M3 mAChRs. Based on the current findings, further SAR is required to 
improve selectivity for M5 over M1-M4 mAChRs. Also, due to the pharmacological 
property of pethidine, it exhibited a weak MOR agonistic activity (Bryant et al., 2010). Thus, 
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when the pethidine structure-based analogs exhibit high affinity for M5 mAChRs, 
selectivity for M5 over MOR needs to be evaluated.  
6.2.3 Affinity and Selectivity of Quinuclidinyl Carbamate Analogs for M5 
mAChRs over M1-M4 mAChRs 
SAR studies using another approach employing a methyl phenylcarbamate 
scaffold were conducted with the goal of improving affinity and selectivity of compound 1 
for M5 over M1-M4 mAChRs. According to previous reports, quinuclidinyl carbamate- 
containing analogs including SVT-40776 exhibited mAChRs antagonism with high affinity 
(Prat et al., 2011). Thus, a new scaffold containing a 3,4-dimethoxyphenethyl group as in 
compound 1 and a quinuclidinyl carbamate was employed at the methyl-1-methyl-4-
phenyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate position to the structure of compound 1. 
Initially compound 12a and its analogs were synthesized (Table 2). Then, reorientation of 
carbamate structure in 12a generated compound 13a and its analogs (Table 3). The 
affinity and selectivity of analogs of quinuclidinyl carbamate analogs (compound 12a-16b) 
were evaluated using [3H]NMS binding assay. Also, a functional assay was conducted 
using the analog that exhibited the highest affinity at mAChRs among the quinuclidinyl 
carbamate scaffold analogs to determine its action as an antagonist at mAChRs. Among 
analogs evaluated, 12j/m/q, 13a/b/c, and 15c exhibited high affinity (Ki<100 nM) for M5. 
However, the highest selectivity for M5 over M1 in the quinuclidinyl carbamate analogs 
was 4.5-fold (compound 12m). The analog exhibiting the highest affinity for M5 was 13c 
(Ki = 1.8 nM).  
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6.2.4 Effect of the Most Potent Quinuclidinyl Carbamate Analog at M5 mAChRs 
on Functional Assay Using Rat Striatal Slices  
To further determine if 13c acted as an antagonist at mAChRs, a functional assay, 
[3H]DA release using rat striatal slices was conducted. Unexpectedly, 13c did not inhibit 
oxotremorine (an agonist of mAChRs)-evoked DA overflow. Further, scopolamine (an 
antagonist of mAChRs) inhibited 13c-evoked DA overflow, indicating an agonist action of 
13c on mAChRs. In contrast to VTA containing predominant M5 mAChRs expression, 
genetic modification studies using mice revealed that M3, M4, and M5 mAChRs mediate 
oxotremorine-evoked DA overflow from striatal slices (Zhang et al., 2002; Yeomans, 2012). 
With the assumption that mAChRs modulation of DA release is similar in rats and mice, 
13c appears to evoke DA release from rat striatal slices either through agonist action at 
M4 and/or M5 mAChRs, or through antagonist action at M3.  
Thus, through evaluation of quinuclidinyl carbamate scaffold containing analogs, 
13c was identified as the most potent (Ki = 1.8 nM) analog interacting with M5 mAChRs. 
Compound 13c achieved 1200-fold greater affinity for M5 compared to compound 1: 
however, 13c lacked selectivity for M5 mAChRs over M1-M4 mAChRs. Also, compound 
1 inhibited oxotremorine-evoked DA release from striatal slices, and 13c augmented 
oxotremorine-evoked DA release, which was inhibited by scopolamine, indicating an 
agonistic action of 13c on mAChRs. 
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6.3 Beneficial of M5 mAChRs Selective Antagonists as Therapeutics for Cocaine 
and Opioid Use Disorders 
Expression of M5 mAChRs is highly concentrated in the brain, specifically on VTA 
DA neurons, indicating low side effects of M5 specific antagonist. Additionally, genetic 
modification studies and pharmacological approaches showed M5 mAChRs as a strong 
therapeutic target for cocaine and opioid use disorders, especially since there is rapid 
increase on co-use of cocaine and synthetic opioids including fentanyl. Between 2015 and 
2016, there was a 300% increase in fentanyl seizures also containing cocaine, known as 
a “speedball” (DEA, 2018). Thus, targeting M5 mAChRs mediating multiple substance-
induced rewarding effects may be an effective treatment approach, which would be 
beneficial for multi-substance users, including cocaine and opioid co-users. However, 
mAChRs contain high amino acids sequence identities among M1-M5 subtypes. Thus, 
there are alternative approaches to discover each subtype selective antagonists. Notable 
achievements were reported from research teams uncovering allosteric antagonists of 
mAChRs instead of orthostatic antagonists.  
6.4 Potential Therapeutic Uses of M3 over M2 mAChRs Selective Antagonists 
Another interesting finding from the quinuclidinyl carbamate scaffold analogs is 
that there were 9 analogs (12d/j/l/n/o/q and 13a/b/c) out of 30 analogs that exhibited high 
affinity (Ki<100 nM) at M3 mAChRs. Among them, 13b exhibited highest selectivity (17-
fold) for M3 over M2 mAChRs. Since antagonism of M3 mAChRs, which is highly 
expressed in the respiratory system results in contraction of smooth muscles and reduced 
mucus secretion, while M2 antagonism induces acetylcholine release from 
parasympathetic nerves. Thus, the selectivity for M3 over M2 is important to be a COPD 
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medication. However, FDA-approved COPD medications targeting M3 including 
tiotropium and umeclidinium exhibit only 2 to 3-fold selectivity at M3 over M2 based on 
[3H]NMS binding assay. Thus, 17-fold selectivity of 13b for M3 over M2 indicated a 
potential of 13b as a COPD medication. Thus, 13b was identified as an analog exhibiting 
high affinity and selectivity for M3 over M2 mAChRs, and may have potential to be 
developed as a COPD treatment. 
6.5 Project 1 Review: Discovery Pharmacotherapeutics for METH Use Disorder 
The first aim of this dissertation is to discover pharmacotherapeutics that treat 
METH use disorders by identifying selective and potent inhibitors of VMAT2 (Chapters 2 
and 3).  
6.5.1 VMAT2 Function is Critical to the Mechanism of Action of METH 
Currently, METH is the second most popular misused substance in the world 
following cannabis (UNODC, 2018). METH is a psychostimulant exhibiting high abuse 
liability (Anglin et al., 2000; Vearrier et al., 2012). Due to the high lipophilicity (logP = 2.10) 
of METH, it is able to penetrate the blood-brain barrier and neuronal cell membranes 
(Gulaboski et al., 2007). Accordingly, in rats, 9.7-fold higher concentrations of METH were 
found in the brain compared to serum 3 h following METH (i.v.)  administration (Riviere et 
al., 2000). METH enters into the CNS and inhibits DA uptake at DAT by acting as a 
substrate, indicating that METH can be taken up via DAT (Zaczek et al., 1991). Also, due 
to the high lipophilicity of METH, it can pass through the plasmalemmal membrane. In the 
cytosol, METH inhibits MAO activity and inhibits DA uptake at VMAT2, resulting in 
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increased cytosolic DA concentrations. METH also is able to pass through vesicular 
membranes within neuronal cells. Once METH enters the vesicles, it interrupts the pH 
gradient between the inside and outside of the vesicles by its weak base properties (Sulzer 
and Rayport, 1990). Additionally, in the presence of VMAT2 inhibitors such as 
dihydrotetrabenazene and lobeline, METH-evoked DA release from human DAT and 
VMAT2 co-expressing cells and from rat striatal brain slices was decreased, suggesting 
that METH induces vesicular DA release by interacting with VMAT2 (Wilhelm et al., 2004; 
Nickell et al., 2010). Consequently, METH inhibits DA uptake at VMAT2 through 
pharmacological inhibition of its DA uptake function and interrupting pH gradient, the 
driving force of DA uptake at VMAT2 (Sulzer and Rayport, 1990; Wilhelm et al., 2004). 
Overall, METH increases the cytosolic DA concentration, which is released via reversing 
DAT function (Goodwin et al., 2009). Thus, the increased cytosolic DA is released into the 
extracellular space cleft via reversal of DAT, which contributes to METH-induced 
rewarding effects. In contrast to cocaine (a DAT inhibitor), METH exhibited reduced DA 
release in the cells expressing DAT, but not VMAT2, compared to cells co-expressing DAT 
and VMAT2, indicating a critical contribution of VMAT2 on METH-evoked DA release (Pifl 
et al., 1995).  
6.5.2 VMAT2 Inhibitors as a Pharmacotherapeutic for METH Use Disorders 
Lobeline (a natural alkaloid extracted from Lobelia inflata) inhibits VMAT2 function 
(Ki = 470 nM) and decreased METH-evokes DA release from rat striatal slices (DK Miller 
et al., 2001; Nickell et al., 2010). Also, lobeline reduced responding for METH i.v. infusion 
in the rat METH self-administration model (Harrod et al., 2001). Accumulated findings 
suggested that VMAT2 as a viable  therapeutic target to treat METH use disorders 
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(Dwoskin and Crooks, 2002; Zheng et al., 2006). In accordance with 
neuropharmacological studies, heterozygotes VMAT2 KO mice exhibiting 60% reduced 
VMAT2 expression, measured by the [3H]DTBZ binding assay, demonstrated significantly 
less preference for amphetamine-paired place in the CPP model compared to wild-type 
control mice. No difference was found for cocaine-paired place in CPP (Takahashi et al., 
1997). Certainly, lobeline completed Clinical Trial Phase Ib and was found to be safe in 
active METH users (Jones, 2007). However, lobeline also interacts with nAChRs, which 
likely contributes to the presentation of undesired side effects such as nausea during the 
clinical trials (Cahill et al., 2007; Glover et al., 2010; Swan et al., 2012). Thus, a series of 
structure-activity relationship (SAR) studies were initiated to discover VMAT2 selective 
compound as a potential METH use disorder treatment.  
Through SAR studies, a lobeline analog containing a de-functionalized linker 
region was identified. Lobelane was exhibited 10.4-fold greater affinity for VMAT2 (Ki = 45 
nM) and greater than 40-fold higher selectivity for VMAT2 over nAChRs compared to 
lobeline (Miller et al., 2004; Nickell et al., 2010). Lobelane also showed ability to decrease 
METH-evoked DA release from rat striatal slices, METH-induced hyperlocomotion activity, 
and METH self-administration (Neugebauer et al., 2007; Nickell et al., 2010). However, 
tolerance developed to the effect of lobelane on METH self-administration (reducing 
response for METH) following repeated lobelane administration (Neugebauer et al., 2007).  
With further SAR studies, GZ-793A, an analog of lobelane containing a substituted  
N-1,2-dihydroxypropyl moiety at N-methyl position was discovered and exhibited 
comparable affinity for VMAT2 (Ki =29 nM) with no affinity for nAChRs over a range of 
concentrations (up to 30 µM) (Nickell et al., 2017). GZ-793A inhibited METH-evoked DA 
release from rat striatal slices and from synaptic vesicular preparation. Also,  GZ-793A 
inhibited METH-induced DA release in the NA (Meyer et al., 2013). Finally, GZ-793A 
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decreased METH self-administration without developing tolerance (Alvers et al., 2012). 
However, GZ-793A exhibited affinity for hERG channels, indicating the possibility of GZ-
793A having cardiotoxicity (Nickell et al., 2017).  
Therefore, this dissertation conducted further SAR studies with the aim of 
eliminating hERG affinity and proposed a new amphetamine-like scaffold as VMAT2 
inhibitors and potential pharmacotherapeutics for METH use disorders. Throughout 
Chapters 2 and 3, two enantiomers in this scaffold inhibiting VMAT2 function were 
evaluated. The new scaffold provided viable candidates as pharmacotherapeutics for 
METH use disorder. In the new scaffold, the N-1,2-dihydroxypropyl piperidine in GZ-793A 
structure was replaced with a phenylalkyl moiety to provide 3-(4-methoxyphenyl)-N-(1-
phenylpropan-2-yl)propan-1-amine. This scaffold contains one chiral center. However, 
racemic mixtures are less likely to be approved by the FDA as medications. Thus, the two 
enantiomers, (R)- and (S)-enantiomer, of the new scaffold were synthesized separately 
and evaluated with findings presented in Chapters 2 and 3, respectively.   
On the other hand, there are VMAT2 inhibitors, reserpine and tetrabenazine, 
known as classic VMAT2 inhibitors (Partilla et al., 2006; summary in Table 4). 
Tetrabenazine and its deuterated form (deutetrabenazine) are FDA-approved 
pharmacotherapeutics to treat Huntington’s disease and tardive dyskinesia associated 
chorea (Yero and Rey, 2008; DeWitt and Maryanoff, 2018). Tetrabenazine inhibits VMAT2 
with high affinity (Ki = 70-97 nM) (Erickson et al., 1996; Meyer et al., 2011). However, 
tetrabenazine showed no selectivity for VMAT2 over DAT (Table 4), which would predict 
high abuse liability of tetrabenazine (Seeman and Lee, 1975; Stathis et al., 1995; Meyer 
et al., 2011). Tetrabenazine (1 mg/kg, s.c.) decreased METH self-administration, but at a 
lower dose (0.1 mg/kg, s.c.) increased responding for METH (Meyer et al., 2011). 
Furthermore, tetrabenazine (1 mg/kg, s.c.) decreased food-maintained responding, 
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indicating non-selective effects of tetrabenazine. Tolerance did not develop to the 
decrease in responding for food, such that nonselective effects were maintained across 
repeated administration. Also, tetrabenazine depleted vesicular DA content and 
exacerbated METH-induced striatal DA depletion (Reches et al., 1983; German et al., 
2015). Since METH use disorder has an 87% chance of relapse within 5 years (Brecht 
and Herbeck, 2014), it might be anticipated that neurotoxicity would be a potential 
outcome during a METH relapsing event if a patient is being treated by tetrabenazine as 
a therapeutic. 
Another VMAT2 inhibitor, reserpine (Ki = 12 nM) was also approved by the FDA 
as an antihypertensive (Erickson et al., 1996). However, reserpine also exhibits no 
selectivity for VMAT2 over DAT (IC50 = 10 nM) (Metzger et al., 2002). Also, reserpine 
depletes striatal DA and exacerbates METH-induced striatal DA depletion, which limits its 
therapeutic use (Smith, 1956; Macarthur, 1957; Brookhart et al., 1987). Thus, classic 
VMAT2 inhibitors, tetrabenazine and reserpine, have several characteristics that prevent 
them from being considered as therapeutics to treat METH use disorder.  
6.5.3 VMAT2 Inhibitors Containing a New Amphetamine-like Scaffold as 
Therapeutics for METH Use Disorder 
The (R)-enantiomer, GZ-11610, exhibited high affinity (Ki = 8.7 nM) for VMAT2 
with high selectivity (288- to >3450-fold) for VMAT2 over DAT, SERT, nAChRs, and hERG 
channels. Also, METH-induced hyperlocomotion in METH-sensitized animals was 
decreased following GZ-11610 (s.c. and oral). Although s.c. GZ-11610 decreased 
locomotor activity nonspecifically, orally administered GZ-11610 specifically decreased 
METH-induced hyperlocomotion by 50% of control. The effective dose of oral GZ-11610 
221 
 
was 20-fold higher compared to the s.c. GZ-11610, which suggests low oral bioavailability. 
Thus, further formulation studies are needed to achieve greater oral bioavailability.    
The (S)-enantiomer, GZ-11608 exhibited high affinity (Ki = 25 nM) for VMAT2 with 
high selectivity (92- to >1180-fold) for VMAT2 over DAT, SERT, nAChRs, and hERG 
channels. GZ-11608 (s.c. and oral) specifically decreased METH sensitization. Oral GZ-
11608 tended to increase locomotor activity in the saline control group in a dose-
dependent manner, which may indicate the potential for GZ-11608 to act like a 
psychostimulant. However, the self-administration study using i.v. GZ-11608 showed that 
GZ-11608 does not serve as a reinforcer in drug naïve animals. Also, GZ-11608 was not 
able to substitute for METH. GZ-11608 had low affinity (Ki = 6 µM) for DAT and high 
selectivity (241-fold) for VMAT2 over DAT. Thus, neurochemical and behavioral studies 
support a low abuse liability of GZ-11608. The METH sensitization study also suggested 
that oral GZ-11608 decreased METH sensitization at 30-fold higher dose compared to s.c. 
GZ-11608, indicating low oral bioavailability of GZ-11608; however, efficacy with s.c. 
administration was observed.  
GZ-11608 and GZ-793A inhibited METH-evoked DA release by competitive and 
allosteric mechanisms, respectively (Summary Table 4; Nickell et al., 2017). 
Tetrabenazine competitively inhibited METH-evoked DA release, like GZ-11608, but 
tetrabenazine showed a biphasic effect on METH self-administration (Meyer et al., 2011). 
Tetrabenazine increased responding for METH at a low dose (0.1 mg/kg, s.c.) and was 
not selective (~2-fold) for VMAT2 over DAT (Erickson et al., 1996; Meyer et al., 2011). 
DAT inhibitory potency is correlated positively with abuse liability (Seeman and Lee, 1975; 
Stathis et al., 1995). Thus, low doses of tetrabenazine may be reinforcing due to its ability 
to inhibit DAT. GZ-11608 exhibited high selectivity (241-fold) for VMAT2 over DAT, and 
GZ-11608 did not show reinforcing effects. The current findings suggest that GZ-11608 
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and the new amphetamine-like scaffold have different underlying mechanisms to decrease 
responding for METH, providing advantages of GZ-11608 as a therapeutic for METH use 
disorder relative to classic VMAT2 inhibitors and previous lead compounds (i.e., lobeline, 
lobelane, and GZ-793A).  
GZ-11608 also has considerable advantages relative to the previous lead 
compounds (lobeline, lobelane, and GZ-793A) emanating from our iterative drug discovery 
program. VMAT2 affinity increased across the successive progression from lead to lead, 
resulting in Ki values in the low nM range, and selectivity for VMAT2 over DAT was 
consistent across the leads (Horton et al., 2011; Summary Table 4). Furthermore, low 
cardiotoxicity is expected with GZ-11608 due to the demonstration of greater than 30-fold 
selectivity for VMAT2 over hERG, which is improved over our previous lead compounds 
(Nickell et al., 2017; Summary Table 4). Several positive properties of the previous lead 
compounds (lobeline, lobelane, and GZ-793A) as therapeutics for METH use disorder 
were retained in the GZ-11608 molecule: 1) GZ-11608 did not exacerbate METH-evoked 
striatal depletion, which is consistent with earlier molecules (Eyerman and Yamamoto, 
2005; Horton et al., 2013) and 2) the efficacy of GZ-11608 to decrease METH self-
administration was comparable with previous molecules. Furthermore, greater specificity 
was observed with GZ-11608 to decrease METH reinforcement relative to previous 
molecules (Harrod et al., 2001; Neugebauer et al., 2007; Meyer et al., 2011; Beckmann et 
al., 2012). With respect to the decrease in  METH self-administration, tolerance developed 
to the efficacy produced by lobelane following repeated administration, whereas, repeated 
GZ-11608, lobeline and GZ-793A, did not result in tolerance (Harrod et al., 2001; 
Neugebauer et al., 2007; Beckmann et al., 2012). Like lobeline and GZ-793A (Harrod et 
al., 2003; Beckmann et al., 2012), GZ-11608 exhibited low abuse liability. Importantly, GZ-
11608 decreased cue- and METH-induced METH-seeking behavior. GZ-793A blocked 
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cue-induced reinstatement of METH-seeking, but GZ-793A and lobeline only marginally 
reduced (30%), and had no effect on METH-induced reinstatement of METH-seeking, 
respectively. This supports the greater potential of GZ-11608 as a METH use disorder 
pharmacotherapeutic relative to lobeline and GZ-793A (Harrod et al., 2003; Alvers et al., 
2012). Thus, the current preclinical research provides evidence supporting the 
pharmacotherapeutic advantages of GZ-11608 for METH use disorder relative to previous 
lead compounds.  
GZ-11608 resulted in a downward and rightward shift in the in the METH self-
administration dose-response curve, whereas lobeline and GZ-793A resulted in only a 
downward shift of the dose-response curve (Harrod et al., 2001; Alvers et al., 2012), 
suggesting different underlying mechanisms in altering behavior. Schild regression on 
METH-evoked vesicular DA release also revealed different underlying mechanisms 
between GZ-11608 and GZ-793A, which may have contributed to the different behavioral 
outcomes (current findings and Horton et al., 2013). 
Altogether, the current findings identified GZ-11608 and GZ-11610, constituting a 
new scaffold that acts as VMAT2 inhibitors. High selectivity of GZ-11608 and GZ-11610 
for VMAT2 over nAChRs, DAT, and hERG indicates a low potential for side effects 
including nausea, abuse liability, and cardiotoxicity. GZ-11610 (s.c.) and GZ-11608 (s.c. 
and oral) specifically decreased METH sensitization. Importantly, GZ-11608 decreased 
METH self-administration and cue- and METH-induced reinstatement of METH-seeking 
behavior without altering food-maintained response and without having abuse liability. 
Also, tolerance did not develop to the efficacy of GZ-11608 to decrease METH self-
administration following repeated GZ-11608 administration. Increasing the unit dose of 
METH was not able to surmount the ability of GZ-11608 to decrease response for METH. 
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Thus, the current study reveals high potential for GZ-11608 as a therapeutic for METH 
use disorder. 
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Table 4. Summary of preclinical findings of VMAT2 inhibitors. 
 
n.d., not determined, a Erickson et al., 1996, b Meyer et al., 2011, c Horton et al., 2011, d Nickell et al., 2009, 
e Metzger et al., 2002 (IC50 value), f  Nickell et al., 2017, g Horton et al., 2013, h Harrod et al., 2001, i 
Beckmann et al., 2012, j Neugebauer et al., 2007, k Lee et al., 2018, l Lee et al., 2019 (under revision)
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6.6 Discussions on New Amphetamine-like Scaffold VMAT2 Inhibitors 
VMAT2 inhibitors containing the new amphetamine-like scaffold include a chiral 
center in the (R)- and (S)-enantiomers (Chapter 2 and 3,). The effect of each enantiomer 
was evaluated using neurochemical and behavioral approaches and is discussed in the 
current section.  
6.6.1 Neurochemical Properties of (R)- and (S)-Enantiomers   
Two enantiomers exhibited comparable affinity for VMAT2, DAT, SERT, hERG and 
nAChRs. The (R)-enantiomer, GZ-11610 (Ki = 8.7 nM), exhibited 2.9-fold higher affinity 
for VMAT2 relative to (S)-enantiomer, GZ-11608 (Ki = 25 nM). Affinity of GZ-11610 and 
GZ-11608 for DAT (Ki = 2.5 and 2.4 µM, respectively), SERT (Ki = 5.6 and 2.4 µM, 
respectively), hERG (Ki = 9.5 and 4.2 µM, respectively), and both enantiomers exhibited 
low affinity (Ki >30 µM) for nAChRs. These data indicate that stereochemistry at the chiral 
center of amphetamine-like scaffold has a minor impact on interactions of enantiomers 
with monoamine transporters, hERG channel, and nAChRs.  
In comparisons of selectivity of enantiomers for VMAT2 over off-target proteins, 
effect of stereochemistry of these two enantiomers were notable relative to affinity 
comparisons. Selectivity of GZ-11610 for VMAT2 over hERG and SERT was 6.7- and 6.9-
fold, respectively, higher than GZ-11608. While the selectivity of GZ-11610 for VMAT2 
over DAT and nAChRs were comparable with GZ-11608. These results indicate that the 
(S)-enantiomer, GZ-11608 would exhibit greater potential for cardiotoxicity than GZ-11610 
at effective dose for decreasing METH effects, but comparable abuse liability would 
expected from both enantiomers, based on selectivity for VMAT2 over DAT (Seeman and 
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Lee, 1975; Abbott et al., 1999; Sanguinetti and Tristani-Firouzi, 2006). Also, low potential 
of nAChRs-related side effects including nausea (Cahill et al., 2007; Swan et al., 2012) 
would be expected from both enantiomers. GZ-11608 exhibited 6.9-fold lower selectivity 
for VMAT2 over SERT relative to GZ-11610, indicating that GZ-11608 may have greater 
potential than GZ-11610 to inhibit 5-HT uptake at SERT at doses effective at decreasing 
METH effects via interacting with VMAT2. However, SERT inhibition reduces anxiety, 
depression, and schizophrenia-related behaviors, which are symptoms often experienced 
by chronic METH users (~40%) (Heisler et al., 1998; Ramboz et al., 1998; van den Buuse 
et al., 2011). Furthermore, psychotic symptoms in chronic METH users may contribute to 
high relapse rate (Glasner-Edwards et al., 2009, 2010; McKetin et al., 2010). Thus, despite 
the fact that GZ-11608 exhibited 6.7-fold lower selectivity for VMAT2 over hERG than GZ-
11610, which may indicate higher cardiotoxic potential of GZ-11608 than GZ-11610, both 
enantiomer exhibited high affinity and selectivity (92- to 3450-fold) for VMAT2 over DAT, 
SERT, nAChRs, and hERG. These findings support the potential of both enantiomers as 
candidates for METH use disorder treatments.       
6.6.2 Behavioral Properties of (R)- and (S)-Enantiomers   
The (R)-enantiomer, GZ-11610 decreased METH sensitized locomotor activity at 
lower dose (3 mg/kg, s.c. and 56 mg/kg, oral) than the (S)-enantiomer (10 mg/kg, s.c. and 
300 mg/kg, oral). GZ-11610 (s.c.) resulted in a nonspecific decrease on locomotor activity 
in the saline control group (Lee et al., 2018). Likely, a decrease in locomotor activity could 
result from sedation or motor impairment  (Castagné et al., 2014). Together, the s.c. GZ-
11610 effect was not specific for METH sensitization. Thus, there is a need to determine 
if tolerance develops to repeated s.c. administration of GZ-11610 on METH sensitization 
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with respect to its nonspecific effects. Perhaps the nonspecific effect of GZ-11610 to 
decrease locomotion develops tolerance, which would enhance the ability to use the 
compound as a therapeutic use. Oral administration of GZ-11610 exhibited specificity for 
decreasing METH sensitized locomotor activity.  But, GZ-11610 significantly decreased 
(by 50% of control) METH sensitization at 56 mg/kg (oral), but 5.4-fold higher dose (300 
mg/kg, oral) also decreased 50% of control METH sensitization. These observations 
suggest GZ-11610 was able to penetrate blood-brain barrier, and achieve sufficient oral 
bioavailability. However, the maximal effect of oral GZ-11610 was about 50% of control, 
for which there are several possible reasons, including low solubility decreasing 
absorption, high metabolism and/or high plasma protein binding (Chung et al., 2004).  
In contrast, the (S)-enantiomer, GZ-11608, decreased METH sensitized locomotor 
activity specifically and in a dose-dependent manner at dose ranges from 10-30 mg/kg 
(s.c.). Also, oral GZ-11608 specifically decreased METH sensitized locomotor activity. The 
effective dose of oral GZ-11608 was 300 mg/kg, which is 5.4-fold higher than effective 
dose of oral GZ-11610, but the efficacy of oral GZ-11608 was higher (60% of control) than 
oral GZ-11610 (<50%) (Lee et al., 2018). These observations support the potential of GZ-
11608 for therapeutics use to treat METH use disorder.  
Interestingly, oral GZ-11608 showed the tendency, but not statistically significant, 
to dose-dependently increase locomotor activity in the saline control group between 56-
300 mg/kg. Oral GZ-11608 (300 mg/kg) resulted in locomotor activity (~ 40 meters) during 
the 45 min session, which is about 20% of METH sensitized locomotor activity. This 
pattern of an increase in locomotor activity in the saline control group suggests a potential 
psychostimulant effect of GZ-11608, and taken one step further, might suggest abuse 
liability. However, SERT inhibitors commonly used to treat depression also increase 
locomotor activity. Inhibitors of SERT including fluoxetine (10 and 30 mg/kg, i.p.), 
229 
escitalopram (0.3-10 mg/kg, i.p.), and sertraline (2.6-10.3 mg/kg), increase locomotor 
activity in a dose-dependent manner in rodents. However, an inhibitor of SERT and NET, 
duloxetine (0.3-30 mg/kg, i.p.) and a NET inhibitor, reboxetine (1-30 mg/kg, i.p.) did not 
alter locomotor activity in rodents (Geyer, 1995; Prinssen et al., 2006). Thus, the tendency 
of GZ-11608 to increase locomotion may indicate that GZ-11608 has psychostimulant 
effects and/or GZ-11608 inhibits SERT at high oral doses. However, the GZ-11608 self-
administration and substitution studies revealed that GZ-11608 has low abuse liability.  
6.6.3 Oral Bioavailability of (R)- and (S)-Enantiomers    
Both (R)- and (S)-enantiomers showed  20- to 30-fold higher effective dose with 
s.c. route than oral administration to decrease METH sensitization, which would indicate
low oral bioavailability of enantiomers. However, orally available therapeutics are 
preferred. Thus, pharmacokinetic studies with an aim of improving oral bioavailability 
would be essential to determine if GZ-11608 and GZ-11610 are orally bioavailable 
pharmacotherapeutics for METH use disorder.  
There are several research approaches to achieve greater oral bioavailability for 
compounds exhibiting high potential as therapeutics or for existing medications with low 
oral bioavailability. For instance, research on nobiletin (2-(3,4-dimethoxyphenyl)-5,6,7,8-
tetramethoxychromen-4-one), a compound exhibiting anti-inflammatory effect and 
rescuing rats from amyloid beta-induced memory impairment, showed 13-fold 
improvement in oral bioavailability by generating nanosized nobiletin as a high-energy 
amorphous solid dispersion (using wet-milled technique) (Onoue et al., 2011). Also, 6.5-
fold greater bioavailability in agomelatine (an antidepressant approved by European Union 
in 2009) was reported (Prajapati et al., 2018). Agomelatine exhibited 1% bioavailability 
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previously, but loading agomelatine into nanostructured lipid carriers resulted in greater 
bioavailability. In the other research, since 90% of agomelatine was metabolized by a 
cytochrome P450 1A2, co-administration of fluvoxamine (an inhibitor of cytochrome P450 
1A2 and an antidepressant) slowed down the metabolism of agomelatine (Sansone and 
Sansone, 2011). According to a report of a company, Servier Laboratories Limited, 
fluvoxamine inhibited metabolism of agomelatine, which  60-fold (range 12 to 412) 
increased agomelatine exposure (Servier Laboratories Limited, 2018). Also, gabapentin 
(therapeutic utility in multiple disease such as epilepsy, neuropathic pain, and anxiety 
disorder) exhibited 17- and 34-fold higher exposure of gabapentin in rats and monkeys, 
respectively, by using a prodrug form. The prodrug, XP13512 (±)-1-([(α-
isobutanoyloxyethoxy)varbonyl]aminomethyl)-1-cyclohexane acetic acid) was designed to 
be recognized by monocarboxylate transporter type 1 and sodium-dependent multivitamin 
transporter have responsible for the absorption of small-chain fatty acids and small-chain 
fatty acids, respectively (Cundy et al., 2004). Thus, the high potential of GZ-11608 as 
therapeutics for METH use disorder in the current study may be improved further with 
additional formulation and pharmacokinetic studies in the future.  
6.6.4 Alternative Administration Routes for (R)- and (S)-Enantiomers 
Data in Chapter 3 support a high potential of GZ-11608 as a therapeutic for METH 
use disorder with s.c. administration. As alternative approaches, the current section 
introduces the potential of combination therapy and extended-release injectable 
suspension. Based on the chemical structure of GZ-11608, it contains multiple moiety 
preferentially metabolized by P450 hepatic enzymes (Vasanthanathan et al., 2010). 
Especially, multiple P450 ligands contain similar chemical structures with GZ-11608 and 
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an antidepressant, fluvoxamine inhibits P450 (Wagner et al., 1994; van Harten, 1995). A 
case study using combination therapy with fluvoxamine and escitalopram to inhibit 
metabolism of escitalopram showed improved symptoms of the patient (Tarutani et al., 
2016). However, another combination therapy using fluvoxamine and clomipramine 
administered to patients resulted greatly elevated serum clomipramine levels. Most of 
patients tolerated pharmacokinetic interactions of the combination therapy, but there were 
several patients exhibiting intracardiac conductance due to the increased serum 
clomipramine level (Szegedi et al., 1996). Currently, there are no pharmacotherapeutics 
for METH use disorder. Since GZ-11608 showed efficacy to reduce METH self-
administration and reinstatement of METH-seeking behavior, combination therapy with 
fluvoxamine may provide an alternative way to improve oral bioavailability of GZ-11608.  
Another potential approach would be to use an intramuscular extended-release 
injectable suspension. A therapeutic for opioids use disorder, naltrexone was initially 
discovered as orally available therapeutic with once a day or once two or three days 
administration. However, naltrexone resulted in gastrointestinal disorders in patients, 
which may contribute to low adherence rate of patients to the treatment program (Ploesser 
et al., 2010). Indeed, 28% of patients were retained with oral naltrexone treatment based 
on 13 studies, whereas extended-release injectable naltrexone required once a month 
injection and showed greater treatment adherence (62% of patients) for 12 months of 
treatment period (Krupitsky et al., 2013). Also, 51% of the remaining patients achieved 12 
months of opioid abstinence, indicating advantages of the extended-release injectable 
suspension as a therapeutic for substance use disorders. The extended-release 
intramuscular naltrexone consisted of biodegradable polylactidecoglycolide polymer 
microspheres and 34% weight/weight naltrexone. The microspheres containing 
naltrexone were reconstructed in an aqueous suspension immediately before the 
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intramuscular injection, which would be expected to be released over 28-day (Swainston 
Harrison et al., 2006). Currently, GZ-11608 has low oral bioavailability. Accumulated data 
suggest that not only the oral administration, but also the extended-release suspension 
form of therapeutics showed >50% of treatment adherence rate in opioids use disorders. 
Thus, the extended-release intramuscular formulation might be an alternative approach 
for GZ-11608.      
6.6.5 Additional Potential for Therapeutic Uses of VMAT2 Selective Inhibitors  
There is another potential therapeutic use of VMAT2 selective inhibitors including 
(R)- and (S)-enantiomers containing the new amphetamine-like scaffold. If GZ-11608 and 
GZ-11610 can be conjugated with radioactive agent, these can contribute to an improved 
diagnosis for idiopathic Parkinson’s disease. Recent research reported VMAT2 selective 
compound based brain imaging improved diagnosis in uncertain Parkinsonian syndromes, 
which led use of appropriate medication, and improved patient outcomes (Arena and 
Stoessl, 2016; Alexander et al., 2017).  
6.6.6 VMAT2 Inhibiter Effects on Other Neurotransmitter Systems 
VMAT2 is expressed on the vesicular membrane in neurons expressing DA, NE, 
and 5-HT, which uptakes DA, NE, and 5-HT from cytosol to vesicles (Eiden and Weihe, 
2011). Since DA, NE, and 5-HT interact at the same binding site on the VMAT2  (Erickson 
and Eiden, 1993; Schütz et al., 1998), compounds that inhibit DA uptake at the VMAT2 
may also interact with NE and 5-HT uptake. For instance, reserpine exhibiting slow off-
rate from VMAT2, which results in quasi-irreversible inhibition of VMAT2 function, 
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decreased the uptake of DA at the VMAT2 (Erickson et al., 1996). It also decreased 5-HT 
uptake according to a cell-based study overexpressing human VMAT2 (Rilstone et al., 
2013). Tetrabenazine inhibiting DA uptake at the VMAT2 depleted not only DA, but also 
5-HT and NE in the brain (Guay, 2010; Meyer et al., 2011), which allows tetrabenazine to
treat several diseases such as Huntington’s and Parkinson’s disease (Suzuki et al., 2001; 
Yero and Rey, 2008; German et al., 2015). However, individuals treated with 
tetrabenazine for their chorea symptoms of Huntington’s disease reported depressed 
mood and suicidal thoughts (Dorsey et al., 2013). Thus, a VMAT2 inhibitor, GZ-11608 
inhibiting DA uptake at the VMAT2, may have potential to interrupt NE and 5-HT uptakes 
at the VMAT2 and alter brain function mediated by NE and 5-HT, such as mood control.  
Based on a lobeline study using striatal slides, lobeline-induced DA overflow was 
observed only at the highest concentration: however, a metabolite of DA, such as 
dihydroxyphenylacetic acid (DOPAC), overflow was increased in a dose dependent 
manner (Teng et al., 1997). This observation indicates lobeline induces an increase in 
cytosolic DA. Though GZ-11608 has potential to increase cytosolic DA, NE, and 5-HT, it 
may increase cytosolic monoamine neurotransmitter concentration acutely: however, they 
will be metabolized without significant alteration on their transmission. When VMAT2 
expression levels were low, cytosolic DA levels were high, but extracellular DA levels 
(following activation of the neuron) were low (Lohr et al., 2017). Thus, GZ-11608 
potentially decreases DA, NE, and 5-HT mediated functions, such as locomotor activity, 
mood control, cognition and memory. However, GZ-11608 did not decrease locomotor 
activity in the control group (Fig. 3.4). Additionally, GZ-11608 did not alter DA content by 
itself and did not exacerbate METH-induced striatal DA depletion (Fig. 3.5.), which, also 
supports the claim that GZ-11608 does not have significant effects on the monoamine 
neurotransmitter system. Sedative studies such as the rotarod test using rotating cylinders 
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or the righting reflex would provide additional information for GZ-11608 effects on mood 
disorders. Based on the current study in Chapter 3, GZ-11608 did not alter locomotor 
activity in the control group, which would indicate that GZ-11608 has low potential to cause 
depression. It is likely that sedation and compound-induced motor impairment would result 
in decreased locomotor activity (Castagné et al., 2014). In contrast, tetrabenazine and 
reserpine deplete neurotransmitters, which are associated often with depression (Guay, 
2010; German et al., 2015).  
6.6.7 Surmountability 
GZ-11608 resulted in a downward and rightward shift in the METH self-
administration dose-response curve (Fig. 3.8, Table 4), indicating that GZ-11608 
decreased METH self-administration via a combination of competitive and allosteric 
inhibitory mechanisms. In contrast, lobeline and GZ-793A resulted in only a downward 
shift at the dose-response curve, indicating an allosteric inhibitory mechanism (Harrod et 
al., 2001; Alvers et al., 2012). The underlying mechanisms were not identical between GZ-
11608 and previous VMAT2 inhibitors, based on this observation (Fig. 3.8). However, the 
peak of response for METH in the GZ-11608 administered group was lower than the no-
treatment group. Since GZ-11608 resulted in not only a rightward shift of METH self-
administration dose-response curve (a typical competitive inhibitory mechanism), but it 
also resulted in a downward shift of the curve. Thus, response for METH in GZ-11608 the 
treatment group was lower than the control group across the various unit dosage of METH 
(0.01-0.25 mg/kg, i.v.). If GZ-11608 effects were surmountable, then the peak of response 
for METH in GZ-11608 administered groups should be comparable with the no-treatment 
group when a higher unit dose of METH was available: however, this was not found in the 
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current study. Thus, effects of GZ-11608 to decrease METH self-administration are not 
surmountable. 
6.6.8 GZ-11608 and GZ-11610 as Pharmacotherapeutics for Cocaine and Opioids 
Use Disorders   
In current study, VMAT2 inhibitors have been considered as therapeutics for METH 
use disorders, but not for other substance use disorders (i.e., cocaine or opioids use 
disorder). Specifically, in cells expressing VMAT2 and DAT, METH showed increased DA 
efflux compared to cells expressing only DAT, indicating that VMAT2 serves an important 
role on METH-evoked DA release (Pifl et al., 1995). Dihydrotetrabenazine (DHTB), a 
VMAT2 inhibitor, decreased METH-evoked DA efflux from 60% to 20% of preloaded 
[3H]DA (Wilhelm et al., 2004). Additionally, lobeline and GZ-793A (VMAT2 inhibitors) 
decreased METH self-administration. Interestingly, the dose of GZ-793A decreasing 
METH self-administration >90% of vehicle treated control decreased cocaine self-
administration by 10% to 20% of control in rats (Beckmann et al., 2012). Also, reserpine 
was not able to decrease cocaine self-administration in monkeys (Wilson and Schuster, 
1974). Additionally, cocaine did not inhibit DHTB binding at the VMAT2 (Hiranita, 2015). 
Together, previously reported VMAT2 inhibitors showed low potential as a therapeutic for 
cocaine use disorder.  
On the other hand, lobeline showed potential as a pharmacotherapeutic for opioids 
use disorder by exhibiting affinity at MOR (Miller et al., 2007). Also, due to the respiratory 
stimulant effects of lobeline, it has been used to treat morphine poisoning (King et al., 
1928; Dwoskin and Crooks, 2002). Reserpine, which depletes monoamines, inhibited 
development of morphine tolerance (Langwinski and Fidecka, 1981). Thus, previously 
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reported VMAT2 inhibitors have shown potential as therapeutics for opioids overdose 
poisoning and development of tolerance. However, research has yet to be conducted on 
the potential of VMAT2 inhibitors as therapeutics for opioid use disorders. 
In this respect, GZ-11608 and GZ-11610 show high affinity for VMAT2. GZ-11608 
specifically inhibits VMAT2 via a competitive mechanism of action. Tetrabenazine also 
competitively inhibit VMAT2 function, but it has nonspecific actions, in that it decreased 
food-maintained responding (Meyer et al., 2011). GZ-11608 administration did not 
produce similar nonspecific behavioral effects.  Importantly, tetrabenzine and reserpine 
deplete DA content (Kenney and Jankovic, 2006; Guay, 2010). Again, GZ-11608 did not 
alter DA content; and thus, untoward consequences are not anticipated with this novel 
compound. Thus, the potential of GZ-11608 and GZ-11610, VMAT2 inhibitors containing 
a new scaffold, as therapeutics for cocaine and opioids use disorders should be 
investigated in future studies.  
6.7 Limitations 
6.7.1 Project 1: Discovery Pharmacotherapeutics for METH Use Disorder 
In the current study, effects of GZ-11608 and GZ-11610 on DA, but not NE and 5-
HT uptake from cytosol to vesicles via VMAT2 were studied. VMAT2 translocates DA, NE, 
and 5-HT when expressed in neurons containing DA, NE, and 5-HT (Erickson et al., 1996; 
Eiden et al., 2004). Although, effects of GZ-11608 and GZ-11610 on NE and 5-HT uptake 
at VMAT2 were not investigated in current study, DA, NE, and 5-HT interact with VMAT2 
at identical binding site and comparable affinity (IC50=1.4, 3.4, and 0.9 µM, respectively; 
Gasnier et al., 1994; Wimalasena, 2011). Thus, effects of GZ-11608 and GZ-11610 on the 
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DA system similarly are predicted for the NE and 5-HT neuronal systems. Furthermore, 
behavioral pharmacological studies in the current dissertation using GZ-11608 and GZ-
11610 potentially reflect combined effects of GZ-11608 and GZ-11610 on DA, NE, and 5-
HT neuronal systems.  
Abuse liability of GZ-11608 was studied using i.v. GZ-11608 self-administration and 
substitution using rats METH self-administered. However, GZ-11608 oral administration 
specifically exhibited pattern of increase on locomotor activity. Since s.c. GZ-11608 did 
not exhibit same pattern on saline control group locomotor activity, metabolite of oral GZ-
11608 may have psychostimulant effects. To evaluate the rewarding effect of oral GZ-
11608, CPP could have been employed.  
Binding site of GZ-11608 at VMAT2 was not studied. Although GZ-11608 inhibits DA 
uptake at VMAT2, and decreased neurochemical and behavioral METH effect, the binding 
site for GZ-11608 was not revealed. GZ-11608 exhibits different neurochemical and 
behavioral effects compared to previous lead compounds. However, the binding site of 
GZ-11608 at VMAT2 was not studied, which limits understanding of mechanism of action 
of GZ-11608.  
Effect of GZ-11608, a VMAT2 inhibitor, on cognition and memory function were not 
evaluated. GZ-11608 inhibits DA uptake at the VMAT2, which would may contribute to 
GZ-11608-induced decreases in responding for METH (i.e., cue- and METH-induced 
reinstatement of METH seeking behavior) (Lohr et al., 2017). This current study provided 
limited evidence, but GZ-11608 showed no significant effect on DA content at the dose 
decreasing responding for METH. This observation would predict that GZ-11608 would 
have no significant depleting effects on other monoaminergic neurons expressing VMAT2 
including NE and 5-HT. However, effects of GZ-11608 on cognition or memory function 
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have not been evaluated. Thus, further study on the effect of GZ-11608 on cognition and 
memory could be evaluated by employing the Morris water maze, radial arm maze, 
multiple choice serial reaction task, and the go/no-go test (Rodriguiz and Wetsel, 2006; 
Vorhees and Williams, 2014).     
6.7.2 Project 2: Discovery Pharmacotherapeutics for Cocaine and Opioid Use 
Disorders 
The [3H]NMS binding assay provides binding affinity of analogs at each subtype of 
mAChRs, but determination of analogs’ effect on function of mAChRs to determine if 
analogs act as antagonist or agonist was not available for each subtype. CHO cell calcium 
concentration based colorimetric assay would provide information if analogs are 
antagonists or agonists. Since antagonists but not agonists can be a therapeutic for 
substance use disorders, the functional property of the analogs is important. Thus, 
separate functional analyses were conducted.     
M5 mAChRs are highly expressed in the VTA, but slices of striatum were used to 
evaluate effect of analogs on functional assay. To understand the functional assay data, 
KO mice studies were used. KO mice studies revealed that M1 or M2 KO mice did not 
alter oxotremorine-induced DA release from the striatal slices, different effects were found 
in M3, M4, or M5 KO mice on oxotremorine-induced DA release (Zhang et al., 2002). Thus, 
observed DA release from rat striatal slices is mediated by M3, M4, and M5 mAChRs. 
Micro infusion of compound 3c into VTA may provide more informative data regarding 
function of compound 3c on M5 mAChRs specifically. Also, cell-based functional assays 
would be able to provide the characteristics of compound 3c for each subtype.  
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6.8 Future directions 
The current dissertation focused on discovering candidate pharmacotherapeutics 
to treat METH, cocaine, and opioids use disorders. Based on Project 1, a VMAT2 inhibitor, 
GZ-11608 exhibited high potential as a therapeutic for METH use disorder. However, 
behavioral studies revealed limited oral bioavailability of GZ-11608. Project 2 revealed 
informative SAR to discover analogs exhibiting high affinity for M5 mAChRs, but the 
analogs showed a lack of selectivity for M5 over M1-M4 mAChRs. As such, evaluation of 
M5 mAChRs antagonists to decrease cocaine and opioids effects was difficult.  
Both Project 1 and 2 are at the preclinical level (Fig. 20). Project 1 needs 
information on drug metabolism (DM) and pharmacokinetics (PK) to determine the 
Absorption, Distribution, Metabolism, and Excretion (ADME) of GZ-11608. Also, studies 
determining GZ-11608 safety and dose translation to clinical studies are needed (Chung 
et al., 2004). For drug metabolism, in vitro assays such as microsome stability, 
permeability, plasma stability, plasma protein binding, CYP450 inhibition need to be 
evaluated. In vivo pharmacokinetic (i.e., Cmax, distribution, clearance, half-life) analysis, 
bioavailability, linearity, metabolism, and routes of excretion need to be evaluated. Also, 
pharmacokinetics at high dose of GZ-11608 (as known as toxicokinetics) needs to be 
evaluated. For toxicokinetic assays, biological matrices need to be collected including 
blood, urine, fat, muscle, liver, kidneys, and brain (the target organ) (Andrade et al., 2016). 
Species-specific pharmacokinetics should be conducted using rodents and another 
species (i.e., dog, monkeys) having similar metabolism with humans. Safety 
pharmacology studies are needed to determine if GZ-1108 presents critical safety issues 
such as high affinity for hERG. After completing preclinical studies and prior to starting 
clinical studies, the FDA requires Investigational New Drug (IND) Application for the new 
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substance, in this case, GZ-11608. After submission of IND application, the FDA reviews 
it and provides permission to administer the new substance to human.  
After authorization from the FDA, clinical trials are initiated. Phase 1 aims to 
evaluate safety of the new substance (GZ-11608) in human healthy volunteers (Phase 1a) 
and in patients with the target disease (Phase 1b). Once safety is determined, then Phase 
2 is initiated with an aim of determining efficacy with short duration of study with the new 
substance in a small number of patients (Phase 2a). Whether the new substance exhibits 
efficacy, then efficacy of GZ-11608 would be determined with longer duration in a larger 
number of patients (Phase 2b). Whether the new substance exhibit efficacy compared to 
placebo control group in Phase 2b, then Phase 3 is initiated. The Phase 3 clinical trial 
evaluates efficacy of the new substance in a large number of patients. Overall risk-benefit 
ratio of the new substance is determined in Phase 3 (Andrade et al., 2016; Van Norman, 
2016). Then, New Drug Application (NDA) is submitted to FDA to be approved for 
marketing the new substance. After reviews of the NDA by the FDA, Phase 4 clinical trials 
may be conducted to evaluate efficacy of the new substance and new indications of the 
substance.   
On the other hand, the Project 2 would need to do further SAR studies to discover 
M5 mAChRs selective antagonist, and then determine effects of analogs in behavioral 
models. After that, the identified M5 selective analogs would follow the new 
pharmacotherapeutics approval process as described above and in Fig. 20.   
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Figure 6.1 New Pharmacotherapeutics Approval Process. IND: Investigational New Drug 
Application, NDA: New Drug Application. 
242 
References 
Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, and 
Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is 
associated with cardiac arrhythmia. Cell 97:175–187. 
Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, and Walker JM (1984) 
Endogenous opioids: biology and function. Annu Rev Neurosci 7:223–255. 
Alexander PK, Lie Y, Jones G, Sivaratnam C, Bozinvski S, Mulligan RS, Young K, 
Villemagne VL, and Rowe CC (2017) Management Impact of Imaging Brain 
Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian 
Syndrome with (18)F-AV133 and PET. J Nucl Med 58:1815–1820. 
Alho H, Sinclair D, Vuori E, and Holopainen A (2007) Abuse liability of buprenorphine-
naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75–78. 
Allouche S, Noble F, and Marie N (2014) Opioid receptor desensitization: mechanisms 
and its link to tolerance. Front Pharmacol 5:280. 
Alvers KM, Beckmann JS, Zheng G, Crooks PA, Dwoskin LP, and Bardo MT (2012) The 
effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-
seeking in rats. Psychopharmacology 224:255–62. 
Amass L, Bickel WK, Higgins ST, and Badger GJ (1994) Alternate-day dosing during 
buprenorphine treatment of opioid dependence. Life Sci 54:1215–1228. 
American Psychiatric Association (1994) Diagnostic and statistical manual of mental 
disorders, 4th ed., American Psychiatric Publishing, Inc., Arlington,  VA,  US. 
American Psychiatric Association (2013) Diagnostic and statistical manual of mental 
disorders : DSM-5 (5th ed.), Arlington, VA: American Psychiatric Publishing. 
American Psychiatric Association (1968) Diagnostic and statistical manual of mental 
disorders : DSM-II (2nd ed.), Arlington, VA: American Psychiatric Publishing, pp. 
42- 45.
American Psychiatric Association (1980) Diagnostic and statistical manual of mental 
disorders : DSM-III (3rd ed.), Arlington, VA: American Psychiatric Publishing, pp. 
163-165.
Anderson AL, Reid MS, Li S-H, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, 
Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, 
Urschel HC 3rd, and Elkashef AM (2009) Modafinil for the treatment of cocaine 
dependence. Drug and alcohol dependence 104:133–139. 
Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, 
Marcon R, and Calixto JB (2016) Non-clinical studies in the process of new drug 
development - Part II: Good laboratory practice, metabolism, pharmacokinetics, 
safety and dose translation to clinical studies. Brazilian journal of medical and 
243 
 
biological research (Revista brasileira de pesquisas medicas e biologicas) 
49:e5646–e5646. 
Anglin MD, Burke C, Perrochet B, Stamper E, and Dawud-Noursi S (2000) History of the 
methamphetamine problem. J Psychoactive Drugs 32:137–141. 
Anne C, and Gasnier B (2014) Vesicular Neurotransmitter Transporters-Chapter 
Three:Mechanistic Aspects, Elsevier Science & Technology. 
Anthony JC, Warner LA, and Kessler RC (1994) Comparative Epidemiology of 
Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants: Basic 
Findings From the National Comorbidity Survey. Experimental and Clinical 
Psychopharmacology 2:244–268. 
Arena JE, and Stoessl AJ (2016) Optimizing diagnosis in Parkinson’s disease: 
Radionuclide imaging. Parkinsonism Relat Disord 22 Suppl 1:S47-51. 
Babic T, and Browning KN (2014) The role of vagal neurocircuits in the regulation of 
nausea and vomiting. European journal of pharmacology 722:38–47. 
Bailey PL, Streisand JB, East KA, East TD, Isern S, Hansen TW, Posthuma EF, 
Rozendaal FW, Pace NL, and Stanley TH (1990) Differences in magnitude and 
duration of opioid-induced respiratory depression and analgesia with fentanyl and 
sufentanil. Anesth Analg 70:8–15. 
Ballester J, Valentine G, and Sofuoglu M (2017) Pharmacological treatments for 
methamphetamine addiction: current status and future directions. Expert Rev 
Clin Pharmacol 10:305–314. 
Balster R, Kilbey M, and Ellinwood E (1976) Methamphetamine self-administration in the 
cat. Psychopharmacologia 46:229–233. 
Balster RL, and Schuster CR (1973) A comparison of d-amphetamine, l-amphetamine, 
and methamphetamine self-administration in rhesus monkeys. Pharmacology, 
biochemistry, and behavior 1:67–71. 
Bardo MT (1998) Neuropharmacological mechanisms of drug reward: beyond dopamine 
in the nucleus accumbens. Crit Rev Neurobiol 12:37–67. 
Bardo MT, and Bevins RA (2000) Conditioned place preference: what does it add to our 
preclinical understanding of drug reward? Psychopharmacology (Berl) 153:31–
43. 
Barnes PJ (1989) Muscarinic receptor subtypes: implications for lung disease. Thorax 
44:161. 
Barocelli E, Ballabeni V, Bertoni S, Dallanoce C, De Amici M, De Micheli C, and 
Impicciatore M (2000) New analogues of oxotremorine and oxotremorine-M: 
Estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes. 
Life Sciences 67:717–723. 
244 
 
Basbaum AI, and Fields HL (1978) Endogenous pain control mechanisms: review and 
hypothesis. Ann Neurol 4:451–462. 
Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M, and 
Wess J (2002) Deletion of the M5 muscarinic acetylcholine receptor attenuates 
morphine reinforcement and withdrawal but not morphine analgesia. Proceedings 
of the National Academy of Sciences of the United States of America 99:11452–
7. 
Bassareo V, and Di Chiara G (1999) Differential responsiveness of dopamine 
transmission to food-stimuli in nucleus accumbens shell/core compartments. 
Neuroscience 89:637–641. 
Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, and Bardo MT (2012) 
The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in 
rats. Psychopharmacology 220:395–403. 
Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, 
Dwoskin LP, and Bardo MT (2010) The novel pyrrolidine nor-lobelane analog 
UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 
function, methamphetamine-evoked dopamine release, and methamphetamine 
self-administration in rats. The Journal of pharmacology and experimental 
therapeutics 335:841–51. 
Bedford JA, Borne RF, and Wilson MC (1980) Comparative behavioral profile of cocaine 
and norcocaine in rats and monkeys. Pharmacol Biochem Behav 13:69–75. 
Belin D, Jonkman S, Dickinson A, Robbins TW, and Everitt BJ (2009) Parallel and 
interactive learning processes within the basal ganglia: relevance for the 
understanding of addiction. Behav Brain Res 199:89–102. 
Bello EP, Mateo Y, Gelman DM, Noaín D, Shin JH, Low MJ, Alvarez VA, Lovinger DM, 
and Rubinstein M (2011) Cocaine supersensitivity and enhanced motivation for 
reward in mice lacking dopamine D(2) autoreceptors. Nat Neurosci 14:1033–
1038. 
Benarroch EE (2012) Endogenous opioid systems: current concepts and clinical 
correlations. Neurology 79:807–814. 
Berman SM, Kuczenski R, McCracken JT, and London ED (2009) Potential adverse 
effects of amphetamine treatment on brain and behavior: a review. Molecular 
psychiatry 14:123–142. 
Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, and Johnson RE (1988) 
Buprenorphine: dose-related blockade of opioid challenge effects in opioid 
dependent humans. J Pharmacol Exp Ther 247:47–53. 
Black KJ, Koller JM, Campbell MC, Gusnard DA, and Bandak SI (2010) Quantification of 
indirect pathway inhibition by the adenosine A2a antagonist SYN115 in 
Parkinson disease. J Neurosci 30:16284–16292. 
245 
 
Blanco-Gandia MC, Mateos-Garcia A, Garcia-Pardo MP, Montagud-Romero S, 
Rodriguez-Arias M, Minarro J, and Aguilar MA (2015) Effect of drugs of abuse on 
social behaviour: a review of animal models. Behav Pharmacol 26:541–570. 
Bodnar RJ (2011) Endogenous opiates and behavior: 2010. Peptides 32:2522–2552. 
Boileau I, Assaad J-M, Pihl RO, Benkelfat C, Leyton M, Diksic M, Tremblay RE, and 
Dagher A (2003) Alcohol promotes dopamine release in the human nucleus 
accumbens. Synapse 49:226–231. 
Bonner TI, Young AC, Brann MR, and Buckley NJ (1988) Cloning and expression of the 
human and rat m5 muscarinic acetylcholine receptor  genes. Neuron 1:403–410. 
Borg PJ, and Taylor DA (1997) Involvement of mu- and delta-opioid receptors in the 
effects of systemic and locally perfused morphine on extracellular levels of 
dopamine, DOPAC and HVA in the nucleus accumbens of the halothane-
anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 355:582–588. 
Bot G, Blake AD, Li S, and Reisine T (1998) Fentanyl and its analogs desensitize the 
cloned mu opioid receptor. J Pharmacol Exp Ther 285:1207–1218. 
Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker WJ, and Holson 
RR (1994) Further studies of the role of hyperthermia in methamphetamine 
neurotoxicity. J Pharmacol Exp Ther 268:1571–1580. 
Bowyer JF, Tank AW, Newport GD, Slikker WJ, Ali SF, and Holson RR (1992) The 
influence of environmental temperature on the transient effects of 
methamphetamine on dopamine levels and dopamine release in rat striatum. J 
Pharmacol Exp Ther 260:817–824. 
Boyce SH, Armstrong PAR, and Stevenson J (2003) Effect of innappropriate naltrexone 
use in a heroin misuser. Emerg Med J 20:381. 
Bradberry CW, Barrett-Larimore RL, Jatlow P, and Rubino SR (2000) Impact of self-
administered cocaine and cocaine cues on extracellular dopamine in mesolimbic 
and sensorimotor striatum in rhesus monkeys. J Neurosci 20:3874–3883. 
Brecht M-L, and Herbeck D (2014) Time to relapse following treatment for 
methamphetamine use: a long-term perspective on patterns and predictors. Drug 
Alcohol Depend 139:18–25. 
Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, 
Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, and Hyman SE 
(1997) Acute effects of cocaine on human brain activity and emotion. Neuron 
19:591–611. 
Britt JP, and McGehee DS (2008) Presynaptic opioid and nicotinic receptor modulation 
of dopamine overflow in the  nucleus accumbens. J Neurosci 28:1672–1681. 
246 
 
Brookhart GL, Edgecomb RS, and Murdock LL (1987) Amphetamine and reserpine 
deplete brain biogenic amines and alter blow fly feeding behavior. J Neurochem 
48:1307–1315. 
Brownell KD, Farley T, Willett WC, Popkin BM, Chaloupka FJ, Thompson JW, and 
Ludwig DS (2009) The public health and economic benefits of taxing sugar-
sweetened beverages. N Engl J Med 361:1599–1605. 
Bryant B, Knights K, and Knights K (2010) Pharmacology for Health Professionals 3rd 
Edition, Mosby Australia. 
Buels KS, and Fryer AD (2012) Muscarinic receptor antagonists: Effects on pulmonary 
function. Handbook of Experimental Pharmacology 208:317–341. 
Cahill K, Stead LF, and Lancaster T (2007) Nicotine receptor partial agonists for 
smoking cessation. Cochrane Database Syst Rev CD006103. 
Caine SB, and Koob GF (1994) Effects of dopamine D-1 and D-2 antagonists on cocaine 
self-administration under  different schedules of reinforcement in the rat. J 
Pharmacol Exp Ther 270:209–218. 
Calatayud J, and Gonzalez A (2003) History of the development and evolution of local 
anesthesia since the coca leaf. Anesthesiology 98:1503–1508. 
Calu DJ, Stalnaker TA, Franz TM, Singh T, Shaham Y, and Schoenbaum G (2007) 
Withdrawal from cocaine self-administration produces long-lasting deficits in 
orbitofrontal-dependent reversal learning in rats. Learn Mem 14:325–328. 
Carfora A, Cassandro P, Feola A, La Sala F, Petrella R, and Borriello R (2018) Ethical 
Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug 
of Abuse Dependence. J Bioeth Inq 15:45–55. 
Carpenter KJ, Chapman V, and Dickenson AH (2000) Neuronal inhibitory effects of 
methadone are predominantly opioid receptor mediated in the rat spinal cord in 
vivo. Eur J Pain 4:19–26. 
Carroll ME, Lac ST, Asencio M, and Kragh R (1990) Fluoxetine reduces intravenous 
cocaine self-administration in rats. Pharmacol Biochem Behav 35:237–244. 
Cartoni E, Puglisi-Allegra S, and Baldassarre G (2013) The three principles of action: a 
Pavlovian-instrumental transfer hypothesis. Frontiers in behavioral neuroscience 
7:153–153. 
Castagné V, Hernier AM, and Porsolt RD (2014) CNS Safety Pharmacology☆, in 
Reference Module in Biomedical Sciences p, Elsevier. 
CBHSQ, Center for Behavioral Health Statistics and Quality (2018) 2017 National 
Survey on Drug Use and Health: Detailed Tables., Substance Abuse and Mental 
Health Services Administration, Rockville, MD. 
247 
 
CDC, Center for Disease Control and Prevention (2017a) Annual Surveillance Report of 
Drug-Related Risks and Outcomes - United States, 2017. Accessed July 2018 
from https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-
report.pdf, Centers for Disease Control and Prevention, U.S. Department of 
Health and Human Services, United States. 
CDC, Center for Disease Control and Prevention (2017b) Drug Overdose Deaths in the 
United States, 1999-2016, 
https://www.cdc.gov/nchs/products/databriefs/db294.htm. 
CDC, Centers for Disease Control and Prevention (2018a) 2018 Annual Surveillance 
Report of Drug-Related Risks and Outcomes — United States. Surveillance 
Special Report. Centers for Disease Control and Prevention, Centers for Disease 
Control and Prevention, U.S. Department of Health and Human Services, United 
Sate. 
CDC, Centers for Disease Control and Prevention (2016) Increases in Drug and Opioid-
Involved Overdose Deaths-United Sates, 2010-2015, 
https://www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm?s_cid=mm655051e
1_x. 
CDC, Centers for Disease Control and Prevention (2015) Increases in Fentanyl Drug 
Confiscations and Fentanyl-related Overdose Fatalities, 
https://emergency.cdc.gov/han/han00384.asp. 
CDC, Centers for Disease Control and Prevention (2018b) Vital Signs: Trends in 
Emergency Department Visits for Suspected Opioid Overdoses-United States, 
July 2016-September 2017, 
https://www.cdc.gov/mmwr/volumes/67/wr/mm6709e1.htm?s_cid=mm6709e1_w
#modalIdString_CDCTable_0. 
Center for Substance Abuse Treatment (2004) Clinical Guidelines for the Use of 
Buprenorphine in the Treatment of Opioid Addiction, Substance Abuse and 
Mental Health Services Administration (US), Rockville (MD). 
Centers for Disease Control and Prevention (2017) Drug Overdose Deaths Data, 
https://www.cdc.gov/drugoverdose/data/statedeaths.html. 
Chambers CD, Inciardi JA, and Stephens RC (1971) A critical review of pentazocine 
abuse. HSMHA health reports 86:627–636. 
Chang L, Alicata D, Ernst T, and Volkow N (2007) Structural and metabolic brain 
changes in the striatum associated with methamphetamine abuse. Addiction 
(Abingdon, England) 102 Suppl 1:16–32. 
Charlton A (2004) Medicinal uses of tobacco in history. J R Soc Med 97:292–296. 
Chartoff EH, and Connery HS (2014) It’s MORe exciting than mu: crosstalk between mu 
opioid receptors and glutamatergic transmission in the mesolimbic dopamine 
system. Front Pharmacol 5:116. 
248 
 
Chatham MS, Dodds Ashley ES, Svengsouk JS, and Juba KM (2013) Dose ratios 
between high dose oral morphine or equivalents and oral methadone. J Palliat 
Med 16:947–950. 
Chaudhry FA, Edwards RH, and Fonnum F (2008) Vesicular neurotransmitter 
transporters as targets for endogenous and exogenous toxic substances. Annu 
Rev Pharmacol Toxicol 48:277–301. 
Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, Ferguson D, Tsai H-
C, Pomeranz L, Christoffel DJ, Nectow AR, Ekstrand M, Domingos A, Mazei-
Robison MS, Mouzon E, Lobo MK, Neve RL, Friedman JM, Russo SJ, 
Deisseroth K, Nestler EJ, and Han M-H (2013) Rapid regulation of depression-
related behaviours by control of midbrain dopamine neurons. Nature 493:532–
536. 
Chem KK (1948) Pharmacology of methadone and related compounds. Ann N Y Acad 
Sci 51:83–97. 
Chen BT, Yau H-J, Hatch C, Kusumoto-Yoshida I, Cho SL, Hopf FW, and Bonci A 
(2013) Rescuing cocaine-induced prefrontal cortex hypoactivity prevents 
compulsive cocaine seeking. Nature 496:359–362. 
Chen JC, Smith ER, Cahill M, Cohen R, and Fishman JB (1993) The opioid receptor 
binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci 
52:389–396. 
Chen X, Deng J, Cui W, Hou S, Zhang J, Zheng X, Ding X, Wei H, Zhou Z, Kim K, Zhan 
C-G, and Zheng F (2018) Development of Fc-Fused Cocaine Hydrolase for 
Cocaine Addiction Treatment: Catalytic and Pharmacokinetic Properties. AAPS J 
20:53. 
Chen Y-H, Wu K-L, Tsai H-M, and Chen C-H (2013) Treatment of methamphetamine 
abuse: an antibody-based immunotherapy approach. J Food Drug Anal 21:S82–
S86. 
Cheng Y, and Prusoff WH (1973) Relationship between the inhibition constant (K1) and 
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an 
enzymatic reaction. Biochem Pharmacol 22:3099–3108. 
Chevrette J, Stellar JR, Hesse GW, and Markou A (2002) Both the shell of the nucleus 
accumbens and the central nucleus of the amygdala support amphetamine self-
administration in rats. Pharmacol Biochem Behav 71:501–507. 
Chin SJ, Durmowicz AG, and Chowdhury BA (2016) Tiotropium respimat is effective for 
the treatment of asthma at a dose lower than that for chronic obstructive 
pulmonary disease. Annals of the American Thoracic Society 13:173–179. 
Chiodo KA, Läck CM, and Roberts DC (2008) Cocaine self-administration reinforced on 
a progressive ratio schedule decreases with continuous D-amphetamine 
treatment in rats. Psychopharmacology 200:465–473. 
249 
 
Cho AK, Melega WP, Kuczenski R, and Segal DS (2001) Relevance of pharmacokinetic 
parameters in animal models of methamphetamine abuse. Synapse 39:161–166. 
Chung TDY, Terry DB, and Smith LH (2004) In Vitro and In Vivo Assessment of ADME 
and PK Properties During Lead Selection and Lead Optimization - Guidelines, 
Benchmarks and Rules of Thumb, in Assay Guidance Manual (Sittampalam GS, 
Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, 
Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, 
Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-
Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJOJ, Weidner JR, Wildey 
MJ, Xia M, and Xu X eds) p, Eli Lilly & Company and the National Center for 
Advancing Translational Sciences, Bethesda (MD). 
Clague J, Belin TR, and Shetty V (2017) Mechanisms underlying methamphetamine-
related dental disease. Journal of the American Dental Association (1939) 
148:377–386. 
Comer SD, and Collins ED (2002) Self-administration of intravenous buprenorphine and 
the buprenorphine/naloxone combination by recently detoxified heroin abusers. J 
Pharmacol Exp Ther 303:695–703. 
Comer SD, Sullivan MA, Vosburg SK, Kowalczyk WJ, and Houser J (2010) Abuse 
liability of oxycodone as a function of pain and drug use history. Drug Alcohol 
Depend 109:130–138. 
Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, and Perez-
Reyes M (1993) Pharmacokinetics of methamphetamine self-administered to 
human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab 
Dispos 21:717–723. 
Copeland AL, and Sorensen JL (2001) Differences between methamphetamine users 
and cocaine users in treatment. Drug Alcohol Depend 62:91–95. 
Courtney KE, and Ray LA (2016) Clinical neuroscience of amphetamine-type stimulants: 
From basic science to treatment development. Prog Brain Res 223:295–310. 
Crane EH (2013) Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings 
on Drug-Related Emergency Department Visits, in The CBHSQ Report pp 1–9, 
Substance Abuse and Mental Health Services Administration (US), Rockville 
(MD). 
Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao 
F, Zou J, Barrett RW, and Gallop MA (2004) XP13512 [(+/-)-1-([(alpha-
isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a 
novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, 
and colonic absorption compared with  gabapentin in rats and monkeys. J 
Pharmacol Exp Ther 311:324–333. 
Cunningham CL, Dickinson SD, Grahame NJ, Okorn DM, and McMullin CS (1999) 
Genetic differences in cocaine-induced conditioned place preference in mice 
depend on conditioning trial duration. Psychopharmacology (Berl) 146:73–80. 
250 
 
Cunningham CL, Ferree NK, and Howard MA (2003) Apparatus bias and place 
conditioning with ethanol in mice. Psychopharmacology (Berl) 170:409–422. 
Cunningham JK, and Liu L-M (2008) Impact of methamphetamine precursor chemical 
legislation, a suppression policy, on the demand for drug treatment. Soc Sci Med 
66:1463–1473. 
Dalley JW, Fryer TD, Brichard L, Robinson ESJ, Theobald DEH, Laane K, Pena Y, 
Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, 
Baron J-C, Everitt BJ, and Robbins TW (2007) Nucleus accumbens D2/3 
receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267–
1270. 
Darvas M, Wunsch AM, Gibbs JT, and Palmiter RD (2014) Dopamine dependency for 
acquisition and performance of Pavlovian conditioned response. Proc Natl Acad 
Sci U S A 111:2764–2769. 
Davis MP, and Walsh D (2001) Methadone for relief of cancer pain: a review of 
pharmacokinetics, pharmacodynamics, drug interactions and protocols of 
administration. Support Care Cancer 9:73–83. 
Day JJ, Roitman MF, Wightman RM, and Carelli RM (2007) Associative learning 
mediates dynamic shifts in dopamine signaling in the nucleus accumbens. Nat 
Neurosci 10:1020–1028. 
De Felice LJ (2016) Chloride requirement for monoamine transporters. Pflugers Archiv : 
European journal of physiology 468:503–511. 
de Ridder M (1994) Heroin: new facts about an old myth. J Psychoactive Drugs 26:65–
68. 
DEA, Drug Enforcement Administration (2017a) 2017 National Drug Threat Assessment 
DEA-DCT-DIR-040-17. 
DEA, Drug Enforcement Administration (2018a) 2018 National Drug Threat Assessment 
DEA-DCT-DIR-032-18. 
DEA, Drug Enforcement Administration (2018b) Controlled Substance Schedules. 
https://www.deadiversion.usdoj.gov/schedules/index.html. Accessed March 1, 
2018. 
DEA, Drug Enforcement Administration (2018c) Controlled Substances Act. 
https://www.dea.gov/druginfo/csa.shtml. Accessed March 1, 2018. 
DEA, Drug Enforcement Administration (2017b) Drug Scheduling, 
https://www.dea.gov/druginfo/ds.shtml. Accessed December 2017. 
DEA, Drug Enforcement Administration (2018d) Title 21 United States Code (USC) 
Controlled Substances Act. 
https://www.deadiversion.usdoj.gov/21cfr/21usc/811.htm. Accessed March 1, 
2018. 
251 
 
DEA, United States Drug Enforcement Administration (2017) Drugs of Abuse. A DEA 
Resource Guide. 2017 Edition. https://www.dea.gov/pr/multimedia-
library/publications/drug_of_abuse.pdf. 
Der-Avakian A, and Markou A (2012) The neurobiology of anhedonia and other reward-
related deficits. Trends Neurosci 35:68–77. 
Derlet RW, and Heischober B (1990) Methamphetamine. Stimulant of the 1990s? 
Western Journal of Medicine 153:625. 
DeWitt SH, and Maryanoff BE (2018) Deuterated Drug Molecules: Focus on FDA-
Approved DeutetrabenazinePublished as part of the Biochemistry series 
“Biochemistry to Bedside”. Biochemistry 57:472–473. 
Di Chiara G (2002) Nucleus accumbens shell and core dopamine: differential role in 
behavior and addiction. Behav Brain Res 137:75–114. 
Di Chiara G (1991) On the preferential release of mesolimbic dopamine by 
amphetamine. Neuropsychopharmacology 5:243–247. 
Di Chiara G, and Bassareo V (2007) Reward system and addiction: what dopamine does 
and doesn’t do. Curr Opin Pharmacol 7:69–76. 
Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni 
E, Valentini V, and Lecca D (2004) Dopamine and drug addiction: the nucleus 
accumbens shell connection. Neuropharmacology 47 Suppl 1:227–241. 
Di Chiara G, and Imperato A (1988a) Drugs abused by humans preferentially increase 
synaptic dopamine concentrations in the mesolimbic system of freely moving 
rats. Proceedings of the National Academy of Sciences of the United States of 
America 85:5274–8. 
Di Chiara G, and Imperato A (1988b) Opposite effects of mu and kappa opiate agonists 
on dopamine release in the nucleus accumbens and in the dorsal caudate of 
freely moving rats. J Pharmacol Exp Ther 244:1067–1080. 
Digby GJ, Shirey JK, and Conn PJ (2010) Allosteric activators of muscarinic receptors 
as novel approaches for treatment of CNS disorders. Molecular bioSystems 
6:1345–1354. 
Dobbs LK, and Mark GP (2008) Comparison of systemic and local methamphetamine 
treatment on acetylcholine and dopamine levels in the ventral tegmental area in 
the mouse. Neuroscience 156:700–11. 
Doggrell SA, and Hancox JC (2014) Cardiac safety concerns for domperidone, an 
antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf 
13:131–138. 
Dorsey ER, Brocht AFD, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, 
Biglan KM, and Shoulson I (2013) Depressed mood and suicidality in individuals 
252 
 
exposed to tetrabenazine in a large Huntington disease observational study. J 
Huntingtons Dis 2:509–515. 
Dourmap N, Clero E, and Costentin J (1997) Involvement of cholinergic neurons in the 
release of dopamine elicited by stimulation of mu-opioid receptors in striatum. 
Brain Res 749:295–300. 
Dowell D, Noonan RK, and Houry D (2017) Underlying Factors in Drug Overdose 
Deaths. JAMA 318:2295–2296. 
Dowell D, Zhang K, Noonan RK, and Hockenberry JM (2016) Mandatory Provider 
Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And 
Overdose Death Rates. Health Aff (Millwood) 35:1876–1883. 
Dowling M, and Charlton S (2006) Quantifying the association and dissociation rates of 
unlabelled antagonists at the muscarinic M3 receptor. British Journal of 
Pharmacology 148:927–37. 
Downes JJ, Kemp RA, and Lambertsen CJ (1967) The magnitude and duration of 
respiratory depression due to fentanyl and meperidine in man. J Pharmacol Exp 
Ther 158:416–420. 
Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, and 
Mathis CA (2001) Amphetamine-induced dopamine release in human ventral 
striatum correlates with euphoria. Biol Psychiatry 49:81–96. 
Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, and Raichle ME (1992) 
A functional anatomical study of unipolar depression. J Neurosci 12:3628–3641. 
Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, and Tassin J-P 
(2002) Alpha1b-adrenergic receptors control locomotor and rewarding effects of 
psychostimulants and opiates. J Neurosci 22:2873–2884. 
Drug Enforcement Administration (2018) Temporary Scheduling Order: Temporary 
Placement of Fentanyl-Related Substances in Schedule I, 
https://www.deadiversion.usdoj.gov/fed_regs/rules/2018/fr0206_4.htm. 
Dudchenko P, and Sarter M (1991) GABAergic control of basal forebrain cholinergic 
neurons and memory. Behav Brain Res 42:33–41. 
Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, and Lasseter KC (2006) 
Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. 
Alcohol Clin Exp Res 30:480–490. 
Dwoskin LP, and Crooks PA (2002) A novel mechanism of action and potential use for 
lobeline as a treatment for psychostimulant abuse. Biochemical pharmacology 
63:89–98. 
Dwoskin LP, Hankosky ER, Paul GEA, and Bardo MT (2017) Methamphetamine, in 
Addiction Science: Science and Practice p, Ed B.A. Johnson, Springer Science. 
253 
 
Eap CB, Buclin T, and Baumann P (2002) Interindividual variability of the clinical 
pharmacokinetics of methadone: implications for the treatment of opioid 
dependence. Clin Pharmacokinet 41:1153–1193. 
Eglen RM (2006) Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic 
function. Autonomic and Autacoid Pharmacology 26:219–233. 
Eiden LE, Schafer MK, Weihe E, and Schutz B (2004) The vesicular amine transporter 
family (SLC18): amine/proton antiporters required for vesicular accumulation and 
regulated exocytotic secretion of monoamines and acetylcholine. Pflugers 
Archiv : European journal of physiology 447:636–40. 
Eiden LE, and Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic 
neuronal function interacting with drugs of abuse. Annals of the New York 
Academy of Sciences 1216:86–98. 
Ellis MS, Kasper ZA, and Cicero TJ (2018) Twin epidemics: The surging rise of 
methamphetamine use in chronic opioid users. Drug Alcohol Depend 193:14–20. 
Erickson JD, and Eiden LE (1993) Functional identification and molecular cloning of a 
human brain vesicle monoamine transporter. J Neurochem 61:2314–2317. 
Erickson JD, Eiden LE, and Hoffman BJ (1992) Expression cloning of a reserpine-
sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A 89:10993–
10997. 
Erickson JD, Schafer MK, Bonner TI, Eiden LE, and Weihe E (1996) Distinct 
pharmacological properties and distribution in neurons and endocrine cells of two 
isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S 
A 93:5166–5171. 
Ersche KD, Roiser JP, Robbins TW, and Sahakian BJ (2008) Chronic cocaine but not 
chronic amphetamine use is associated with perseverative  responding in 
humans. Psychopharmacology (Berl) 197:421–431. 
Eshleman AJ, Henningsen RA, Neve KA, and Janowsky A (1994) Release of dopamine 
via the human transporter. Mol Pharmacol 45:312–316. 
Ettenberg A, Pettit H, Bloom F, and Koob G (1982) Heroin and cocaine intravenous self-
administration in rats: Mediation by separate neural systems. 
Psychopharmacology 78:204–209. 
European Food Safety Authority P on C in the FC (2011) Scientific Opinion on the risks 
for public health related to the presence of opium alkaloids in poppy seeds. 
EFSA Journal 9. 
Evans SM, Foltin RW, Hicks MJ, Rosenberg JB, De BP, Janda KD, Kaminsky SM, and 
Crystal RG (2016) Efficacy of an adenovirus-based anti-cocaine vaccine to 
reduce cocaine self-administration and reacqusition using a choice procedure in 
rhesus macaques. Pharmacol Biochem Behav 150–151:76–86. 
254 
 
Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, and Robbins TW (2008) 
Review. Neural mechanisms underlying the vulnerability to develop compulsive 
drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 
363:3125–3135. 
Everitt BJ, and Robbins TW (2013) From the ventral to the dorsal striatum: devolving 
views of their roles in drug addiction. Neurosci Biobehav Rev 37:1946–1954. 
Everitt BJ, and Robbins TW (2005) Neural systems of reinforcement for drug addiction: 
from actions to habits to compulsion. Nat Neurosci 8:1481–1489. 
Eyerman DJ, and Yamamoto BK (2005) Lobeline attenuates methamphetamine-induced 
changes in vesicular monoamine transporter 2 immunoreactivity and monoamine 
depletions in the striatum. J Pharmacol Exp Ther 312:160–169. 
Farzinpour Z, Taslimi Z, Azizbeigi R, Karimi-Haghighi S, and Haghparast A (2019) 
Involvement of orexinergic receptors in the nucleus accumbens, in the effect of 
forced swim stress on the reinstatement of morphine seeking behaviors. 
Behavioural Brain Research 356:279–287. 
Feng Y, He X, Yang Y, Chao D, Lazarus LH, and Xia Y (2012) Current Research on 
Opioid Receptor Function. Curr Drug Targets 13:230–246. 
Finch JS, and DeKornfeld TJ (1967) Clinical investigation of the analgesic potency and 
respiratory depressant activity of fentanyl, a new narcotic analgesic. J Clin 
Pharmacol J New Drugs 7:46–51. 
Fink-Jensen A, Fedorova I, Wortwein G, Woldbye DP, Rasmussen T, Thomsen M, 
Bolwig TG, Knitowski KM, McKinzie DL, Yamada M, Wess J, and Basile A (2003) 
Role for M5 muscarinic acetylcholine receptors in cocaine addiction. Journal of 
neuroscience research 74:91–6. 
Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, 
Marcovitch I, and Brandeis R (2003) M1 muscarinic agonists can modulate some 
of the hallmarks in Alzheimer’s disease: implications in future therapy. Journal of 
molecular neuroscience : MN 20:349–356. 
Flagel SB, Clark JJ, Robinson TE, Mayo L, Czuj A, Willuhn I, Akers CA, Clinton SM, 
Phillips PEM, and Akil H (2011) A selective role for dopamine in stimulus-reward 
learning. Nature 469:53–57. 
Flagel SB, Robinson TE, Clark JJ, Clinton SM, Watson SJ, Seeman P, Phillips PEM, 
and Akil H (2010) An animal model of genetic vulnerability to behavioral 
disinhibition and responsiveness to reward-related cues: implications for 
addiction. Neuropsychopharmacology 35:388–400. 
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, and Hanson GR (2007) New insights into 
the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 
47:681–698. 
255 
 
Food and Drug Administration (1992) FDA’s policy statement for the development of 
new stereoisomeric drugs. Chirality 4:338–340. 
Food and Drug Administration (2015) U.S. Food and Drug Administration. Drugs@FDA. 
Approval History and Summary Review for Spiriva Respimat NDA 207070 
https://www.accessdata.fda.gov/scripts/ 
cder/daf/index.cfm?event=overview.process&applno=021395. 
Food and Drug Administration Public Health Service Department of Health and Human 
Services (2007) Death, Narcotic Overdose, and Serious Cardiac Arrhythmias: 
Information for Healthcare Professionals on Methadone. Journal of Pain & 
Palliative Care Pharmacotherapy 21:69–71. 
Forster GL, and Blaha CD (2000) Laterodorsal tegmental stimulation elicits dopamine 
efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate 
receptors in the ventral tegmental area. The European journal of neuroscience 
12:3596–604. 
Forster GL, Yeomans JS, Takeuchi J, and Blaha CD (2002) M5 muscarinic receptors are 
required for prolonged accumbal dopamine release after electrical stimulation of 
the pons in mice. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 22:Rc190. 
Foster SL, and Weinshenker D (2019) Chapter 15 - The Role of Norepinephrine in Drug 
Addiction: Past, Present, and Future, in Neural Mechanisms of Addiction 
(Torregrossa M ed) pp 221–236, Academic Press. 
Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang G-J, Wong C, Ma Y, Kriplani 
A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, 
Shea C, Xu Y, Muench L, and Apelskog K (2008) Fast uptake and long-lasting 
binding of methamphetamine in the human brain: comparison with cocaine. 
Neuroimage 43:756–763. 
Fox H, and Sinha R (2014) Chapter Six - The Role of Guanfacine as a Therapeutic 
Agent to Address Stress-Related Pathophysiology in Cocaine-Dependent 
Individuals, in Emerging Targets & Therapeutics in the Treatment of 
Psychostimulant Abuse (Dwoskin LP ed) pp 217–265, Academic Press. 
Frauger E, Pauly V, Pradel V, Rouby F, Arditti J, Thirion X, Lapeyre Mestre M, and 
Micallef J (2011) Evidence of clonazepam abuse liability: results of the tools 
developed by the French Centers for Evaluation and Information on 
Pharmacodependence (CEIP) network. Fundam Clin Pharmacol 25:633–641. 
Froehlich JC (1997) Opioid peptides. Alcohol Health Res World 21:132–136. 
Fukumura M, Cappon GD, Pu C, Broening HW, and Vorhees CV (1998) A single dose 
model of methamphetamine-induced neurotoxicity in rats: effects on  neostriatal 
monoamines and glial fibrillary acidic protein. Brain Res 806:1–7. 
Gabay M (2013) The federal controlled substances act: schedules and pharmacy 
registration. Hosp Pharm 48:473–474. 
256 
 
Garcia Pardo MP, Roger Sanchez C, De la Rubia Orti JE, and Aguilar Calpe MA (2017) 
Animal models of drug addiction. Adicciones 29:278–292. 
Garcia-Romeu A, Kersgaard B, and Addy PH (2016) Clinical applications of 
hallucinogens: A review. Exp Clin Psychopharmacol 24:229–268. 
Gasnier B, Krejci E, Botton D, Massoulie J, and Henry JP (1994) Expression of a bovine 
vesicular monoamine transporter in COS cells. FEBS Lett 342:225–229. 
Gawin FH, and Kleber HD (1986) Abstinence symptomatology and psychiatric diagnosis 
in cocaine abusers. Clinical  observations. Arch Gen Psychiatry 43:107–113. 
Gearhardt AN, Davis C, Kuschner R, and Brownell KD (2011) The addiction potential of 
hyperpalatable foods. Curr Drug Abuse Rev 4:140–145. 
Gentry WB, Rüedi-Bettschen D, and Owens SM (2009) Development of active and 
passive human vaccines to treat methamphetamine addiction. Human vaccines 
5:206–213. 
German CL, Baladi MG, McFadden LM, Hanson GR, and Fleckenstein AE (2015) 
Regulation of the Dopamine and Vesicular Monoamine Transporters: 
Pharmacological  Targets and Implications for Disease. Pharmacol Rev 
67:1005–1024. 
Geyer MA (1995) Serotonergic functions in arousal and motor activity. Behavioural Brain 
Research 73:31–35. 
Giovanni A, Liang LP, Hastings TG, and Zigmond MJ (1995) Estimating hydroxyl radical 
content in rat brain using systemic and intraventricular salicylate: impact of 
methamphetamine. J Neurochem 64:1819–1825. 
Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, and Rawson R 
(2009) Depression among methamphetamine users: association with outcomes 
from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment 
Dis 197:225–231. 
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, and Rawson 
RA (2010) Psychopathology in methamphetamine-dependent adults 3 years after 
treatment. Drug Alcohol Rev 29:12–20. 
Glover ED, Rath JM, Sharma E, Glover PN, Laflin M, Tonnesen P, Repsher L, and 
Quiring J (2010) A multicenter phase 3 trial of lobeline sulfate for smoking 
cessation. Am J Health Behav 34:101–109. 
Goldenberg MM (2014) Pharmaceutical approval update. P and T 39. 
Goldstein RA, DesLauriers C, and Burda AM (2009) Cocaine: history, social 
implications, and toxicity-a review. Dis Mon 55:6–38. 
Goldstein RZ, and Volkow ND (2011) Dysfunction of the prefrontal cortex in addiction: 
neuroimaging findings and clinical implications. Nat Rev Neurosci 12:652–669. 
257 
 
Gonzales R, Mooney L, and Rawson RA (2010) The methamphetamine problem in the 
United States. Annu Rev Public Health 31:385–398. 
Gonzales R, and Rawson R (2005) Methamphetamine addiction treatment: Does it work. 
Counselor 6:16–23. 
Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, De Felice LJ, and 
Khoshbouei H (2009) Amphetamine and methamphetamine differentially affect 
dopamine transporters in vitro and in vivo. J Biol Chem 284:2978–2989. 
Gorman AL, Elliott KJ, and Inturrisi CE (1997) The d- and l-isomers of methadone bind 
to the non-competitive site on the. Neurosci Lett 223:5–8. 
Gosens R, Zaagsma J, Meurs H, and Halayko AJ (2006) Muscarinic receptor signaling 
in the pathophysiology of asthma and COPD. Respiratory Research 7:73. 
Gourlay GK, Cherry DA, and Cousins MJ (1986) A comparative study of the efficacy and 
pharmacokinetics of oral methadone and morphine in the treatment of severe 
pain in patients with cancer. Pain 25:297–312. 
Grant S, London ED, Newlin DB, Villemagne VL, Liu X, Contoreggi C, Phillips RL, Kimes 
AS, and Margolin A (1996) Activation of memory circuits during cue-elicited 
cocaine craving. Proc Natl Acad Sci U S A 93:12040–12045. 
Grant Welker (2018) Opioid shortage: While addiction issues loom, hospitals run short 
on necessary painkillers. 
Greenwald MK, Lundahl LH, and Steinmiller CL (2010) Sustained release d-
amphetamine reduces cocaine but not ’speedball’-seeking in buprenorphine-
maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin 
polydrug abusers. Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 35:2624–2637. 
Greydanus DE, Nazeer A, and Patel DR (2009) Psychopharmacology of ADHD in 
pediatrics: current advances and issues. Neuropsychiatric disease and treatment 
5:171–181. 
Grinspoon L, and Bakalar JB (1981) Coca and cocaine as medicines: an historical 
review. J Ethnopharmacol 3:149–159. 
Guay DRP (2010) Tetrabenazine, a monoamine-depleting drug used in the treatment of 
hyperkinetic movement disorders. Am J Geriatr Pharmacother 8:331–373. 
Gulaboski R, Cordeiro MNDS, Milhazes N, Garrido J, Borges F, Jorge M, Pereira CM, 
Bogeski I, Morales AH, Naumoski B, and Silva AF (2007) Evaluation of the 
lipophilic properties of opioids, amphetamine-like drugs, and metabolites through 
electrochemical studies at the interface between two immiscible solutions. Anal 
Biochem 361:236–243. 
Gysling K, and Wang RY (1983) Morphine-induced activation of A10 dopamine neurons 
in the rat. Brain Res 277:119–127. 
258 
 
Haazen L, Noorduin H, Megens A, and Meert T (1999) The constipation-inducing 
potential of morphine and transdermal fentanyl. European Journal of Pain 3:9–
15. 
Han B, Compton WM, Blanco C, Crane E, Lee J, and Jones CM (2017) Prescription 
Opioid Use, Misuse, and Use Disorders in U.S. Adults. Ann Intern Med 167. 
Han DD, and Gu HH (2006) Comparison of the monoamine transporters from human 
and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6. 
Haney M, Gunderson EW, Jiang H, Collins ED, and Foltin RW (2010) Cocaine-specific 
antibodies blunt the subjective effects of smoked cocaine in humans. Biological 
psychiatry 67:59–65. 
Hao DC, Gu X-J, and Xiao PG (2015) 6 - Phytochemical and biological research of 
Papaver pharmaceutical resources, in Medicinal Plants pp 217–251, Woodhead 
Publishing. 
Harris DS, Jones RT, Welm S, Upton RA, Lin E, and Mendelson J (2000) Buprenorphine 
and naloxone co-administration in opiate-dependent patients stabilized on 
sublingual buprenorphine. Drug Alcohol Depend 61:85–94. 
Harrod SB, Dwoskin LP, and Bardo MT (2004) Lobeline produces conditioned taste 
avoidance in rats. Pharmacol Biochem Behav 78:1–5. 
Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, and Bardo MT (2001) Lobeline 
attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther 
298:172–179. 
Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, and Bardo MT (2003) Lobeline does not 
serve as a reinforcer in rats. Psychopharmacology (Berl) 165:397–404. 
Hashimoto T, Saito Y, Yamada K, Hara N, Kirihara Y, and Tsuchiya M (2006) 
Enhancement of morphine analgesic effect with induction of mu-opioid receptor 
endocytosis in rats. Anesthesiology 105:574–580. 
Haumann J, Geurts JW, van Kuijk SMJ, Kremer B, Joosten EA, and van den Beuken-
van Everdingen MHJ (2016) Methadone is superior to fentanyl in treating 
neuropathic pain in patients with head-and-neck cancer. Eur J Cancer 65:121–
129. 
Hay CE, Gonzalez GA 3rd, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-
Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, and Peterson EC 
(2018) Development and testing of AAV-delivered single-chain variable 
fragments for the  treatment of methamphetamine abuse. PLoS One 
13:e0200060. 
Heal DJ, Smith SL, Gosden J, and Nutt DJ (2013) Amphetamine, past and present--a 
pharmacological and clinical perspective. J Psychopharmacol 27:479–496. 
259 
 
Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, and Tecott LH 
(1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A 
receptor mutant mice. Proc Natl Acad Sci U S A 95:15049–15054. 
Hiranita T (2015) Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 
Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats. J 
Alcohol Drug Depend 3:e127. 
Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K, Sato A, Hasegawa T, 
Nishikibe M, Mitsuya M, Ohtake N, Mase T, and Noguchi K (2001) 
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-
yl] -2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: A novel 
muscarinic antagonist with M2-sparing antagonistic activity. Journal of 
Pharmacology and Experimental Therapeutics 297:790–797. 
Hodgson E (2012) Toxins and venoms. Prog Mol Biol Transl Sci 112:373–415. 
Hogarth L, Retzler C, Munafo MR, Tran DMD, Troisi JR 2nd, Rose AK, Jones A, and 
Field M (2014) Extinction of cue-evoked drug-seeking relies on degrading 
hierarchical instrumental expectancies. Behav Res Ther 59:61–70. 
Holland JG, and Skinner BF (1961) The analysis of behavior: A program for self-
instruction., McGraw-Hill, New York,  NY,  US. 
Hollerman JR, and Schultz W (1998) Dopamine neurons report an error in the temporal 
prediction of reward during learning. Nat Neurosci 1:304–309. 
Holuj M, Bisaga A, and Popik P (2013) Conditioned rewarding effects of morphine and 
methadone in mice pre-exposed to cocaine. Pharmacol Rep 65:1176–1184. 
Horton DB, Nickell JR, Zheng G, Crooks PA, and Dwoskin LP (2013) GZ-793A, a 
lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit 
the effect of methamphetamine. Journal of neurochemistry 127:177–86. 
Horton David B., Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, 
Harrod SB, Deaciuc AG, Bardo MT, Crooks PA, and Dwoskin LP (2011) meso-
Transdiene analogs inhibit vesicular monoamine transporter-2 function and 
methamphetamine-evoked dopamine release. J Pharmacol Exp Ther 336:940–
951. 
Horton D. B., Siripurapu KB, Zheng G, Crooks PA, and Dwoskin LP (2011) Novel N-1,2-
dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 
function and methamphetamine-evoked dopamine release. The Journal of 
pharmacology and experimental therapeutics 339:286–97. 
Howell LL, and Negus SS (2014) Monoamine transporter inhibitors and substrates as 
treatments for stimulant abuse. Adv Pharmacol 69:129–176. 
Huestis MA, and Cone EJ (2007) Methamphetamine disposition in oral fluid, plasma, 
and urine. Ann N Y Acad Sci 1098:104–121. 
260 
 
Huskinson SL, Naylor JE, Rowlett JK, and Freeman KB (2014) Predicting abuse 
potential of stimulants and other dopaminergic drugs: overview and 
recommendations. Neuropharmacology 87:66–80. 
Hustveit O, and Setekleiv J (1993) Fentanyl and pethidine are antagonists on muscarinic 
receptors in guinea-pig ileum. Acta Anaesthesiol Scand 37:541–544. 
Ikegami A, and Duvauchelle CL (2004) Dopamine mechanisms and cocaine reward. Int 
Rev Neurobiol 62:45–94. 
Imperato A, and Di Chiara G (1986) Preferential stimulation of dopamine release in the 
nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 
239:219–228. 
Imperato A, Mulas A, and Di Chiara G (1986) Nicotine preferentially stimulates 
dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 
132:337–338. 
Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, and Houde RW (1984) The 
pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 
310:1213–1217. 
Inturrisi CE, Portenoy RK, Max MB, Colburn WA, and Foley KM (1990) Pharmacokinetic-
pharmacodynamic relationships of methadone infusions in patients  with cancer 
pain. Clin Pharmacol Ther 47:565–577. 
Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, and Simon EJ (1983) Evidence from 
opiate binding studies that heroin acts through its metabolites. Life Sci 33 Suppl 
1:773–776. 
Ito R, Dalley JW, Howes SR, Robbins TW, and Everitt BJ (2000) Dissociation in 
conditioned dopamine release in the nucleus accumbens core and shell in 
response to cocaine cues and during cocaine-seeking behavior in rats. J 
Neurosci 20:7489–7495. 
Ito R, Dalley JW, Robbins TW, and Everitt BJ (2002) Dopamine release in the dorsal 
striatum during cocaine-seeking behavior under the control of a drug-associated 
cue. J Neurosci 22:6247–6253. 
Jasinski DR (2000) An evaluation of the abuse potential of modafinil using 
methylphenidate as a reference. J Psychopharmacol 14:53–60. 
Jasinski DR, and Preston KL (1986) Comparison of intravenously administered 
methadone, morphine and heroin. Drug Alcohol Depend 17:301–310. 
Jeal W, and Benfield P (1997) Transdermal fentanyl. A review of its pharmacological 
properties and therapeutic  efficacy in pain control. Drugs 53:109–138. 
Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, and Cook CE (1989) Cocaine 
disposition in humans after intravenous injection, nasal insufflation (snorting), or 
smoking. Drug Metab Dispos 17:153–159. 
261 
 
Jentsch JD, and Taylor JR (1999) Impulsivity resulting from frontostriatal dysfunction in 
drug abuse: implications for the control of behavior by reward-related stimuli. 
Psychopharmacology (Berl) 146:373–390. 
Jiang R, Lee I, Lee TA, and Pickard AS (2017) The societal cost of heroin use disorder 
in the United States. PLoS One 12:e0177323. 
Jiang S, Li Y, Zhang C, Zhao Y, Bu G, Xu H, and Zhang Y-W (2014) M1 muscarinic 
acetylcholine receptor in Alzheimer’s disease. Neurosci Bull 30:295–307. 
Jimenez-Rivera CA, Feliu-Mojer M, and Vazquez-Torres R (2006) Alpha-noradrenergic 
receptors modulate the development and expression of cocaine  sensitization. 
Ann N Y Acad Sci 1074:390–402. 
Jo SH, Youm JB, Lee CO, Earm YE, and Ho WK (2000) Blockade of the HERG human 
cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol 
129:1474–1480. 
Johnson RA, Eshleman AJ, Meyers T, Neve KA, and Janowsky A (1998) [3H]substrate- 
and cell-specific effects of uptake inhibitors on human dopamine and serotonin 
transporter-mediated efflux. Synapse 30:97–106. 
Johnson SW, and North RA (1992) Opioids excite dopamine neurons by 
hyperpolarization of local interneurons. J Neurosci 12:483–488. 
Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, and Simopoulos TT (2018) A Brief 
History of the Opioid Epidemic and Strategies for Pain Medicine. Pain Ther, doi: 
10.1007/s40122-018-0097-6. 
Jones R (2007) Double-blind, placebo-controlled, cross-over assessment of intravenous 
methamphetamine and sublingual lobeline interactions. NCT00439504. Clinical 
Trials.gov. 
Just WW, and Hoyer J (1977) The local anesthetic potency of norcocaine, a metabolite 
of cocaine. Experientia 33:70–71. 
Kakko J, Svanborg KD, Kreek MJ, and Heilig M (2003) 1-year retention and social 
function after buprenorphine-assisted relapse prevention treatment for heroin 
dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361:662–
668. 
Kalivas PW, and Stewart J (1991) Dopamine transmission in the initiation and 
expression of drug- and stress-induced sensitization of motor activity. Brain Res 
Brain Res Rev 16:223–244. 
Kalso E (2005) Oxycodone. J Pain Symptom Manage 29:S47-56. 
Kandel DB, Hu M-C, Griesler P, and Wall M (2017) Increases from 2002 to 2015 in 
prescription opioid overdose deaths in combination with other substances. Drug 
and Alcohol Dependence 178:501–511. 
262 
 
Kapitzke D, Vetter I, and Cabot PJ (2005) Endogenous opioid analgesia in peripheral 
tissues and the clinical implications for pain control. Ther Clin Risk Manag 1:279–
297. 
Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, Monteillet-Agius G, Stewart 
PL, Evans CJ, and von Zastrow M (1998) mu-Opioid receptor internalization: 
opiate drugs have differential effects on a conserved endocytic mechanism in 
vitro and in the mammalian brain. Mol Pharmacol 53:377–384. 
Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von Zastrow 
M (1996) Morphine activates opioid receptors without causing their rapid 
internalization. J Biol Chem 271:19021–19024. 
Kelly PH, and Iversen SD (1976) Selective 60HDA-induced destruction of mesolimbic 
dopamine neurons: Abolition of psychostimulant-induced locomotor activity in 
rats. European Journal of Pharmacology 40:45–56. 
Kenakin T (1997) Molecular Pharmacology, Wiley. 
Kenakin T, Jenkinson S, and Watson C (2006) Determining the potency and molecular 
mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 
319:710–723. 
Kenney C, and Jankovic J (2006) Tetrabenazine in the treatment of hyperkinetic 
movement disorders. Expert Rev Neurother 6:7–17. 
Kenny PJ, Hoyer D, and Koob GF (2018) Animal Models of Addiction and 
Neuropsychiatric Disorders and Their Role in Drug  Discovery: Honoring the 
Legacy of Athina Markou. Biol Psychiatry, doi: 10.1016/j.biopsych.2018.02.009. 
Kharasch ED (2011) Intraoperative methadone: Rediscovery, reappraisal, and 
reinvigoration? Anesth Analg 112:13–16. 
Kieffer BL, and Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. 
Prog Neurobiol 66:285–306. 
King MJ, Hosmer HR, and Dresbach M (1928) Physiological reactions induced by alpha-
lobelin I. Intravenous injections during anesthesia and certain other forms of 
depression. J Pharmacol Exp Ther 32:241. 
Kirkpatrick MG, Gunderson EW, Johanson C-E, Levin FR, Foltin RW, and Hart CL 
(2012) Comparison of intranasal methamphetamine and d-amphetamine self-
administration by humans. Addiction 107:783–791. 
Kleber HD, Kosten TR, Gaspari J, and Topazian M (1985) Nontolerance to the opioid 
antagonism of naltrexone. Biol Psychiatry 20:66–72. 
Knipper E, Banta-Green CJ, and Jimenez N (2017) Opioid use disorder and misuse: A 
review of the epidemiology and medical implications for pediatric 
anesthesiologists. Paediatr Anaesth 27:1070–1076. 
263 
 
Kõks S (2015) Chapter Six - Experimental Models on Effects of Psychostimulants, in 
International Review of Neurobiology (Taba P, Lees A, and Sikk K eds) pp 107–
129, Academic Press. 
Koob GF (1992) Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654:171–
191. 
Koob GF, Sanna PP, and Bloom FE (1998) Neuroscience of addiction. Neuron 21:467–
476. 
Koob GF, and Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. 
Lancet Psychiatry 3:760–773. 
Kornetsky C, and Esposito RU (1981) Reward and detection thresholds for brain 
stimulation: dissociative effects of cocaine. Brain Res 209:496–500. 
Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, 
Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, and Manfredi PL 
(2003) QTc interval prolongation associated with intravenous methadone. Pain 
105:499–506. 
Kosten T, and Owens SM (2005) Immunotherapy for the treatment of drug abuse. 
Pharmacol Ther 108:76–85. 
Kosten TA, Shen XY, Kinsey BM, Kosten TR, and Orson FM (2014) Attenuation of 
cocaine-induced locomotor activity in male and female mice by active 
immunization. Am J Addict 23:604–607. 
Kosterlitz HW (1985) The Wellcome Foundation lecture, 1982. Opioid peptides and their 
receptors. Proc R Soc Lond B Biol Sci 225:27–40. 
Koyyalagunta D (2007) chapter 113 - Opioid Analgesics, in Pain Management (Waldman 
SD, and Bloch JI eds) pp 939–964, W.B. Saunders, Philadelphia. 
Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, and Silverman BL (2013) 
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-
term  safety and effectiveness. Addiction 108:1628–1637. 
Kuhlman JJJ, Lalani S, Magluilo JJ, Levine B, and Darwin WD (1996) Human 
pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal 
Toxicol 20:369–378. 
Kulkarni AD, Patel HM, Surana SJ, Belgamwar VS, and Pardeshi CV (2016) Brain-blood 
ratio: implications in brain drug delivery. Expert Opin Drug Deliv 13:85–92. 
Kuo A, Wyse BD, Meutermans W, and Smith MT (2015) In vivo profiling of seven 
common opioids for antinociception, constipation and respiratory depression: no 
two opioids have the same profile. Br J Pharmacol 172:532–548. 
Landauer TK (1969) Reinforcement as consolidation. Psychol Rev 76:82–96. 
264 
 
Langwinski R, and Fidecka S (1981) Central action of narcotic analgesics. VII. The role 
of serotonin in the development of morphine tolerance in the locomotor activity 
test in mice and rats. Pol J Pharmacol Pharm 33:193–202. 
Larsen KE, Fon EA, Hastings TG, Edwards RH, and Sulzer D (2002) Methamphetamine-
induced degeneration of dopaminergic neurons involves autophagy and 
upregulation of dopamine synthesis. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 22:8951–60. 
Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, 
Robbins TW, and Sahakian BJ (1998) Evidence for specific cognitive deficits in 
preclinical Huntington’s disease. Brain 121 ( Pt 7):1329–1341. 
Le Merrer J, Becker JAJ, Befort K, and Kieffer BL (2009) Reward processing by the 
opioid system in the brain. Physiol Rev 89:1379–1412. 
Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, 
Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, and 
Lindsley CW (2010) Discovery and Characterization of Novel Subtype-Selective 
Allosteric Agonists for the Investigation of M1 Receptor Function in the Central 
Nervous System. ACS Chem Neurosci 1:104–121. 
Lee N-R, Zhang X, Darna M, Dwoskin LP, and Zheng G (2015) Muscarinic acetylcholine 
receptor binding affinities of pethidine analogs. Bioorganic & Medicinal Chemistry 
Letters 25:5032–5035. 
Lee N-R, Zheng G, Crooks PA, Bardo MT, and Dwoskin LP (2018) New Scaffold for 
Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J 20:29. 
Leikin J, and Paloucek F (2008) Cocaine. Poisoning and Toxicology Handbook, 4th ed., 
4th ed., CRC Press, New York, NY. 
Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, 
Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook 
BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, 
Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, 
Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley 
C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, 
Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, 
Lake JH, Laramee AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, 
Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, 
Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, 
Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, 
Shapovalova NV, Sivisay T, Slaughterbeck CR, Smith SC, Smith KA, Smith BI, 
Sodt AJ, Stewart NN, Stumpf KR, Sunkin SM, Sutram M, Tam A, Teemer CD, 
Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock RM, Wohnoutka PE, et 
al. (2007) Genome-wide atlas of gene expression in the adult mouse brain. 
Nature 445:168–76. 
265 
 
Leite-Morris KA, Fukudome EY, Shoeb MH, and Kaplan GB (2004) GABA(B) receptor 
activation in the ventral tegmental area inhibits the acquisition and expression of 
opiate-induced motor sensitization. J Pharmacol Exp Ther 308:667–678. 
Leone P, Pocock D, and Wise RA (1991) Morphine-dopamine interaction: ventral 
tegmental morphine increases nucleus accumbens dopamine release. 
Pharmacol Biochem Behav 39:469–472. 
Lerma-Cabrera JM, Carvajal F, and Lopez-Legarrea P (2016) Food addiction as a new 
piece of the obesity framework. Nutrition journal 15:5–5. 
Letchworth SR, Nader MA, Smith HR, Friedman DP, and Porrino LJ (2001) Progression 
of changes in dopamine transporter binding site density as a result of cocaine 
self-administration in rhesus monkeys. J Neurosci 21:2799–2807. 
Levey AI (1996) Muscarinic acetylcholine receptor expression in memory circuits: 
Implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 
93:13541. 
Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, and Dagher A (2002) 
Amphetamine-induced increases in extracellular dopamine, drug wanting, and 
novelty seeking: a PET/[11C]raclopride study in healthy men. 
Neuropsychopharmacology 27:1027–1035. 
Licko V (1981) Overview of human pharmacokinetics of naltrexone. NIDA Res Monogr 
28:161–171. 
Lipari RN, and Van Horn SL (2017) Trends in substance use disorders among adults 
aged 18 or older, in The CBHSQ Report p, Substance Abuse and Mental Health 
Services Administration (US). 
Lisberg P, and Scheinmann F (2013) Is it Time to Consider Use of Levo-methadone (R-
(-)-Methadone) to Replace Racemic Methadone? J Develop Drugs 2:doi: 
10.4172/2329-6631.1000109. 
Liu Y, Lin D, Wu B, and Zhou W (2016) Ketamine abuse potential and use disorder. 
Brain Res Bull 126:68–73. 
Ljungberg T, Apicella P, and Schultz W (1992) Responses of monkey dopamine neurons 
during learning of behavioral reactions. J Neurophysiol 67:145–163. 
Lohr KM, Masoud ST, Salahpour A, and Miller GW (2017) Membrane transporters as 
mediators of synaptic dopamine dynamics: implications for disease. Eur J 
Neurosci 45:20–33. 
London ED, Kohno M, Morales AM, and Ballard ME (2015) Chronic methamphetamine 
abuse and corticostriatal deficits revealed by neuroimaging. Brain research 
1628:174–185. 
266 
 
Longoni R, Spina L, Mulas A, Carboni E, Garau L, Melchiorri P, and Di Chiara G (1991) 
(D-Ala2)deltorphin II: D1-dependent stereotypies and stimulation of dopamine 
release in the nucleus accumbens. J Neurosci 11:1565–1576. 
Lopez G (2018) Why America’s cocaine problem is now a fentanyl problem too, 
https://www.vox.com/science-and-health/2018/5/4/17307296/cocaine-opioid-
crisis-fentanyl-overdose. 
Lovibond PF (1983) Facilitation of instrumental behavior by a Pavlovian appetitive 
conditioned stimulus. J Exp Psychol Anim Behav Process 9:225–247. 
Luft A, and Mendes FF (2007) Anesthesia in cocaine users. Rev Bras Anestesiol 
57:307–314. 
Lukas SE (1996) CNS effects and abuse liability of anabolic-androgenic steroids. Annu 
Rev Pharmacol Toxicol 36:333–357. 
Lundberg GD, Garriott JC, Reynolds PC, Cravey RH, and Shaw RF (1977) Cocaine-
related death. J Forensic Sci 22:402–408. 
Luo Z, Volkow ND, Heintz N, Pan Y, and Du C (2011) Acute cocaine induces fast 
activation of D1 receptor and progressive deactivation of D2 receptor striatal 
neurons: in vivo optical microprobe [Ca2+]i imaging. J Neurosci 31:13180–
13190. 
Lynch WJ, Nicholson KL, Dance ME, Morgan RW, and Foley PL (2010) Animal models 
of substance abuse and addiction: implications for science, animal  welfare, and 
society. Comp Med 60:177–188. 
Lyness WH, Friedle NM, and Moore KE (1979) Destruction of dopaminergic nerve 
terminals in nucleus accumbens: effect on d-amphetamine self-administration. 
Pharmacology, biochemistry, and behavior 11:553–6. 
Macarthur JG (1957) The complications of reserpine therapy. Postgrad Med J 33:544–
547. 
Madia PA, Dighe SV, Sirohi S, Walker EA, and Yoburn BC (2009) Dosing protocol and 
analgesic efficacy determine opioid tolerance in the mouse. 
Psychopharmacology (Berl) 207:413–422. 
Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, and Loew G (1992) 
Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate 
receptors. Eur J Pharmacol 213:219–225. 
Magura S, Nwakeze PC, and Demsky SY (1998) Pre- and in-treatment predictors of 
retention in methadone treatment using survival analysis. Addiction 93:51–60. 
Malcolm R, Swayngim K, Donovan JL, DeVane CL, Elkashef A, Chiang N, Khan R, 
Mojsiak J, Myrick DL, Hedden S, Cochran K, and Woolson RF (2006) Modafinil 
and cocaine interactions. Am J Drug Alcohol Abuse 32:577–587. 
267 
 
Malik VS, Schulze MB, and Hu FB (2006) Intake of sugar-sweetened beverages and 
weight gain: a systematic review. The American journal of clinical nutrition 
84:274–288. 
Mantle TJ, Tipton KF, and Garrett NJ (1976) Inhibition of monoamine oxidase by 
amphetamine and related compounds. Biochem Pharmacol 25:2073–2077. 
Marquez J, Campos-Sandoval JA, Penalver A, Mates JM, Segura JA, Blanco E, Alonso 
FJ, and de Fonseca FR (2017) Glutamate and Brain Glutaminases in Drug 
Addiction. Neurochem Res 42:846–857. 
Martin WR (1967) Opioid antagonists. Pharmacol Rev 19:463–521. 
Martini L, and Whistler JL (2007) The role of mu opioid receptor desensitization and 
endocytosis in morphine tolerance and dependence. Current Opinion in 
Neurobiology 17:556–564. 
Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, di 
Giannantonio M, and Lerner AG (2018) Hallucinogen Persisting Perception 
Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sci 8. 
Matsui A, and Alvarez VA (2018) Cocaine Inhibition of Synaptic Transmission in the 
Ventral Pallidum Is Pathway-Specific and Mediated by Serotonin. Cell reports 
23:3852–3863. 
Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich 
A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, and Kieffer BL (1996) 
Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in 
mice lacking the mu-opioid-receptor gene. Nature 383:819–823. 
Mattick RP, Breen C, Kimber J, and Davoli M (2014) Buprenorphine maintenance versus 
placebo or methadone maintenance for opioid dependence. Cochrane Database 
Syst Rev CD002207. 
Maxwell JC, and Brecht ML (2011) Methamphetamine: here we go again? Addictive 
behaviors 36:1168–73. 
Maxwell JC, Maxwell JC, Rutkowski BA, Maxwell JC, and Rutkowski BA (2008) The 
prevalence of methamphetamine and amphetamine abuse in North America: a 
review of the indicators, 1992–2007. Drug and alcohol review 27:229–235. 
Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, and Jerabek 
PA (2000) Regional metabolic effects of fluoxetine in major depression: serial 
changes and  relationship to clinical response. Biol Psychiatry 48:830–843. 
McCall Jones C, Baldwin GT, and Compton WM (2017) Recent Increases in Cocaine-
Related Overdose Deaths and the Role of Opioids. Am J Public Health 107:430–
432. 
Mccance-Katz EF (2011) (R)-methadone versus racemic methadone: what is best for 
patient care? Addiction (Abingdon, England) 106:687–688. 
268 
 
McClenny R (1991) Cocaine: a brief history. Neonatal Netw 10:53–57. 
McDonald J, and Lambert D (2005) Opioid receptors. Continuing Education in 
Anaesthesia Critical Care & Pain 5:22–25. 
McKetin R, Hickey K, Devlin K, and Lawrence K (2010) The risk of psychotic symptoms 
associated with recreational methamphetamine use. Drug Alcohol Rev 29:358–
363. 
McLellan AT, Lewis DC, O’Brien CP, and Kleber HD (2000) Drug dependence, a chronic 
medical illness: implications for treatment, insurance, and outcomes evaluation. 
JAMA 284:1689–1695. 
McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, and Owens SM 
(2004) Effects of murine-derived anti-methamphetamine monoclonal antibodies 
on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 
309:1248–1255. 
Melega WP, Williams AE, Schmitz DA, DiStefano EW, and Cho AK (1995) 
Pharmacokinetic and pharmacodynamic analysis of the actions of D-
amphetamine and. J Pharmacol Exp Ther 274:90–96. 
Melis M, Gessa GL, and Diana M (2000) Different mechanisms for dopaminergic 
excitation induced by opiates and cannabinoids in the rat midbrain. Prog 
Neuropsychopharmacol Biol Psychiatry 24:993–1006. 
Mello NK, Lukas SE, Bree MP, and Mendelson JH (1988) Progressive ratio performance 
maintained by buprenorphine, heroin and methadone in Macaque monkeys. Drug 
Alcohol Depend 21:81–97. 
Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P 3rd, Everhart ET, 
and Jones RT (2006) Human pharmacology of the methamphetamine 
stereoisomers. Clin Pharmacol Ther 80:403–420. 
Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW, Hanson GR, and 
Fleckenstein AE (2002) Inhibitory effect of reserpine on dopamine transporter 
function. European Journal of Pharmacology 456:39–43. 
Meule A, and Gearhardt AN (2014) Food addiction in the light of DSM-5. Nutrients 
6:3653–3671. 
Mews P, and Calipari ES (2017) Chapter 2 - Cross-talk between the epigenome and 
neural circuits in drug addiction, in Progress in Brain Research (Calvey T, and 
Daniels WMU eds) pp 19–63, Elsevier. 
Meyer AC, Horton DB, Neugebauer NM, Wooters TE, Nickell JR, Dwoskin LP, and 
Bardo MT (2011) Tetrabenazine inhibition of monoamine uptake and 
methamphetamine behavioral effects: locomotor activity, drug discrimination and 
self-administration. Neuropharmacology 61:849–56. 
269 
 
Meyer AC, Neugebauer NM, Zheng G, Crooks PA, Dwoskin LP, and Bardo MT (2013) 
Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced 
changes in dopamine release, metabolism and synthesis in vivo. Journal of 
neurochemistry 127:187–98. 
Meyer PJ, King CP, and Ferrario CR (2016) Motivational Processes Underlying 
Substance Abuse Disorder. Curr Top Behav Neurosci 27:473–506. 
Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667–
1671. 
Mignat C, Wille U, and Ziegler A (1995) Affinity profiles of morphine, codeine, 
dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sciences 
56:793–799. 
Milano G, Saenz E, Clark N, Busse A, Gale J, Campello G, Mattfeld E, Maalouf W, 
Heikkila H, Martelli A, Morales B, and Gerra G (2017) Report on the International 
Workshop on Drug Prevention and Treatment in Rural Settings Organized by 
United Nation Office on Drugs and Crime (UNODC) and World Health 
Organization (WHO). Subst Use Misuse 52:1801–1807. 
Miller DK, Crooks PA, Teng L, Witkin JM, Munzar P, Goldberg SR, Acri JB, and Dwoskin 
LP (2001) Lobeline inhibits the neurochemical and behavioral effects of 
amphetamine. The Journal of pharmacology and experimental therapeutics 
296:1023–34. 
Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, and Dwoskin LP (2004) 
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and 
vesicular monoamine transporters. The Journal of pharmacology and 
experimental therapeutics 310:1035–45. 
Miller DK, Harrod SB, Green TA, Wong M-Y, Bardo MT, and Dwoskin LP (2003) 
Lobeline attenuates locomotor stimulation induced by repeated nicotine 
administration in rats. Pharmacol Biochem Behav 74:279–286. 
Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, and Kracke GR (2007) Lobeline, a 
potential pharmacotherapy for drug addiction, binds to mu opioid receptors and 
diminishes the effects of opioid receptor agonists. Drug Alcohol Depend 89:282–
291. 
Miller GM, Yatin SM, De La Garza II R, Goulet M, and Madras BK (2001) Cloning of 
dopamine, norepinephrine and serotonin transporters from monkey brain: 
relevance to cocaine sensitivity11Published on the World Wide Web on 22 
January 2001. Molecular Brain Research 87:124–143. 
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, and Verster A (2011) Oral 
naltrexone maintenance treatment for opioid dependence. Cochrane Database 
Syst Rev CD001333. 
270 
 
Mirecki A, Fitzmaurice P, Ang L, Kalasinsky KS, Peretti FJ, Aiken SS, Wickham DJ, 
Sherwin A, Nobrega JN, Forman HJ, and Kish SJ (2004) Brain antioxidant 
systems in human methamphetamine users. J Neurochem 89:1396–1408. 
Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine 
receptors: from structure to function. Physiol Rev 78:189–225. 
Mitler MM, Aldrich MS, Koob GF, and Zarcone VP (1994) Narcolepsy and its treatment 
with stimulants. ASDA standards of practice. Sleep 17:352–371. 
Mittleman RE, and Wetli CV (1984) Death caused by recreational cocaine use. An 
update. JAMA 252:1889–1893. 
Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, and Ogawa 
N (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by 
quinone-formation-related molecules. FASEB J 20:571–573. 
Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, Hanoune J, and 
Borsodi A (1999) Opioid binding profiles of new hydrazone, oxime, carbazone 
and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 64:2011–2020. 
Moore BJ, Stocks C, and Owens PL (2017) Trends in Emergency Department Visits, 
2006–2014. HCUP Statistical Brief #227., Agency for Healthcare Research and 
Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb227-
Emergency-Department-VisitTrends.pdf. 
Morgan WW (1990) Abuse liability of barbiturates and other sedative-hypnotics. Adv 
Alcohol Subst Abuse 9:67–82. 
Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, and Hirotsu I (1999) Affinity profiles 
of various muscarinic antagonists for cloned human muscarinic acetylcholine 
receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. 
Life Sciences 64:2351–2358. 
Mumford GK, Evans SM, Fleishaker JC, and Griffiths RR (1995) Alprazolam absorption 
kinetics affects abuse liability. Clin Pharmacol Ther 57:356–365. 
Myrick H, Malcolm R, Taylor B, and LaRowe S (2004) Modafinil: preclinical, clinical, and 
post-marketing surveillance--a review of abuse liability issues. Ann Clin 
Psychiatry 16:101–109. 
Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, Ehrenkaufer R, 
and Mach RH (2006) PET imaging of dopamine D2 receptors during chronic 
cocaine self-administration in monkeys. Nat Neurosci 9:1050–1056. 
Najafipour H, and Beik A (2016) The Impact of Opium Consumption on Blood Glucose, 
Serum Lipids and Blood Pressure, and Related Mechanisms. Front Physiol 7. 
Napier TC, Herrold AA, and de Wit H (2013) Using conditioned place preference to 
identify relapse prevention medications. Neuroscience and biobehavioral reviews 
37:2081–2086. 
271 
 
Narayanaswami V, Thompson AC, Cassis LA, Bardo MT, and Dwoskin LP (2013) Diet-
induced obesity: dopamine transporter function, impulsivity and motivation. Int J 
Obes (Lond) 37:1095–1103. 
Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus 
monkeys: effects of environmental manipulations and treatment with d-
amphetamine and flupenthixol. Neuropsychopharmacology 28:919. 
Negus SS, and Mello NK (2003) Effects of chronic d-amphetamine treatment on 
cocaine- and food-maintained responding under a second-order schedule in 
rhesus monkeys. Drug Alcohol Depend 70:39–52. 
Negus SS, Mello NK, Blough BE, Baumann MH, and Rothman RB (2007) Monoamine 
releasers with varying selectivity for dopamine/norepinephrine versus serotonin 
release as candidate “agonist” medications for cocaine dependence: studies in 
assays of cocaine discrimination and cocaine self-administration in rhesus 
monkeys. J Pharmacol Exp Ther 320:627–636. 
Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, and Bardo MT (2007) 
Lobelane decreases methamphetamine self-administration in rats. Eur J 
Pharmacol 571:33–38. 
Neves SR, Ram PT, and Iyengar R (2002) G protein pathways. Science 296:1636–1639. 
Newman AH, and Rothman RB (2007) 6.07 - Addiction, in Comprehensive Medicinal 
Chemistry II (Taylor JB, and Triggle DJ eds) pp 169–191, Elsevier, Oxford. 
Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks 
PA, and Dwoskin LP (2010) Lobelane inhibits methamphetamine-evoked 
dopamine release via inhibition of the vesicular monoamine transporter-2. The 
Journal of pharmacology and experimental therapeutics 332:612–21. 
Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, and Dwoskin LP (2017) GZ-
793A inhibits the neurochemical effects of methamphetamine via a selective 
interaction with the vesicular monoamine transporter-2. Eur J Pharmacol 
795:143–149. 
Nickell JR, Siripurapu KB, Vartak A, Crooks PA, and Dwoskin LP (2014) The vesicular 
monoamine transporter-2: an important pharmacological target for the discovery 
of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol 69:71–
106. 
NIDA, National Institute on Drug Abuse (2015) Nationwide Trends, 
https://www.drugabuse.gov/publications/drugfacts/nationwide-trends. 
NIDA, National Institute on Drug Abuse (2018a) Opioids. National Institute on Drug 
Abuse website. https://www.drugabuse.gov/drugs-abuse/opioids. 
NIDA, National Institute on Drug Abuse (2017) Overdose Death Rates, 
https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. 
272 
 
NIDA, National Institute on Drug Abuse (2018b) Overdose Death Rates, 
https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. 
Norrholm SD, Horton DB, and Dwoskin LP (2007) The promiscuity of the dopamine 
transporter: implications for the kinetic analysis of [3H]serotonin uptake in rat 
hippocampal and striatal synaptosomes. Neuropharmacology 53:982–989. 
Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, and Gastfriend 
DR (2015) Treating Opioid Dependence With Injectable Extended-Release 
Naltrexone (XR-NTX):  Who Will Respond? J Addict Med 9:238–243. 
Oakman SA, Faris PL, Kerr PE, Cozzari C, and Hartman BK (1995) Distribution of 
pontomesencephalic cholinergic neurons projecting to substantia nigra differs 
significantly from those projecting to ventral tegmental area. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 15:5859–69. 
O’Connor PG, and Kosten TR (1998) Rapid and ultrarapid opioid detoxification 
techniques. JAMA 279:229–234. 
Oldendorf WH, Hyman S, Braun L, and Oldendorf SZ (1972) Blood-brain barrier: 
penetration of morphine, codeine, heroin, and methadone after carotid injection. 
Science 178:984–986. 
O’Leary ME, and Hancox JC (2010) Role of voltage-gated sodium, potassium and 
calcium channels in the development of cocaine-associated cardiac arrhythmias. 
British journal of clinical pharmacology 69:427–442. 
Omelchenko N, and Sesack SR (2006) Cholinergic axons in the rat ventral tegmental 
area synapse preferentially onto mesoaccumbens dopamine neurons. J Comp 
Neurol 494:863–875. 
ONDCP, Office of National Drug Control Policy (2016) National Drug Control Strategy, 
Data Supplement 2016. 
Onoue S, Uchida A, Takahashi H, Seto Y, Kawabata Y, Ogawa K, Yuminoki K, 
Hashimoto N, and Yamada S (2011) Development of high-energy amorphous 
solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with 
improved oral bioavailability. J Pharm Sci 100:3793–3801. 
Owens SM, Atchley WT, Hambuchen MD, Peterson EC, and Gentry WB (2011) 
Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-
methamphetamine addiction. CNS Neurol Disord Drug Targets 10:892–898. 
Owesson-White CA, Cheer JF, Beyene M, Carelli RM, and Wightman RM (2008) 
Dynamic changes in accumbens dopamine correlate with learning during 
intracranial self-stimulation. Proc Natl Acad Sci U S A 105:11957–11962. 
Packard MG, and White NM (1991) Dissociation of hippocampus and caudate nucleus 
memory systems by posttraining intracerebral injection of dopamine agonists. 
Behav Neurosci 105:295–306. 
273 
 
Pan W-J, and Hedaya MA (1998) An Animal Model for Simultaneous 
Pharmacokinetic/Pharmacodynamic Investigations: Application to Cocaine. 
Journal of Pharmacological and Toxicological Methods 39:1–8. 
Panlilio LV, and Goldberg SR (2007) Self-administration of drugs in animals and humans 
as a model and an investigative tool. Addiction (Abingdon, England) 102:1863–
1870. 
Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, and Rothman RB 
(2006) Interaction of amphetamines and related compounds at the vesicular 
monoamine transporter. J Pharmacol Exp Ther 319:237–246. 
Paterson NE, Myers C, and Markou A (2000) Effects of repeated withdrawal from 
continuous amphetamine administration on brain reward function in rats. 
Psychopharmacology (Berl) 152:440–446. 
Pathan H, and Williams J (2012) Basic opioid pharmacology: an update. Br J Pain 6:11–
16. 
Patierno S, Anselmi L, Jaramillo I, Scott D, Garcia R, and Sternini C (2011) Morphine 
induces μ opioid receptor endocytosis in guinea pig enteric neurons following 
prolonged receptor activation. Gastroenterology 140:618–626. 
Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, 
Sahakian BJ, Dunnett SB, and Piccini P (2003) Progressive striatal and cortical 
dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain 
126:1127–1135. 
Peckham EM, and Traynor JR (2006) Comparison of the antinociceptive response to 
morphine and morphine-like compounds in male and female Sprague-Dawley 
rats. J Pharmacol Exp Ther 316:1195–1201. 
Pentney RJ, and Gratton A (1991) Effects of local delta and mu opioid receptor 
activation on basal and stimulated  dopamine release in striatum and nucleus 
accumbens of rat: an in vivo electrochemical study. Neuroscience 45:95–102. 
Peter D, Jimenez J, Liu Y, Kim J, and Edwards RH (1994) The chromaffin granule and 
synaptic vesicle amine transporters differ in substrate recognition and sensitivity 
to inhibitors. J Biol Chem 269:7231–7237. 
Pettit HO, Ettenberg A, Bloom FE, and Koob GF (1984) Destruction of dopamine in the 
nucleus accumbens selectively attenuates cocaine but not heroin self-
administration in rats. Psychopharmacology (Berl) 84:167–173. 
Pifl C, Drobny H, Reither H, Hornykiewicz O, and Singer EA (1995) Mechanism of the 
dopamine-releasing actions of amphetamine and cocaine: plasmalemmal 
dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 
47:368–373. 
Ploesser J, Weinstock LB, and Thomas E (2010) Low dose naltrexone: side effects and 
efficacy in gastrointestinal disorders. Int J Pharm Compd 14:171–173. 
274 
 
Polchert SE, and Morse RM (1985) Pemoline abuse. JAMA 254:946–947. 
Ponsoda X, Bort R, Jover R, Gomez-Lechon MJ, and Castell JV (1999) Increased 
toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. 
Biochem Pharmacol 58:1579–1585. 
Portenoy RK, and Foley KM (1986) Chronic use of opioid analgesics in non-malignant 
pain: report of 38 cases. Pain 25:171–186. 
Poyhia R, Vainio A, and Kalso E (1993) A review of oxycodone’s clinical 
pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63–67. 
Prajapati JB, Verma SD, and Patel AA (2018) Oral bioavailability enhancement of 
agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting 
approach. Int J Nanomedicine 13:35–38. 
Prat M, Buil MA, Fernandez MD, Castro J, Monleon JM, Tort L, Casals G, Ferrer M, 
Huerta JM, Espinosa S, Lopez M, Segarra V, Gavalda A, Miralpeix M, Ramos I, 
Vilella D, Gonzalez M, Cordoba M, Cardenas A, Anton F, Beleta J, and Ryder H 
(2011) Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl 
carbamates as potent and long acting muscarinic antagonists. Bioorg Med Chem 
Lett 21:3457–3461. 
Preston KL, Bigelow GE, and Liebson IA (1990) Effects of sublingually given naloxone in 
opioid-dependent human volunteers. Drug Alcohol Depend 25:27–34. 
Prinssen EPM, Ballard TM, Kolb Y, and Nicolas LB (2006) The effects of serotonin 
reuptake inhibitors on locomotor activity in gerbils. Pharmacology, Biochemistry 
and Behavior 85:44–49. 
Rady JJ, Aksu F, and Fujimoto JM (1994) The heroin metabolite, 6-
monoacetylmorphine, activates delta opioid receptors to  produce antinociception 
in Swiss-Webster mice. J Pharmacol Exp Ther 268:1222–1231. 
Rady JJ, Baemmert D, Takemori AE, Portoghese PS, and Fujimoto JM (1997) Spinal 
delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss Webster 
mice. Pharmacol Biochem Behav 56:243–249. 
Raffa RB (2009) The M5 muscarinic receptor as possible target for treatment of drug 
abuse. Journal of clinical pharmacy and therapeutics 34:623–9. 
Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ, Brunner 
D, and Hen R (1998) Serotonin receptor 1A knockout: an animal model of 
anxiety-related disorder. Proc Natl Acad Sci U S A 95:14476–14481. 
Rassool GH (2011) Addiction for Nurses, Wiley-Blackwell, Hoboken, New Jersey. 
Rassool GH (2009) Alcohol and Drug Misuse: A Handbook for Students and Health 
Professionals.  p. 113., Routledge Taylor & Francis Group, London and New 
York. 
275 
 
Rau T, Ziemniak J, and Poulsen D (2016) The neuroprotective potential of low-dose 
methamphetamine in preclinical models of stroke and traumatic brain injury. Prog 
Neuropsychopharmacol Biol Psychiatry 64:231–236. 
Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, and Reisine T (1994) 
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid 
receptors. Mol Pharmacol 45:330–334. 
Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, and Fahn S (1983) 
Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat 
brain. J Pharmacol Exp Ther 225:515–521. 
Redgrave P, Prescott TJ, and Gurney K (1999) Is the short-latency dopamine response 
too short to signal reward error? Trends Neurosci 22:146–151. 
Redman M (2011) Cocaine: What is the Crack? A Brief History of the Use of Cocaine as 
an Anesthetic. Anesth Pain Med 1:95–97. 
Reisine T, and Pasternak WG (1996) Opioid analgesics and antagonists. In: 
Pharmacological Basis of Therapeutics, 9th, Hardman JG, Gilman A, Limbird LE 
(Eds), McGraw-Hill, p.521., New York. 
Reith MEA, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, 
Rothman RB, and Katz JL (2015) Behavioral, biological, and chemical 
perspectives on atypical agents targeting the dopamine transporter. Drug and 
Alcohol Dependence 147:1–19. 
Rescorla RA, and Solomon RL (1967) Two-process learning theory: Relationships 
between Pavlovian conditioning and instrumental learning. Psychol Rev 74:151–
182. 
Rettig RA, and Yarmolinsky A (eds) (1995) Federal Regulation of Methadone Treatment, 
National Academies Press (US), Washington (DC). 
Reynolds AR, Strickland JC, Stoops WW, Lile JA, and Rush CR (2017) Buspirone 
maintenance does not alter the reinforcing, subjective, and cardiovascular effects 
of intranasal methamphetamine. Drug Alcohol Depend 181:25–29. 
Richards JR, Hamidi S, Grant CD, Wang CG, Tabish N, Turnipseed SD, and Derlet RW 
(2017) Methamphetamine Use and Emergency Department Utilization: 20 Years 
Later. J Addict 2017:4050932. 
Richards JR, Harms BN, Kelly A, and Turnipseed SD (2018) Methamphetamine use and 
heart failure: Prevalence, risk factors, and predictors. Am J Emerg Med, doi: 
10.1016/j.ajem.2018.01.001. 
Riezzo I, Fiore C, De Carlo D, Pascale N, Neri M, Turillazzi E, and Fineschi V (2012) 
Side effects of cocaine abuse: multiorgan toxicity and pathological 
consequences. Curr Med Chem 19:5624–5646. 
276 
 
Rilstone JJ, Alkhater RA, and Minassian BA (2013) Brain Dopamine–Serotonin Vesicular 
Transport Disease and Its Treatment. N Engl J Med 368:543–550. 
Risinger RC, Salmeron BJ, Ross TJ, Amen SL, Sanfilipo M, Hoffmann RG, Bloom AS, 
Garavan H, and Stein EA (2005) Neural correlates of high and craving during 
cocaine self-administration using BOLD fMRI. Neuroimage 26:1097–1108. 
Riviere GJ, Gentry WB, and Owens SM (2000) Disposition of methamphetamine and its 
metabolite amphetamine in brain and other  tissues in rats after intravenous 
administration. J Pharmacol Exp Ther 292:1042–1047. 
Robbins TW, Giardini V, Jones GH, Reading P, and Sahakian BJ (1990) Effects of 
dopamine depletion from the caudate-putamen and nucleus accumbens septi on 
the acquisition and performance of a conditional discrimination task. Behav Brain 
Res 38:243–261. 
Roberts DC, Koob GF, Klonoff P, and Fibiger HC (1980) Extinction and recovery of 
cocaine self-administration following 6-hydroxydopamine lesions of the nucleus 
accumbens. Pharmacol Biochem Behav 12:781–787. 
Roberts DCS, Zis AP, and Fibiger HC (1975) Ascending catecholamine pathways and 
amphetamine-induced locomotor activity: Importance of dopamine and apparent 
non-involvement of norepinephrine. Brain Research 93:441–454. 
Robinson SM, and Adinoff B (2016) The Classification of Substance Use Disorders: 
Historical, Contextual, and Conceptual Considerations. Behav Sci (Basel) 6. 
Robinson TE, and Berridge KC (2001) Incentive-sensitization and addiction. Addiction 
96:103–114. 
Robinson TE, and Berridge KC (2008) The incentive sensitization theory of addiction: 
some current issues. Philosophical transactions of the Royal Society of London 
Series B, Biological sciences 363:3137–3146. 
Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, and 
Caron MG (1998) Cocaine self-administration in dopamine-transporter knockout 
mice. Nat Neurosci 1:132–137. 
Rodriguiz RM, and Wetsel WC (2006) Assessments of Cognitive Deficits in Mutant Mice, 
in Animal Models of Cognitive Impairment (Levin ED, and Buccafusco JJ eds) p, 
CRC Press/Taylor & Francis, Boca Raton (FL). 
Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, 
Hunter J, Carthy T, Booker E, London M, Deakin JF, Sahakian BJ, and Robbins 
TW (1999) Dissociable deficits in the decision-making cognition of chronic 
amphetamine abusers, opiate abusers, patients with focal damage to prefrontal 
cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic 
mechanisms. Neuropsychopharmacology 20:322–339. 
Rohrig TP, and Hicks CA (2014) Brain Tissue: A Viable Postmortem Toxicological 
Specimen. Journal of Analytical Toxicology 39:137–139. 
277 
 
Romberg R, Sarton E, Teppema L, Matthes HWD, Kieffer BL, and Dahan A (2003) 
Comparison of morphine-6-glucuronide and morphine on respiratory depressant 
and antinociceptive responses in wild type and mu-opioid receptor deficient mice. 
Br J Anaesth 91:862–870. 
Roncero C, Ros-Cucurull E, Daigre C, and Casas M (2012) Prevalence and risk factors 
of psychotic symptoms in cocaine-dependent patients. Actas Esp Psiquiatr 
40:187–197. 
Rook EJ, van Ree JM, van den Brink W, Hillebrand MJX, Huitema ADR, Hendriks VM, 
and Beijnen JH (2006) Pharmacokinetics and pharmacodynamics of high doses 
of pharmaceutically prepared  heroin, by intravenous or by inhalation route in 
opioid-dependent patients. Basic Clin Pharmacol Toxicol 98:86–96. 
Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, and Kosten 
TR (1994) Buprenorphine: duration of blockade of effects of intramuscular 
hydromorphone. Drug Alcohol Depend 35:141–149. 
Ross FB, and Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear 
to be kappa-opioid receptor mediated. Pain 73:151–157. 
Russo SJ, and Nestler EJ (2013) The brain reward circuitry in mood disorders. Nat Rev 
Neurosci 14:609–625. 
Rzasa Lynn R, and Galinkin JL (2018) Naloxone dosage for opioid reversal: current 
evidence and clinical implications. Therapeutic advances in drug safety 9:63–88. 
Sagara Y, Sagara T, Uchiyama M, Otsuki S, Kimura T, Fujikawa T, Noguchi K, and 
Ohtake N (2006) Identification of a novel 4-aminomethylpiperidine class of M 3 
muscarinic receptor antagonists and structural insight into their M 3 selectivity. 
Journal of Medicinal Chemistry 49:5653–5663. 
Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and 
wakefulness. Nat Rev Neurosci 8:171–181. 
Salmon M, Walsh DA, Huang TJ, Barnes PJ, Leonard TB, Hay DW, and Chung KF 
(1999) Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA 
synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J 
Pharmacol 127. 
SAMHSA, Substance Abuse and Mental Health Services Administration (2017a) Key 
substance use and mental health indicators in the United States: Results from 
the 2016 National Survey on Drug Use and Health, (HHS Publication No. SMA 
17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health 
Statistics and Quality, Substance Abuse and Mental Health Services 
Administration. Retrieved from https://www.samhsa.gov/data/. 
SAMHSA, Substance Abuse and Mental Health Services Administration (2014a) Results 
from the 2013 National Survey on Drug Use and Health: Summary of National 
Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, 
MD: Substance Abuse and Mental Health Services Administration, 2014. 
278 
 
SAMHSA, Substance Abuse and Mental Health Services Administration (2017b) Results 
from the 2016 National Survey on Drug Use and Health: Detailed Tables, 
https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-
DetTabs-2016.pdf, Substance Abuse and Mental Health Services Administration 
(SAMHSA), Center for Behavioral Health Statistics andQuality. 
SAMHSA, Substance Abuse and Mental Health Services Administration (2014b) 
Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to 
Substance Abuse Treatment Services, Center for Behavioral Health Statistics 
and Quality, HHS Publication No. (SMA) 14-4850, Rockville, MD: Substance 
Abuse and Mental Health Services Administration. 
Sanguinetti MC, and Tristani-Firouzi M (2006) hERG potassium channels and cardiac 
arrhythmia. Nature 440:463–469. 
Sansone RA, and Sansone LA (2011) Agomelatine: A Novel Antidepressant. Innovations 
in Clinical Neuroscience 8:10–14. 
Schiller EY, and Mechanic OJ (2018) Opioid, Overdose, in StatPearls p, StatPearls 
Publishing, Treasure Island (FL). 
Schiltz CA (2006) Habitual responding and the dorsal striatum. J Neurosci 26:1891–
1892. 
Schoenbaum G, Saddoris MP, Ramus SJ, Shaham Y, and Setlow B (2004) Cocaine-
experienced rats exhibit learning deficits in a task sensitive to orbitofrontal cortex 
lesions. Eur J Neurosci 19:1997–2002. 
Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, and Rudnick G (1993) 
Amphetamine derivatives interact with both plasma membrane and secretory 
vesicle  biogenic amine transporters. Mol Pharmacol 44:1227–1231. 
Schuller AG, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, 
Unterwald EM, Pasternak GW, and Pintar JE (1999) Retention of heroin and 
morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of 
MOR-1. Nat Neurosci 2:151–156. 
Schultz W (2007) Behavioral dopamine signals. Trends Neurosci 30:203–210. 
Schultz W, Dayan P, and Montague PR (1997) A neural substrate of prediction and 
reward. Science 275:1593–1599. 
Schütz B, Schäfer MK-H, Eiden LE, and Weihe E (1998) Vesicular amine transporter 
expression and isoform selection in developing brain, peripheral nervous system 
and gut. Developmental Brain Research 106:181–204. 
Seeman P, and Lee T (1975) Antipsychotic drugs: direct correlation between clinical 
potency and presynaptic  action on dopamine neurons. Science 188:1217–1219. 
279 
 
Sellings LHL, and Clarke PBS (2003) Segregation of amphetamine reward and 
locomotor stimulation between nucleus accumbens medial shell and core. J 
Neurosci 23:6295–6303. 
Servier Laboratories Limited (2018) Valdoxan (agomelatine): Summary of product 
characteristics (online), accessed September 2018. 
Sevak RJ, Stoops WW, Hays LR, and Rush CR (2009) Discriminative stimulus and 
subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, 
and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 
328:1007–1018. 
Shalabi AR, Walther D, Baumann MH, and Glennon RA (2017) Deconstructed 
Analogues of Bupropion Reveal Structural Requirements for Transporter 
Inhibition versus Substrate-Induced Neurotransmitter Release. ACS chemical 
neuroscience 8:1397–1403. 
Sharbaf Shoar N, and Molla M (2019) Dextroamphetamine-Amphetamine, in StatPearls 
p, StatPearls Publishing, Treasure Island (FL). 
Shuster L, Quimby F, Bates A, and Thompson ML (1977) Liver damage from cocaine in 
mice. Life Sci 20:1035–1041. 
Silsby HD, Kruzich DJ, and Hawkins MR (1984) Fentanyl citrate abuse among health 
care professionals. Mil Med 149:227–228. 
Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR, and Wexler 
BE (2005) Neural activity associated with stress-induced cocaine craving: a 
functional magnetic resonance imaging study. Psychopharmacology (Berl) 
183:171–180. 
Skopp G, Ganssmann B, Cone EJ, and Aderjan R (1997) Plasma concentrations of 
heroin and morphine-related metabolites after intranasal and intramuscular 
administration. J Anal Toxicol 21:105–111. 
Smith GR (1956) Federal ruling on products containing reserpine and Rauwolfia 
products issued by  the Food and Drug Administration of the U.S. Department of 
Health, Education, and Welfare. R I Med J 39:512–514. 
Smith MJ, Thirthalli J, Abdallah AB, Murray RM, and Cottler LB (2009) Prevalence of 
psychotic symptoms in substance users: a comparison across substances. 
Compr Psychiatry 50:245–250. 
Smith RJ, and Aston-Jones G (2014) Incentive learning for morphine-associated stimuli 
during protracted abstinence increases conditioned drug preference. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 39:373–379. 
Smith RJ, and Laiks LS (2017) Behavioral and neural mechanisms underlying habitual 
and compulsive drug seeking. Prog Neuropsychopharmacol Biol Psychiatry, doi: 
10.1016/j.pnpbp.2017.09.003. 
280 
 
Solecki W, Wickham RJ, Behrens S, Wang J, Zwerling B, Mason GF, and Addy NA 
(2013) Differential role of ventral tegmental area acetylcholine and N-methyl-D-
aspartate receptors in cocaine-seeking. Neuropharmacology 75:9–18. 
Solinas M, Ferre S, You Z-B, Karcz-Kubicha M, Popoli P, and Goldberg SR (2002) 
Caffeine induces dopamine and glutamate release in the shell of the nucleus 
accumbens. J Neurosci 22:6321–6324. 
Sommers I, Baskin D, and Baskin-Sommers A (2006) Methamphetamine use among 
young adults: Health and social consequences. Addictive Behaviors 31:1469–
1476. 
Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, Wichems C, Lesch KP, Murphy 
DL, and Uhl GR (2001) Molecular mechanisms of cocaine reward: combined 
dopamine and serotonin transporter knockouts eliminate cocaine place 
preference. Proc Natl Acad Sci U S A 98:5300–5305. 
Spanagel R, Herz A, and Shippenberg TS (1992) Opposing tonically active endogenous 
opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad 
Sci U S A 89:2046–2050. 
Spanagel R, Herz A, and Shippenberg TS (1990) The effects of opioid peptides on 
dopamine release in the nucleus accumbens: an in vivo microdialysis study. J 
Neurochem 55:1734–1740. 
Sporer KA (1999) Acute heroin overdose. Ann Intern Med 130:584–590. 
Spyraki C, Fibiger HC, and Phillips AG (1983) Attenuation of heroin reward in rats by 
disruption of the mesolimbic dopamine system. Psychopharmacology (Berl) 
79:278–283. 
Stalnaker TA, Roesch MR, Franz TM, Burke KA, and Schoenbaum G (2006) Abnormal 
associative encoding in orbitofrontal neurons in cocaine-experienced rats during 
decision-making. Eur J Neurosci 24:2643–2653. 
Stanley TH (2014) The fentanyl story. J Pain 15:1215–1226. 
Stathis M, Scheffel U, Lever SZ, Boja JW, Carroll FI, and Kuhar MJ (1995) Rate of 
binding of various inhibitors at the dopamine transporter in vivo. 
Psychopharmacology (Berl) 119:376–384. 
Stedman TL (1976) Stedman’s Medical Dictionary: A Vocabulary of Medicine and Its 
Allied Sciences, 23rd Edition. Baltimore, MD, The Williams & Wilkins Company. 
Steffensen SC, Taylor SR, Horton ML, Barber EN, Lyle LT, Stobbs SH, and Allison DW 
(2008) Cocaine disinhibits dopamine neurons in the ventral tegmental area via 
use-dependent blockade of GABA neuron voltage-sensitive sodium channels. 
Eur J Neurosci 28:2028–2040. 
281 
 
Steidl S, Miller AD, Blaha CD, and Yeomans JS (2011) M5 muscarinic receptors mediate 
striatal dopamine activation by ventral tegmental morphine and pedunculopontine 
stimulation in mice. PLoS One 6:e27538. 
Steidl S, and Yeomans JS (2009) M5 muscarinic receptor knockout mice show reduced 
morphine-induced locomotion but increased locomotion after cholinergic 
antagonism in the ventral tegmental area. J Pharmacol Exp Ther 328:263–275. 
Steinberg EE, Boivin JR, Saunders BT, Witten IB, Deisseroth K, and Janak PH (2014) 
Positive reinforcement mediated by midbrain dopamine neurons requires D1 and 
D2 receptor activation in the nucleus accumbens. PLoS One 9:e94771. 
Sternini C, Spann M, Anton B, Keith DEJ, Bunnett NW, von Zastrow M, Evans C, and 
Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by 
neurons in vivo. Proc Natl Acad Sci U S A 93:9241–9246. 
Stevens MW, Henry RL, Owens SM, Schutz R, and Gentry WB (2014) First human 
study of a chimeric anti-methamphetamine monoclonal antibody in healthy 
volunteers. MAbs 6:1649–1656. 
Stoller KB, Bigelow GE, Walsh SL, and Strain EC (2001) Effects of 
buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 
(Berl) 154:230–242. 
Stoops WW, and Rush CR (2013) Agonist replacement for stimulant dependence: a 
review of clinical research. Current pharmaceutical design 19:7026–7035. 
Strain EC, Walsh SL, and Bigelow GE (2002) Blockade of hydromorphone effects by 
buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl) 
159:161–166. 
Su H, Zhang J, Ren W, Xie Y, Tao J, Zhang X, and He J (2017) Anxiety level and 
correlates in methamphetamine-dependent patients during acute withdrawal. 
Medicine (Baltimore) 96:e6434. 
Substance Abuse and Mental Health Service Administration (2014) Emergency 
department visits involving methamphetamine: 2007 to 2011. 
Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, and Ewing A (1995) Amphetamine 
redistributes dopamine from synaptic vesicles to the cytosol and promotes 
reverse transport. J Neurosci 15:4102–4108. 
Sulzer D, and Rayport S (1990) Amphetamine and other psychostimulants reduce pH 
gradients in midbrain dopaminergic neurons and chromaffin granules: a 
mechanism of action. Neuron 5:797–808. 
Sulzer D, Sonders MS, Poulsen NW, and Galli A (2005) Mechanisms of neurotransmitter 
release by amphetamines: a review. Prog Neurobiol 75:406–433. 
282 
 
Suzuki M, Desmond TJ, Albin RL, and Frey KA (2001) Vesicular neurotransmitter 
transporters in Huntington’s disease: initial observations and comparison with 
traditional synaptic markers. Synapse 41:329–336. 
Svingos AL, Chavkin C, Colago EE, and Pickel VM (2001) Major coexpression of kappa-
opioid receptors and the dopamine transporter in nucleus accumbens axonal 
profiles. Synapse 42:185–192. 
Sviripa VM, Zhang W, Balia AG, Tsodikov OV, Nickell JR, Gizard F, Yu T, Lee EY, 
Dwoskin LP, Liu C, and Watt DS (2014) 2’,6’-Dihalostyrylanilines, pyridines, and 
pyrimidines for the inhibition of the  catalytic subunit of methionine S-
adenosyltransferase-2. J Med Chem 57:6083–6091. 
Swainston Harrison T, Plosker GL, and Keam SJ (2006) Extended-release intramuscular 
naltrexone. Drugs 66:1741–1751. 
Swan GE, Javitz HS, Jack LM, Wessel J, Michel M, Hinds DA, Stokowksi RP, McClure 
JB, Catz SL, Richards J, Zbikowski SM, Deprey M, McAfee T, Conti DV, and 
Bergen AW (2012) Varenicline for smoking cessation: nausea severity and 
variation in nicotinic receptor genes. Pharmacogenomics J 12:349–358. 
Swanson JM, and Volkow ND (2003) Serum and brain concentrations of 
methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 
27:615–621. 
Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, 
and Charlton SJ (2012) The Influence of receptor kinetics on the onset and 
duration of action and the therapeutic index of NVA237 and tiotropium. The 
Journal of pharmacology and experimental therapeutics 343:520. 
Szegedi A, Wetzel H, Leal M, Hartter S, and Hiemke C (1996) Combination treatment 
with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. 
J Clin Psychiatry 57:257–264. 
Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, 
Przedborski S, and Uhl GR (1997) VMAT2 knockout mice: heterozygotes display 
reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, 
and enhanced MPTP toxicity. Proceedings of the National Academy of Sciences 
94:9938–9943. 
Takahashi N, and Uhl G (1997) Murine vesicular monoamine transporter 2: molecular 
cloning and genomic structure. Molecular Brain Research 49:7–14. 
Tam SW (1985) (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, μ, κ, δ and 
phencyclidine binding sites in guinea pig brain membranes. European Journal of 
Pharmacology 109:33–41. 
Tarutani S, Kikuyama H, Tamura Y, Okayama T, Toyoda K, Kanazawa T, Ohta M, 
Yasui-Furukori N, Okamura T, and Yoneda H (2016) Escitalopram and 
fluvoxamine combination therapy in a patient with treatment-resistant obsessive-
compulsive disorder: A case report. 
283 
 
Tella SR (1995) Effects of monoamine reuptake inhibitors on cocaine self-administration 
in rats. Pharmacol Biochem Behav 51:687–692. 
Teng L, Crooks PA, and Dwoskin LP (1998) Lobeline displaces 
[3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal 
synaptic vesicles: comparison with d-amphetamine. Journal of neurochemistry 
71:258–65. 
Teng L, Crooks PA, Sonsalla PK, and Dwoskin LP (1997) Lobeline and nicotine evoke 
[3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential 
inhibition of synaptosomal and vesicular [3H]dopamine uptake. The Journal of 
pharmacology and experimental therapeutics 280:1432–44. 
Teschemacher AG, Seward EP, Hancox JC, and Witchel HJ (1999) Inhibition of the 
current of heterologously expressed HERG potassium channels by  imipramine 
and amitriptyline. Br J Pharmacol 128:479–485. 
Tetrault JM, and Fiellin DA (2012) Current and potential pharmacological treatment 
options for maintenance therapy in opioid-dependent individuals. Drugs 72:217–
228. 
Thanos PK, Kim R, Delis F, Rocco MJ, Cho J, and Volkow ND (2017) Effects of chronic 
methamphetamine on psychomotor and cognitive functions and dopamine 
signaling in the brain. Behav Brain Res 320:282–290. 
Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, Ingram DK, and 
Hitzemann R (2001) Overexpression of dopamine D2 receptors reduces alcohol 
self-administration. J Neurochem 78:1094–1103. 
Thomsen M, Hall FS, Uhl GR, and Caine SB (2009) Dramatically decreased cocaine 
self-administration in dopamine but not serotonin  transporter knock-out mice. J 
Neurosci 29:1087–1092. 
Thomsen M, Woldbye DPD, Wortwein G, Fink-Jensen A, Wess J, and Caine SB (2005) 
Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-
deficient mice. J Neurosci 25:8141–8149. 
Thorn CF, Klein TE, and Altman RB (2009) Codeine and morphine pathway. 
Pharmacogenet Genomics 19:556–558. 
Thorndike EL (1898) Animal intelligence: An experimental study of the associative 
processes in animals. The Psychological Review: Monograph Supplements 2:i–
109. 
Tiffany ST (1990) A cognitive model of drug urges and drug-use behavior: role of 
automatic and nonautomatic processes. Psychol Rev 97:147–168. 
Toombs JD, and Kral LA (2005) Methadone treatment for pain states. Am Fam 
Physician 71:1353–1358. 
284 
 
Travagli RA, Hermann GE, Browning KN, and Rogers RC (2006) Brainstem circuits 
regulating gastric function. Annu Rev Physiol 68:279–305. 
Trudeau MC, Warmke JW, Ganetzky B, and Robertson GA (1995) HERG, a human 
inward rectifier in the voltage-gated potassium channel family. Science 269:92–
95. 
Umans JG, and Inturrisi CE (1982) Heroin: analgesia, toxicity and disposition in the 
mouse. Eur J Pharmacol 85:317–323. 
Umans JG, and Inturrisi CE (1981) Pharmacodynamics of subcutaneously administered 
diacetylmorphine,. J Pharmacol Exp Ther 218:409–415. 
UNODC, United Nations Office on Drugs and Crime (1953) History of Heroin, 
http://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1953-01-
01_2_page004.html#f006. 
UNODC, United Nations Office on Drugs and Crime (2014) World Drug Report 2014, 
United Nations publication, Sales No. E.14.XI.7, Vienna, Austria. 
UNODC, United Nations Office on Drugs and Crime (2015) World Drug Report 2015, 
United Nations publication, Sales No. E.15.XI.6, Vienna, Austria. 
UNODC, United Nations Office on Drugs and Crime (2017) World Drug Report 2017, 
United Nations publication, Sales No. E.17.XI.7, Vienna, Austria. 
UNODC, United Nations Office on Drugs and Crime (2018) World Drug Report 2018, 
United Nations publication, Sales No. E.18.XI.9, Vienna, Austria. 
van den Buuse M, Ruimschotel E, Martin S, Risbrough VB, and Halberstadt AL (2011) 
Enhanced effects of amphetamine but reduced effects of the hallucinogen,. 
Neuropharmacology 61:209–216. 
van der Schier R, Roozekrans M, van Velzen M, Dahan A, and Niesters M (2014) 
Opioid-induced respiratory depression: reversal by non-opioid drugs. 
F1000Prime Reports 6:79. 
Van Dyke HB (1949) New analgesic drugs. Bull N Y Acad Med 25:152–175. 
van Harten J (1995) Overview of the pharmacokinetics of fluvoxamine. Clin 
Pharmacokinet 29 Suppl 1:1–9. 
Van Norman GA (2016) Drugs, Devices, and the FDA: Part 1. BTS 1:170. 
Vardanyan R, and Hruby V (2016) Chapter 3 - Analgesics, in Synthesis of Best-Seller 
Drugs (Vardanyan R, and Hruby V eds) pp 15–64, Academic Press, Boston. 
Vasanthanathan P, Olsen L, Jorgensen FS, Vermeulen NPE, and Oostenbrink C (2010) 
Computational prediction of binding affinity for CYP1A2-ligand complexes using 
empirical free energy calculations. Drug Metab Dispos 38:1347–1354. 
285 
 
Vearrier D, Greenberg MI, Miller SN, Okaneku JT, and Haggerty DA (2012) 
Methamphetamine: history, pathophysiology, adverse health effects, current 
trends, and hazards associated with the clandestine manufacture of 
methamphetamine. Disease-a-month : DM 58:38–89. 
Verebey K, and Gold MS (1988) From coca leaves to crack: The effects of dose and 
routes of administration in abuse liability. Psychiatric Annals 18:513–520. 
Vezina P, Lorrain DS, Arnold GM, Austin JD, and Suto N (2002) Sensitization of 
midbrain dopamine neuron reactivity promotes the pursuit of amphetamine. J 
Neurosci 22:4654–4662. 
Vilaro MT, Palacios JM, and Mengod G (1990) Localization of m5 muscarinic receptor 
mRNA in rat brain examined by in situ hybridization histochemistry. 
Neuroscience letters 114:154–9. 
Volkow ND, Baler RD, and Goldstein RZ (2011) Addiction: pulling at the neural threads 
of social behaviors. Neuron 69:599–602. 
Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, 
Gatley J, Hitzemann R, Gifford A, Wong C, and Pappas N (2001) Low level of 
brain dopamine D2 receptors in methamphetamine abusers: association  with 
metabolism in the orbitofrontal cortex. Am J Psychiatry 158:2015–2021. 
Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, 
Hitzemann R, Ding YS, and Logan J (2001) Loss of dopamine transporters in 
methamphetamine abusers recovers with protracted abstinence. J Neurosci 
21:9414–9418. 
Volkow ND, Fowler JS, Wang G-J, Swanson JM, and Telang F (2007) Dopamine in drug 
abuse and addiction: results of imaging studies and treatment implications. Arch 
Neurol 64:1575–1579. 
Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, 
Bendriem B, and Christman D (1990) Effects of chronic cocaine abuse on 
postsynaptic dopamine receptors. Am J Psychiatry 147:719–724. 
Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Dewey SL, and Handlesman L 
(1992) Long-term frontal brain metabolic changes in cocaine abusers. Synapse 
11:184–190. 
Volkow ND, Koob GF, and McLellan AT (2016) Neurobiologic Advances from the Brain 
Disease Model of Addiction. N Engl J Med 374:363–371. 
Volkow ND, and Morales M (2015) The Brain on Drugs: From Reward to Addiction. Cell 
162:712–725. 
Volkow ND, and Swanson JM (2003) Variables that affect the clinical use and abuse of 
methylphenidate in the treatment of ADHD. Am J Psychiatry 160:1909–1918. 
286 
 
Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, 
Logan J, Gatley SJ, Pappas N, Hitzemann R, and Shea CE (1997) Relationship 
between subjective effects of cocaine and dopamine transporter occupancy. 
Nature 386:827–830. 
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, 
and Pappas N (1999) Prediction of reinforcing responses to psychostimulants in 
humans by brain dopamine D2 receptor levels. Am J Psychiatry 156:1440–1443. 
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey 
SL, and Pappas N (1997) Decreased striatal dopaminergic responsiveness in 
detoxified cocaine-dependent subjects. Nature 386:830–833. 
Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, 
and Piscani K (1996) Decreases in dopamine receptors but not in dopamine 
transporters in alcoholics. Alcohol Clin Exp Res 20:1594–1598. 
Volkow ND, Wang G-J, Fowler JS, Thanos PPK, Logan J, Gatley SJ, Gifford A, Ding Y-
S, Wong C, and Pappas N (2002) Brain DA D2 receptors predict reinforcing 
effects of stimulants in humans: replication study. Synapse 46:79–82. 
Volkow ND, Wang G-J, Fowler JS, Tomasi D, and Telang F (2011) Addiction: beyond 
dopamine reward circuitry. Proc Natl Acad Sci U S A 108:15037–15042. 
Volkow ND, Wang G-J, Telang F, Fowler JS, Logan J, Childress A-R, Jayne M, Ma Y, 
and Wong C (2006) Cocaine cues and dopamine in dorsal striatum: mechanism 
of craving in cocaine addiction. J Neurosci 26:6583–6588. 
Volkow ND, Wang G-J, Telang F, Fowler JS, Logan J, Childress A-R, Jayne M, Ma Y, 
and Wong C (2008) Dopamine increases in striatum do not elicit craving in 
cocaine abusers unless they are coupled with cocaine cues. Neuroimage 
39:1266–1273. 
Volkow ND, Wise RA, and Baler R (2017) The dopamine motive system: implications for 
drug and food addiction. Nat Rev Neurosci 18:741–752. 
Vorhees CV, and Williams MT (2014) Assessing spatial learning and memory in rodents. 
ILAR J 55:310–332. 
Vree TB, van Dongen RT, and Koopman-Kimenai PM (2000) Codeine analgesia is due 
to codeine-6-glucuronide, not morphine. Int J Clin Pract 54:395–398. 
Wagner W, Zaborny BA, and Gray TE (1994) Fluvoxamine. A review of its safety profile 
in world-wide studies. Int Clin Psychopharmacol 9:223–227. 
Wallace E, Ridley J, Bryson J, Mak E, and Zimmermann C (2013) Addition of 
methadone to another opioid in the management of moderate to severe cancer 
pain: a case series. J Palliat Med 16:305–309. 
Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, Hoffman W, 
Jayne M, Alia-Klein N, Thanos P, and Fowler JS (2012) Decreased dopamine 
287 
 
activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17:918–
925. 
Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, 
and Pascani K (1997) Dopamine D2 receptor availability in opiate-dependent 
subjects before and after naloxone-precipitated withdrawal. 
Neuropsychopharmacology 16:174–182. 
Wang Q, Li D, Bubula N, Campioni MR, McGehee DS, and Vezina P (2017) Sensitizing 
exposure to amphetamine increases AMPA receptor phosphorylation without 
increasing cell surface expression in the rat nucleus accumbens. 
Neuropharmacology 117:328–337. 
Warner EA (1993) Cocaine abuse. Ann Intern Med 119:226–235. 
Wasserman DI, Wang HG, Rashid AJ, Josselyn SA, and Yeomans JS (2013) 
Cholinergic control of morphine‐induced locomotion in rostromedial tegmental 
nucleus versus ventral tegmental area sites. European Journal of Neuroscience 
38:2774–2785. 
Way EL, Kemp JW, Young JM, and Grassetti DR (1960) The pharmacologic effects of 
heroin in relationship to its rate of biotransformation. J Pharmacol Exp Ther 
129:144–154. 
Weiner DM, Levey AI, and Brann MR (1990) Expression of muscarinic acetylcholine and 
dopamine receptor mRNAs in rat basal ganglia. Proceedings of the National 
Academy of Sciences of the United States of America 87:7050–4. 
Weiss AJ, Barrett ML, Heslin KC, and Stocks C (2016) Trends in Emergency 
Department Visits Involving Mental and Substance Use Disorders, 2006-2013: 
Statistical Brief #216, in Healthcare Cost and Utilization Project (HCUP) 
Statistical Briefs p, Agency for Healthcare Research and Quality (US), Rockville 
(MD). 
Weiss F, Maldonado-Vlaar CS, Parsons LH, Kerr TM, Smith DL, and Ben-Shahar O 
(2000) Control of cocaine-seeking behavior by drug-associated stimuli in rats: 
Effects on recovery of extinguished operant-responding and extracellular 
dopamine levels in amygdala and nucleus accumbens. Proc Natl Acad Sci USA 
97:4321. 
Weiss F, Markou A, Lorang MT, and Koob GF (1992) Basal extracellular dopamine 
levels in the nucleus accumbens are decreased during cocaine withdrawal after 
unlimited-access self-administration. Brain Res 593:314–318. 
Weiss F, Paulus MP, Lorang MT, and Koob GF (1992) Increases in extracellular 
dopamine in the nucleus accumbens by cocaine are inversely related to basal 
levels: effects of acute and repeated administration. J Neurosci 12:4372–4380. 
Welsh C, and Valadez-Meltzer A (2005) Buprenorphine: a (relatively) new treatment for 
opioid dependence. Psychiatry (Edgmont (Pa : Township)) 2:29–39. 
288 
 
Welter M, Vallone D, Samad TA, Meziane H, Usiello A, and Borrelli E (2007) Absence of 
dopamine D2 receptors unmasks an inhibitory control over the brain circuitries 
activated by cocaine. Proc Natl Acad Sci U S A 104:6840–6845. 
White NM (1989) Reward or reinforcement: what’s the difference? Neurosci Biobehav 
Rev 13:181–186. 
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, 
Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, and Kleijnen J (2015) 
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 
313:2456–2473. 
Wilhelm CJ, Johnson RA, Eshleman AJ, and Janowsky A (2008) Lobeline effects on 
tonic and methamphetamine-induced dopamine release. Biochem Pharmacol 
75:1411–1415. 
Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, and Janowsky A (2004) Effects of 
methamphetamine and lobeline on vesicular monoamine and dopamine 
transporter-mediated dopamine release in a cotransfected model system. J 
Pharmacol Exp Ther 310:1142–1151. 
Williamson A, Darke S, Ross J, and Teesson M (2006) The effect of persistence of 
cocaine use on 12-month outcomes for the treatment of heroin dependence. 
Drug Alcohol Depend 81:293–300. 
Wilmouth CE, Zheng G, Crooks PA, Dwoskin LP, and Bardo MT (2013) Oral 
administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine 
self-administration in rats. Pharmacology, biochemistry, and behavior 112:29–33. 
Wilson GT (2010) Eating disorders, obesity and addiction. European Eating Disorders 
Review 18:341–351. 
Wilson MC, and Schuster CR (1974) Aminergic influences on intravenous cocaine self-
administration by Rhesus monkeys. Pharmacol Biochem Behav 2:563–571. 
Wimalasena K (2011) Vesicular monoamine transporters: structure-function, 
pharmacology, and medicinal chemistry. Medicinal research reviews 31:483–
519. 
Wise RA (2008) Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox 
Res 14:169–183. 
Wise RA, and Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 
40:191–225. 
Worley J (2017) Recovery in Substance Use Disorders: What to Know to Inform 
Practice. Issues Ment Health Nurs 38:80–91. 
Yager LM, Garcia AF, Wunsch AM, and Ferguson SM (2015) The ins and outs of the 
striatum: role in drug addiction. Neuroscience 301:529–541. 
289 
 
Yamada M, Basile AS, Fedorova I, Zhang W, Duttaroy A, Cui Y, Lamping KG, Faraci 
FM, Deng CX, and Wess J (2003) Novel insights into M5 muscarinic 
acetylcholine receptor function by the use of gene targeting technology. Life Sci 
74:345–353. 
Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA, Weisstein JS, Spagnola BV, 
and Wolfe BB (1993) Development of antisera selective for m4 and m5 
muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. 
Mol Pharmacol 43:149–157. 
Yeomans JS (2012) Muscarinic receptors in brain stem and mesopontine cholinergic 
arousal functions. Handbook of experimental pharmacology 243–59. 
Yero T, and Rey JA (2008) Tetrabenazine (Xenazine), An FDA-Approved Treatment 
Option For Huntington’s Disease-Related Chorea. P T 33:690–694. 
Yoshida Y, Koide S, Hirose N, Takada K, Tomiyama K, Koshikawa N, and Cools AR 
(1999) Fentanyl increases dopamine release in rat nucleus accumbens: 
involvement of mesolimbic mu- and delta-2-opioid receptors. Neuroscience 
92:1357–1365. 
Zaczek R, Culp S, and De Souza EB (1991) Interactions of [3H]amphetamine with rat 
brain synaptosomes. II. Active transport. J Pharmacol Exp Ther 257:830–835. 
Zallar LJ, Farokhnia M, Tunstall BJ, Vendruscolo LF, and Leggio L (2017) The Role of 
the Ghrelin System in Drug Addiction. Int Rev Neurobiol 136:89–119. 
Zaveri NT (2016) Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress 
in Translation from Preclinical Research to Clinical Utility. Journal of medicinal 
chemistry 59:7011–7028. 
Zaveri NT, Marquez PV, Meyer ME, Hamid A, and Lutfy K (2018) The Nociceptin 
Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-
Induced Conditioned Place Preference in Mice. Frontiers in Psychiatry 9:638. 
Zhang T, Zheng X, Zhou Z, Chen X, Jin Z, Deng J, Zhan C-G, and Zheng F (2017) 
Clinical Potential of an Enzyme-based Novel Therapy for Cocaine Overdose. Sci 
Rep 7:15303. 
Zhang W, Yamada M, Gomeza J, Basile AS, and Wess J (2002) Multiple muscarinic 
acetylcholine receptor subtypes modulate striatal dopamine release, as studied 
with M1-M5 muscarinic receptor knock-out mice. J Neurosci 22:6347–6352. 
Zheng F, Yang W, Ko M-C, Liu J, Cho H, Gao D, Tong M, Tai H-H, Woods JH, and Zhan 
C-G (2008) Most Efficient Cocaine Hydrolase Designed by Virtual Screening of 
Transition States. J Am Chem Soc 130:12148–12155. 
Zheng F, and Zhan C-G (2012) Are pharmacokinetic approaches feasible for treatment 
of cocaine addiction and overdose? Future Med Chem 4:125–128. 
290 
 
Zheng G, Dwoskin LP, and Crooks PA (2006) Vesicular monoamine transporter 2: role 
as a novel target for drug development. The AAPS journal 8:E682-92. 
Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, and Crooks PA (2005) 
Defunctionalized lobeline analogues: structure-activity of novel ligands for the 
vesicular monoamine transporter. Journal of medicinal chemistry 48:5551–60. 
Zheng G, Smith AM, Huang X, Subramanian KL, Siripurapu KB, Deaciuc A, Zhan CG, 
and Dwoskin LP (2013) Structural modifications to tetrahydropyridine-3-
carboxylate esters en route to the discovery of M5-preferring muscarinic receptor 
orthosteric antagonists. Journal of medicinal chemistry 56:1693–703. 
Zheng X, Zhou Z, Zhang T, Jin Z, Chen X, Deng J, Zhan C-G, and Zheng F (2017) 
Effectiveness of a Cocaine Hydrolase for Cocaine Toxicity Treatment in Male and 
Female Rats. AAPS J 20:3. 
Zito KA, Vickers G, and Roberts DC (1985) Disruption of cocaine and heroin self-
administration following kainic acid lesions of the nucleus accumbens. Pharmacol 
Biochem Behav 23:1029–1036. 
Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, and 
Baumann MH (2009) Evidence for the involvement of dopamine transporters in 
behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329:738–746. 
Zunkler BJ, and Wos-Maganga M (2010) Comparison of the effects of methadone and 
heroin on human ether-a-go-go-related  gene channels. Cardiovasc Toxicol 
10:161–165. 
 
 
  
291 
VITA 
Na-Ra Lee 
College of Pharmacy, University of Kentucky 
A. EDUCATION
2012 - Present Ph.D. Candidate in Department of Pharmaceutical Sciences, 
College of Pharmacy, University of Kentucky, Lexington, KY, 
U.S.A. 
Dissertation title: Discovery Novel Pharmacotherapeutics for 
Substance Use Disorders (Expected Graduation in August 2019) 
Advisor: Linda P. Dwoskin, Ph.D. 
2007 - 2009 M.S. in Department of Bio and Nanochemistry, Biochemistry 
Major  
College of Nature Science, Kookmin University, Seoul, South 
Korea  
Thesis title: Enzymatic Properties of Severe Acute Respiratory 
Syndrome (SARS) Coronavirus Helicase, 
 Adviser: Yong-Joo Jeong, Ph.D. 
2003 - 2007 B.S. in Department of Bio and Nanochemistry 
College of Natural Science, Kookmin University, Seoul, South 
Korea 
292 
 
B. RESEARCH AND PROFESSIONAL POSITIONS 
 
2012 - Present Graduate Student and Research Assistant (Ph.D. Candidate) 
Research Project 1: Discover M5 muscarinic acetylcholine 
receptor as a novel treatment target for substance use disorders 
Research Project 2: Discover vesicular monoamine transporter-2 
(VMAT2) selective inhibitors as pharmacological treatments for 
methamphetamine use disorders 
Research Project 3: The underlying mechanism on tolerance 
development following repeated VMAT2 administration     
Department of Pharmaceutical Sciences, University of Kentucky, 
Lexington, KY, U.S.A., Advisor: Linda P. Dwoskin, Ph.D. 
 
2010 - 2012 Research Assistant 
 Research Project: Discover immunoproteasome subtype selective 
inhibitors as a cancer treatment 
Department of Pharmaceutical Sciences, University of Kentucky, 
Lexington, KY, U.S.A., Research Advisor: Kyung Bo Kim, Ph.D. 
 
2009 - 2010 Research Assistant 
 Research Project: Characterize helicase enzyme working 
mechanism of severe acute respiratory syndrome (SARS) 
coronavirus 
Department of Bioscience and Biotechnology, Konkuk University, 
Seoul, South Korea, Research Advisor: Dong-Eun Kim, Ph.D. 
293 
 
2007 - 2009 Graduate Student and Research Assistant 
 Research Project 1: Enzymatic properties of severe acute 
respiratory syndrome (SARS) coronavirus helicase 
 Research Project 2: Discover inhibitors of SARS helicase as anti-
viral materials  
Department of Bio and Nano-Chemistry, Kookmin University, 
Seoul, South Korea, Research Advisor: Yong-Joo Jeong, Ph.D. 
 
C. PUBLICATIONS 
 
1. Jang KJ, Lee N-R, Yeo WS, Jeong YJ, Kim DE. (2008) Biochem Biophys Res 
Comm 366(3):738–44. PMID: 18082623 
2. Lee C, Lee JM, Lee N-R, Jin BS, Jang KJ, Kim DE, Jeong YJ, Chong Y. (2009) 
Bioorg Med Chem Lett 19(6):1636–38. PMID: 19233643 
3. Lee N-R, Lee AR, Lee B, Kim DE, Jeong YJ. (2009) Bull Korean Chem Soc 
30(8):1724-28 
4. Lee C, Lee JM, Lee N-R, Kim DE, Jeong YJ, Chong Y. (2009) Bioorg Med Chem 
Lett 19(16):4538–41. PMID: 19625187 
5. Lee N-R, Kwon HM, Park K, Jeong YJ, Kim DE. (2010) Nucleic Acids Res 
38(21):7626–36. PMID: 20671029 
6. Carmony KC, Lee DM, Wu Y, Lee N-R, Wehenkel M, Lee J, Zhan CG, Kim KB. 
(2012) Bioorg Med Chem 20(2):607–13. PMID: 21741845 
7. Sharma LK, Lee N-R, Jang ER, Lei B, Zhan CG, Lee W, Kim KB. (2012) 
Chembiochem 13(13):1899-903. PMID: 22807337 
294 
 
8. Jang ER, Lee N-R, Han S, Wu Y, Sharma LK, Carmony KC, Marks J, Lee DM, Ban 
JO, Wehenkel M, Hong JT, Kim KB, Lee W. (2012) Mol Biosyst 8(9):2295–302. PMID: 
22722901 
9. Kasam V, Lee N-R, Kim KB, Zhan CG. (2014) Bioorg Med Chem Lett 24(15):3514-
7. PMID: 24913713 
10. Miller Z, Kim KS, Lee DM, Kasam V, Baek SE, Lee KH, Zhang YY, Ao L, Carmony 
K, Lee N-R, Zhou S, Zhao Q, Jang Y, Jeong HY, Zhan CG, Lee W, Kim DE, Kim KB. 
(2015) J Med Chem 58(4):2036-41. PMID: 25658656 
11. Lee N-R, Zhang X, Darna M, Dwoskin LP, Zheng G. (2015) Bioorg Med Chem Lett 
25(22):5032-5. PMID: 26494260 
12. Bommagani S, Lee N-R, Zhang X, Dwoskin LP, Zheng G. (2015) Tetrahedron 
Letters 56(46):6472-4  
13. Lee N-R, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. (2018) AAPS J 20(2):29 
14. Lee N-R, Gujarathi S, Bommagani S, Siripurapu S, Zheng G and Dwoskin LP. 
(2019) Bioorg Med Chem Lett 29(3):471-476 
15. Lee N-R, Zheng G, Nickell JR, Janganati V, Crooks PA, Bardo MT, Dwoskin LP.    
J Pharmacol Exp Ther, under revision, 2019 
 
 D. PATENT 
 
1. U.S. Patent No. 9,586,946: Zhan, C.-G.; Kim, K.-B.; Kasam, V.; Lee, N.-R. “Selective 
Immunoproteasome Inhibitors with Non-peptide Scaffolds”. Date of Patent issued: 
March 7, 2017. 
2. U.S. Patent Application No. 2017/0304227 A1: Dwoskin, L.P.; Crooks, P.A.; Nickell, 
J.R.; Zheng, G; Zheng, C; Lee, N.-R. “Vesicular Monoamine Transporter-2 Ligands 
and Their Use in the Treatment of Psychostimulant Abuse”. Date of Patent 
Application Published: October 26th, 2017. 
295 
 
E. FELLOWSHIPS AND AWARDS 
 
2017 Poster Presentation Award Winner Student Second Place  
 The Drug Discovery and Development Colloquium at Little Rock, 
AR, Sponsored by AAPS (June, 17) 
 
2017 Oral Presentation Certification Awarded, The Drug 
Development and Discovery Colloquium 2017, Sponsored by 
American Association of Pharmaceutical Scientists (AAPS), Little 
Rock, Arkansas (June 15-17) 
 
2015 Outstanding Presentation Award  
 2015 KSEA-KY Winter Conference at Lexington, KY, Sponsored 
by KSEA (December, 19) 
 
2014 Center of Membrane Sciences (CMS) Graduate Student 
Mentoring Fellowship Merit Award, Lexington, KY (May, 2) 
 
2012 - 2013 Teaching Assistantship  
 University of Kentucky, Lexington, Kentucky, USA  
 (August 2012 – July 2013) 
 
F. LEADERSHIP ROLES 
 
2016 Jan. – 2016 Dec. Drug Discovery Representative  
American Association of Pharmaceutical Scientists (AAPS) 
Student    Chapter at the University of Kentucky, Lexington, KY 
2016 Aug. – 2017 Jul. Vice President 
Korean Scholars Association at University of Kentucky (KSAUK) 
in Korean-American Scientists and Engineers Association 
(KASEA)-Kentucky Chapter, Lexington, KY 
296 
 
2015 Aug. – 2016 Jul. Vice President 
Korean Bio-Scientists Association at University of Kentucky 
(KBAUK) in Korean-American Scientists and Engineers 
Association (KASEA)-Kentucky Chapter, Lexington, KY 
2015 Aug. – 2016 Dec.2015 Winter Conference Organizing Committee 
Korean-American Scientists and Engineers Association (KASEA)- 
Kentucky Chapter, Lexington, KY 
 
 
G. TEACHING EXPERIENCES 
 
2017 Invited Lecturer  
 Behavioral Pharmacology Class, Transylvania University,  
 Lexington, KY, USA, May 17 
 
2012 - 2013 Teaching Assistant for Accommodations 
 Department of Pharmaceutical Sciences, University of Kentucky, 
Lexington, KY, U.S.A. 
 
2008 - 2009 Teaching Assistant/ Lecturer for Biochemistry Lab 
      Department of Bio and Nanochemistry, College of Natural 
Science, Kookmin University, Seoul, South Korea 
 
2007 - 2009 Teaching Assistant/ Lecturer for General Chemistry Lab 
      Department of Bio and Nanochemistry, College of Natural 
Science, Kookmin University, Seoul, South Korea 
 
 
297 
 
H. ORAL PRESENTATIONS 
 
National 
2016 Enantiomers of (±)GZ-888 Potently and Selectively Inhibit Vesicular 
Monoamine Transporter-2 Function and Methamphetamine-stimulated 
Locomotor Activity, College on Problems of Drug Dependence (CPDD), 
oral presentation, Palm Springs, CA, USA, Jun. 11-16 
2017  The potent and selective vesicular monoamine transporter-2 inhibitor, GZ-
11608, Decreases behavioral response to methamphetamine, The Drug 
Discovery and Development Colloquium 2017 (DDDC 2017), oral 
presentation, Little Rock, AR, USA, Jun. 15-17 
Local 
2016 Enantiomers of (±)GZ-888 Potently and Selectively Inhibit Vesicular 
Monoamine Transporter-2 Function and Methamphetamine-stimulated 
Locomotor Activity, 2016 Ashland Inc. Distinguished Lectures & 
Symposium on Drug Discovery & Development (DDD), oral 
presentation, Lexington, KY, USA, Nov. 4 
 
I. POSTER PRESENTATIONS 
International 
2007 Enzymatic properties of Severe Acute Respiratory Syndrome (SARS) 
Coronavirus helicase, II33P165, The 100th National Meeting of the Korean 
Chemical Society, Daegu, South Korea, Oct. 18-19 
2008 The study of steady state ATP hydrolysis by SARS Coronavirus helicase, 
The 101st National Meeting of the Korean Chemical Society, Ilsan, South 
Korea, Apr. 17-18 
2008 ATP hydrolysis assays of SARS Coronavirus helicase in the presence of 
single-stranded nucleic acids, The 102nd National Meeting of the Korean 
Chemical Society, Jeju, South Korea, Oct. 16-17 
2009 Characterization of Severe Acute Respiratory Syndrome (SARS) 
Coronavirus helicase, The 103rd National Meeting of the Korean Chemical 
Society, Seoul, South Korea, Apr. 16-17 
2009 Biochemical analysis of ATP hydrolysis and DNA unwinding activity of the 
Severe Acute Respiratory Syndrome Coronavirus (SARS CoV) helicase, 
H-12-22, The 66th KSBMB annual meeting 2009, Seoul, South Korea, 
May 12-13 
298 
 
2009 Kinetic measurement of nucleic acid unwinding by Severe Acute 
Respiratory Syndrome Coronavirus (SARS-CoV) helicase, II36P179, The 
104th National Meeting of the Korean Chemical Society, Daejeon, South 
Korea, Oct. 28-30 
2010 The effects of substrate composition on helicase unwinding activity of 
SARS coronavirus nsP13, II36P226, The 105th National Meeting of the 
Korean Chemical Society, Incheon, South Korea, Apr. 29-30 
National 
2013 Discovery of M5-preferring muscarinic receptor antagonists: evaluation of 
a series of 3-phenyl propyl 1,2,5,6-tetrahydropyridine-3-carboxylates, 
Pharmaceutics Graduate Student Research Meeting (PGSRM), Iowa 
City, IA, USA, Jun. 6-8 
2015 Discovery of M5 muscarinic acetylcholine receptor antagonists: 1-methyl-
4-phenylpiperidine analogs, Experimental Biology, Boston, MA, USA, 
Mar.28-Apr.1 
2015 Discovery of vesicular monoamine transporter-2 inhibitors as potential 
treatment for methamphetamine abuse: N-Butyl(1-methyl-2-
phenylethyl)amine isomers, Pharmaceutics Graduate Student Research 
Meeting (PGSRM), Lexington, KY, USA, Jun. 11-13 
2017 The potent and selective vesicular monoamine transporter-2 inhibitor, GZ-
11608, Decreases behavioral response to methamphetamine, The Drug 
Discovery and Development Colloquium 2017 (DDDC 2017), poster 
presentation, Little Rock, AR, USA, Jun. 15-17 
Local 
2015 Discovery of M5 muscarinic acetylcholine receptor antagonists: 1-methyl-
4-phenylpiperidine analogs, Blue Grass Society for Neuroscience 
(BGSFN) Spring Neuroscience Day, Lexington, KY, USA, Mar. 25 
2015 Discovery of M5 muscarinic acetylcholine receptor antagonists: 1-methyl-
4-phenylpiperidine analogs, Rho Chi Alpha Xi chapter of the University of 
Kentucky hosts Research Day, Lexington, KY, USA, Apr. 17 
2017 (S)‐GZ‐11608, a Vesicular Monoamine Transporter‐2 Inhibitor, 
Specifically and Potently Decreases the Behavioral Response to 
Methamphetamine, Blue Grass Society for Neuroscience (BGSFN) 
Spring Neuroscience Day, Lexington KY, USA, Apr. 21 
 
 
